The O
specific O
phosphorylation O
of O
Ser O
280 O
by O
hallucinogens O
was O
further O
validated O
by O
quantitative O
mass O
spectrometry O
analysis O
of O
immunopurified O
receptor O
digests O
and O
by O
Western O
blotting O
using O
a O
phosphosite O
specific O
antibody O
. O

The O
mutation B
of I
Ser I
280 I
to I
aspartic I
acid I
( O
to O
mimic O
phosphorylation O
) O
reduced O
receptor O
desensitization O
by O
nonhallucinogenic O
agonists O
, O
whereas O
its B
mutation I
to I
alanine I
increased O
the O
ability O
of O
hallucinogens O
to O
desensitize O
the O
receptor O
. O

They O
also O
provide O
convergent O
evidence O
indicating O
that O
the O
different O
effects O
of O
hallucinogenic O
versus O
non O
hallucinogenic O
agonists O
upon O
receptor O
desensitization O
reflect O
their O
differential O
capacity O
to O
promote O
Ser O
280 O
phosphorylation O
: O
( O
1 O
) O
mutating B
Ser I
280 I
into I
alanine I
or I
aspartate I
abolished O
the O
difference O
in O
the O
agonist O
effects O
upon O
receptor O
desensitization O
; O
( O
2 O
) O
hallucinogens O
were O
able O
to O
desensitize O
S O
280 O
A O
receptor O
to O
an O
extent O
comparable O
to O
that O
induced O
by O
nonhallucinogenic O
agonists O
in O
cells O
expressing O
wild O
type O
receptor O
and O
( O
3 O
) O
nonhallucinogenic O
agonists O
did O
not O
promote O
desensitization O
of O
the O
Ser O
280 O
D O
receptor O
mutant O
. O

These O
findings O
contrast O
with O
a O
previous O
study O
which O
showed O
that O
mutating B
into I
alanine I
two I
serine I
residues I
, I
one I
( I
Ser I
421 I
) I
located I
in I
the I
receptor I
C I
terminus I
and I
the I
other I
( I
Ser I
188 I
) I
in O
the O
i O
2 O
loop O
, O
strongly O
reduced O
quipazine O
- O
mediated O
receptor O
desensitization O
, O
whereas O
the O
deletion O
of O
residues O
280 O
– O
296 O
or O
residues B
280 I
– I
310 I
in O
the O
i O
3 O
loop O
( O
i O
. O
e O
. O

However O
, O
it O
is O
likely O
that O
the O
agonist O
used O
to O
induce O
receptor O
desensitization O
( O
quipazine O
) O
, O
which O
is O
devoid O
of O
hallucinogenic O
activity O
in O
humans O
( O
42 O
) O
, O
does O
not O
induce O
S O
280 O
phosphorylation O
, O
like O
lisuride O
and O
ergotamine O
. O

The O
resultant O
frame B
- I
shift I
is I
predicted I
to I
replace I
the I
terminal I
15 I
amino I
acids I
with I
a I
novel I
43 I
amino I
acid I
terminal I
sequence I
( O
V O
232 O
fs O
) O
( O
figure O
1 O
F O
) O
. O

When O
the O
critical O
histidine B
residue I
473 I
in I
CPT I
I I
( I
327 I
in I
COT I
) I
, I
localized I
in I
the I
acyl I
- I
Co I
A I
pocket I
in I
the I
model I
, I
was I
mutated I
to I
alanine I
, O
the O
catalytic O
activity O
was O
abolished O
. O

Mutation B
of I
the I
conserved I
alanine I
residue I
to I
aspartic I
acid I
, O
A O
381 O
D O
( O
in O
CPT O
I O
) O
and O
A O
238 O
D O
( O
in O
COT O
) O
, O
which O
are O
92 O
/ O
89 O
amino O
acids O
far O
from O
the O
catalytic O
histidine O
, O
respectively O
( O
but O
very O
close O
to O
the O
acyl O
- O
Co O
A O
pocket O
in O
the O
structural O
model O
) O
, O
decreased O
the O
activity O
by O
86 O
and O
80 O
% O
, O
respectively O
. O

The O
structural O
model O
explains O
the O
loss O
of O
activity O
reported O
for O
the O
CPT O
I O
mutations O
R O
451 O
A O
, O
W O
452 O
A O
, O
D O
454 O
G O
, O
W O
391 O
A O
, O
del O
R O
395 O
, O
P O
479 O
L O
, O
and O
L O
484 O
P O
, O
all O
of O
which O
occur O
in O
or O
near O
the O
modeled O
catalytic O
domain O
. O

In O
this O
report O
we O
describe O
the O
phenotype O
produced O
by O
stochastic B
mutations I
of I
the I
zinc I
finger I
region I
. O

Nevertheless O
, O
we O
found O
two O
unexpected O
phenotypes O
. O

Secondly O
, O
substitution B
of I
the I
conserved I
Lys I
461 I
results O
in O
an O
abnormal O
behavior O
of O
the O
mutated O
GR O
. O

Here O
we O
demonstrate O
that O
lfm O
( O
3 O
) O
7 O
contains O
a O
nonsense O
mutation B
within I
codon I
355 I
of O
the O
act O
88 O
F O
actin O
gene O
. O

A O
single B
G I
greater I
than I
A I
transition I
converts I
a I
tryptophan I
( I
TGG I
) I
codon I
to I
an I
opal I
( I
TGA I
) I
terminator I
, O
thus O
deleting B
the I
carboxy I
- I
terminal I
20 I
amino I
acids I
of O
an O
actin O
isoform O
that O
accumulates O
only O
in O
thoracic O
flight O
muscles O
. O

To O
assess O
a O
role O
of O
each O
of O
these O
residues O
, O
we O
have O
expressed O
, O
purified O
, O
and O
characterized O
enzymes O
with O
the O
point B
mutations I
of O
putative O
active O
site O
residues O
( O
His O
311 O
, O
Asn O
312 O
, O
Glu O
341 O
, O
Asp O
343 O
, O
His O
356 O
, O
Glu O
390 O
, O
Lys O
438 O
, O
Lys O
440 O
, O
Ser O
522 O
, O
Arg O
549 O
, O
and O
Tyr O
551 O
) O
and O
residues O
from O
the O
hydrophobic O
ridge O
( O
Leu O
320 O
, O
Phe O
360 O
, O
and O
Trp O
555 O
) O
. O

The O
replacements B
of I
most I
active I
site I
residues I
by I
alanine I
resulted O
in O
a O
great O
reduction O
( O
1 O
, O
000 O
- O
200 O
, O
000 O
- O
fold O
) O
of O
PLC O
activity O
analyzed O
in O
an O
inositol O
lipid O
/ O
sodium O
cholate O
mixed O
micelle O
assay O
. O

Measurements O
of O
the O
enzyme O
activity O
toward O
phosphatidylinositol O
, O
phosphatidylinositol O
4 O
- O
monophosphate O
, O
and O
phosphatidylinositol O
4 O
, O
5 O
- O
bis O
- O
phosphate O
( O
PIP O
2 O
) O
identified O
Ser O
522 O
, O
Lys O
438 O
, O
and O
Arg O
549 O
as O
important O
for O
preferential O
hydrolysis O
of O
polyphosphoinositides O
, O
whereas O
replacement B
of I
Lys I
440 I
selectively O
affected O
only O
hydrolysis O
of O
PIP O
2 O
. O

When O
PLC O
activity O
was O
analyzed O
at O
different O
calcium O
concentrations O
, O
substitutions B
of I
Asn I
312 I
, I
Glu I
390 I
, I
Glu I
341 I
, I
and I
Asp I
343 I
resulted O
in O
a O
shift O
toward O
higher O
calcium O
concentrations O
required O
for O
PIP O
2 O
hydrolysis O
, O
suggesting O
that O
all O
these O
residues O
contribute O
toward O
Ca O
2 O
+ O
binding O
. O

Functional O
role O
of O
a O
conserved O
motif O
in O
TM O
6 O
of O
the O
rat O
mu O
opioid O
receptor O
: O
constitutively O
active O
and O
inactive O
receptors O
result O
from O
substitutions B
of I
Thr I
6 I
. I
34 I
( I
279 I
) I
with I
Lys I
and I
Asp I
. O

In O
this O
study O
, O
T B
6 I
. I
34 I
( I
279 I
) I
at I
the I
X I
3 I
locus I
of I
the I
rat I
mu I
opioid I
receptor I
was I
mutated I
to I
Lys I
and I
Asp I
, O
and O
the O
mutants O
were O
examined O
for O
binding O
and O
signaling O
properties O
. O

The O
interaction O
of O
T O
6 O
. O
34 O
( O
279 O
) O
with O
R O
3 O
. O
50 O
( O
165 O
) O
in O
the O
mu O
opioid O
receptor O
is O
considered O
to O
stabilize O
the O
inactive O
conformations O
. O

( O
b O
) O
LIG O
3 O
: O
DNA O
ligase O
3 O
is O
thought O
to O
function O
in O
mitochondrial O
base O
excision O
repair O
( O
43 O
) O
and O
interacts O
with O
POLG O
. O

In O
P O
22 O
we O
identified O
a O
novel O
heterozygous O
nonsense O
mutation O
p O
. O
Q O
172 O
X O
in O
exon O
5 O
( O
c O
. O
533 O
C O
> O
T O
) O
causing O
a O
termination B
( I
CAA I
- I
TAA I
) I
at I
peptide I
position I
172 I
likely O
leading O
to O
a O
truncated O
product O
and O
nonsense O
- O
mediated O
m O
RNA O
decay O
. O

Haplotype O
insufficiency O
was O
proposed O
as O
a O
disease O
cause O
in O
mt O
DNA O
maintenance O
disorders O
[ O
POLG O
2 O
( O
44 O
) O
] O
but O
we O
did O
not O
find O
support O
for O
such O
mechanism O
for O
TOP O
1 O
MT O
homologues O
in O
other O
organisms O
such O
as O
yeast O
( O
45 O
) O
. O

Disease O
onset O
occurred O
at O
26 O
months O
of O
age O
with O
predominantly O
cutaneous O
( O
urticarial O
rash O
) O
and O
neurologic O
( O
headache O
, O
chronic O
meningitis O
) O
symptoms O
including O
early O
bilateral O
optic O
nerve O
atrophy O
, O
whereas O
articular O
manifestations O
were O
mild O
. O

A O
T O
515 O
C O
transition O
led O
to O
the O
replacement B
of I
isoleucine I
by I
threonine I
at I
amino I
acid I
position I
172 I
( O
I O
172 O
T O
) O
in O
a O
region O
of O
cryopyrin O
flanking O
the O
PYRIN O
and O
NACHT O
domains O
. O

Here O
, O
we O
demonstrate O
that O
the O
mf O
locus O
maps O
to O
the O
distal O
end O
of O
rat O
chromosome O
14 O
, O
a O
region O
syntenic O
to O
human O
2 O
p O
13 O
- O
p O
16 O
and O
proximal O
mouse O
11 O
. O

This O
change O
resulted O
in O
the O
substitution B
of I
a I
highly I
conserved I
cysteine I
for I
tyrosine I
at I
amino I
acid I
450 I
. O

Point O
mutations O
in O
awd O
Kpn O
which O
revert O
the O
prune O
/ O
Killer B
of I
prune I
lethal O
interaction O
affect O
conserved O
residues O
that O
are O
involved O
in O
nucleoside O
diphosphate O
kinase O
substrate O
binding O
and O
catalysis O
. O

Killer B
of I
prune I
( O
Kpn O
) O
is O
a O
mutation O
in O
the O
awd O
gene O
which O
substitutes O
Ser B
for I
Pro I
at I
position I
97 I
and O
causes O
dominant O
lethality O
in O
individuals O
that O
do O
not O
have O
a O
functional O
prune O
gene O
. O

In O
order O
to O
understand O
why O
the O
prune O
/ O
Killer B
of I
prune I
combination O
is O
lethal O
, O
even O
in O
the O
presence O
of O
an O
adequate O
NDP O
kinase O
specific O
activity O
level O
, O
and O
to O
understand O
the O
biochemical O
basis O
for O
the O
conditional O
lethality O
of O
the O
awd O
Kpn O
mutation O
, O
we O
generated O
second O
site O
mutations O
which O
revert O
this O
lethal O
interaction O
. O

Three O
revertants O
have O
deletions O
of O
the O
awd O
Kpn O
protein O
coding O
region O
. O

Deletion B
of O
the O
XRN O
1 O
gene O
causes O
pleiotropic O
phenotypes O
, O
which O
have O
been O
interpreted O
as O
indirect O
consequences O
of O
the O
RNA O
turnover O
defect O
. O

The O
significance O
of O
motif O
II O
has O
been O
confirmed O
by O
mutant O
analysis O
with O
Xrn O
1 O
p O
. O

The O
lev O
- O
11 O
( O
x O
12 O
) O
mutation O
, O
isolated O
as O
an O
allele O
of O
levamisole O
resistance O
, O
occurred O
in O
exon O
7 O
and O
results O
in O
amino O
acid O
substitution B
at I
234 I
from I
Glu I
to I
Lys I
. O

Mutation O
site O
of O
pat O
- O
10 O
( O
st O
575 O
) O
was O
Asp B
64 I
to I
Asn I
and O
Trp B
153 I
to I
termination I
in O
the O
troponin O
C O
. O
The O
first O
mutation O
site O
was O
in O
the O
second O
calcium O
binding O
site O
and O
the O
second O
mutation O
raised O
the O
deletion B
of I
H I
helix I
in O
the O
troponin O
C O
. O
Both O
might O
affect O
the O
calcium O
binding O
or O
the O
retaining O
of O
the O
conformation O
for O
its O
function O
. O

Results O
presented O
here O
will O
be O
useful O
to O
understand O
the O
interaction O
site O
between O
the O
tropomyosin O
and O
troponin O
complex O
. O

Mutations O
in O
GPR O
143 O
were O
identified O
in O
each O
of O
the O
six O
families O
: O
c O
. O
849 O
del O
T O
( O
p O
. O
Val O
284 O
Ser O
fs O
X O
15 O
) O
; O
c O
. O
238 O
_ O
240 O
del O
CTC O
( O
p O
. O
Leu O
80 O
del O
) O
; O
c O
. O
658 O
+ O
1 O
G O
> O
A O
, O
c O
. O
353 O
G O
> O
A O
( O
p O
. O
Gly O
118 O
Glu O
) O
; O
g O
. O
1103 O
_ O
7266 O
del O
6164 O
( O
p O
. O
Gly O
84 O
Ala O
fs O
X O
65 O
) O
, O
which O
resulted O
in O
a O
deletion O
of O
exons O
2 O
and O
3 O
; O
and O
g O
. O
25985 O
_ O
26546 O
del O
562 O
( O
p O
. O
Gly O
296 O
Val O
fs O
X O
26 O
) O
, O
which O
resulted O
in O
a O
deletion B
of I
exon I
8 I
. I

The O
c O
. O
238 O
_ O
240 O
del O
CTC O
mutation O
resulted O
in O
a O
leucine O
deletion O
in O
the O
80 O
th O
amino O
acid O
position O
, O
and O
the O
c O
. O
353 O
G O
> O
A O
mutation O
resulted O
in O
a O
replacement O
of O
glutamic B
acid I
with I
glycine I
in I
the I
118 I
th I
amino I
acid I
positions O
. O

Bassi O
et O
al O
. O

The O
c O
. O
353 O
G O
> O
A O
( O
p O
. O
Gly O
118 O
Glu O
) O
mutation O
, O
resulting O
in O
the O
replacement O
of O
glutamic B
acid I
with I
glycine I
at I
the I
118 I
th I
amino I
acid I
position O
, O
has O
been O
identified O
in O
Caucasian O
populations O
[ O
3 O
] O
and O
patients O
from O
the O
Netherlands O
[ O
23 O
] O
. O

Recent O
studies O
have O
implicated O
mutations O
in O
the O
ATP O
- O
binding O
cassette O
transporter O
A O
1 O
, O
ABCA O
1 O
, O
as O
a O
cause O
of O
Tangier O
disease O
( O
TD O
) O
and O
familial O
hypoalphalipoproteinemia O
( O
FHA O
) O
. O

The O
second O
mutation O
was O
a O
single B
- I
nucleotide I
deletion I
of I
thymidine I
in I
a I
polypyrimidine I
tract I
located I
33 I
to I
46 I
bps I
upstream I
to I
the I
start I
of I
exon I
47 I
. O

D O
3 O
. O
49 O
( O
164 O
) O
in O
the O
highly O
conserved O
DRY B
motif I
was I
mutated I
to I
13 I
amino I
acids I
. O

D B
3 I
. I
49 I
( I
164 I
) I
H I
, I
- I
Q I
, I
- I
Y I
, I
- I
M I
, I
and I
- I
E I
mutants O
were O
further O
studied O
. O

D B
3 I
. I
32 I
( I
147 I
) I
was I
substituted I
with I
A I
or I
N I
. O
All O
seven O
mutants O
exhibited O
similar O
binding O
affinities O
for O
the O
antagonist O
[ O
( O
3 O
) O
H O
] O
diprenorphine O
as O
the O
wild O
- O
type O
. O

The O
D B
3 I
. I
49 I
( I
164 I
) I
H I
, I
- I
Q I
, I
- I
Y I
, I
and I
- I
M I
mutants O
, O
but O
not O
the O
D O
3 O
. O
49 O
( O
164 O
) O
E O
and O
D O
3 O
. O
32 O
( O
147 O
) O
mutants O
, O
exhibited O
enhanced O
basal O
[ O
( O
35 O
) O
S O
] O
GTPgamma O
S O
binding O
which O
was O
comparable O
to O
the O
maximally O
activated O
level O
of O
the O
wild O
- O
type O
and O
was O
related O
to O
expression O
levels O
. O

Treatment O
of O
the O
D O
3 O
. O
49 O
( O
164 O
) O
Y O
mutant O
with O
pertussis O
toxin O
greatly O
reduced O
the O
basal O
[ O
( O
35 O
) O
S O
] O
GTPgamma O
S O
binding O
, O
demonstrating O
constitutive O
activation O
of O
Galpha O
( O
i O
) O
/ O
Galpha O
( O
o O
) O
. O

The O
D B
3 I
. I
49 I
( I
164 I
) I
H I
, I
- I
Y I
, I
- I
M I
, I
and I
- I
Q I
mutants O
had O
higher O
affinities O
for O
DAMGO O
than O
the O
wild O
- O
type O
, O
which O
were O
not O
significantly O
lowered O
by O
GTPgamma O
S O
. O

Thus O
, O
mutation O
of O
D B
3 I
. I
49 I
( I
164 I
) I
to I
H I
, I
Y I
, I
M I
, I
or I
Q I
in O
RMOR O
resulted O
in O
receptor O
assuming O
activated O
conformations O
. O

There O
are O
exceptionally O
wide O
inter O
- O
and O
intraspecies O
differences O
in O
sensitivity O
to O
TCDD O
toxicity O
with O
Han O
/ O
Wistar O
( O
H O
/ O
W O
) O
( O
Kuopio O
) O
rats O
being O
the O
most O
resistant O
mammals O
tested O
. O

In O
the O
present O
study O
, O
molecular O
cloning O
and O
sequencing O
of O
the O
H O
/ O
W O
rat O
Ah O
R O
revealed O
that O
the O
reason O
for O
its O
smaller O
size O
is O
a O
deletion B
/ I
insertion I
- I
type I
change I
at I
the I
3 I
' I
end I
of I
exon I
10 I
in O
the O
receptor O
c O
DNA O
. O

This O
change O
emanates O
from O
a O
single B
point I
mutation I
at I
the I
first I
nucleotide I
of I
intron I
10 I
, O
resulting O
in O
altered O
m O
RNA O
splicing O
. O

At O
the O
protein O
level O
, O
the O
mutation O
leads O
to O
a O
total B
loss I
of I
either I
43 I
or I
38 I
amino I
acids I
( O
with O
altered O
sequence O
for O
the O
last O
seven O
amino O
acids O
in O
the O
latter O
case O
) O
toward O
the O
carboxyl O
- O
terminal O
end O
in O
the O
trans O
- O
activation O
domain O
of O
the O
Ah O
R O
. O

H O
/ O
W O
rats O
also O
harbor O
a O
point B
mutation I
in I
exon I
10 I
that O
will O
cause O
a O
Val B
- I
to I
- I
Ala I
substitution I
in I
codon I
497 I
, O
but O
this O
occurs O
in O
a O
variable O
region O
of O
the O
Ah O
R O
. O

In O
particular O
, O
D O
801 O
N O
, O
one O
of O
the O
ATP O
1 O
A O
3 O
mutations O
identified O
in O
the O
present O
study O
, O
affected O
D O
801 O
, O
where O
D O
801 O
Y O
had O
been O
found O
in O
RDP O
. O

The O
position B
42474557 I
of I
chromosome I
19 I
, I
where I
the I
G I
to I
A I
transversion I
resulted O
in O
D O
801 O
N O
identified O
by O
our O
exome O
sequencing O
, O
had O
been O
registered O
as O
the O
nucleotide O
where O
the O
G O
to O
T O
transition O
is O
identified O
in O
rapid O
- O
onset O
dystonia O
- O
parkinsonism O
. O

( O
F O
) O
Aprataxin O
FHA O
GST O
pull O
downs O
from O
He O
La O
cells O
expressing O
wild O
- O
type O
GFP O
- O
MDC O
1 O
, O
a O
mutant O
containing O
a O
deletion B
of I
the I
SDTD I
region I
( O
Δ O
SDTD O
) O
, O
and O
a O
mutant O
where O
the O
Thr B
residues I
contained I
in I
the I
SDTD I
sequence I
were I
replaced I
by I
Ala I
( O
SDAD O
) O
2 O
. O

( O
A O
) O
Substitution B
of I
Arg I
29 I
and O
Lys B
38 I
to I
Ala I
abrogated O
the O
interaction O
between O
aprataxin O
and O
MDC O
1 O
as O
determined O
by O
pull O
- O
down O
assays O
as O
described O
earlier O
. O

We O
report O
the O
detection O
of O
a O
homozygous O
G O
to O
A O
mutation O
converting O
codon O
Gly B
15 I
into I
Asp I
15 I
in O
the O
type O
II O
3 O
beta O
- O
hydroxysteroid O
dehydrogenase O
/ O
delta O
5 O
- O
delta O
4 O
- O
isomerase O
( O
3 O
beta O
- O
HSD O
) O
gene O
in O
a O
male O
pseudo O
- O
hermaphrodite O
born O
from O
consanguineous O
parents O
and O
suffering O
from O
severe O
salt O
- O
losing O
3 O
beta O
- O
HSD O
deficiency O
. O

To O
investigate O
further O
the O
potential O
involvement O
of O
residue O
15 O
in O
the O
beta O
alpha O
beta O
dinucleotide O
- O
binding O
fold O
, O
we O
have O
studied O
the O
effect O
of O
substituting O
Gly B
15 I
for I
Ala I
15 I
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Mutation O
analysis O
of O
ESRRB O
, O
a O
candidate O
gene O
in O
the O
overlapping O
region O
, O
revealed O
a O
homozygous B
7 I
bp I
duplication I
in I
exon I
8 I
in O
all O
affected O
individuals O
. O

This O
duplication O
results O
in O
a O
frame O
shift O
and O
premature O
stop O
codon O
. O

Vif O
forms O
a O
complex O
with O
APOBEC O
3 O
G O
and O
enhances O
APOBEC O
3 O
G O
ubiquitination O
, O
resulting O
in O
reduced O
steady O
- O
state O
APOBEC O
3 O
G O
levels O
and O
a O
decrease O
in O
protein O
half O
- O
life O
. O

A O
mutation B
of I
highly I
conserved I
cysteines I
or O
the O
deletion B
of I
a I
conserved I
SLQ I
( I
Y I
/ I
F I
) I
LA I
motif O
in O
Vif O
results O
in O
mutants O
that O
fail O
to O
induce O
APOBEC O
3 O
G O
degradation O
and O
produce O
non O
- O
infectious O
HIV O
- O
1 O
; O
however O
, O
mutations B
of I
conserved I
phosphorylation I
sites I
in O
Vif O
that O
impair O
viral O
replication O
do O
not O
affect O
APOBEC O
3 O
G O
degradation O
, O
suggesting O
that O
Vif O
is O
important O
for O
other O
functions O
in O
addition O
to O
inducing O
proteasomal O
degradation O
of O
APOBEC O
3 O
G O
. O

( O
C O
) O
The O
short O
fragments O
( O
* O
) O
represent O
the O
previously O
described O
ε B
IVS I
11 I
+ I
10 I
del I
20 I
polymorphism I
in I
intron I
11 I
of O
the O
ε O
subunit O
gene O
, O
which O
has O
an O
allelic O
frequency O
of O
22 O
/ O
248 O
. O

In O
FZD O
7 O
, O
we O
observed O
two O
synonymous O
variants O
, O
L O
23 O
L O
and O
L O
26 O
L O
, O
which O
are O
both O
in O
close O
proximity O
to O
a O
common O
SNP B
in I
codon I
24 I
that O
results O
in O
a O
conservative O
shift O
from O
glycine O
to O
arginine O
. O

Our O
data O
suggest O
a O
regulatory O
mechanism O
mediated O
by O
AIRE O
– O
PHD O
1 O
that O
differs O
from O
that O
of O
ING O
2 O
and O
BTPF O
, O
the O
PHD O
fingers O
of O
which O
bind O
to O
H O
3 O
K O
4 O
me O
3 O
and O
discriminate O
against O
H O
3 O
K O
4 O
me O
0 O
. O

Instead O
, O
the O
crucial O
elements O
of O
the O
methylated O
lysine O
- O
binding O
aromatic O
cage O
seen O
in O
ING O
2 O
and O
BPTF O
( O
supplementary O
Fig O
S O
6 O
online O
) O
are O
substituted B
by I
negatively I
charged I
( I
D I
297 I
) I
and O
small O
hydrophobic O
( O
A O
317 O
) O
residues O
in O
AIRE O
– O
PHD O
1 O
. O

Germline B
mutations I
in O
BHD O
are O
associated O
with O
the O
susceptibility O
for O
BHDS O
. O

DNA O
sequencing O
of O
PLC O
- O
delta O
c O
DNA O
cloned O
from O
an O
aortic O
c O
DNA O
library O
of O
SHR O
revealed O
a O
total O
of O
three O
SHR O
- O
specific O
point O
mutations O
, O
two O
of O
which O
resulted O
in O
amino O
acid O
substitutions O
. O

The O
first O
point O
mutation O
( O
A B
to I
T I
) I
was I
detected I
at I
the I
Xho I
I I
site I
, O
changing O
a O
threonine O
( O
ACG O
) O
to O
a O
serine O
( O
TCG O
) O
, O
and O
the O
second O
point B
mutation I
( I
A I
to I
G I
) I
was O
discovered O
in O
the O
vicinity O
of O
the O
first O
one O
, O
changing O
an O
isoleucine O
( O
ATA O
) O
to O
a O
methionine O
( O
ATG O
) O
. O

Underlying O
mutations O
in O
the O
DEB O
phenotype O
have O
been O
detected O
in O
the O
gene O
encoding O
type O
VII O
collagen O
( O
COL O
7 O
A O
1 O
) O
, O
both O
in O
the O
dominant O
and O
recessive O
forms O
of O
DEB O
. O

Direct O
sequencing O
of O
the O
PCR O
fragment O
containing O
exon O
3 O
revealed O
a O
previously O
reported O
A B
- I
to I
- I
G I
transition I
in I
the I
5 I
' I
donor I
splice I
site I
of I
exon I
3 I
in O
the O
proband O
and O
in O
the O
clinically O
unaffected O
father O
, O
while O
direct O
sequencing O
of O
the O
PCR O
fragment O
containing O
exon O
53 O
revealed O
a O
novel O
glycine O
substitution O
G O
1652 O
R O
in O
the O
proband O
and O
in O
the O
clinically O
unaffected O
mother O
. O

These O
studies O
revealed O
three O
heterozygous B
overlapping I
deletions I
solely I
affecting I
the I
forkhead I
box I
P I
1 I
( O
FOXP O
1 O
) O
gene O
. O

All O
three O
patients O
had O
moderate O
mental O
retardation O
and O
significant O
language O
and O
speech O
deficits O
. O

Since O
our O
results O
are O
consistent O
with O
a O
de O
novo O
occurrence O
of O
these O
deletions O
, O
we O
considered O
them O
as O
causal O
although O
we O
detected O
a O
single B
large I
deletion I
including O
FOXP O
1 O
and O
additional O
genes O
in O
4104 O
ancestrally O
matched O
controls O
. O

Copy O
number O
analysis O
revealed O
overlapping O
deletions B
at I
chromosome I
3 I
p I
14 I
. I
1 I
affecting O
solely O
the O
FOXP O
1 O
gene O
in O
three O
unrelated O
cases O
, O
two O
males O
and O
one O
female O
aged O
between O
5 O
. O
5 O
to O
7 O
years O
. O

We O
found O
that O
the O
deleted O
alleles O
were O
of O
paternal O
origin O
in O
all O
three O
patients O
. O

( O
A O
) O
Schematic O
presentation O
of O
the O
position O
and O
size O
of O
the O
deleted B
regions I
( I
grey I
bars I
) I
at I
chromosome I
3 I
p I
14 I
. I
1 I
in O
three O
patients O
with O
MR O
and O
in O
a O
control O
individual O
. O

Table O
S O
1 O
) O
. O

Copy O
number O
analysis O
in O
the O
4104 O
control O
individuals O
revealed O
the O
presence O
of O
a O
single B
large I
3 I
p I
14 I
. I
1 I
p I
13 I
deletion I
of O
approximately O
1 O
. O
3 O
Mb O
affecting O
FOXP O
1 O
, O
EIF O
4 O
E O
3 O
( O
MIM O
# O
609896 O
) O
, O
PROK O
2 O
( O
MIM O
# O
607002 O
) O
and O
GPR O
27 O
( O
MIM O
# O
605187 O
) O
in O
an O
individual O
of O
the O
LLI O
study O
, O
with O
no O
indications O
of O
a O
comparable O
MR O
phenotype O
. O

This O
is O
the O
first O
report O
of O
3 B
p I
14 I
. I
1 I
deletions I
that O
solely O
affect O
the O
FOXP O
1 O
gene O
in O
three O
unrelated O
patients O
with O
moderate O
mental O
retardation O
in O
combination O
with O
a O
significant O
impairment O
of O
speech O
and O
language O
abilities O
. O

We O
investigated O
a O
large O
control O
population O
and O
the O
apparent O
finding O
of O
a O
large O
3 B
p I
14 I
. I
1 I
p I
13 I
deletion I
in O
this O
cohort O
affecting O
FOXP O
1 O
and O
further O
genes O
illustrates O
the O
difficulties O
to O
assess O
the O
significance O
of O
rare O
mutational O
events O
in O
extremely O
heterogeneous O
diseases O
and O
may O
point O
to O
incomplete O
penetrance O
. O

As O
our O
patients O
did O
not O
show O
any O
of O
the O
other O
clinical O
signs O
like O
contractures O
, O
hypertonia O
and O
blepharophimosis O
, O
present O
in O
the O
boy O
carrying O
the O
larger O
3 B
p I
14 I
. I
1 I
p I
13 I
deletion I
( O
Pariani O
, O
et O
al O
. O
, O
2009 O
) O
, O
these O
might O
rather O
be O
caused O
by O
the O
haploinsufficiency O
of O
the O
additionally O
affected O
genes O
. O

A O
similar O
phenotype O
, O
including O
a O
3 O
- O
fold O
increase O
in O
the O
half O
- O
time O
of O
secretion O
, O
disruption O
of O
the O
disulfide O
bonding O
arrangement O
, O
and O
inefficient O
complement O
fixation O
, O
is O
observed O
when O
nearby O
glucosylgalactosyl B
hydroxylysine I
residues I
at I
positions I
27 I
and I
30 I
are I
replaced I
with I
arginine I
residues O
. O

Deletion B
of I
the I
Ser I
- I
Arg I
- I
lle I
- I
Gly I
residues I
( I
amino I
acids I
79 I
- I
82 I
; I
SRIG I
) I
had O
no O
effect O
on O
the O
Vpr O
localization O
. O

However O
, O
deletion B
of I
the I
Arg I
- I
Gln I
- I
Arg I
- I
Arg I
residues I
( I
amino I
acids I
85 I
- I
88 I
; I
RQRR I
) I
resulted O
in O
a O
smooth O
perinuclear O
staining O
pattern O
. O

Substitution O
of O
five O
Arg O
residues O
with O
Asn O
( O
amino B
acids I
80 I
, I
85 I
, I
87 I
, I
88 I
, I
and I
90 I
; I
R I
- I
- I
> I
N I
5 I
) O
resulted O
in O
a O
diffuse O
cytoplasmic O
staining O
. O

Subcellular O
fractionation O
analyses O
support O
the O
immunofluorescence O
staining O
results O
. O

Both O
SRIG O
and O
R O
- O
- O
> O
N O
5 O
mutants O
lost O
their O
cell O
cycle O
arrest O
activities O
and O
the O
RQRR B
deletion I
only O
exhibited O
a O
low O
level O
of O
cell O
arrest O
activity O
. O

( O
b O
and O
c O
) O
Suv O
39 O
h O
1 O
- O
WT O
but O
not O
a O
catalytically O
inactive O
mutant O
Suv O
39 O
h O
1 O
- O
H O
324 O
L O
restores O
the O
PCH O
localization O
of O
Atrx O
in O
DKO O
cells O
. O

( O
f O
) O
Deletion B
of I
Px I
Vx I
L I
motif I
resulted O
in O
partial O
loss O
of O
PCH O
localization O
. O

Three O
zinc O
ions O
and O
water O
molecules O
are O
depicted O
as O
large O
blue O
and O
small O
red O
spheres O
, O
respectively O
. O

R O
2 O
A O
, O
K O
4 O
A O
, O
K O
9 O
A O
: O
Arg O
2 O
, O
Lys O
4 O
, O
Lys B
9 I
to I
alanine I
substitution I
, O
respectively O
; O
AAH O
3 O
: O
H O
3 O
N O
- O
terminal O
double O
alanine O
extension O
; O
R O
2 O
me O
2 O
s O
: O
Arg O
2 O
symmetrical O
dimethylation O
; O
R O
2 O
me O
2 O
a O
: O
Arg O
2 O
asymmetrical O
dimethylation O
; O
K O
9 O
me O
3 O
: O
Lys O
9 O
trimethylation O
; O
K O
9 O
ac O
: O
Lys O
9 O
acetylation O
; O
n O
. O
d O
. O
, O
not O
determined O
. O

We O
have O
thus O
directly O
sequenced O
DNA O
fragments O
generated O
by O
PCR O
amplification O
of O
the O
four O
exons O
, O
exon O
- O
intron O
boundaries O
, O
and O
the O
5 O
' O
- O
flanking O
regions O
of O
the O
HSD O
3 O
B O
2 O
gene O
. O

Sequencing O
of O
exon O
II O
revealed O
the O
presence O
of O
a O
C B
to I
A I
transversion I
in I
both I
alleles I
of I
these I
two I
cases I
, O
thus O
converting B
codon I
10 I
( I
GCA I
) I
, I
which I
codes I
for I
Ala I
, I
into I
GAA I
, I
encoding I
Glu I
. O

Changes O
of O
residue B
401 I
to I
either I
leucine I
or I
alanine I
( I
but I
not I
phenylalanine I
) I
and O
residue B
414 I
to I
leucine I
resulted O
in O
major O
reductions O
in O
beta O
- O
galactosidase O
activity O
produced O
from O
the O
reporter O
gene O
as O
compared O
to O
yeast O
expressing O
wild O
- O
type O
p O
66 O
bait O
and O
p O
51 O
prey O
fusions O
. O

Examination O
of O
the O
RT O
structures O
revealed O
that O
K O
331 O
in O
p O
51 O
makes O
multiple O
hydrogen O
bond O
contacts O
with O
residues O
in O
the O
p O
66 O
loop O
spanned O
by O
W O
401 O
and O
W O
414 O
. O

We O
conclude O
that O
mutations B
at I
codons I
401 I
and I
414 I
in O
p O
66 O
impair O
dimerization O
by O
altering O
the O
proper O
positioning O
of O
structural O
elements O
in O
between O
these O
residues O
that O
make O
important O
contacts O
with O
p O
51 O
. O

The O
mutations B
on I
positions I
256 I
and I
267 I
strongly O
altered O
the O
interaction O
of O
the O
permeation O
pathway O
with O
external O
Ca O
2 O
+ O
ions O
. O

Point B
mutations I
on I
position I
256 I
in O
KAT O
1 O
affected O
the O
affinity O
towards O
Ca O
2 O
+ O
, O
the O
voltage O
dependence O
as O
well O
as O
kinetics O
of O
the O
Ca O
2 O
+ O
blocking O
reaction O
. O

Mutating O
histidine B
267 I
to I
alanine I
, O
a O
substitution O
strongly O
affecting O
C O
- O
type O
inactivation O
in O
Shaker O
, O
this O
apparent O
inactivation O
could O
be O
linked O
to O
a O
very O
slow O
calcium O
block O
. O

The O
mutation O
H O
267 O
A O
did O
not O
affect O
gating O
but O
hastened O
the O
Ca O
2 O
+ O
block O
/ O
unblock O
kinetics O
and O
increased O
the O
Ca O
2 O
+ O
affinity O
of O
KAT O
1 O
. O

Sequence O
comparison O
with O
a O
prototypical O
type O
I O
PDZ O
domain O
predicts O
that O
PDZ O
2 O
is O
the O
best O
candidate O
among O
the O
five O
PDZ O
domains O
to O
recognize O
eye O
- O
PKC O
that O
contains O
a O
type O
I O
PDZ O
ligand O
, O
Ile O
- O
Thr O
- O
Ile O
- O
Ile O
, O
at O
its O
carboxyl O
terminus O
. O

Replacement B
of I
Ile I
( I
- I
3 I
) I
in I
eye I
- I
PKC I
with I
charged I
residues I
resulted O
in O
a O
drastic O
reduction O
of O
the O
PDZ O
2 O
interaction O
. O

Substitution O
of O
a O
conserved O
His B
with I
Arg I
at I
the I
second I
alpha I
- I
helix I
of I
PDZ I
2 I
led O
to O
a O
reduced O
binding O
; O
however O
, O
a O
Leu B
replacement I
resulted O
in O
an O
enhanced O
eye O
- O
PKC O
association O
. O

Translation O
of O
coding O
sequences O
from O
three O
wild O
- O
type O
alleles O
revealed O
three B
SNPs I
affecting I
residues I
, I
282 I
, I
319 I
, I
and I
333 I
of O
INAD O
. O

To O
further O
define O
the O
sequence O
responsible O
for O
the O
nuclear O
targeting O
, O
the O
cells O
were O
transfected O
with O
ND O
20 O
APE O
1 O
- O
EGFP O
, O
deleting B
the I
N I
- I
terminal I
20 I
amino I
acid I
residues I
( O
Figure O
1 O
D O
and O
Table O
2 O
) O
. O

The O
intracellular O
distribution O
of O
ND O
20 O
APE O
1 O
was O
similar O
to O
that O
of O
ND O
41 O
APE O
1 O
or O
EGFP O
alone O
. O

The O
G O
→ O
A O
point O
mutation O
that O
results O
in O
the O
substitution B
of I
lysine I
for I
glutamic I
acid I
at I
amino I
acid I
17 I
was O
introduced O
using O
Quick O
- O
Change O
Site O
- O
Directed O
Mutagenesis O
( O
Stratagene O
, O
La O
Jolla O
, O
CA O
, O
USA O
) O
. O

Here O
we O
report O
on O
two O
causative O
mutations O
of O
the O
XPD O
gene O
in O
XP O
61 O
OS O
, O
a O
Japanese O
XP O
group O
D O
patient O
who O
has O
only O
mild O
skin O
symptoms O
of O
XP O
without O
CS O
, O
TTD O
, O
or O
other O
neurological O
complications O
. O

One O
of O
the O
mutations O
was O
the O
4 B
- I
bp I
deletion I
at I
nucleotides I
668 I
- I
671 I
, O
resulting O
in O
frameshift O
and O
truncation O
of O
the O
protein O
. O

The O
other O
was O
a O
nucleotide O
substitution O
leading O
to O
Ser B
- I
541 I
to I
Arg I
( O
S O
541 O
R O
) O
in O
helicase O
domain O
IV O
of O
the O
XPD O
protein O
. O

RT O
– O
PCR O
analysis O
for O
BRCA O
2 O
R O
2336 O
H O
in O
the O
last O
codon O
of O
exon O
13 O
was O
not O
yet O
described O
and O
revealed O
the O
wild O
- O
type O
allele O
and O
three O
smaller O
transcripts O
, O
representing O
a O
complete O
loss B
of I
exon I
13 I
, O
loss B
of I
exon I
12 I
and O
loss B
of I
exons I
12 I
and I
13 I
. O

RT O
– O
PCR O
on O
RNA O
from O
the O
patient O
carrying O
BRCA O
2 O
R O
2336 O
H O
( O
lane O
1 O
) O
showed O
a O
full O
- O
length O
fragment O
of O
767 O
bp O
and O
three O
faster O
migrating O
bands O
( O
697 B
bp I
: I
skipping I
of I
out I
of I
frame I
exon I
13 I
( I
stop I
2345 I
) I
; O
671 B
bp I
: I
skipping I
of I
in I
- I
frame I
exon I
12 I
( I
deletion I
of I
32 I
amino I
acids I
) I
; O
601 B
bp I
: I
skipping I
of I
out I
of I
frame I
exons I
12 I
and I
13 I
( I
stop I
2311 I
) I
) O
. O

BRCA O
1 O
5382 O
ins O
C O
, O
an O
Ashkenazi O
Jewish O
founder O
mutation O
and O
the O
most O
frequent O
mutation O
in O
many O
European O
populations O
, O
was O
identified O
in O
only O
one O
Belgian O
family O
. O

The O
deletion B
of I
BRCA I
1 I
exon I
22 I
, O
the O
most O
recurrent O
Dutch O
mutation O
, O
was O
identified O
in O
one O
Belgian O
patient O
with O
a O
Dutch O
mother O
. O

Consistent O
with O
this O
model O
, O
a O
truncated O
CDPK O
( O
Delta O
NC O
) O
in O
which O
the O
Ca B
M I
- I
LD I
has I
been I
deleted I
can O
be O
activated O
in O
a O
bimolecular O
interaction O
with O
an O
isolated O
Ca O
M O
- O
LD O
or O
calmodulin O
, O
similar O
to O
the O
activation O
of O
a O
calmodulin O
- O
dependent O
protein O
kinase O
( O
Ca O
MK O
) O
by O
calmodulin O
. O

Interestingly O
, O
intramolecular O
but O
not O
bimolecular O
activation O
was O
disrupted O
by O
insertion B
mutations I
placed I
immediately I
downstream I
of I
I I
444 I
. O

To O
show O
that O
mutant O
enzymes O
were O
not O
misfolded O
, O
latent O
kinase O
activity O
was O
stimulated O
through O
binding O
of O
an O
antijunction O
antibody O
. O

The O
RAF O
kinase O
family O
is O
essential O
in O
mediating O
signal O
transduction O
from O
RAS O
to O
ERK O
. O

Substitution O
of O
BRAF O
lysine B
578 I
with I
arginine I
( O
K O
578 O
R O
) O
inhibited O
BRAF O
- O
mediated O
ERK O
activation O
. O

Since O
substitution O
of O
constitutively O
active O
BRAF O
V O
600 O
E O
or O
K O
601 O
E O
mutant O
Lys B
578 I
with I
Arg I
abolishes O
its O
Lys O
63 O
- O
linked O
polyubiquitination O
and O
BRAF O
V O
600 O
E O
or O
K O
601 O
E O
- O
mediated O
ERK O
activation O
, O
we O
conclude O
that O
the O
Lys O
63 O
- O
linked O
polyubiquitination O
is O
essential O
in O
BRAF O
V O
600 O
E O
or O
K O
601 O
E O
mutant O
- O
mediated O
oncogenic O
signaling O
. O

Ubiquitin O
K O
63 O
R O
, O
K O
48 O
R O
and O
ubiquitin O
with O
all B
lysine I
to I
arginine I
mutation I
except I
Lys I
63 I
or I
Lys I
48 I
were O
sub O
- O
cloned O
into O
mammalian O
expression O
vector O
pc O
DNA O
3 O
. O
1 O
with O
HA O
- O
tag O
at O
their O
N O
- O
terminal O
and O
verified O
by O
DNA O
sequencing O
analysis O
. O

Direct O
DNA O
sequence O
analysis O
from O
all O
patients O
and O
obligate O
carriers O
reveals O
a O
c O
. O
812 O
G O
> O
T O
missense O
mutation O
in O
exon O
9 O
, O
which O
would O
result O
in O
a O
substitution B
of I
the I
cysteine I
residue I
at I
codon I
271 I
by I
a I
phenylalanine I
residue I
( O
C O
271 O
F O
, O
Figure O
2 O
A O
) O
. O

Sequence O
analysis O
revealed O
a O
c O
. O
70 O
G O
> O
T O
missense O
mutation O
in O
exon O
2 O
in O
all O
patients O
and O
obligate O
carriers O
, O
which O
would O
result O
in O
a O
substitution B
of I
the I
glycine I
residue I
at I
codon I
24 I
by I
a I
tryptophan I
residue I
( O
Figure O
2 O
D O
) O
. O

A O
direct O
sequence O
of O
all O
affected O
patients O
in O
families O
E O
and O
F O
revealed O
the O
same O
sequence O
change O
in O
exon O
9 O
, O
a O
c O
. O
782 O
G O
> O
A O
missense O
mutation O
, O
which O
would O
result O
in O
substitution B
of I
the I
arginine I
residue I
at I
codon I
260 I
by I
a I
glutamine I
residue I
( O
R O
260 O
Q O
, O
Figure O
2 O
E O
, O
F O
) O
. O

Sequence O
analysis O
of O
all O
patients O
and O
obligate O
carriers O
in O
family O
G O
revealed O
a O
c O
. O
910 O
C O
> O
T O
nonsense O
mutation O
in O
exon O
10 O
, O
which O
would O
result O
in O
substitution B
of I
the I
arginine I
residue I
at I
codon I
303 I
by I
a I
stop I
codon I
( O
R O
303 O
X O
, O
Figure O
2 O
G O
) O
. O

These O
genes O
encode O
enzymes O
that O
demethylate O
( O
UTX O
, O
JARID O
1 O
C O
) O
or O
methylate O
( O
SETD O
2 O
) O
key O
lysine O
residues O
of O
histone O
H O
3 O
. O

Modification B
of I
the I
methylation I
state I
of I
these I
lysine I
residues I
of I
histone I
H I
3 I
regulates O
chromatin O
structure O
and O
is O
implicated O
in O
transcriptional O
control O
3 O
. O

Although O
the O
first B
Glu I
in I
the I
common I
motif I
is I
replaced I
by I
Gln I
( I
Q I
207 I
EEVLIP O
) O
in O
rat O
T O
lymphocyte O
alloantigens O
RT O
6 O
. O
1 O
and O
RT O
6 O
. O
2 O
, O
the O
two O
RT O
6 O
s O
appear O
to O
have O
both O
activities O
of O
NAD O
+ O
glycohydrolase O
and O
ADP O
- O
ribosyltransferase O
to O
a O
lesser O
extent O
. O

To O
investigate O
the O
significance O
of O
the O
Glu O
- O
rich O
motif O
in O
the O
two O
enzyme O
activities O
, O
we O
produced O
a O
mutant O
RT O
6 O
. O
1 O
( O
Q O
207 O
E O
) O
, O
in O
which O
Gln B
207 I
was I
replaced I
by I
Glu I
, O
together O
with O
wild O
- O
type O
RT O
6 O
s O
, O
in O
Escherichia O
coli O
. O

Kinetic O
analysis O
revealed O
that O
there O
were O
no O
marked O
differences O
in O
the O
Vmax O
and O
Km O
values O
of O
NAD O
+ O
glycohydrolases O
among O
the O
three O
recombinant O
proteins O
. O

A O
mutation O
( O
Pro B
- I
30 I
to I
Leu I
) O
in O
CYP O
21 O
represents O
a O
potential O
nonclassic O
steroid O
21 O
- O
hydroxylase O
deficiency O
allele O
. O

We O
report O
the O
molecular O
analysis O
of O
four O
PMD O
patients O
in O
three O
unrelated O
families O
and O
describe O
a O
point O
mutation O
( O
G B
- I
- I
> I
A I
transition I
) I
in I
exon I
V I
which O
leads O
to O
the O
substitution B
of I
Gly I
216 I
by I
a I
serine I
residue O
in O
a O
highly O
conserved O
extracytosolic O
domain O
and O
a O
Mae O
I O
RFLP O
. O

Osteogenesis O
imperfecta O
( O
OI O
) O
is O
a O
genetic O
disorder O
of O
connective O
tissue O
characterized O
by O
bone O
fragility O
and O
alteration O
in O
synthesis O
and O
posttranslational B
modification I
of I
type I
I I
collagen I
. O

Recently O
, O
the O
molecular O
spectrum O
of O
OI O
has O
been O
expanded O
with O
the O
description O
of O
the O
basis O
of O
a O
unique O
posttranslational B
modification I
of I
type I
I I
procollagen I
, O
that O
is O
, O
3 O
- O
prolyl O
- O
hydroxylation O
. O

Here O
we O
describe O
five O
families O
with O
OI O
- O
like O
bone O
fragility O
in O
association O
with O
congenital O
contractures O
who O
all O
had O
FKBP O
10 O
mutations O
. O

Mutations B
in I
genes I
encoding I
type I
I I
procollagen I
or O
proteins O
responsible O
for O
posttranslational O
modifications O
of O
the O
type O
I O
collagen O
heterotrimer O
may O
result O
in O
the O
brittle O
bone O
disorder O
osteogenesis O
imperfecta O
( O
OI O
) O
. O

Classic O
OI O
, O
an O
autosomal O
dominant O
heritable O
disorder O
, O
has O
been O
linked O
to O
mutations O
in O
the O
COL O
1 O
A O
1 O
and O
COL O
1 O
A O
2 O
genes O
, O
which O
code O
for O
procollagen O
α O
components O
of O
the O
type O
I O
collagen O
heterotrimer O
[ O
α O
1 O
( O
I O
) O
2 O
and O
α O
2 O
( O
I O
) O
1 O
] O
. O

( O
1 O
– O
4 O
) O
Furthermore O
, O
mutations O
in O
all O
three O
proteins O
now O
have O
been O
shown O
to O
cause O
recessive O
forms O
of O
OI O
in O
part O
by O
leading O
to O
loss B
of I
hydroxylation I
at I
proline I
residue I
986 I
of I
the I
α I
1 I
( O
I O
) O
triple O
- O
helical O
domain O
and O
subsequent O
collagen O
overmodification O
. O

Figure O
depicts O
proteins O
involved O
in O
posttranslational B
modification I
of I
type I
I I
collagen I
and O
mutated O
in O
osteogenesis O
imperfecta O
( O
OI O
) O
or O
Bruck O
syndrome O
. O

These O
proteins O
modify B
collagen I
by I
3 I
- I
prolyl I
- I
hydroxylation I
and O
serve O
as O
endoplasmic O
reticulum O
chaperones O
, O
respectively O
. O

( O
18 O
) O
Loss O
of O
the O
FKBP O
10 O
/ O
SERPINH O
1 O
complex O
owing O
to O
deletion B
of O
the O
SERPINH O
1 O
gene O
was O
shown O
originally O
to O
cause O
recessive O
OI O
in O
a O
dachshund O
model O
. O

The O
child O
was O
found O
to O
have O
a O
homozygous B
missense I
mutation I
in O
the O
coding O
region O
of O
SERPINH O
1 O
. O

( O
5 O
) O

Finally O
, O
with O
the O
discovery O
of O
disease O
- O
causing O
FKBP O
10 O
and O
SERPINH O
1 O
mutations O
, O
defects B
in I
ER I
chaperone I
protein I
complexes I
have O
been O
noted O
to O
cause O
recessive O
OI O
. O

The O
first O
change O
( O
left O
) O
is O
a O
single B
- I
nucleotide I
base I
- I
pair I
duplication I
( O
c O
. O
831 O
dup O
) O
that O
results O
in O
a O
frameshift O
mutation O
. O

The O
second O
( O
right O
) O
is O
a O
single B
- I
nucleotide I
base I
pair I
duplication I
( O
c O
. O
1276 O
dup O
) O
that O
results O
in O
a O
frameshift O
mutation O
. O

The O
OI O
phenotype O
in O
all O
patients O
with O
FKBP O
10 O
mutations O
reported O
so O
far O
is O
milder O
than O
the O
severe O
- O
to O
- O
lethal O
recessive O
OI O
phenotypes O
caused O
by O
mutations B
in I
the I
genes I
of I
the I
prolyl I
- I
3 I
- I
hydroxylation I
complex I
( O
CRTAP O
, O
LEPRE O
1 O
, O
or O
PPIB O
) O
. O

4 O
a O
) O
. O

Additionally O
, O
family O
F O
51426 O
carried O
a O
heterozygous O
W O
150 O
R O
change O
shown O
to O
be O
functionally O
null O
in O
the O
in O
vivo O
zebrafish O
rescue O
assay O
, O
and O
a O
splice O
variant O
predicted O
to O
result O
in O
a O
54 B
- I
amino I
acid I
deletion I
( O
Fig O
. O

Changing O
the O
conserved O
residue O
His B
- I
16 I
either I
to I
Cys I
or I
to I
Val I
in O
a O
proposed O
zinc O
- O
finger O
region O
had O
minimal O
effect O
on O
IN O
activities O
. O

We O
conclude O
that O
not O
all O
highly O
conserved O
IN O
residues O
are O
essential O
for O
IN O
activities O
in O
vitro O
, O
zinc O
coordination O
by O
the O
proposed O
zinc O
- O
finger O
domain O
may O
not O
be O
required O
for O
the O
activities O
assayed O
, O
alteration O
of O
single O
residues O
can O
yield O
differential O
effects O
on O
IN O
activities O
, O
and O
target O
site O
selection O
into O
naked O
DNA O
is O
not O
necessarily O
altered O
by O
changes O
in O
strand O
transfer O
activity O
. O

We O
report O
that O
r O
Su O
( O
b O
) O
is O
a O
missense O
mutation O
resulting O
in O
a O
glutamate B
to I
lysine I
substitution I
within I
the I
second I
ATP I
binding I
site I
( I
i I
. I
e I
. I

When O
a O
transgene O
expressing O
the O
Glu B
- I
- I
> I
Lys I
substitution I
was O
introduced O
into O
Drosophila O
lines O
homozygous O
for O
the O
black O
mutation O
, O
the O
resulting O
flies O
exhibited O
the O
Su O
( O
b O
) O
phenotype O
. O

In O
the O
patient O
with O
a O
putative O
deletion B
of I
exons I
10 I
- I
16 I
we O
amplified O
the O
c O
DNA O
with O
primers O
that O
matched O
exons O
9 O
and O
17 O
, O
and O
confirmed O
the O
skipping O
of O
exons O
10 O
- O
16 O
( O
Figure O
2 O
D O
) O
. O

We O
found O
several O
polymorphisms O
in O
the O
two O
genes O
( O
Additional O
file O
1 O
, O
Table O
S O
3 O
) O
. O

However O
, O
the O
electrophoretic O
pattern O
of O
bands O
after O
double O
restriction O
enzyme O
digestion O
( O
Mnl O
I O
+ O
Mbo O
I O
) O
of O
the O
exon O
5 O
fragment O
indicated O
that O
the O
mutation O
was O
in O
cis B
with I
the I
c I
. I
844 I
A I
allele O
( O
data O
not O
shown O
) O
. O

In O
C O
57 O
BL O
/ O
10 O
Sc O
Cr O
mice O
the O
gene B
is I
deleted I
, O
yielding O
a O
recessive O
abolition O
of O
the O
LPS O
response O
. O

Deleterious B
mutations I
of O
TLR O
4 O
might O
reasonably O
be O
sought O
in O
individuals O
who O
have O
developed O
serious O
Gram O
- O
negative O
infections O
, O
on O
the O
premise O
that O
mice O
with O
deleterious O
mutations O
of O
Tlr O
4 O
are O
rendered O
susceptible O
to O
such O
infections O
. O

Beyond O
this O
, O
it O
may O
be O
assumed O
, O
given O
the O
powerful O
pro O
- O
inflammatory O
activity O
of O
the O
receptor O
, O
that O
germline O
or O
somatic B
mutations I
of O
TLR O
4 O
could O
in O
some O
instances O
cause O
constitutive O
signal O
transduction O
( O
as O
observed O
with O
the O
Drosophila O
Toll O
locus O
[ O
31 O
] O
) O
. O

The O
three O
principal O
exons O
of O
Tlr O
4 O
were O
amplified O
independently O
from O
mouse O
genomic O
DNA O
samples O
, O
leaving O
a O
margin O
of O
approximately O
50 O
bp O
to O
each O
side O
of O
the O
exons O
so O
as O
to O
indentify O
intronic B
mutations I
that O
might O
alter O
splicing O
. O

The O
CAPN O
5 O
gene O
harbors O
mutations B
in I
exon I
6 I
of O
ADNIV O
subjects O
. O

Both O
ADNIV O
mutations O
( O
red O
arrows O
) O
are O
located O
in O
exon O
6 O
, O
which O
encodes O
a O
portion O
of O
the O
catalytic O
domain O
and O
two O
of O
three O
catalytic O
residues O
( O
blue O
arrows O
) O
. O

Secondary O
structure O
modeling O
shows O
that O
the O
two B
mutations I
are I
within I
a I
putative I
alpha I
helical I
domain I
. O

In O
contrast O
, O
the O
disease O
- O
causing O
mutation O
at O
this O
codon O
introduces B
a I
new I
proline I
bend I
within I
a I
putative I
alpha I
helix I
. O

In O
both O
disorders O
, O
the O
non O
- O
mutant O
calpain O
molecules O
display O
functionally O
critical O
subcellular O
localization O
[ O
17 O
] O
, O
[ O
18 O
] O
, O
[ O
20 O
] O
, O
[ O
30 O
] O
. O

Capn O
5 O
knockout B
mice O
have O
no O
observable O
phenotype O
[ O
32 O
] O
, O
and O
several O
human O
neurological O
disorders O
have O
been O
associated O
with O
excess O
calpain O
activity O
[ O
17 O
] O
, O
[ O
33 O
] O
, O
including O
photoreceptor O
degeneration O
[ O
34 O
] O
. O

Further O
characterization O
of O
the O
mutants B
in I
position I
383 I
revealed O
that O
[ O
Y O
383 O
H O
] O
, O
[ O
Y O
383 O
F O
] O
, O
and O
[ O
Y O
383 O
Q O
] O
leukotriene O
A O
4 O
hydrolases O
catalyzed O
hydrolysis O
of O
leukotriene O
A O
4 O
into O
a O
novel O
enzymatic O
metabolite O
. O

The O
kinetic O
parameters O
for O
the O
formation O
of O
5 O
S O
, O
6 O
S O
- O
DHETE O
and O
leukotriene O
B O
4 O
were O
found O
to O
be O
similar O
. O

In O
one O
family O
, O
an O
in B
- I
frame I
3 I
nt I
deletion I
removes I
codon I
581 I
- I
( I
or I
582 I
) I
and O
, O
thereby O
, O
one O
of O
two O
phenylalanines O
that O
invariably O
occupy O
adjacent O
positions O
in O
the O
N O
- O
terminal O
alpha O
- O
helical O
region O
of O
the O
DBD O
in O
the O
steroid O
/ O
thyroid O
/ O
vitamin O
D O
receptor O
superfamily O
. O

In O
the O
second O
, O
an O
in B
- I
frame I
3 I
nt I
loss I
deletes I
Arg I
614 I
, O
an O
invariant O
residue O
in O
the O
C O
- O
terminal O
alpha O
- O
helix O
of O
the O
DBD O
. O

Following O
transient O
transfection O
of O
COS O
cells O
with O
each O
mutant O
AR O
plasmid O
, O
there O
is O
a O
normal O
concentration O
of O
specific O
androgen O
- O
binding O
activity O
that O
has O
a O
reduced O
ability O
to O
bind O
two O
types O
of O
androgen O
response O
element O
( O
ARE O
) O
, O
and O
to O
transregulate O
an O
androgen O
- O
responsive O
human O
growth O
hormone O
reporter O
gene O
. O

Most O
mutations O
complemented O
the O
growth O
phenotype O
of O
vma O
4 O
Delta O
mutants O
, O
including O
T O
6 O
A O
and O
D O
233 O
A O
, O
which O
only O
had O
25 O
% O
of O
the O
wild O
- O
type O
ATPase O
activity O
. O

These O
results O
indicated O
communication O
between O
subunit O
E O
and O
the O
catalytic O
sites O
at O
the O
A O
( O
3 O
) O
B O
( O
3 O
) O
hexamer O
and O
suggest O
potential O
regulatory O
roles O
for O
the O
carboxyl O
end O
of O
subunit O
E O
. O
At O
the O
carboxyl O
end O
, O
alanine B
substitution I
of I
Asp I
- I
233 I
significantly O
reduced O
ATP O
hydrolysis O
, O
although O
the O
truncation B
229 I
- I
233 I
Delta I
and O
the O
point O
mutation O
K O
230 O
A O
did O
not O
affect O
assembly O
and O
activity O
. O

Thus O
, O
in O
this O
study O
, O
we O
screened O
the O
entire O
coding O
region O
of O
FOXP O
1 O
( O
exons O
and O
flanking O
intronic O
sequence O
) O
for O
nucleotide O
changes O
in O
a O
panel O
of O
probands O
used O
earlier O
to O
detect O
novel O
mutations O
in O
FOXP O
2 O
. O

A O
non O
- O
synonymous O
coding O
change O
was O
identified O
in O
a O
single O
proband O
, O
yielding O
a O
proline B
- I
to I
- I
alanine I
change I
( O
P O
215 O
A O
) O
. O

We O
screened O
these O
exons O
and O
flanking O
intronic O
sequence O
in O
49 O
probands O
with O
clinically O
diagnosed O
DVD O
plus O
their O
siblings O
( O
59 O
individuals O
in O
total O
) O
. O

This O
change O
constituted O
a O
heterozygous B
C I
- I
to I
- I
G I
transversion I
, O
yielding O
a O
proline B
- I
to I
- I
alanine I
substitution I
at I
position I
215 I
of O
the O
encoded O
protein O
. O

The O
same O
heterozygous B
C I
- I
to I
- I
G I
change I
was O
identified O
in O
a O
single O
chromosome O
within O
the O
controls O
( O
Figure O
1 O
b O
) O
. O

A O
heterozygous B
C I
- I
to I
- I
A I
transversion I
in I
the I
intron I
downstream I
of I
exon I
15 I
( O
Figure O
1 O
, O
Table O
1 O
) O
was O
found O
in O
10 O
of O
the O
49 O
probands O
( O
an O
SNP O
frequency O
of O
∼ O
10 O
% O
) O
. O

A O
heterozygous O
FOXP O
1 O
coding O
change O
was O
identified O
in O
a O
proband O
with O
no O
affected O
siblings O
. O

The O
resulting O
substitution O
( O
P O
215 O
A O
) O
replaced B
a I
proline I
with I
an I
alanine I
in I
the I
region I
encoded I
by I
exon I
5 I
. O

An O
in O
vitro O
splicing O
assay O
revealed O
that O
the O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
mutation O
causes O
a O
4 B
amino I
acid I
deletion I
( O
p O
. O
T O
159 O
_ O
Q O
162 O
del O
) O
. O

The O
17 B
p I
11 I
. I
2 I
duplication I
or I
deletion I
, O
and O
mutations O
in O
PMP O
22 O
, O
CX O
32 O
and O
its O
promoter O
, O
and O
TTR O
had O
been O
excluded O
first O
by O
DNA O
analysis O
of O
the O
proband O
in O
each O
family O
. O

Analysis O
of O
abnormal O
splicing O
at O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
, O
the O
splice B
acceptor I
mutation I
in O
MFN O
2 O
intron O
5 O
, O
using O
the O
minigene O
method O

( O
A O
) O
Sense O
strand O
electropherogram O
of O
patient O
and O
control O
genomic O
DNA O
, O
showing O
the O
heterozygous O
AARS O
mutation O
c O
. O
211 O
A O
> O
T O
in O
the O
patient O
DNA O
, O
corresponding O
to O
the O
amino B
acid I
substitution I
N I
71 I
Y I
. O

( O
A O
) O
Sense O
strand O
electropherogram O
of O
patient O
and O
control O
genomic O
DNA O
, O
showing O
the O
heterozygous O
HSPB O
1 O
mutation O
c O
. O
490 O
A O
> O
G O
in O
the O
patients O
DNA O
, O
corresponding O
to O
the O
amino B
acid I
substitution I
T I
164 I
A I
. O

The O
minigene O
assay O
showed O
that O
the O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
mutation O
, O
which O
affects O
the O
AG O
splice O
acceptor O
site O
, O
results O
in O
a O
deletion B
of I
12 I
nucleotides I
in I
the I
m I
RNA I
( O
c O
. O
475 O
_ O
486 O
del O
ACTGTGAACCAG O
) O
, O
corresponding O
to O
the O
loss O
of O
4 O
amino O
acid O
residues O
in O
the O
protein O
( O
p O
. O
T O
159 O
_ O
Q O
162 O
del O
; O
Figure O
4 O
) O
. O

The O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
splice O
acceptor O
site O
mutation O
resulting O
in O
a O
4 B
- I
amino I
acid I
deletion I
. O

( O
A O
) O
The O
genetic O
DNA O
electropherograms O
of O
the O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
mutation O
and O
wild O
type O
MFN O
2 O
. O

The O
wild O
type O
construct O
( O
WT O
) O
is O
correctly O
spliced O
, O
whereas O
the O
mutant O
construct O
( O
Mut O
) O
containing O
the O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
is O
aberrantly O
spliced O
, O
leading O
to O
a O
12 B
- I
bp I
c I
DNA I
fragment I
deletion I
. O

The O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
splice O
acceptor O
site O
mutation O
causes O
a O
12 B
- I
bp I
deletion I
in I
the I
c I
DNA I
( O
c O
. O
475 O
_ O
486 O
del O
ACTGTGAACCAG O
) O
and O
putatively O
a O
deletion B
of I
4 I
amino I
acids I
in O
the O
MFN O
2 O
protein O
( O
p O
. O
T O
159 O
_ O
Q O
162 O
del O
) O
. O

We O
also O
used O
the O
minigene O
assay O
to O
demonstrate O
that O
the O
MFN O
2 O
splice O
acceptor O
site O
mutation O
c O
. O
475 O
- O
1 O
G O
> O
T O
may O
cause O
abnormal O
m O
RNA O
splicing O
and O
result O
in O
a O
4 B
- I
amino I
acid I
deletion I
( O
p O
. O
T O
159 O
_ O
Q O
162 O
del O
) O
. O

A O
single O
mutation B
in I
the I
helical I
domain I
of I
Ala I
RS I
( O
p O
. O
R O
329 O
H O
) O
was O
recently O
described O
in O
two O
families O
with O
autosomal O
dominant O
axonal O
CMT O
( O
CMT O
2 O
N O
) O
[ O
16 O
] O
. O

This O
study O
helps O
confirm O
the O
involvement O
of O
AARS O
mutations O
in O
CMT O
and O
further O
demonstrates O
the O
role O
of O
aminoacyl O
- O
t O
RNA O
synthetase O
in O
its O
pathogenesis O
. O

Patient O
10 O
carries O
a O
rare O
, O
novel O
MFN O
2 O
acceptor O
splice O
site O
mutation O
, O
that O
alters B
the I
consensus I
acceptor I
splice I
site I
of I
intron I
5 I
from I
AG I
to I
AT I
and O
affects O
MFN O
2 O
splicing O
and O
expression O
. O

Functional O
analysis O
revealed O
that O
this O
splice O
site O
mutation O
might O
lead O
to O
four O
aberrant O
m O
RNA O
transcripts O
, O
which O
are O
predicted O
to O
result O
in O
two O
different O
truncating O
frameshift O
mutations O
with O
two O
approximate O
260 O
- O
amino O
acid O
deletions O
, O
one O
mutation O
with O
a O
15 B
- I
amino I
acid I
insertion I
and O
one O
mutation O
with O
a O
4 B
- I
amino I
acid I
deletion I
[ O
28 O
] O
. O

The O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
, O
which O
is O
carried O
by O
Patient O
10 O
, O
was O
found O
to O
cause O
a O
deletion B
of I
4 I
amino I
acids I
( O
p O
. O
T O
159 O
_ O
Q O
162 O
del O
) O
, O
and O
this O
may O
explain O
his O
relatively O
mild O
polyneuropathy O
. O

Patients O
12 O
and O
13 O
both O
carry O
the O
de O
novo O
MFN O
2 O
p O
. O
R O
364 O
W O
mutation O
and O
both O
had O
severe O
and O
early O
onset O
CMT O
2 O
. O

Methylation B
and I
deamination I
of I
cytosine I
within I
a I
Cp I
G I
dinucleotide I
, O
which O
results O
in O
transitions O
of O
cytosine O
to O
thymine O
[ O
44 O
] O
, O
may O
play O
an O
important O
role O
in O
the O
recurrent O
mutations O
of O
NEFL O
p O
. O
E O
396 O
K O
( O
c O
. O
1186 O
G O
> O
A O
, O
which O
causes O
ggc O
GAG O
> O
ggc O
AAG O
) O
, O
MFN O
2 O
R O
364 O
W O
( O
c O
. O
1090 O
C O
> O
T O
, O
which O
causes O
CGG O
> O
TGG O
) O
, O
and O
MFN O
2 O
R O
364 O
P O
( O
c O
. O
1091 O
G O
> O
A O
, O
which O
causes O
CGG O
> O
TAG O
) O
, O
as O
they O
each O
occur O
at O
the O
cytosine O
residue O
of O
a O
Cp O
G O
dinucleotide O
in O
the O
sense O
or O
antisense O
strand O
. O

A O
point O
mutation O
of O
YPD O
1 O
that O
led O
to O
a O
substitution B
of I
the I
74 I
th I
glycine I
( I
Gly I
74 I
) I
to I
cysteine I
( I
Cys I
) I
was O
identified O
in O
a O
mutant O
strain O
NH O
1 O
. O

It O
was O
therefore O
suggested O
that O
the O
substitution B
of I
Gly I
74 I
to I
Cys I
altered O
the O
Ypd O
1 O
structure O
, O
which O
resulted O
in O
the O
resistance O
to O
pradimicin O
. O

When O
compared O
to O
Aldh O
21 O
of O
Sprague O
- O
Dawley O
, O
94 O
% O
of O
the O
UCh O
A O
( O
low O
drinker O
) O
rats O
( O
n O
= O
61 O
) O
, O
presented O
a O
mutation O
that O
changes O
Gln B
67 I
to I
Arg I
in O
the O
mature O
enzyme O
( O
allele O
referred O
to O
as O
Aldh O
22 O
) O
. O

In O
UCh O
B O
( O
high O
drinker O
) O
rats O
( O
n O
= O
69 O
) O
, O
58 O
% O
presented O
the O
Aldh O
21 O
allele O
, O
while O
42 O
% O
presented O
the O
Gln O
67 O
Arg O
change O
plus O
a O
second O
mutation O
that O
changed O
Glu B
479 I
to I
Lys I
( O
allele O
Aldh O
23 O
) O
. O

Overall O
, O
the O
data O
show O
that O
alleles O
of O
Aldh O
2 O
strongly O
segregate O
with O
the O
phenotype O
of O
ethanol O
consumption O
and O
the O
relative O
K O
( O
m O
) O
for O
NAD O
+ O
of O
ALDH O
2 O
. O

Mutations O
have O
been O
identified O
in O
18 O
of O
20 O
possible O
alleles O
, O
including O
Glu O
80 O
Lys O
( O
2 O
patients O
) O
, O
Pro O
664 O
Leu O
( O
3 O
patients O
) O
, O
Asp O
69 O
Gly O
, O
Cys O
176 O
Arg O
, O
Cys O
227 O
Tyr O
, O
Ser O
265 O
Arg O
, O
Asp O
280 O
Ala O
, O
Asp O
283 O
Glu O
, O
Arg O
329 O
Pro O
, O
Asp O
461 O
Asn O
, O
Leu O
578 O
Ser O
, O
a O
single B
bp I
deletion I
in I
exon I
15 I
, O
a O
21 O
bp O
duplication O
of O
codons O
200 O
- O
206 O
and O
two O
large O
deletions O
. O

These O
observations O
confirm O
the O
striking O
heterogeneity O
underlying O
FH O
in O
most O
populations O
and O
demonstrate O
the O
variability O
in O
phenotype O
between O
patients O
with O
the O
same O
mutation O
. O

The O
situation O
pertaining O
with O
the O
p O
. O
K O
88 O
X O
mutation O
( O
occurring O
in O
trans O
to O
p O
. O
Y O
490 O
N O
in O
patient O
# O
17 O
) O
was O
however O
found O
to O
be O
more O
complex O
in O
that O
it O
also O
impacts O
on O
splicing O
. O

Both O
fragments O
were O
cloned O
and O
sequenced O
; O
although O
the O
603 O
bp O
fragment O
did O
not O
exhibit O
any O
alteration O
within O
the O
region O
analysed O
, O
the O
smaller O
561 O
bp O
fragment O
was O
found O
to O
contain O
a O
69 B
bp I
in I
- I
frame I
deletion I
corresponding I
to I
the I
entire I
length I
of I
exon I
2 I
( O
Figure O
2 O
) O
. O

Table O
S O
1 O
) O
, O
revealing O
the O
presence O
of O
an O
abnormally O
shorter O
GALC O
transcript O
( O
561 O
- O
bp O
) O
in O
addition O
to O
the O
normally O
- O
sized O
product O
( O
630 O
- O
bp O
) O
. O

The O
analysis O
demonstrated O
normal O
splicing O
( O
unbroken O
red O
line O
) O
of O
the O
630 O
- O
bp O
fragment O
and O
abnormal O
splicing O
( O
dotted O
red O
line O
) O
of O
the O
561 O
- O
bp O
product O
resulting O
in O
a O
69 B
- I
bp I
in I
- I
frame I
deletion I
corresponding I
to I
the I
entire I
exon I
2 I
of O
GALC O
in O
the O
shorter O
product O
. O

The O
AAG B
> I
TAG I
transversion I
, I
affecting I
the I
last I
codon I
of I
exon I
2 I
, O
is O
given O
. O

Although O
sequence O
analysis O
of O
the O
two O
RT O
- O
PCR O
products O
confirmed O
the O
presence O
of O
the O
microdeletion O
c O
. O
1901 O
del O
T O
in O
the O
apparently O
normally O
- O
sized O
c O
DNA O
product O
, O
only O
partial O
skipping O
of O
exon O
13 O
was O
evident O
, O
with O
the O
shorter O
transcript O
lacking O
the O
last O
27 O
nucleotides O
( O
c O
. O
1463 O
_ O
1489 O
) O
( O
Figure O
3 O
) O
. O

The O
junction O
between O
nucleotides O
c O
. O
1462 O
( O
exon O
13 O
) O
and O
c O
. O
1490 O
( O
exon O
14 O
) O
at O
the O
new O
donor O
splice O
- O
site O
( O
probably O
mediated O
by O
the O
use O
of O
the O
cryptic O
exonic O
GT O
dinucleotide O
at O
c O
. O
1463 O
- O
1464 O
) O
, O
gave O
rise O
to O
a O
serine B
to I
asparagine I
substitution I
at I
residue I
495 I
followed O
by O
a O
frameshift O
that O
is O
predicted O
to O
lead O
to O
the O
premature O
termination O
of O
translation O
( O
p O
. O
S O
488 O
Nfs O
X O
200 O
) O
. O

Consistent O
with O
previous O
studies O
, O
the O
common O
30 B
kb I
deletion I
( I
c I
. I
1161 I
+ I
6532 I
_ I
poly I
A I
+ I
9 I
kbdel I
) I
was I
invariably I
found I
in I
cis I
to I
c I
. I
550 I
T I
( I
502 I
T I
) I
, O
and O
frequently O
in O
patients O
with O
the O
infantile O
form O
of O
the O
disease O
( O
but O
sometimes O
also O
with O
the O
juvenile O
form O
, O
depending O
on O
the O
precise O
combination O
with O
the O
other O
mutant O
alleles O
) O
. O

The O
replacement B
of I
a I
cyclic I
uncharged I
proline I
( I
P I
) I
with I
a I
basic I
charged I
arginine I
( I
R I
) I
in I
position I
318 I
was O
predicted O
by O
Mut O
Pred O
to O
impact O
upon O
protein O
structure O
both O
in O
terms O
of O
solvent O
accessibility O
( O
P O
= O
0 O
. O
0179 O
) O
and O
secondary O
structure O
( O
loop O
→ O
helix O
; O
P O
= O
0 O
. O
0259 O
) O
( O
Table O
2 O
) O
. O

Another O
in O
silico O
hypothesis O
was O
available O
for O
the O
novel O
missense O
mutation O
p O
. O
Y O
490 O
N O
: O
the O
non O
- O
conservative O
substitution B
of I
tyrosine I
( I
Y I
) I
by I
asparagine I
( I
N I
) I
is O
predicted O
to O
lead O
to O
the O
loss O
of O
a O
phosphorylation O
site O
at O
residue O
490 O
( O
P O
= O
0 O
. O
0245 O
) O
, O
consistent O
with O
the O
severe O
infantile O
form O
of O
the O
patient O
# O
17 O
( O
Table O
1 O
) O
. O

The O
second O
allele O
in O
this O
patient O
( O
# O
17 O
) O
is O
the O
nonsense O
mutation O
( O
p O
. O
K O
88 O
X O
) O
, O
discussed O
above O
, O
that O
predicts O
premature O
termination B
of I
translation I
at I
codon I
88 I
. O

In O
accordance O
with O
in O
vitro O
expression O
studies O
which O
indicated O
that O
no O
GALC O
enzymatic O
activity O
was O
evident O
in O
association O
with O
p O
. O
G O
553 O
R O
( O
G O
537 O
R O
) O
[ O
De O
Gasperi O
et O
al O
. O
, O
1999 O
] O
, O
Mut O
Pred O
analysis O
postulated O
a O
change O
in O
the O
alpha O
- O
helical O
secondary O
structure O
as O
consequence O
of O
the O
replacement B
of I
a I
glycine I
with I
an I
arginine I
at I
residue I
553 I
. O

Sequencing O
revealed O
the O
presence O
of O
a O
homozygous B
missense I
mutation I
( O
R O
80 O
W O
) O
in O
exon O
3 O
of O
the O
17 O
beta O
- O
HSD O
3 O
gene O
, O
which O
was O
also O
present O
in O
single O
doses O
in O
both O
parents O
, O
in O
accordance O
with O
the O
recessive O
inheritance O
of O
the O
defect O
. O

Confirming O
the O
abnormal O
delta O
4 O
- O
androstenedione O
/ O
testosterone O
ratios O
that O
suggested O
17 O
beta O
- O
HSD O
deficiency O
, O
a O
homozygous B
missense I
mutation I
in O
the O
gene O
coding O
for O
this O
enzyme O
was O
identified O
in O
the O
patient O
with O
MPH O
. O

Deletion B
of I
ZF I
1 I
- I
2 I
caused O
cytoplasmic O
accumulation O
of O
ZNF O
24 O
. O

Co O
- O
immunoprecipitation O
demonstrated O
that O
ZNF O
24 O
interacted O
with O
importin O
- O
β O
and O
this O
interaction O
required O
the O
ZF O
moti O
fs O
. O

( O
A O
) O
Schematic O
of O
full O
- O
length O
and O
deletion B
ZNF O
24 O
- O
GFP O
constructs O
used O
in O
this O
study O
( O
not O
to O
scale O
) O
. O

All O
deletion O
constructs O
were O
fused O
to O
the O
N O
terminus O
of O
the O
GFP O
. O

Figure O
2 O
A O
illustrates O
a O
schematic O
of O
these O
deletions O
. O

Deletion B
of I
the I
ZF I
4 I
( I
p I
1 I
- I
329 I
- I
GFP I
) I
or I
the I
ZF I
3 I
- I
4 I
( I
p I
1 I
- I
301 I
- I
GFP I
) I
had O
no O
effect O
on O
the O
nuclear O
localization O
of O
ZNF O
24 O
( O
Figure O
2 O
B O
) O
. O

However O
, O
deletion B
of I
the I
ZF I
2 I
- I
4 I
( O
p O
1 O
- O
273 O
- O
GFP O
) O
led O
to O
both O
nuclear O
and O
cytoplasmic O
localization O
with O
brighter O
staining O
intensity O
in O
the O
nucleus O
. O

Deletion B
of I
whole I
ZF I
region I
( O
p O
1 O
- O
250 O
- O
GFP O
) O
led O
to O
diffusively O
present O
throughout O
the O
cell O
with O
similar O
staining O
intensity O
in O
the O
nucleus O
and O
cytoplasm O
( O
Figure O
2 O
B O
) O
. O

To O
further O
verify O
this O
notion O
, O
we O
made O
an O
internal O
deletion B
of I
the I
ZF I
1 I
- I
2 I
region I
( O
Figure O
2 O
A O
, O
d O
ZF O
1 O
- O
2 O
) O
and O
found O
that O
indeed O
all O
of O
the O
cells O
showed O
both O
nuclear O
and O
cytoplasmic O
localization O
of O
the O
mutant O
protein O
( O
Figure O
2 O
B O
, O
d O
ZF O
1 O
- O
2 O
) O
. O

We O
therefore O
sequentially O
replaced B
each I
lysine I
and I
arginine I
in I
ZF I
1 I
and I
ZF I
2 I
with I
alanine I
to O
investigate O
which O
amino O
acid O
residues O
are O
essential O
for O
the O
ZNF O
24 O
NLS O
. O

The O
mutation O
of O
basic O
residues B
286 I
or I
290 I
to I
alanine I
( O
K O
286 O
A O
or O
R O
290 O
A O
) O
resulted O
in O
a O
partial O
mislocalization O
of O
the O
protein O
to O
the O
cytoplasm O
, O
whereas O
the O
nuclear O
localization O
of O
the O
other O
mutants O
did O
not O
significantly O
change O
( O
Figure O
5 O
B O
) O
. O

These O
results O
indicate O
that O
the O
basic O
residues O
286 O
and O
290 O
within O
the O
ZF O
1 O
and O
ZF O
2 O
region O
play O
an O
important O
role O
in O
nuclear O
localization O
. O

To O
further O
identify O
critical O
residues O
within O
the O
ZF O
1 O
and O
ZF O
2 O
region O
, O
we O
further O
mutated O
the O
serine O
, O
threonine O
or O
tyrosine B
residues I
within I
this I
region I
( O
Figure O
5 O
A O
) O
, O
since O
these O
residues O
were O
potential O
targets O
for O
posttranslational O
modifications O
or O
interaction O
with O
importins O
that O
would O
contribute O
to O
nuclear O
transport O
[ O
25 O
, O
33 O
, O
34 O
] O
. O

The O
first O
and O
second O
ZFs O
are O
necessary O
for O
efficient O
nuclear O
localization O
; O
deletion B
of I
ZF I
1 I
or I
ZF I
2 I
results O
in O
partial O
loss O
of O
nuclear O
targeting O
( O
Figure O
2 O
B O
) O
, O
whereas O
deletion B
of I
ZF I
1 I
- I
2 I
resulted O
in O
the O
nuclear O
and O
cytoplasmic O
localization O
( O
Figure O
2 O
B O
) O
. O

Our O
results O
also O
demonstrate O
that O
the O
ZF O
region O
is O
also O
critical O
for O
the O
nuclear O
localization O
of O
ZNF O
24 O
is O
consistent O
with O
previous O
reports O
that O
the O
ZFs O
of O
many O
ZF O
- O
containing O
transcription O
factors O
play O
an O
additional O
role O
as O
NLSs O
[ O
18 O
] O
. O

Our O
results O
suggest O
that O
the O
presence O
of O
ZF O
1 O
- O
2 O
is O
required O
for O
the O
nuclear O
localization O
of O
ZNF O
24 O
, O
since O
removal B
of I
ZF I
1 I
- I
2 I
inhibited O
the O
nuclear O
localization O
of O
ZNF O
24 O
and O
removal B
of I
ZF I
3 I
or I
ZF I
4 I
did O
not O
affect O
the O
nuclear O
localization O
of O
ZNF O
24 O
. O

Using O
classical O
heteronuclear O
and O
isotope O
- O
filtered O
NMR O
experiments O
, O
we O
determined O
the O
three O
- O
dimensional O
solution O
structure O
of O
AIRE O
- O
PHD O
1 O
in O
complex O
with O
H O
3 O
K O
4 O
me O
0 O
( O
Figure O
1 O
A O
– O
C O
, O
Table O
1 O
for O
structural O
statistics O
) O
. O

The O
complex O
is O
stabilized O
by O
complementary O
surface O
interactions O
, O
whereby O
the O
side O
chains O
of O
the O
first O
four O
H O
3 O
tail O
residues O
snugly O
fit O
inside O
the O
pre O
- O
formed O
AIRE O
- O
PHD O
1 O
- O
binding O
groove O
, O
previously O
identified O
by O
chemical O
shift O
perturbation O
methods O
( O
22 O
) O
( O
Figure O
1 O
C O
) O
. O

We O
tested O
whether O
the O
multiple O
interactions O
between O
the O
R O
2 O
guanidinium O
group O
and O
AIRE O
- O
PHD O
1 O
are O
specifically O
crucial O
for O
substrate O
recognition O
. O

Indeed O
, O
mutation O
of O
R B
2 I
into I
lysine I
destabilizes O
the O
complex O
, O
as O
assessed O
by O
ITC O
and O
fluorescence O
measurements O
( O
Table O
2 O
) O
. O

Here O
, O
we O
demonstrate O
that O
also O
Asn O
295 O
plays O
a O
fundamental O
role O
in O
histone O
H O
3 O
recognition O
, O
as O
mutation B
into I
alanine I
has O
a O
detrimental O
effect O
on O
complex O
formation O
( O
Table O
2 O
) O
. O

In O
particular O
, O
the O
side O
chain O
of O
Asp O
304 O
, O
which O
engages O
in O
multiple O
interactions O
with O
both O
K O
9 O
and O
R O
8 O
, O
seems O
to O
play O
an O
important O
role O
in O
complex O
stabilization O
, O
as O
mutation B
into I
alanine I
results O
in O
a O
strong O
enthalpic O
penalty O
, O
associated O
to O
a O
20 O
- O
fold O
reduction O
in O
binding O
affinity O
( O
Table O
2 O
) O
. O

Recent O
efforts O
to O
improve O
the O
understanding O
of O
renal O
cystogenesis O
have O
been O
greatly O
enhanced O
by O
studies O
in O
rodent O
models O
of O
PKD O
. O

This O
article O
reports O
the O
positional O
cloning O
and O
mutation O
analysis O
of O
the O
rat O
PKD O
gene O
, O
which O
revealed O
a O
C O
to O
T O
transition O
that O
replaces O
an O
arginine B
by I
a I
tryptophan I
at I
amino I
acid I
823 I
in O
the O
protein O
sequence O
. O

Previously O
, O
we O
have O
reported O
the O
molecular O
cloning O
of O
ara O
genes O
encoding O
a O
small O
GTP O
- O
binding O
protein O
from O
Arabidopsis O
thaliana O
. O

A O
point O
mutation O
of O
Asn B
at I
position I
72 I
for O
ARA O
- O
2 O
, O
or O
71 O
for O
ARA O
- O
4 O
, O
to B
Ile I
decreased O
GTP O
- O
binding O
and O
a O
point O
mutation O
of O
Gln B
at I
position I
126 I
for O
ARA O
- O
2 O
, O
or O
125 O
for O
ARA O
- O
4 O
, O
to B
Leu I
suppressed O
GTP O
- O
hydrolysis O
activity O
. O

2002 O
) O
. O

These O
ten O
strains O
show O
a O
16 O
- O
fold O
difference O
in O
the O
mutation O
rate O
to O
5 O
FOA O
resistance O
, O
and O
the O
majority O
of O
these O
mutations O
resulted O
from O
frameshift B
mutations I
within I
the I
poly I
GT I
tract I
( O
not O
mutations O
in O
the O
URA O
3 O
coding O
sequence O
) O
. O

The O
resulting O
plasmid O
, O
p O
GIL O
001 O
, O
is O
p O
FA O
6 O
a O
- O
Kan O
MX O
4 O
with O
a O
1 O
. O
8 O
- O
kb O
URA O
3 O
fragment O
is O
inserted O
in O
the O
Kan O
MX O
4 O
cassette O
. O

One O
mutation O
( O
an B
insertion I
of I
a I
T I
to I
a I
run I
of I
seven I
T I
' I
s I
in I
the I
promoter I
region I
) O
was O
created O
during O
the O
construction O
of O
this O
plasmid O
. O

Only O
one O
of O
these O
seven O
mutations O
is O
in O
the O
coding O
sequence O
and O
results O
in O
the O
substitution B
of I
serine I
for I
alanine I
at I
position I
160 I
. O

Plasmid O
p O
GIL O
008 O
was O
constructed O
to O
facilitate O
deletion B
of I
ARS I
607 I
. O

To O
manipulate O
replication O
timing O
, O
a O
two O
- O
step O
method O
was O
used O
in O
order O
to O
create O
a O
clean O
deletion B
of I
the I
early I
and I
efficient I
origin I
, I
ARS I
607 I
( O
supplementary O
fig O
. O

Deletion B
of I
ARS I
607 I
was O
determined O
by O
PCR O
using O
primers O
ARS O
607 O
ext O
_ O
F O
1 O
and O
ARS O
607 O
ext O
_ O
R O
1 O
, O
which O
flank O
the O
ARS O
607 O
sequence O
. O

Following O
popout O
of O
URA O
3 O
at O
the O
deleted B
ARS I
607 I
locus O
, O
the O
URA O
3 O
gene O
was O
integrated O
in O
place O
of O
the O
Kan O
MX O
4 O
cassette O
to O
create O
the O
strain O
GL O
· O
36 O
ARS O
607 O
Δ O
. O

Deletion B
of I
REV I
1 I
was O
verified O
phenotypically O
by O
assaying O
for O
UV O
sensitivity O
and O
by O
PCR O
using O
primers O
REV O
1 O
int O
F O
1 O
/ O
REV O
1 O
ext O
R O
3 O
and O
Kan O
MXint O
F O
/ O
REV O
1 O
ext O
R O
3 O
. O

A O
blue O
arrow O
below O
the O
mutation O
rate O
plot O
indicates O
the O
location O
selected O
to O
test O
mutation O
rate O
before O
and O
after O
ARS O
607 O
disruption O
. O

A O
green O
arrow O
above O
the O
mutation O
rate O
plot O
indicates O
the O
locations O
selected O
to O
test O
mutation O
rate O
following O
the O
deletion B
of I
rev I
1 I
( O
see O
fig O
. O

ARS B
605 I
, I
ARS I
606 I
, I
and I
ARS I
608 I
are I
deleted I
in O
strains O
GL O
· O
25 O
, O
GL O
· O
31 O
, O
and O
GL O
· O
39 O
, O
respectively O
. O

Disruption B
of I
ARS I
605 I
should O
have O
a O
small O
effect O
due O
to O
its O
close O
proximity O
to O
earlier O
firing O
ARS O
603 O
. O
5 O
. O

Strain O
GL O
· O
31 O
was O
not O
used O
in O
the O
analysis O
because O
it O
affected O
growth O
on O
5 O
FOA O
( O
see O
Materials O
and O
Methods O
) O
; O
however O
, O
interestingly O
, O
this O
strain O
had O
a O
high O
mutation O
rate O
( O
6 O
. O
5 O
× O
10 O
− O
8 O
) O
compared O
with O
other O
URA O
3 O
reporters O
in O
the O
same O
region O
, O
which O
may O
be O
partly O
attributable O
to O
disruption B
of I
ARS I
606 I
. O

To O
test O
if O
disruption O
of O
an O
origin O
of O
replication O
can O
increase O
the O
local O
mutation O
rate O
in O
an O
early O
- O
replicating O
/ O
low O
mutation O
rate O
region O
, O
the O
earliest O
and O
most O
efficient O
origin O
, O
ARS B
607 I
, I
was I
deleted I
in O
strain O
GL O
· O
36 O
, O
where O
the O
URA O
3 O
gene O
is O
located O
3 O
kb O
away O
from O
the O
origin O
. O

Deletion B
of I
ARS I
607 I
increased O
the O
mutation O
rate O
at O
URA O
3 O
by O
30 O
% O
( O
from O
2 O
. O
21 O
× O
10 O
− O
7 O
to O
2 O
. O
88 O
× O
10 O
− O
7 O
) O
without O
increasing O
the O
mutation O
rate O
at O
CAN O
1 O
( O
0 O
. O
81 O
× O
10 O
− O
7 O
in O
GL O
· O
36 O
and O
0 O
. O
76 O
× O
10 O
− O
7 O
in O
GL O
· O
36 O
ARS O
607 O
Δ O
) O
. O

It O
is O
possible O
that O
deletion B
of I
ARS I
607 I
did O
not O
significantly O
delay O
replication O
timing O
in O
the O
region O
. O

We O
deleted B
the I
REV I
1 I
gene O
from O
four O
strains O
( O
two O
early O
- O
replicating O
/ O
low O
mutation O
rate O
and O
two O
late O
- O
replicating O
/ O
elevated O
mutation O
rate O
) O
. O

To O
test O
the O
hypothesis O
that O
the O
correlation O
between O
replication O
time O
and O
mutation O
rate O
is O
due O
to O
the O
temporal O
separation O
of O
template O
switching O
and O
translesion O
synthesis O
, O
REV O
1 O
( O
which O
encodes O
a O
translesion O
polymerase O
essential O
for O
translesion O
synthesis O
) O
was B
deleted I
in O
four O
strains O
that O
show O
variation O
in O
mutation O
rate O
and O
replication O
timing O
. O

Interestingly O
, O
Rev O
1 O
, O
a O
translesion O
DNA O
polymerase O
essential O
for O
translesion O
synthesis O
, O
is O
not O
expressed O
until O
late O
in O
S O
- O
phase O
and O
into O
mitosis O
, O
after O
most O
of O
the O
DNA O
has O
been O
replicated O
( O
Waters O
and O
Walker O
2006 O
) O
. O

In O
support O
of O
this O
model O
, O
we O
show O
that O
deleting B
the I
translesion I
polymerase I
REV I
1 I
lowers O
the O
mutation O
specifically O
in O
late O
- O
replicating O
/ O
high O
mutation O
rate O
regions O
. O

Further O
analysis O
of O
the O
data O
suggests O
that O
much O
of O
the O
observed O
variation O
can O
be O
attributed O
to O
the O
orientation O
of O
the O
t O
RNA O
gene O
relative O
to O
the O
nearest O
origin O
of O
replication O
. O

Ochre O
suppressors O
arise O
by O
a O
GC B
to I
TA I
transversion I
in I
the I
anticodon I
of I
t I
RNA I
- I
Tyr I
. O

Out O
of O
the O
40 O
pathogenic O
sequence O
variants O
reported O
in O
frataxin O
, O
at O
least O
15 O
missense O
point O
mutations O
have O
been O
described O
. O

The O
G B
> I
T I
transversion I
at I
nucleotide I
389 I
leading O
to O
the O
G O
130 O
V O
replacement O
is O
the O
most O
frequent O
missense O
mutation O
in O
FRDA O
, O
found O
in O
more O
than O
ten O
Caucasian O
patients O
from O
five O
families O
( O
[ O
18 O
] O
, O
[ O
23 O
] O
– O
[ O
25 O
] O
and O
MK O
unpublished O
data O
) O
. O

Complete O
frataxin O
deletion B
in O
murine O
fibroblasts O
is O
not O
viable O
and O
can O
be O
rescued O
by O
transgenic O
expression O
of O
m O
Fxn O

To O
confirm O
that O
frataxin O
deletion B
is O
the O
cause O
of O
cell O
detachment O
and O
subsequent O
death O
, O
we O
determined O
whether O
transgenic O
expression O
of O
murine O
frataxin O
( O
m O
Fxn O
) O
could O
rescue O
the O
phenotype O
. O

Nineteen O
clones O
overexpressing O
mouse O
frataxin O
( O
Frda O
L O
3 O
/ O
L O
- O
; O
m O
Fxn O
) O
presented O
a O
complete B
deletion I
of O
the O
endogenous O
frataxin O
gene O
( O
Fig O
. O

Only O
five O
clones O
were O
obtained O
from O
the O
cells O
transfected O
with O
the O
empty O
vector O
( O
Frda O
L O
3 O
/ O
L O
- O
; O
p O
SG O
5 O
) O
. O

These O
clones O
clearly O
stopped O
dividing O
. O

Genotyping O
demonstrated O
a O
complete B
deletion I
of O
the O
endogenous O
murine O
frataxin O
gene O
for O
each O
clone O
, O
hereafter O
referred O
as O
h O
FXN O
, O
h O
FXNG O
130 O
V O
and O
h O
FXNI O
154 O
F O
clones O
( O
Fig O
. O

Interestingly O
, O
all O
I O
154 O
F O
clones O
showed O
a O
high O
expression O
level O
of O
the O
h O
FXNI O
154 O
F O
protein O
compared O
to O
the O
wild O
- O
type O
or O
h O
FXNG O
130 O
V O
proteins O
, O
correlating O
with O
a O
4 O
– O
10 O
fold O
increased O
level O
of O
the O
transcript O
( O
data O
not O
shown O
) O
. O

Through O
this O
novel O
in O
vitro O
system O
, O
we O
generated O
two O
humanized O
cell O
models O
by O
combining O
the O
deletion B
of O
the O
endogenous O
murine O
conditional O
frataxin O
allele O
with O
the O
expression O
of O
human O
frataxin O
carrying O
either O
the O
G O
130 O
V O
or O
I O
154 O
F O
missense O
mutations O
found O
in O
compound O
heterozygous O
FRDA O
patients O
. O

The O
valine B
226 I
substitution I
has O
been O
identified O
in O
five O
patients O
with O
a O
Kim O
variant O
phenotype O
from O
Japan O
/ O
Korea O
. O

In O
Abcg O
8 O
, O
a O
large O
insertional O
polymorphism O
was O
identified O
in O
exon O
13 O
, O
that O
resulted O
in O
the O
insertion B
of I
143 I
nucleotides I
in I
the I
3 I
' I
UTR I
( I
* I
2099 I
_ I
2100 I
ins I
143 I
nt I
) I
. O

Healthy O
WKA O
and O
GH O
rat O
strains O
were O
also O
generated O
from O
outbred O
Wistar O
rat O
strains O
, O
but O
these O
strains O
were O
isolated O
independently O
in O
Japan O
and O
New O
Zealand O
, O
respectively O
( O
and O
maintained O
at O
other O
sites O
as O
well O
) O
. O

In O
contrast O
, O
the O
143 B
nucleotide I
fragment I
insertion I
polymorphism I
in I
the I
3 I
' I
- I
UTR I
of O
Abcg O
8 O
may O
have O
resulted O
from O
acquisition O
of O
a O
foreign O
chromosomal O
fragment O
during O
the O
Wistar O
rat O
strain O
breeding O
and O
established O
as O
homozygous O
change O
in O
the O
WKY O
, O
SHR O
and O
SHRSP O
, O
as O
well O
as O
GH O
rat O
strains O
. O

Mutagenesis O
identified O
the O
affected O
ubiquitination O
sites O
as O
three B
lysine I
residues I
located I
in I
the I
vicinity I
of I
A I
323 I
. O

These O
findings O
indicate O
that O
post O
- O
translational O
modification O
of O
NEMO O
through O
K O
63 O
- O
linked O
polyubiquitination O
is O
a O
key O
event O
in O
IKK O
activation O
and O
that O
perturbation O
of O
this O
step O
may O
cause O
human O
pathophysiology O
. O

The O
c O
. O
694 O
C O
> O
T O
mutation O
was O
detected O
in O
the O
discovery O
screen O
and O
was O
not O
detected O
in O
204 O
other O
patient O
chromosomes O
or O
84 O
Hap O
Map O
control O
chromosomes O
. O

The O
c O
. O
1289 O
A O
> O
G O
mutation O
was O
inherited O
from O
the O
patient O
’ O
s O
mother O
, O
and O
is O
predicted O
to O
cause O
the O
substitution B
of I
a I
highly I
conserved I
asparagine I
residue I
with I
a I
serine I
( O
p O
. O
N O
430 O
S O
) O
( O
Supplementary O
Fig O
. O

Initial O
experiments O
using O
this O
vector O
did O
not O
rescue O
CI O
activity O
so O
site O
- O
directed O
mutagenesis O
was O
performed O
to O
change B
codon I
343 I
from I
CCA I
( I
proline I
) I
( I
db I
SNP I
rs I
17855445 I
) I
to I
the I
hg I
18 I
reference I
codon I
GCA I
( I
alanine I
) I
using O
Quik O
Change O
II O
XL O
site O
- O
directed O
mutagenesis O
kit O
( O
Stratagene O
) O
according O
to O
manufacturer O
’ O
s O
instructions O
( O
primers O
listed O
in O
Supplementary O
Table O
5 O
) O
to O
generate O
the O
Ref O
Seq O
FOXRED O
1 O
- O
V O
5 O
p O
Dest O
vector O
. O

This O
FOXL O
2 O
c O
. O
402 O
C O
> O
G O
mutation O
changes B
a I
highly I
conserved I
cysteine I
residue I
to I
a I
tryptophan I
( O
p O
. O
C O
134 O
W O
) O
. O

C O
: O
Amino O
acid O
conservation O
map O
across O
species O
demonstrating O
that O
glycine B
at I
position I
603 I
is O
conserved O
lower O
down O
to O
sticklebacks O
and O
zebrafish O
. O

The O
novel O
c O
. O
1807 O
G O
> O
C O
change O
was O
not O
seen O
in O
360 O
control O
chromosomes O
, O
and O
the O
glycine B
at I
position I
603 I
is O
conserved O
in O
lower O
vertebrates O
such O
as O
stickleback O
and O
zebrafish O
( O
UCSC O
Conservation O
track O
; O
Figure O
1 O
C O
) O
. O

The O
mutation O
was O
predicted O
also O
to O
affect O
protein O
function O
by O
SIFT O
with O
a O
score O
of O
0 O
. O
00 O
. O

64 O
, O
243 O
- O
249 O
] O
. O

Molecular O
modeling O
indicates O
that O
the O
introduction B
of I
an I
arginine I
residue I
at I
position I
235 I
results O
in O
a O
major O
rearrangement O
of O
the O
metal O
ligands O
that O
compromise O
Mn O
( O
II O
) O
binding O
. O

Congenital O
adrenal O
hyperplasia O
( O
CAH O
) O
is O
a O
common O
recessive O
genetic O
disease O
caused O
mainly O
by O
steroid O
21 O
- O
hydroxylase O
( O
P O
450 O
c O
21 O
) O
deficiency O
. O

In O
the O
patient O
, O
a O
single O
base O
substitution O
replaced B
Ile I
172 I
( I
ATC I
) I
with I
Asn I
( I
AAC I
) I
in O
one O
allele O
while O
Arg B
356 I
( I
CGG I
) I
was I
converted I
to I
Trp I
( I
TGG I
) I
in O
the O
other O
. O

An O
analysis O
of O
mutant O
S O
. O
cerevisiae O
strains O
selected O
for O
their O
ability O
to O
increase O
transcription O
by O
RNA O
polymerase O
( O
pol O
) O
III O
has O
identified O
14 O
isolates O
in O
which O
this O
phenotype O
is O
recessive O
. O

Site O
- O
directed O
mutagenesis O
at B
amino I
acid I
728 I
generated I
one I
allele I
, O
pcf O
1 O
- O
4 O
, O
with O
a O
stronger O
phenotype O
than O
pcf O
1 O
- O
3 O
. O

In O
one O
of O
these O
families O
( O
WWS O
- O
31 O
) O
, O
the O
homozygous O
region O
was O
delimited O
by O
SNP B
_ I
A I
- I
4215126 I
at I
11 I
q I
13 I
. I
1 I
and O
SNP B
_ I
A I
- I
2154685 I
at I
11 I
q I
13 I
. I
3 I
( O
UCSC O
hg O
19 O
database O
, O
http O
: O
/ O
/ O
genome O
. O
ucsc O
. O
edu O
, O
last O
accessed O
date O
on O
30 O
January O
, O
2013 O
) O
, O
representing O
a O
5 O
. O
24 O
Mb O
haplotype O
that O
was O
shared O
among O
the O
three O
affected O
individuals O
but O
different O
from O
that O
in O
an O
unaffected O
sibling O
. O

Both O
mutations O
are O
absent O
in O
5379 O
control O
samples O
from O
the O
NHLBI O
GO O
Exome O
Sequencing O
Project O
( O
Exome O
Variant O
Server O
, O
http O
: O
/ O
/ O
evs O
. O
gs O
. O
washington O
. O
edu O
/ O
EVS O
, O
last O
accessed O
date O
on O
30 O
January O
, O
2013 O
) O
and O
in O
672 O
exomes O
of O
our O
in O
- O
house O
database O
. O

Much O
less O
is O
known O
about O
Ape O
2 O
, O
but O
its O
importance O
is O
emphasized O
by O
the O
growth O
retardation O
and O
dyshematopoiesis O
accompanied O
by O
G O
2 O
/ O
M O
arrest O
phenotype O
of O
the O
APE O
2 O
- O
null O
mice O
. O

Mutation O
of O
the O
active O
- O
site O
residue O
Asp B
277 I
to I
Ala I
in O
Ape O
2 O
inactivates O
all O
these O
activities O
. O

We O
also O
made O
a O
similar O
construct O
expressing O
the O
Ape O
2 O
D O
277 O
A O
protein O
containing O
a O
point B
mutation I
at I
the I
D I
277 I
residue I
, O
which O
corresponds O
to O
a O
conserved O
metal O
- O
binding O
site O
in O
the O
active O
center O
of O
class O
II O
AP O
endonucleases O
( O
21 O
) O
( O
Figure O
1 O
A O
) O
. O

To O
confirm O
that O
the O
observed O
3 O
′ O
- O
exonuclease O
, O
3 O
′ O
- O
phosphodiesterase O
and O
the O
extremely O
weak O
AP O
- O
endonuclease O
activities O
are O
intrinsic O
to O
Ape O
2 O
, O
we O
also O
purified O
a O
mutant O
Ape O
2 O
protein O
, O
in O
which O
we O
altered O
the O
conserved O
Asp B
277 I
residue I
to I
Ala I
. O

Analysis O
of O
the O
APP O
exon O
16 O
in O
the O
proband O
showed O
a O
GAC B
to I
AAC I
nucleotide I
substitution I
in I
codon I
678 I
of O
the O
APP O
gene O
, O
causing O
an O
amino O
acid O
substitution O
of O
Asp B
to I
Asn I
( I
D I
678 I
N I
) I
. O

We O
removed O
the O
selenocysteine O
insertion O
sequence O
in O
the O
rat O
gene O
, O
and O
we O
changed B
the I
Se I
Cys I
( I
498 I
) I
encoded I
by I
TGA I
to I
Cys I
or I
Ser I
by O
mutagenesis O
. O

The O
truncated O
protein O
having O
the O
C B
- I
terminal I
Se I
Cys I
- I
Gly I
dipeptide I
deleted I
, O
expected O
in O
selenium O
deficiency O
, O
was O
also O
engineered O
. O

The O
p O
H O
optimum O
of O
the O
Se O
Cys O
( O
498 O
) O
- O
- O
> O
Cys O
mutant O
enzyme O
was O
9 O
as O
opposed O
to O
7 O
for O
the O
wild O
type O
Trx O
R O
, O
strongly O
suggesting O
involvement O
of O
the O
low O
p O
K O
( O
a O
) O
Se O
Cys O
selenol O
in O
the O
enzyme O
mechanism O
. O

Moreover O
, O
two B
G I
to I
D I
mutations I
near I
the I
DGH I
motif I
eliminated O
PP O
2 O
C O
activity O
but O
displayed O
opposite O
effects O
on O
ABA O
signaling O
. O

This O
study O
suggests O
a O
mechanism O
for O
the O
action O
of O
dominant O
PP O
2 O
C O
mutants O
that O
could O
serve O
as O
valuable O
tools O
to O
understand O
protein O
- O
protein O
interactions O
mediating O
ABA O
signal O
transduction O
in O
higher O
plants O
. O

Case O
1 O
was O
a O
compound O
heterozygote O
for O
a O
previously O
described O
cytosine B
insertion I
into I
exon I
2 I
causing I
a I
frameshift I
and O
nonsense O
codon O
severely O
truncating O
the O
H O
6 O
PDH O
protein O
, O
and O
a O
novel O
p O
. O
P O
146 O
L O
missense O
mutation O
, O
which O
we O
have O
shown O
through O
in O
silico O
three O
- O
dimensional O
protein O
modelling O
to O
potentially O
impact O
upon O
cofactor O
binding O
, O
thus O
rendering O
NADPH O
production O
to O
be O
abolished O
. O

In O
seven O
patients O
with O
CPHD O
from O
four O
consanguineous O
pedigrees O
, O
four O
novel O
, O
recessive O
mutations O
were O
identified O
: O
a B
deletion I
of I
the I
entire I
gene I
( O
del O
/ O
del O
) O
, O
mutations O
causing O
truncated O
proteins O
( O
E O
173 O
ter O
, O
W O
224 O
ter O
) O
, O
and O
a O
mutation O
causing O
a O
substitution O
in O
the O
homeodomain O
( O
A O
210 O
V O
) O
. O

( O
C O
) O
A O
second O
series O
of O
obscurin O
fragments O
was O
prepared O
to O
further O
restrict O
the O
sequence O
responsible O
for O
binding O
with O
ank O
1 O
. O
5 O
to O
25 O
aa O
of O
obscurin O
( O
aa O
6236 O
– O
6260 O
) O
. O

( O
D O
) O
Mutagenesis B
of I
the I
aa I
in I
the I
COOH I
terminus I
of O
obscurin O
( O
aa O
6236 O
– O
6260 O
) O
capable O
of O
mediating O
binding O
to O
ank O
1 O
. O
5 O
was O
performed O
and O
mutant O
proteins O
were O
tested O
against O
GST O
– O
ank O
1 O
. O
5 O
in O
in O
vitro O
binding O
assays O
. O

Characterization O
of O
a O
second O
set O
of O
obscurin O
fragments O
restricted O
the O
domain O
in O
the O
COOH O
- O
terminal O
region O
of O
obscurin O
capable O
of O
mediating O
the O
interaction O
with O
ank O
1 O
. O
5 O
to O
a O
minimal O
region O
of O
25 O
aa O
( O
residues O
6236 O
– O
6260 O
) O
( O
Fig O
. O

Site O
- O
directed O
mutagenesis O
of O
these O
25 O
aa O
indicated O
that O
the O
substitution B
of I
three I
threonine I
residues I
( I
T I
6238 I
, I
T I
6240 I
, I
and I
T I
6241 I
) I
drastically O
impaired O
the O
ability O
of O
obscurin O
to O
bind O
to O
ank O
1 O
. O
5 O
( O
Fig O
. O

Both O
two O
- O
hybrid O
and O
in O
vitro O
binding O
assays O
demonstrated O
that O
only O
ank O
1 O
. O
5 O
is O
capable O
of O
binding O
the O
obscurin O
subclone O
A O
7 O
. O

( O
D O
) O
Site O
- O
directed O
mutagenesis B
of I
aa I
97 I
– I
123 I
of O
ank O
1 O
. O
5 O
was O
performed O
and O
the O
in O
vitro O
– O
transcribed O
and O
– O
translated O
mutant O
proteins O
were O
used O
in O
binding O
experiments O
with O
the O
GST O
– O
Obs O
6215 O
– O
6353 O
fusion O
protein O
. O

Mutagenesis B
of I
any I
of I
four I
aa I
residues I
( I
T I
99 I
, I
K I
101 I
, I
R I
104 I
, I
and I
K I
105 I
) I
of O
ank O
1 O
. O
5 O
strongly O
reduced O
the O
ability O
to O
bind O
to O
obscurin O
. O

To O
identify O
the O
critical O
aa O
that O
in O
ank O
1 O
. O
5 O
are O
required O
for O
the O
interaction O
with O
the O
COOH O
terminus O
of O
obscurin O
, O
site O
- O
directed O
mutagenesis B
of I
aa I
97 I
– I
123 I
of O
ank O
1 O
. O
5 O
was O
performed O
, O
and O
the O
in O
vitro O
– O
transcribed O
and O
– O
translated O
mutant O
proteins O
were O
used O
in O
binding O
experiments O
with O
the O
GST O
– O
Obs O
6215 O
– O
6353 O
fusion O
protein O
. O

Deletion B
of I
the I
N I
- I
terminal I
Atg O
5 O
binding O
domain O
( O
1 O
– O
78 O
aa O
) O
or O
C O
- O
terminal O
WD O
domain O
( O
266 O
– O
623 O
aa O
) O
had O
no O
effect O
on O
the O
Atg O
16 O
L O
1 O
- O
WIPI O
2 O
b O
interaction O
in O
GFP O
pull O
- O
down O
experiments O
( O
Figure O
2 O
B O
) O
. O

We O
refined O
the O
interaction O
site O
using O
truncation O
mutants O
of O
FLAG O
- O
Atg O
16 O
L O
1 O
constructs O
, O
with O
GFP O
and O
CFP O
- O
Atg O
5 O
as O
controls O
, O
and O
GFP O
- O
WIPI O
1 O
a O
or O
GFP O
- O
WIPI O
2 O
b O
( O
Figures O
2 O
C O
and O
S O
2 O
C O
) O
. O

Mutation B
of I
either I
residue I
E I
226 I
or I
E I
230 I
to I
arginine I
( O
E O
226 O
R O
and O
E O
230 O
R O
) O
abolished O
binding O
of O
Atg O
16 O
L O
1 O
to O
WIPI O
2 O
b O
, O
and O
E O
208 O
R O
or O
D O
212 O
R O
mutants O
reproducibly O
showed O
reduced O
binding O
. O

This O
region O
encompasses O
part O
of O
the O
WIP O
2 O
b O
binding O
site O
, O
so O
we O
asked O
if O
the O
WIPI O
2 O
and O
FIP O
200 O
binding O
sites O
overlapped O
by O
testing O
if O
our O
FLAG O
- O
Atg O
16 O
L O
1 O
constructs O
could O
bind O
FIP O
200 O
( O
Figures O
3 O
D O
and O
3 O
E O
) O
. O

However O
, O
the O
Atg O
16 O
L O
1 O
point B
mutations I
from I
E I
235 I
to I
E I
241 I
bound O
very O
weakly O
or O
not O
at O
all O
to O
FIP O
200 O
. O

WIPI O
2 O
b O
is O
a O
member O
of O
the O
WD O
- O
repeat O
SVP O
1 O
- O
like O
family O
of O
seven O
- O
bladed O
β O
- O
propeller O
proteins O
that O
bind O
phosphatidylinositols O
( O
PROPPINs O
) O
( O
Dove O
et O
al O
. O
, O
2004 O
) O
. O

Inhibition O
of O
Ptd O
Ins O
( O
3 O
) O
P O
binding O
through O
mutation B
of I
the I
Ptd I
Ins I
( I
3 I
) I
P I
binding I
motif I
FRRG I
to I
FTTG I
( O
GFP O
- O
WIPI O
2 O
b O
FTTG O
) O
had O
no O
significant O
effect O
on O
the O
ability O
of O
WIPI O
2 O
b O
to O
bind O
Atg O
16 O
L O
1 O
( O
Figures O
4 O
A O
and O
4 O
B O
) O
. O

Mutation B
of I
R I
108 I
to I
glutamate I
( O
WIPI O
2 O
b O
R O
108 O
E O
) O
reduced O
Atg O
16 O
L O
1 O
binding O
dramatically O
, O
while O
R O
125 O
E O
showed O
decreased O
binding O
( O
Figure O
4 O
D O
) O
. O

ACAP O
2 O
was O
cloned O
from O
a O
Super O
Script O
human O
leukocyte O
c O
DNA O
library O
( O
Life O
Technologies O
) O
using O
a O
2 O
- O
kb O
Kpn O
I O
fragment O
from O
KIAA O
0041 O
( O
Dr O
. O
Takahiro O
Nagese O
) O
as O
a O
probe O
. O

The O
products O
were O
purified O
, O
mixed O
in O
equimolar O
amounts O
, O
and O
used O
as O
template O
for O
combinatorial O
PCR O
. O

Glutamine B
mutations I
in I
arginine I
448 I
of O
ACAP O
1 O
and O
arginine O
442 O
of O
ACAP O
2 O
were O
introduced O
using O
a O
kit O
( O
Quikchange O
; O
Stratagene O
) O
. O

When O
we O
determined O
the O
sequences O
, O
one O
case O
with O
lymph O
node O
metastasis O
showed O
an O
ATG B
( I
Met I
) I
to I
ACG I
( I
Thr I
) I
missense I
mutation I
in I
codon I
168 I
. O

Another O
case O
showed O
a O
CGA B
( I
Arg I
) I
to I
GGA I
( I
Gly I
) I
mutation I
in I
codon I
201 I
, O
which O
might O
be O
a O
polymorphic O
change O
, O
and O
two O
other O
mutations O
resulting O
in O
no O
amino O
acid O
change O
. O

These O
results O
indicate O
that O
alterations O
of O
the O
DCC O
gene O
are O
related O
to O
the O
degree O
of O
lymph O
node O
metastasis O
and O
the O
degree O
of O
differentiation O
. O

A O
mutation O
, O
which O
changes O
a O
highly O
conserved O
Cys B
to I
Tyr I
in I
transmembrane I
domain I
IS I
1 I
, O
identifies O
a O
residue O
important O
for O
channel O
function O
not O
only O
in O
Drosophila O
muscle O
but O
also O
in O
mammalian O
cardiac O
channels O
. O

Amino O
acid O
substitutions B
at I
this I
Cys I
position I
in I
the I
cardiac I
alpha I
1 I
subunit I
show O
that O
the O
size O
of O
the O
side O
chain O
, O
rather O
than O
its O
ability O
to O
form O
disulfide O
bonds O
, O
affects O
channel O
activation O
. O

Three O
point B
mutations I
in I
exon I
73 I
caused O
glycine O
substitutions O
G O
2006 O
D O
, O
G O
2034 O
R O
, O
and O
G O
2015 O
E O
in O
the O
triple O
helical O
domain O
of O
collagen O
VII O
and O
interfered O
with O
its O
folding O
and O
secretion O
. O

Limited O
proteolytic O
digestions O
of O
mutant O
procollagen O
VII O
produced O
aberrant O
fragments O
and O
revealed O
reduced O
stability O
of O
the O
triple O
helix O
. O

The O
systematic O
use O
of O
antivitamin O
K O
anticoagulants O
( O
AVK O
) O
as O
rodenticides O
caused O
the O
selection O
of O
rats O
resistant O
to O
AVKs O
. O

In O
this O
report O
, O
we O
showed O
that O
mutations B
at I
Leu I
- I
120 I
and I
Tyr I
- I
139 I
dramatically O
affect O
the O
vitamin O
K O
epoxide O
reductase O
activity O
. O

On O
the O
contrary O
, O
vit O
K O
requirements O
in O
resistant O
rats O
from O
Scotland O
( O
i O
. O
e O
. O
, O
homozygous O
for O
L O
128 O
Q O
) O
[ O
27 O
] O
are O
described O
to O
be O
similar O
to O
vit O
K O
requirements O
of O
susceptible O
rats O
. O

Only O
the O
resistance O
due O
to O
a O
mutation B
of I
the I
Tyr I
- I
139 I
residue O
might O
be O
associated O
with O
a O
biological O
cost O
. O

In O
this O
patient O
, O
the O
Tyr B
- I
139 I
residue I
is I
replaced I
by I
a I
His I
residue I
[ O
31 O
] O
. O

This O
mutation O
was O
demonstrated O
to O
lead O
to O
resistance O
to O
AVK O
without O
modifying O
the O
catalytic O
efficiency O
to O
produce O
vit O
K O
[ O
21 O
] O
. O

A O
statistically O
significant O
association O
between O
a O
silent O
mutation O
( O
102 O
T O
/ O
C O
) O
in O
the O
serotonin O
- O
2 O
A O
( O
5 O
- O
HT O
2 O
A O
) O
receptor O
gene O
and O
schizophrenia O
has O
recently O
been O
reported O
in O
a O
sample O
of O
Japanese O
patients O
and O
healthy O
controls O
. O

Two O
sequence O
changes O
would O
result O
in O
protein O
alterations O
: O
a O
substitution B
of I
threonine I
by I
asparagine I
at I
position I
25 I
( O
Thr O
25 O
Asn O
) O
, O
and O
a O
substitution B
of I
histidine I
by I
tyrosine I
at I
position I
452 I
( O
His O
452 O
Tyr O
) O
. O

Interaction O
between O
cellular O
APE O
1 O
and O
C O
464 O
A O
MDM O
2 O
was O
detected O
by O
FLAG O
co O
- O
immunoprecipitation O
assay O
using O
FLAG O
- O
tagged O
APE O
1 O
( O
lane O
1 O
, O
Fig O
. O

Deleting B
APE I
1 I
’ I
s I
N I
- I
terminal I
41 I
amino I
acid I
( I
a I
. I
a I
. I
) I
residues I
( O
ND O
42 O
) O
caused O
no O
detectable O
effect O
on O
the O
MDM O
2 O
co O
- O
immunoprecipitation O
( O
lane O
2 O
) O
, O
suggesting O
that O
the O
N O
- O
terminal O
region O
was O
not O
required O
for O
the O
interaction O
. O

Interestingly O
, O
the O
C B
- I
terminal I
20 I
a I
. I
a I
. I
deletion I
of O
APE O
1 O
( O
CD O
20 O
) O
repeatedly O
resulted O
in O
much O
more O
efficient O
co O
- O
precipitation O
of O
MDM O
2 O
than O
the O
full O
- O
length O
APE O
1 O
. O

It O
is O
likely O
that O
the O
C B
- I
terminal I
deletion I
exposed O
the O
presumptive O
interaction O
domain O
of O
APE O
1 O
. O

While O
ubiquitination O
of O
ND O
21 O
APE O
1 O
( O
20 B
a I
. I
a I
. I
N I
- I
terminal I
deletion I
) O
was O
comparable O
to O
that O
of O
the O
full O
- O
length O
APE O
1 O
( O
lane O
2 O
) O
, O
ubiquitination O
of O
the O
ND O
42 O
APE O
1 O
( O
42 B
a I
. I
a I
. I
N I
- I
terminal I
deletion I
) O
was O
not O
detected O
( O
lane O
3 O
) O
, O
indicating O
that O
the O
ubiquitination O
occurred O
inside O
of O
21 O
- O
42 O
from O
the O
APE O
1 O
N O
- O
terminus O
. O

Because O
there O
were O
still O
six O
Lys O
residues O
in O
the O
segment O
( O
i O
. O
e O
. O
, O
24 B
K I
, I
25 I
K I
, I
27 I
K I
, I
31 I
K I
, I
32 I
K I
, I
and I
35 I
K I
) I
, I
we I
mutated I
each I
individually I
to I
Arg I
in O
the O
ND O
21 O
background O
. O

4 O
) O
. O

Therefore O
, O
we O
predict O
that O
ubiquitination O
reactions O
at O
these O
sites O
occur O
to O
all O
mammalian O
APE O
1 O
s O
. O

In O
addition O
, O
one O
lipodystrophy O
- O
associated O
missense O
mutation O
has O
been O
described O
, O
causing O
substitution B
of I
alanine I
at I
codon I
212 I
for I
proline I
( O
4 O
) O
. O

4 O
B O
) O
. O

Analysis O
of O
naturally O
occurring O
pathogenic O
mutants O
of O
BSCL O
2 O
. O

A O
: O
Murine O
C O
3 O
H O
10 O
T O
1 O
/ O
2 O
pluripotent O
cells O
were O
transfected O
with O
empty O
vector O
( O
mock O
) O
, O
myc O
- O
tagged O
wild O
- O
type O
human O
BSCL O
2 O
( O
WT O
) O
, O
or O
myc O
- O
tagged O
wild O
- O
type O
human O
BSCL O
2 O
prematurely O
truncated B
at I
amino I
acid I
R I
275 I
( O
R O
275 O
X O
) O
or O
bearing O
a O
point O
mutation O
causing O
amino O
acid O
substitution O
A O
212 O
P O
. O

The O
first O
mutation O
at O
the O
codon O
347 O
cause O
a O
change B
in I
reading I
frame I
after I
Ala I
- I
347 I
and I
premature I
termination I
of I
translation I
in I
amino I
acid I
400 I
, O
which O
has O
been O
previously O
reported O
in O
Italian O
family O
with O
GSD O
- O
1 O
b O
( O
6 O
) O
. O

The O
second O
mutation B
at I
the I
codon I
148 I
, O
novel O
mutation O
was O
a O
missence O
mutation O
from O
alanine B
to I
valine I
at I
codon I
148 I
. O

Sequencing O
FRMD O
7 O
revealed O
a O
G O
> O
T O
transversion O
( O
c O
. O
812 O
G O
> O
T O
) O
in O
exon O
9 O
, O
which O
caused O
a O
conservative O
substitution B
of I
Cys I
to I
Phe I
at I
codon I
271 I
( O
p O
. O
C O
271 O
F O
) O
. O

Sequence O
analysis O
revealed O
a O
G B
> I
T I
transversion I
in I
exon I
9 I
( O
Figure O
3 O
) O
that O
caused O
a O
conservative O
substitution B
of I
Cys I
to I
Phe I
at I
codon I
271 I
( O
p O
. O
C O
271 O
F O
) O
. O

There O
is O
a O
single O
base O
G B
> I
T I
transversion I
in I
exon I
9 I
of O
FRMD O
7 O
that O
causes O
a O
conservative O
substitution B
of I
Cys I
to I
Phe I
at I
codon I
271 I
( O
p O
. O
C O
271 O
F O
) O
. O

The O
software O
determined O
that O
the O
substitution B
of I
Cys I
to I
Phe I
at I
position I
271 I
was O
deleterious O
. O

[ O
5 O
] O
identified O
five O
novel O
mutations O
in O
six O
families O
with O
XLICN O
. O

Among O
these O
22 O
mutations O
, O
a O
missense B
mutation I
of I
C I
271 I
Y I
in I
exon I
9 I
was O
detected O
in O
a O
Scottish O
family O
. O

Primary O
coenzyme O
Q O
( O
10 O
) O
deficiency O
represents O
a O
clinically O
heterogeneous O
condition O
suggestive O
of O
genetic O
heterogeneity O
, O
and O
several O
disease O
genes O
have O
been O
previously O
identified O
. O

Various O
missense O
mutations O
( O
R O
213 O
W O
, O
G O
272 O
V O
, O
G O
272 O
D O
, O
and O
E O
551 O
K O
) O
modifying O
highly O
conserved O
amino O
acids O
of O
the O
protein O
and O
a O
1 B
bp I
frameshift I
insertion I
c I
. I
[ I
1812 I
_ I
1813 I
ins I
G I
] I
were O
identified O
. O

This O
nucleotide O
change O
causes O
the O
amino O
- O
acid O
order O
from O
proline B
to I
leucine I
at I
codon I
233 I
. O

Complete O
sequencing O
of O
the O
C O
5 O
L O
2 O
region O
that O
included O
a O
portion O
of O
the O
upstream O
region O
, O
1 O
intron O
, O
and O
the O
exon O
with O
the O
complete O
coding O
region O
was O
initially O
conducted O
on O
48 O
subjects O
with O
CAD O
. O

A O
novel O
SNP O
( O
698 O
C O
> O
T O
) O
causes O
the O
change O
in O
amino O
acids O
from O
proline B
to I
leucine I
at I
codon I
233 I
. O

This O
was O
a O
non O
- O
synonymous O
mutation O
; O
it O
was O
an O
AGC O
→ O
ATC O
variant O
resulting O
in O
a O
S B
323 I
- I
to I
- I
I I
substitution O
which O
was O
associated O
with O
familial O
combined O
hyperlipidemia O
in O
a O
French O
– O
Canadian O
family O
. O

These O
data O
suggested O
that O
C O
5 O
L O
2 O
was O
associated O
with O
hyperlipidemia O
and O
diabetes O
, O
which O
have O
been O
reported O
to O
be O
risk O
factors O
of O
CAD O
. O

Patient O
1 O
was O
shown O
to O
have O
a O
14 O
. O
83 O
Mb O
deletion O
which O
extended O
from O
FREM O
1 O
intron O
9 O
to O
the O
chromosome O
9 O
p O
telomere O
, O
deleting B
exons I
10 I
- I
37 I
of O
FREM O
1 O
. O

Patient O
2 O
had O
a O
complex O
chromosome B
9 I
deletion I
- I
duplication I
mutation O
with O
a O
breakpoint O
within O
FREM O
1 O
. O

The O
deletion O
component O
of O
this O
re O
- O
arrangement O
extended O
from O
FREM O
1 O
intron O
6 O
to O
the O
9 O
p O
telomere O
, O
deleting B
exons I
7 I
- I
37 I
of O
FREM O
1 O
. O

The O
third O
CNV O
was O
a O
15 B
. I
32 I
Mb I
deletion I
in O
Patient O
3 O
which O
extended O
from O
the O
chromosome O
9 O
p O
telomere O
to O
the O
intergenic O
region O
between O
TTC O
39 O
B O
and O
SNAPC O
3 O
resulting O
in O
the O
deletion B
of I
the I
entire I
FREM O
1 O
locus O
. O

Patient O
4 O
had O
the O
smallest O
CNV O
; O
a O
2 B
. I
14 I
Mb I
interstitial I
9 I
p I
deletion I
between I
genomic I
co I
- I
ordinates I
14 I
. I
20 I
and I
16 I
. I
34 I
Mb I
[ O
hg O
18 O
] O
which O
involved O
only O
9 O
genes O
. O

This O
region O
extends O
from O
NFIB O
intron O
2 O
to O
the O
intergenic O
region O
between O
C O
9 O
orf O
93 O
and O
BNC O
2 O
also O
deleting B
FREM O
1 O
. O

In O
summary O
, O
morphometric O
analysis O
of O
skulls O
from O
bat O
homozygous O
and O
heterozygous O
mice O
identified O
craniofacial O
malformations O
consistent O
with O
the O
craniofacial O
features O
, O
in O
particular O
MC O
and O
midfacial O
asymmetry O
/ O
hypoplasia O
, O
seen O
in O
the O
9 B
p I
22 I
deletion I
syndrome O
, O
with O
the O
penetrance O
of O
the O
phenotypes O
in O
mice O
correlated O
to O
mutant O
gene O
dosage O
. O

To O
investigate O
whether O
either O
of O
the O
two O
remaining O
genes O
within O
the O
refined O
critical O
interval O
might O
also O
contribute O
to O
the O
craniofacial O
phenotype O
of O
the O
9 B
p I
22 I
deletion I
syndrome O
, O
we O
first O
analyzed O
a O
small O
number O
of O
Zdhhc O
21 O
dep O
/ O
dep O
homozygotes O
. O

ETF O
deficiency O
can O
be O
demonstrated O
in O
individuals O
affected O
by O
a O
severe O
metabolic O
disorder O
, O
glutaric O
acidemia O
type O
II O
( O
GAII O
) O
. O

One O
allele O
is O
carrying O
a O
G B
to I
A I
transition I
at I
nucleotide I
518 I
, O
causing O
a O
missense B
mutation I
at I
codon I
164 I
. O

The O
other O
allele O
carries O
a O
G B
to I
C I
transversion I
at I
the I
first I
nucleotide I
of I
the I
intron I
donor I
site I
, O
downstream O
of O
an O
exon O
that O
is O
skipped O
during O
the O
splicing O
event O
. O

The O
sequence O
analysis O
of O
the O
beta O
- O
ETF O
coding O
sequence O
in O
P O
485 O
showed O
only O
a O
C B
to I
T I
transition I
at I
nucleotide I
488 I
that O
causes O
a O
Thr B
154 I
to I
Met I
substitution O
and O
the O
elimination O
of O
a O
Hga O
I O
restriction O
site O
. O

All O
Nijmegen O
samples O
were O
analysed O
using O
SNP O
microarray O
analysis O
prior O
to O
exome O
sequencing O
and O
this O
had O
excluded O
larger O
CNVs O
in O
all O
patients O
apart O
from O
one O
deletion B
of I
exons I
81 I
– I
83 I
identified O
in O
patient O
JATD O
- O
6 O
, O
who O
additionally O
carried O
two O
heterozygous O
missense O
changes O
identified O
by O
Sanger O
sequencing O
. O

JATD O
- O
6 O
carried O
the O
common O
mutation O
p O
. O
D O
3015 O
G O
, O
and O
a O
large O
deletion B
p I
. I
G I
3891 I
_ I
Q I
4020 I
; O
the O
third O
variant O
is O
a O
heterozygous O
missense O
change O
p O
. O
R O
3813 O
C O
. O

However O
, O
this O
interaction O
does O
not O
occur O
in O
the O
opioid O
receptors O
, O
which O
have O
L O
275 O
at O
6 O
. O
30 O
. O

On O
the O
basis O
of O
our O
findings O
that O
mutations O
of O
T B
6 I
. I
34 I
( I
279 I
) I
to I
K I
and I
D I
produced O
, O
respectively O
, O
a O
constitutively O
active O
and O
an O
inactive O
form O
of O
the O
mu O
opioid O
receptor O
, O
we O
previously O
suggested O
that O
the O
functional O
role O
of O
the O
6 O
. O
30 O
( O
275 O
) O
residue O
could O
be O
assumed O
by O
T O
6 O
. O
34 O
( O
279 O
) O
, O
but O
the O
interplay O
between O
residues O
at O
positions O
6 O
. O
30 O
and O
6 O
. O
34 O
remained O
unresolved O
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
introducing B
an I
E I
in I
position I
6 I
. I
30 I
( I
275 I
) I
of O
the O
wild O
type O
( O
WT O
) O
and O
of O
the O
T O
6 O
. O
34 O
( O
279 O
) O
mutants O
of O
the O
mu O
opioid O
receptor O
to O
compare O
the O
participation O
of O
the O
6 O
. O
30 O
locus O
in O
molecular O
events O
during O
activation O
in O
this O
receptor O
with O
its O
role O
in O
other O
GPCRs O
. O

When O
L B
6 I
. I
30 I
( I
275 I
) I
is I
mutated I
to I
E I
, O
the O
favorable O
E O
6 O
. O
30 O
( O
275 O
) O
- O
R O
3 O
. O
50 O
( O
165 O
) O
interaction O
stabilizes O
an O
inactive O
state O
, O
as O
in O
rhodopsin O
, O
and O
hence O
reduces O
the O
activities O
of O
T O
6 O
. O
34 O
( O
279 O
) O
mutants O
. O

Adducin O
is O
a O
membrane O
skeletal O
protein O
that O
binds O
to O
actin O
filaments O
( O
F O
- O
actin O
) O
and O
thereby O
promotes O
the O
association O
of O
spectrin O
with O
F O
- O
actin O
to O
form O
a O
spectrin O
- O
actin O
meshwork O
beneath O
plasma O
membranes O
such O
as O
ruffling O
membranes O
. O

The O
microinjection O
of O
Botulinum O
C O
3 O
ADP O
- O
ribosyl O
- O
transferase O
, O
dominant O
negative O
Rho O
- O
kinase O
, O
or O
alpha O
- O
adducin O
T O
445 O
A O
, O
T O
480 O
A O
( O
substitution B
of I
Thr I
445 I
and O
Thr B
480 I
by I
Ala I
) O
inhibited O
the O
TPA O
- O
induced O
membrane O
ruffling O
in O
MDCK O
cells O
and O
wound O
- O
induced O
migration O
in O
NRK O
49 O
F O
cells O
. O

alpha O
- O
Adducin O
T O
445 O
D O
, O
T O
480 O
D O
( O
substitution B
of I
Thr I
445 I
and O
Thr B
480 I
by I
Asp I
) O
, O
but O
not O
alpha O
- O
adducin O
T O
445 O
A O
, O
T O
480 O
A O
, O
counteracted O
the O
inhibitory O
effect O
of O
the O
dominant O
negative O
Rho O
- O
kinase O
on O
the O
TPA O
- O
induced O
membrane O
ruffling O
in O
MDCK O
cells O
. O

Western O
blotting O
revealed O
absence O
of O
2 O
- O
MBCDase O
protein O
in O
fibroblast O
extracts O
; O
DNA O
sequencing O
identified O
a O
single B
778 I
C I
> I
T I
substitution I
in O
the O
2 O
- O
MBCDase O
coding O
region O
( O
778 O
C O
> O
T O
) O
, O
substituting B
phenylalanine I
for I
leucine I
at I
amino I
acid I
222 I
( O
L O
222 O
F O
) O
and O
absence O
of O
enzyme O
activity O
for O
the O
2 O
- O
MBCDase O
protein O
expressed O
in O
Escherichia O
coli O
. O

NEPH O
1 O
, O
a O
member O
of O
the O
immunoglobulin O
superfamily O
, O
is O
structurally O
related O
to O
nephrin O
. O

All O
three O
NEPH O
proteins O
share O
a O
conserved O
podocin O
- O
binding O
motif O
; O
mutation B
of I
a I
centrally I
located I
tyrosine I
residue I
dramatically O
lowers O
the O
affinity O
of O
NEPH O
1 O
for O
podocin O
. O

Although O
many O
commonly O
used O
drugs O
block O
I O
( O
Kr O
) O
, O
in O
certain O
individuals O
, O
this O
action O
evokes O
a O
paradoxical O
life O
- O
threatening O
cardiac O
rhythm O
disturbance O
, O
known O
as O
the O
acquired O
long O
QT O
syndrome O
( O
a O
LQTS O
) O
. O

Examination O
of O
the O
human O
KCR O
1 O
sequence O
in O
patients O
with O
drug O
- O
induced O
cardiac O
repolarization O
defects O
revealed O
a O
sequence O
variation O
( O
the O
substitution B
of I
isoleucine I
447 I
by I
valine I
, O
I O
447 O
V O
) O
that O
occurs O
at O
a O
reduced O
frequency O
( O
1 O
. O
1 O
% O
) O
relative O
to O
a O
matched O
control O
population O
( O
7 O
. O
0 O
% O
) O
, O
suggesting O
that O
I O
447 O
V O
may O
be O
an O
allele O
for O
reduced O
a O
LQTS O
susceptibility O
. O

Two O
homozygous O
point O
mutations O
were O
found O
in O
a O
patient O
with O
factor O
X O
( O
FX O
) O
deficiency O
; O
One O
results O
in O
substitution O
of O
Lys B
for I
Gla I
+ I
14 I
and O
the O
second O
causes O
a O
Lys B
substitution I
for I
Glu I
102 I
. O

The O
substitution B
of I
Lys I
for I
Glu I
102 I
in O
FX O
deficiency O
has O
been O
reported O
previously O
in O
a O
heterozygous O
state O
in O
conjunction O
with O
a O
Lys O
for I
Gla I
+ I
14 I
substitution I
and O
with O
a O
Pro B
for I
Ser I
334 I
substitution O
. O

The O
contribution O
of O
the O
Lys B
for I
Glu I
102 I
substitution O
in O
the O
observed O
combined O
FX O
defect O
in O
these O
patients O
was O
unclear O
. O

The O
data O
presented O
show O
that O
the O
substitution B
of I
Lys I
for I
Glu I
102 I
results O
in O
a O
minor O
functional O
defect O
of O
the O
FX O
molecule O
. O

Compounds O
examined O
include O
4 O
- O
bromoethylimidazole O
( O
4 O
- O
BEI O
) O
, O
2 O
- O
chloromethylimidazole O
( O
2 O
- O
CMI O
) O
, O
4 O
- O
chloromethylimidazole O
( O
4 O
- O
CMI O
) O
, O
and O
a O
triazole O
analog O
. O

Modification O
of O
the O
introduced B
Cys I
131 I
with O
4 O
- O
BEI O
and O
4 O
- O
CMI O
resulted O
in O
enhancements O
of O
up O
to O
threefold O
in O
catalytic O
activity O
. O

Mutation B
of I
Cys I
341 I
in I
the I
carboxyl I
tail I
leads O
to O
an O
uncoupled O
nonpalmitoylated O
form O
of O
the O
receptor O
. O

Mutation O
of O
Cys B
341 I
to I
glycine I
results O
in O
a O
nonpalmitoylated O
form O
of O
the O
receptor O
that O
exhibits O
a O
drastically O
reduced O
ability O
to O
mediate O
isoproterenol O
stimulation O
of O
adenylyl O
cyclase O
. O

Our O
previous O
work O
showed O
that O
Bad O
is O
also O
phosphorylated O
in O
response O
to O
cytokines O
at O
another O
site O
, O
which O
we O
now O
identify O
as O
Ser O
- O
170 O
. O

In O
general O
, O
mutation O
of O
Ser B
- I
170 I
to I
Ala I
results O
in O
a O
protein O
with O
increased O
ability O
to O
induce O
apoptosis O
, O
similar O
to O
the O
S O
112 O
A O
mutant O
. O

Mutation O
of O
Ser B
- I
170 I
to I
Asp I
, O
mimicking O
a O
constitutively O
phosphorylated O
site O
, O
results O
in O
a O
protein O
that O
is O
virtually O
unable O
to O
induce O
apoptosis O
. O

Most O
patients O
with O
MCAD O
deficiency O
are O
homozygous O
for O
a O
single O
disease O
- O
causing O
mutation O
( O
G O
985 O
) O
, O
causing O
a O
change B
from I
lysine I
to I
glutamate I
at I
position I
304 I
( I
K I
304 I
E I
) I
in O
the O
mature O
MCAD O
. O

Only O
seven O
non O
- O
G O
985 O
mutations O
, O
all O
of O
which O
are O
rare O
, O
have O
been O
reported O
. O

Because O
the O
G B
985 I
mutation I
and O
three B
of I
the I
non I
- I
G I
985 I
mutations I
are I
located I
in I
exon I
11 I
, O
it O
has O
been O
suggested O
that O
this O
exon O
may O
be O
a O
mutational O
hot O
spot O
. O

We O
have O
shown O
previously O
that O
a O
variant O
allele O
of O
the O
short O
- O
chain O
acyl O
- O
Co O
A O
dehydrogenase O
( O
SCAD O
) O
gene O
, O
625 O
G O
- O
- O
> O
A O
, O
is O
present O
in O
homozygous O
form O
in O
7 O
% O
of O
control O
individuals O
and O
in O
60 O
% O
of O
135 O
patients O
with O
elevated O
urinary O
excretion O
of O
ethylmalonic O
acid O
( O
EMA O
) O
. O

The O
second O
patient O
carried O
a O
1147 B
C I
- I
- I
> I
T I
mutation I
and O
the B
625 I
G I
- I
- I
> I
A I
polymorphism O
in O
one O
allele O
, O
and O
a O
single O
point O
mutation O
, O
511 O
C O
- O
- O
> O
T O
, O
in O
the O
other O
. O

The O
1147 O
C O
- O
- O
> O
T O
mutation O
was O
not O
present O
in O
98 O
normal O
alleles O
, O
but O
was O
detected O
in O
three O
alleles O
of O
133 O
patients O
with O
elevated O
EMA O
excretion O
, O
consistently O
as O
a O
625 B
A I
- I
1147 I
T I
allele I
. O

On O
the O
other O
hand O
, O
the O
511 B
C I
- I
- I
> I
T I
mutation I
was O
present O
in O
13 O
of O
130 O
and O
15 O
of O
67 O
625 O
G O
alleles O
, O
respectively O
, O
of O
normal O
controls O
and O
patients O
with O
elevated O
EMA O
excretion O
, O
and O
was O
never O
associated O
with O
the O
625 O
A O
variant O
allele O
. O

Expression O
of O
the O
variant O
R O
147 O
W O
SCAD O
protein O
, O
encoded O
by O
the O
511 O
T O
- O
625 O
G O
allele O
, O
in O
COS O
- O
7 O
cells O
showed O
45 O
% O
activity O
at O
37 O
degrees O
C O
in O
comparison O
with O
the O
wild O
- O
type O
protein O
, O
comparable O
levels O
of O
activity O
at O
26 O
degrees O
C O
, O
and O
13 O
% O
activity O
when O
incubated O
at O
41 O
degrees O
C O
. O
This O
temperature O
profile O
is O
different O
from O
that O
observed O
for O
the O
variant O
G O
185 O
S O
SCAD O
protein O
, O
encoded O
by O
the O
511 O
C I
- I
625 I
A I
allele I
, I
where O
higher O
than O
normal O
activity O
was O
found O
at O
26 O
and O
37 O
degrees O
C O
, O
and O
58 O
% O
activity O
was O
present O
at O
41 O
degrees O
C O
. O
These O
results O
corroborate O
the O
notion O
that O
the O
511 O
C I
- I
625 I
A I
variant I
allele I
is I
one O
of O
the O
possible O
underlying O
causes O
of O
ethylmalonic O
aciduria O
, O
and O
suggest O
that O
the O
511 O
C O
- O
- O
> O
T O
mutation O
represents O
a O
second O
susceptibility O
variation O
in O
the O
SCAD O
gene O
. O

Endopeptidase O
cleavage O
at O
Lys O
( O
91 O
) O
generates O
a O
cleaved O
globular O
g O
CTRP O
12 O
isoform O
, O
the O
expression O
of O
which O
is O
increased O
by O
insulin O
. O

Cleavage O
at O
Lys O
( O
91 O
) O
is O
context O
- O
dependent O
: O
mutation B
of I
the I
charged I
Arg I
( I
93 I
) I
to I
Ala I
on I
the I
P I
2 I
' I
position I
enhanced O
cleavage O
, O
and O
triple O
mutations O
( O
K O
90 O
A O
/ O
K O
91 O
A O
/ O
R O
93 O
A O
) O
abolished O
cleavage O
. O

ABCB O
11 O
mutations O
were O
functionally O
characterized O
by O
taurocholate O
transport O
in O
SF O
9 O
cells O
transfected O
with O
human O
ABCB O
11 O
. O

RESULTS O
: O
The O
PFIC O
2 O
patient O
was O
compound O
heterozygous O
for O
a O
splicing O
mutation O
in O
intron B
4 I
( I
( I
+ I
3 I
) I
A I
> I
C I
) I
combined O
with O
an O
early B
stop I
codon I
at I
position I
930 I
( O
R O
930 O
X O
) O
, O
while O
the O
BRIC O
2 O
patient O
was O
compound O
heterozygous O
for O
two O
nonsynonymous O
mutations O
in O
exon O
9 O
( O
E O
297 O
G O
) O
and O
exon O
12 O
( O
R O
432 O
T O
) O
, O
respectively O
. O

CONCLUSIONS O
: O
The O
intron B
4 I
( I
+ I
3 I
) I
A I
> I
C I
, O
R O
930 O
X O
and O
R O
432 O
T O
represent O
previously O
undescribed O
mutations O
of O
the O
ABCB O
11 O
gene O
that O
confer O
a O
PFIC O
2 O
and O
a O
BRIC O
2 O
phenotype O
, O
respectively O
. O

Molecular O
basis O
of O
an O
adult O
form O
of O
Sandhoff O
disease O
: O
substitution B
of I
glutamine I
for I
arginine I
at I
position I
505 I
of O
the O
beta O
- O
chain O
of O
beta O
- O
hexosaminidase O
results O
in O
a O
labile O
enzyme O
. O

Hexosaminidase O
activity O
is O
negligible O
in O
infantile O
Sandhoff O
disease O
whereas O
residual O
activity O
is O
present O
in O
juvenile O
and O
adult O
forms O
. O

Sequence O
analysis O
of O
the O
entire O
c O
DNA O
prepared O
from O
poly O
- O
adenylated O
RNA O
showed O
that O
only O
one O
point O
mutation O
was O
present O
, O
consisting O
of O
a O
G B
- I
- I
> I
A I
transition I
at I
nucleotide I
position I
1514 I
. O

This O
mutation O
changes B
the I
electric I
charge I
at I
amino I
acid I
position I
505 I
by I
substitution I
of I
glutamine I
for I
arginine I
in O
a O
highly O
conserved O
part O
of O
the O
beta O
- O
chain O
, O
present O
even O
in O
the O
slime O
mold O
Dictyostelium O
discoideum O
. O

We O
hypothesized O
that O
the O
ACTH O
receptor O
gene O
might O
be O
defective O
in O
IGD O
. O

The O
proband O
was O
a O
compound O
heterozygote O
for O
two O
different O
point O
mutations O
, O
one O
in O
each O
allele O
: O
( O
a O
) O
a O
substitution O
( O
C O
- O
- O
> O
T O
) O
, O
also O
found O
in O
one O
allele O
of O
the O
mother O
and O
maternal O
grandmother O
, O
which O
introduced O
a O
premature B
stop I
codon I
( I
TGA I
) I
at I
position I
201 I
of O
the O
protein O
; O
this O
mutant B
receptor I
lacks I
its I
entire I
carboxy I
- I
terminal I
third I
and O
, O
if O
expressed O
, O
should O
be O
unable O
to O
transduce O
the O
signal O
; O
and O
( O
b O
) O
a O
substitution O
( O
C O
- O
- O
> O
G O
) O
, O
also O
found O
in O
one O
of O
the O
paternal O
alleles O
, O
which O
changed B
neutral I
serine I
120 I
in I
the I
apolar I
third I
transmembrane I
domain I
of I
the I
receptor I
to I
a I
positively I
charged I
arginine I
, O
probably O
disrupting O
the O
ligand O
- O
binding O
site O
. O

Previous O
studies O
have O
identified O
three O
mutations B
at I
APP I
codon I
717 I
which O
are O
pathogenic O
for O
Alzheimer O
disease O
( O
AD O
) O
. O

One O
variant O
at O
APP O
codon B
693 I
resulted I
in I
a I
Glu I
- I
- I
> I
Gly I
change I
. O

This O
is O
the O
same O
codon O
as O
the O
hereditary O
cerebral O
hemorrhage O
with O
amyloidosis O
- O
Dutch O
type O
Glu O
- O
- O
> O
Gln O
mutation O
. O

Another O
single B
- I
base I
change I
at I
APP I
codon I
708 I
did O
not O
alter O
the O
amino O
acid O
encoded O
at O
this O
site O
. O

Two O
point O
mutations O
and O
a O
6 B
- I
bp I
deletion I
were I
identified I
in I
the I
intronic I
sequences I
surrounding I
exon I
17 I
. O

The O
recombinant O
protein O
showed O
spectral O
features O
and O
a O
range O
of O
substrate O
specificity O
similar O
to O
the O
native O
protein O
purified O
from O
mouse O
liver O
. O

Site O
- O
directed O
mutagenesis B
of I
amino I
acids I
Val I
806 I
, I
Met I
884 I
and I
Glu I
1265 I
at O
the O
active O
site O
resulted O
in O
a O
drastic O
decrease O
in O
the O
oxidation O
of O
aldehydes O
with O
no O
increase O
in O
the O
oxidation O
of O
purine O
substrates O
. O

22 O
, O
517 O
- O
554 O
) O
. O

Chimeric O
plasmids O
between O
the O
two O
c O
DNAs O
and O
site O
- O
directed O
mutagenesis O
revealed O
two O
critical O
alterations O
responsible O
for O
the O
reduced O
ligand O
binding O
activity O
: O
an O
Ala B
375 I
to I
Val I
alteration O
and O
an O
elongated O
carboxyl O
- O
terminal O
sequence O
due O
to O
a O
T B
to I
C I
mutation I
at I
the I
first I
letter I
of I
the I
termination I
codon I
of O
C O
57 O
BL O
Ah O
R O
. O

Importance O
of O
the O
amino O
acid O
at O
position O
381 O
of O
human O
Ah O
R O
( O
equivalent O
to O
position O
375 O
of O
mouse O
Ah O
R O
) O
in O
the O
ligand O
binding O
was O
confirmed O
by O
the O
fact O
that O
the O
mutation O
of O
Val B
381 I
to I
Asp I
completely O
abolished O
the O
ligand O
binding O
activity O
of O
human O
Ah O
R O
. O

Furthermore O
, O
an O
A B
to I
C I
base I
change I
, I
at I
nucleotide I
854 I
, O
has O
been O
found O
in O
85 O
% O
of O
the O
34 O
Canavan O
alleles O
tested O
so O
far O
. O

This O
base O
change O
results O
in O
a O
missense B
Glu I
285 I
Ala I
mutation O
that O
is O
predicted O
to O
be O
part O
of O
the O
catalytic O
domain O
of O
aspartoacylase O
. O

In O
this O
study O
, O
we O
show O
that O
deletion B
of I
both O
BCAP O
and O
CD O
19 O
leads O
to O
an O
almost O
complete O
block O
of O
BCR O
- O
mediated O
Akt O
activation O
and O
to O
severe O
defects O
in O
generation O
of O
immature O
and O
mature O
B O
cells O
. O

In O
eukaryotic O
cells O
, O
the O
completion O
of O
cytokinesis O
is O
dependent O
on O
membrane O
trafficking O
events O
to O
deliver O
membrane O
to O
the O
site O
of O
abscission O
. O

Deletion B
of I
the I
C I
- I
terminal I
autoinhibitory O
domain O
of O
CHMP O
3 O
inhibits O
cytokinesis O
. O

Tyr O
- O
615 O
was O
phosphorylated O
to O
the O
highest O
stoichiometry O
, O
suggesting O
that O
phosphorylation O
at O
this O
site O
may O
have O
a O
physiologically O
important O
role O
. O

Upon O
conservative O
mutation B
of I
Tyr I
- I
838 I
located O
in O
the O
tyrosine O
kinase O
domain O
, O
the O
catalytic O
activity O
of O
Eph O
A O
8 O
was O
strikingly O
reduced O
both O
in O
vitro O
and O
in O
vivo O
, O
whereas O
a O
mutation B
at I
Tyr I
- I
615 I
in O
the O
juxtamembrane O
domain O
did O
not O
impair O
the O
tyrosine O
kinase O
activity O
. O

In O
contrast O
, O
the O
association O
of O
full O
- O
length O
Fyn O
to O
Eph O
A O
8 O
containing O
mutation B
at I
either I
Tyr I
- I
615 I
or I
Tyr I
- I
838 I
was O
greatly O
reduced O
. O

Down O
- O
regulation O
of O
MAP O
kinase O
activity O
can O
be O
initiated O
by O
multiple O
serine O
/ O
threonine O
phosphatases O
, O
tyrosine O
- O
specific O
phosphatases O
, O
and O
dual O
specificity O
phosphatases O
( O
MAP O
kinase O
phosphatases O
) O
. O

Our O
results O
indicated O
the O
following O
: O
( O
i O
) O
p O
38 O
alpha O
phosphorylated O
at O
both O
Thr O
- O
180 O
and O
Tyr O
- O
182 O
was O
10 O
- O
20 O
- O
fold O
more O
active O
than O
p O
38 O
alpha O
phosphorylated O
at O
Thr O
- O
180 O
only O
, O
whereas O
p O
38 O
alpha O
phosphorylated O
at O
Tyr O
- O
182 O
alone O
was O
inactive O
; O
( O
ii O
) O
the O
dual O
- O
specific O
MKP O
5 O
, O
the O
tyrosine O
- O
specific O
hematopoietic O
protein O
- O
tyrosine O
phosphatase O
, O
and O
the O
serine O
/ O
threonine O
- O
specific O
PP O
2 O
Calpha O
are O
all O
highly O
specific O
for O
the O
dephosphorylation O
of O
p O
38 O
alpha O
, O
and O
the O
dephosphorylation O
rates O
were O
significantly O
affected O
by O
different O
phosphorylated O
states O
of O
p O
38 O
alpha O
; O
( O
iii O
) O
the O
N O
- O
terminal O
domain O
of O
MPK O
5 O
has O
no O
effect O
on O
enzyme O
catalysis O
, O
whereas O
deletion B
of I
the I
MAP I
kinase I
- I
binding I
domain I
in O
MKP O
5 O
leads O
to O
a O
370 O
- O
fold O
decrease O
in O
k O
( O
cat O
) O
/ O
K O
( O
m O
) O
for O
the O
dephosphorylation O
of O
p O
38 O
alpha O
. O

The O
693 O
C O
- O
- O
> O
A O
and O
914 O
C O
- O
- O
> O
A O
base O
changes O
, O
resulting O
in O
nonsense B
tyr I
231 I
- I
- I
> I
ter I
and O
missense B
ala I
305 I
- I
- I
> I
glu I
mutations O
, O
respectively O
, O
lead O
to O
complete O
loss O
of O
ASPA O
activity O
in O
in O
vitro O
expression O
studies O
. O

The O
854 B
A I
- I
- I
> I
C I
transversion I
converted I
glu I
to I
ala I
in I
codon I
285 I
. O

A O
fourth O
mutation O
, O
433 B
- I
- I
2 I
( I
A I
- I
- I
> I
G I
) I
transition I
, O
was O
identified O
at O
the O
splice O
- O
acceptor O
site O
in O
intron O
2 O
. O

Predominant O
occurrence O
of O
certain O
mutations O
among O
Ashkenazi O
Jewish O
and O
non O
- O
Jewish O
patients O
with O
Canavan O
disease O
would O
suggest O
a O
founding O
- O
father O
effect O
in O
propagation O
of O
these O
mutant O
chromosomes O
. O

This O
sequence O
was O
used O
to O
study O
3 O
families O
with O
P O
5 O
' O
N O
- O
1 O
deficiency O
. O

Three O
homozygous O
mutations O
were O
identified O
in O
this O
gene O
in O
4 O
subjects O
with O
P O
5 O
' O
N O
- O
1 O
deficiency O
: O
codon B
98 I
GAT I
- I
- I
> I
GTT I
, I
Asp I
- I
- I
> I
Val I
( O
linked O
to O
a O
silent O
polymorphism O
codon B
92 I
, I
TAC I
- I
- I
> I
TAT I
) O
, O
codon B
177 I
, I
CAA I
- I
- I
> I
TAA I
, I
Gln I
- I
- I
> I
termination I
, O
and O
IVS O
9 O
- O
1 O
, O
G O
- O
- O
> O
T O
. O

The O
latter O
mutation O
results O
in O
the O
loss B
of I
exon I
9 I
( I
201 I
bp I
) O
from O
the O
c O
DNA O
. O

Cloning O
and O
sequencing O
of O
the O
10 O
, O
627 O
- O
bp O
- O
long O
region O
containing O
the O
Mnichinan O
gene O
and O
the O
normal O
M O
1 O
( O
Val O
213 O
) O
alpha O
1 O
- O
AT O
gene O
revealed O
all O
five O
exons O
of O
the O
Mnichinan O
gene O
to O
be O
identical O
with O
the O
M O
1 O
( O
Val O
213 O
) O
alpha O
1 O
- O
AT O
gene O
, O
except O
for O
two O
changes O
: O
a O
TTC B
trinucleotide I
deletion I
in I
the I
codon I
for I
amino I
acid I
Phe I
52 I
and O
a O
G B
- I
A I
substitution I
, I
by I
which I
the I
normal I
Gly I
148 I
( I
GGG I
) I
became I
Arg I
148 I
( I
AGG I
) I
. O

The O
G B
- I
A I
substitution I
in I
codon I
148 I
of O
the O
Mnichinan O
gene O
could O
not O
be O
responsible O
for O
the O
alpha O
1 O
- O
AT O
deficiency O
phenotype O
because O
Arg O
- O
and O
not O
Gly O
- O
was O
located O
at O
the O
corresponding O
position O
of O
the O
protein O
C O
inhibitor O
belonging O
to O
the O
serine O
protease O
inhibitor O
superfamily O
. O

The O
deletion B
of I
Phe I
52 I
may O
cause O
the O
newly O
synthesized O
alpha O
1 O
- O
AT O
protein O
to O
aggregate O
, O
resulting O
in O
alpha O
1 O
- O
AT O
deficiency O
. O

Comparison O
of O
the O
alpha O
1 O
- O
AT O
gene O
sequences O
available O
indicated O
that O
the O
C B
- I
T I
substitution I
at I
the I
Cp I
G I
dinucleotide I
has O
an O
important O
role O
in O
generation O
of O
variants O
and O
nucleotide O
changes O
in O
the O
noncoding O
regions O
of O
the O
alpha O
1 O
- O
AT O
gene O
. O

Harlequin O
ichthyosis O
( O
HI O
) O
is O
one O
of O
the O
most O
devastating O
genodermatoses O
. O

This O
patient O
with O
moderate O
clinical O
severity O
was O
compound O
heterozygous O
for O
a O
novel O
de O
novo O
missense O
mutation O
1160 B
G I
> I
A I
( I
S I
387 I
N I
) I
in I
exon I
10 I
and O
a O
maternal O
deletion B
mutation I
4158 I
_ I
4160 I
del I
TAC I
( I
T I
1387 I
del I
) I
in I
exon I
28 I
of O
ABCA O
12 O
. O

T O
1387 O
del O
was O
a O
deletion B
of I
a I
highly I
conserved I
threonine I
residue I
within I
the I
first I
adenosine I
5 I
' I
triphosphate I
- I
binding I
domain I
and O
is O
thought O
to O
seriously O
affect O
the O
function O
of O
the O
ABCA O
12 O
protein O
. O

Two O
splice O
variants O
of O
protein O
kinase O
B O
gamma O
have O
different O
regulatory O
capacity O
depending O
on O
the O
presence B
or I
absence I
of I
the I
regulatory I
phosphorylation I
site I
serine I
472 I
in I
the I
carboxyl I
- I
terminal I
hydrophobic I
domain I
. O

We O
have O
reported O
previously O
the O
cloning O
and O
characterization O
of O
human O
and O
mouse O
protein O
kinase O
B O
gamma O
( O
PKB O
gamma O
) O
, O
the O
third O
member O
of O
the O
PKB O
family O
of O
second O
messenger O
- O
regulated O
serine O
/ O
threonine O
kinases O
( O
Brodbeck O
, O
D O
. O
, O
Cron O
, O
P O
. O
, O
and O
Hemmings O
, O
B O
. O

Here O
we O
report O
the O
isolation O
of O
human O
and O
mouse O
PKB O
gamma O
1 O
, O
a O
splice B
variant I
lacking I
the I
second I
regulatory I
phosphorylation I
site I
Ser I
- I
472 I
in I
the I
hydrophobic I
C I
- I
terminal I
domain I
. O

METHODS O
: O
We O
assessed O
the O
sequences O
of O
the O
gene O
encoding O
C O
5 O
in O
patients O
with O
PNH O
who O
had O
either O
a O
good O
or O
poor O
response O
to O
eculizumab O
. O

CONCLUSIONS O
: O
The O
functional O
capacity O
of O
C O
5 O
variants O
with O
mutations B
at I
Arg I
885 I
, O
together O
with O
their O
failure O
to O
undergo O
blockade O
by O
eculizumab O
, O
account O
for O
the O
poor O
response O
to O
this O
agent O
in O
patients O
who O
carry O
these O
mutations O
. O

Increased O
fatty O
acid O
synthesis O
is O
required O
to O
meet O
the O
demand O
for O
membrane O
expansion O
of O
rapidly O
growing O
cells O
. O

Substitution B
of I
3 I
K I
abolishes O
ACLY O
ubiquitylation O
and O
promotes O
de O
novo O
lipid O
synthesis O
, O
cell O
proliferation O
, O
and O
tumor O
growth O
. O

In O
five O
members O
of O
a O
family O
and O
another O
unrelated O
person O
affected O
by O
a O
slow O
- O
channel O
congenital O
myasthenic O
syndrome O
( O
SCCMS O
) O
, O
molecular O
genetic O
analysis O
of O
acetylcholine O
receptor O
( O
ACh O
R O
) O
subunit O
genes O
revealed O
a O
heterozygous O
G B
to I
A I
mutation I
at I
nucleotide I
457 I
of I
the I
alpha I
subunit I
, O
converting B
codon I
153 I
from I
glycine I
to I
serine I
( I
alpha I
G I
153 I
S I
) I
. O

Deletion B
of I
the I
EWV I
signal I
impairs O
the O
recycling O
of O
MT O
5 O
- O
MMP O
without O
affecting O
its O
internalization O
, O
leading O
to O
decreased O
activity O
on O
the O
cell O
surface O
. O

Mint O
- O
3 O
stimulates O
MT O
5 O
- O
MMP O
activity O
when O
expressed O
at O
low O
levels O
in O
an O
EWV O
- O
dependent O
fashion O
, O
but O
inhibits O
its O
activity O
at O
higher O
levels O
independent O
of O
the O
EWV O
motif O
. O

Here O
, O
we O
analyze O
the O
effects O
of O
a O
mutation O
in O
1 O
of O
4 O
homologous O
subunits O
in O
the O
ACh O
R O
from O
a O
CM O
patient O
, O
a O
Leu B
to I
Pro I
mutation I
at I
position I
42 I
of O
the O
delta O
subunit O
. O

Substitutions B
of I
Gly I
, I
Lys I
, I
or I
Asp I
for I
delta I
L I
42 I
, I
or I
substitutions I
of I
Pro I
along O
the O
local O
protein O
chain O
, O
also O
slowed O
channel O
opening O
. O

Substitution B
of I
Pro I
for I
Leu I
in I
the I
epsilon I
subunit I
slowed O
opening O
, O
whereas O
this O
substitution O
had O
no O
effect O
in O
the O
beta O
subunit O
and O
actually O
sped O
opening O
in O
the O
alpha O
subunit O
. O

The O
first O
is O
a O
nonstop B
mutation I
in I
the I
normal I
stop I
codon I
373 I
of I
the I
gene I
in I
exon I
IV I
[ I
TGA I
( I
Stop I
) I
- I
- I
> I
TGC I
( I
Cys I
) I
= O
Stop O
373 O
C O
) O
identified O
from O
one O
allele O
of O
a O
female O
child O
with O
premature O
pubarche O
whose O
second O
allele O
had O
an O
E O
142 O
K O
mutation O
. O

The O
second O
is O
a O
homozygous O
missense O
mutation B
in I
codon I
222 I
[ I
CCA I
( I
Pro I
) I
- I
- I
> I
ACT I
( I
Thr I
) I
= O
P O
222 O
T O
] O
in O
the O
gene O
identified O
from O
a O
female O
neonate O
with O
salt O
- O
wasting O
disorder O
. O

The O
undetectable O
Stop O
373 O
C O
and O
P O
222 O
T O
enzymes O
on O
Western O
blottings O
, O
together O
with O
the O
respective O
in O
vivo O
and O
in O
vitro O
data O
, O
suggest O
that O
a O
relative O
instability O
of O
Stop O
373 O
C O
enzyme O
and O
a O
profound O
instability O
of O
the O
P O
222 O
T O
enzyme O
are O
likely O
the O
detrimental O
molecular O
mechanisms O
. O

Here O
we O
report O
the O
identification O
of O
a O
somatic O
mutation O
in O
human O
breast O
, O
colorectal O
and O
ovarian O
cancers O
that O
results O
in O
a O
glutamic B
acid I
to I
lysine I
substitution I
at I
amino I
acid I
17 I
( O
E O
17 O
K O
) O
in O
the O
lipid O
- O
binding O
pocket O
of O
AKT O
1 O
. O

A O
common O
single O
- O
nucleotide O
polymorphism O
in O
the O
brain O
- O
derived O
neurotrophic O
factor O
( O
BDNF O
) O
gene O
, O
a O
methionine B
( I
Met I
) I
substitution I
for I
valine I
( I
Val I
) I
at I
codon I
66 I
( O
Val O
66 O
Met O
) O
, O
is O
associated O
with O
alterations O
in O
brain O
anatomy O
and O
memory O
, O
but O
its O
relevance O
to O
clinical O
disorders O
is O
unclear O
. O

Other O
members O
of O
this O
family O
, O
the O
Xenopus O
laevis O
IU O
12 O
and O
the O
human O
KIAA O
0245 O
c O
DNAs O
, O
also O
co O
- O
express O
amino O
acid O
transport O
activity O
with O
4 O
F O
2 O
hc O
in O
oocytes O
, O
with O
characteristics O
that O
are O
compatible O
with O
those O
of O
systems O
L O
and O
y O
+ O
L O
, O
respectively O
. O

Mutation O
of O
the O
human O
4 O
F O
2 O
hc O
residue O
cysteine B
109 I
( I
Cys I
- I
109 I
) I
to I
serine I
abolishes O
the O
formation O
of O
this O
heterodimer O
and O
drastically O
reduces O
the O
co O
- O
expressed O
transport O
activity O
. O

A O
polymorphism O
in O
the O
coding O
portion O
of O
the O
alpha O
4 O
gene O
was O
found O
( O
1587 B
A I
to I
G I
) O
which O
should O
result O
in O
a O
threonine B
/ I
alanine I
substitution I
at I
position I
529 I
( O
T O
529 O
A O
) O
. O

The O
potential O
consequences O
of O
the O
alpha O
4 O
polymorphism O
were O
evaluated O
using O
an O
ion O
( O
86 O
Rb O
+ O
) O
flux O
assay O
that O
likely O
measures O
the O
function O
of O
alpha O
4 O
beta O
2 O
- O
type O
receptors O
. O

A O
leucine B
55 I
- I
to I
- I
proline I
substitution O
causing O
a O
defective O
ACT O
allele O
( O
Bochum O
- O
1 O
) O
was O
observed O
in O
a O
family O
with O
COPD O
in O
three O
subsequent O
generations O
. O

Another O
mutation O
, O
proline B
229 I
- I
to I
- I
alanine I
( O
Bonn O
- O
1 O
) O
, O
was O
associated O
with O
ACT O
serum O
deficiency O
in O
four O
patients O
with O
a O
positive O
family O
history O
. O

Our O
biochemical O
study O
verifies O
that O
ezrin O
binds O
to O
PALS O
1 O
via O
its O
N O
terminus O
and O
is O
co O
- O
localized O
with O
PALS O
1 O
to O
the O
apical O
membrane O
of O
gastric O
parietal O
cells O
. O

Furthermore O
, O
our O
study O
shows O
that O
PALS O
1 O
is O
essential O
for O
the O
apical O
localization O
of O
ezrin O
, O
as O
either O
suppression O
of O
PALS O
1 O
protein O
accumulation O
or O
deletion B
of I
the I
PALS I
1 I
- I
binding I
domain I
of O
ezrin O
eliminated O
the O
apical O
localization O
of O
ezrin O
. O

Studies O
of O
decay O
- O
accelerating O
factor O
( O
DAF O
) O
or O
CD O
59 O
in O
either O
the O
C O
32 O
cell O
line O
or O
the O
He O
La O
cell O
line O
transfected O
with O
PTK O
c O
DNA O
demonstrated O
that O
the O
GPI O
- O
anchored O
proteins O
associated O
noncovalently O
with O
p O
56 O
lck O
and O
p O
59 O
fyn O
but O
not O
with O
p O
60 O
src O
. O

Mutation O
of O
cysteine B
to I
serine I
at I
positions I
3 I
and I
6 I
in O
p O
59 O
fyn O
or O
positions O
3 O
and O
5 O
in O
p O
56 O
lck O
abolished O
the O
association O
of O
these O
kinases O
with O
DAF O
. O

Mutation O
of O
serine B
to I
cysteine I
at I
positions I
3 I
and I
6 I
in O
p O
60 O
src O
conferred O
on O
p O
60 O
src O
the O
ability O
to O
associate O
with O
DAF O
. O

Mutation O
of O
Ser B
193 I
to I
Ala I
also O
abolishes O
the O
ability O
of O
C O
/ O
EBPalpha O
to O
cause O
growth O
arrest O
because O
of O
a O
lack O
of O
interactions O
with O
cdk O
2 O
and O
E O
2 O
F O
- O
Rb O
complexes O
. O

Deletion B
of I
chromosome I
11 I
q I
23 I
is O
a O
common O
alteration O
in O
parathyroid O
adenomas O
and O
hyperplasias O
. O

A O
previously O
identified O
germline B
G I
- I
A I
transition I
( I
GGC I
- I
GAC I
) I
in I
codon I
90 I
, I
changing I
glycine I
( I
Gly I
) I
to I
aspartic I
acid I
( I
Asp I
) I
, O
was O
detected O
in O
one O
adenoma O
. O

The O
overall O
incidence O
was O
1 O
: O
40 O
, O
400 O
, O
but O
in O
one O
area O
of O
Central O
Finland O
it O
was O
as O
high O
as O
1 O
: O
3 O
, O
200 O
. O

Sequence O
analysis O
revealed O
a O
novel O
point O
mutation O
in O
exon O
4 O
of O
SUR O
1 O
, O
predicting O
a O
valine B
to I
aspartic I
acid I
change I
at I
amino I
acid I
187 I
( I
V I
187 I
D I
) I
. O

We O
have O
analysed O
by O
heteroduplex O
formation O
( O
HF O
) O
, O
single O
stranded O
conformational O
polymorphism O
( O
SSCP O
) O
, O
denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
, O
and O
nucleotide O
sequencing O
the O
c O
DNAs O
of O
the O
Ahrb O
- O
1 O
and O
Ahrd O
allelic O
forms O
of O
the O
aromatic O
hydrocarbon O
receptor O
( O
Ah O
R O
) O
present O
in O
inbred O
strains O
of O
mice O
. O

Of O
the O
other O
five O
, O
one O
changes O
the O
opal B
termination I
codon I
in I
Ahrb I
- I
1 I
to I
the I
codon I
for I
Arg I
in O
Ahrd O
, O
extending O
translation O
of O
the O
m O
RNA O
by O
43 O
amino O
acids O
and O
accounting O
for O
the O
larger O
size O
of O
the O
Ah O
R O
peptide O
in O
DBA O
/ O
2 O
mice O
. O

One O
of O
the O
four O
remaining O
differences O
causes O
the O
replacement B
of I
a I
leucine I
residue I
in I
Ahrb I
- I
1 I
by I
a I
proline I
residue I
in I
Ahrd I
, I
and I
breaks I
a I
potential I
alpha I
- I
helix I
near I
the I
Ah I
R I
Q I
- I
rich I
region I
; O
it O
is O
likely O
that O
structural O
changes O
associated O
with O
this O
amino O
acid O
change O
are O
responsible O
for O
the O
differences O
in O
agonist O
affinity O
observed O
between O
the O
Ah O
receptors O
of O
these O
two O
strains O
of O
mice O
. O

Substitutions B
for I
glycine I
alpha I
1 I
- I
637 I
and I
glycine I
alpha I
2 I
- I
694 I
of O
type O
I O
procollagen O
in O
lethal O
osteogenesis O
imperfecta O
. O

One O
was O
a O
substitution B
of I
valine I
for I
glycine I
alpha I
1 I
- I
637 I
, O
and O
the O
other O
was O
a O
substitution B
of I
arginine I
for I
glycine I
alpha I
2 I
- I
694 I
. O

The O
collagenase O
A O
fragment O
from O
the O
collagen O
containing O
the O
arginine B
alpha I
2 I
- I
694 I
substitution I
was O
cleaved O
at O
about O
amino O
acid O
700 O
when O
incubated O
with O
trypsin O
at O
30 O
- O
35 O
degrees O
C O
. O
Therefore O
, O
there O
was O
micro O
- O
unfolding O
of O
the O
triple O
helix O
at O
a O
site O
close O
to O
the O
glycine O
substitution O
. O

Surprisingly O
, O
however O
, O
the O
collagenase O
A O
fragment O
with O
the O
valine B
alpha I
1 I
- I
637 I
substitution I
was O
also O
cleaved O
at O
about O
amino O
acid O
700 O
under O
the O
same O
conditions O
. O

Site O
- O
directed O
mutagenesis O
studies O
on O
a O
putative O
fifth O
iron O
ligand O
of O
mouse O
8 O
S O
- O
lipoxygenase O
: O
retention O
of O
catalytic O
activity O
on O
mutation O
of O
serine B
- I
558 I
to I
asparagine I
, I
histidine I
, I
or I
alanine I
. O

Mouse O
8 O
- O
LOX O
and O
its O
homologues O
( O
e O
. O
g O
. O
, O
human O
15 O
- O
LOX O
- O
2 O
) O
are O
unique O
in O
having O
a O
serine B
in I
place I
of I
the I
usual I
Asn I
or I
His I
in I
this I
fifth I
position I
. O

To O
investigate O
the O
importance O
of O
the O
residue O
in O
mouse O
8 O
- O
LOX O
structure O
- O
function O
, O
the O
serine B
- I
558 I
was I
replaced I
by I
asparagine I
, I
histidine I
, I
or I
alanine I
using O
oligonucleotide O
- O
directed O
mutagenesis O
. O

We O
conclude O
that O
mouse O
8 O
- O
LOX O
is O
catalytically O
competent O
with O
only O
four O
amino O
acid O
iron O
ligands O
, O
and O
that O
Ser O
- O
558 O
of O
the O
wild O
- O
type O
enzyme O
does O
not O
play O
an O
essential O
role O
in O
catalysis O
. O

We O
previously O
demonstrated O
increased O
LCAD O
lysine O
acetylation O
in O
SIRT O
3 O
knockout B
mice O
concomitant O
with O
reduced O
LCAD O
activity O
and O
reduced O
fatty O
acid O
oxidation O
. O

Residues O
Lys O
- O
318 O
and O
Lys O
- O
322 O
were O
identified O
as O
SIRT O
3 O
- O
targeted O
lysines O
. O

Arginine B
substitutions I
at I
Lys I
- I
318 I
and I
Lys I
- I
322 I
prevented O
the O
acetylation O
- O
induced O
activity O
loss O
. O

Functionally O
, O
we O
demonstrated O
that O
centaurin O
- O
alpha O
1 O
could O
complement O
a O
yeast O
strain O
deficient O
in O
the O
ADP O
- O
ribosylation O
factor O
( O
ARF O
) O
GTPase O
- O
activating O
protein O
Gcs O
1 O
; O
a O
complementation O
that O
was O
blocked O
by O
mutagenesis B
of I
conserved I
cysteine I
residues I
within I
the I
ARF I
GTPase I
- I
activating I
protein I
analogous I
domain I
of I
centaurin I
- I
alpha I
1 I
. O

The O
insert B
contains I
the I
coding I
sequences I
for I
the I
mature I
alpha I
2 I
M I
polypeptide I
( I
1451 I
amino I
acids I
) I
and O
for O
a O
23 B
- I
amino I
acid I
signal I
peptide I
at I
the I
NH I
2 I
terminus I
of I
the I
precursor I
pro I
- I
alpha I
2 I
M I
. O

At B
the I
3 I
' I
end I
of I
the I
insert I
a I
poly I
( I
A I
) I
addition I
signal I
A I
- I
A I
- I
T I
- I
A I
- I
A I
- I
A I
and I
part I
of I
the I
poly I
( I
A I
) I
tail I
of I
the I
messenger I
RNA I
were I
found I
. O

Although O
site O
- O
specific O
DNA O
binding O
by O
EKLF O
is O
unaffected O
by O
the O
acetylation O
status O
of O
either O
of O
these O
lysines O
, O
directed O
mutagenesis B
of I
Lys I
- I
288 I
( I
but I
not I
Lys I
- I
302 I
) I
decreases O
the O
ability O
of O
EKLF O
to O
transactivate O
the O
beta O
- O
globin O
promoter O
in O
vivo O
and O
renders O
it O
unable O
to O
be O
superactivated O
by O
coexpressed O
p O
300 O
or O
CBP O
. O

Finally O
, O
acetylated O
EKLF O
has O
a O
higher O
affinity O
for O
the O
SWI O
- O
SNF O
chromatin O
remodeling O
complex O
and O
is O
a O
more O
potent O
transcriptional O
activator O
of O
chromatin O
- O
assembled O
templates O
in O
vitro O
. O

Here O
, O
we O
addressed O
the O
role O
of O
endogenous O
caspase O
- O
8 O
in O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
- O
induced O
activation O
of O
NF O
- O
kappa O
B O
. O

In O
contrast O
to O
wild O
- O
type O
caspase O
- O
8 O
, O
death O
effector O
domain O
mutant O
replacing O
Asp B
73 I
with I
Ala I
( O
caspase O
- O
8 O
( O
D O
73 O
A O
) O
) O
failed O
to O
activate O
NF O
- O
kappa O
B O
and O
to O
bind O
FLICE O
- O
associated O
huge O
protein O
( O
FLASH O
) O
in O
vitro O
and O
in O
vivo O
. O

Two O
kinetically O
and O
pharmacologically O
distinct O
transient O
outward O
K O
+ O
currents O
, O
referred O
to O
as O
Ito O
, O
f O
and O
Ito O
, O
s O
, O
have O
been O
distinguished O
in O
mouse O
left O
ventricular O
myocytes O
. O

Electrophysiological O
recordings O
from O
ventricular O
myocytes O
isolated O
from O
animals O
with O
a O
targeted O
deletion B
of I
the I
Kv I
1 I
. I
4 I
gene O
( O
Kv O
1 O
. O
4 O
- O
/ O
- O
mice O
) O
reveal O
that O
Ito O
, O
s O
is O
undetectable O
in O
cells O
isolated O
from O
the O
left O
ventricular O
septum O
( O
n O
= O
26 O
) O
. O

Ito O
, O
f O
density O
in O
both O
apex O
and O
septum O
cells O
, O
in O
contrast O
, O
is O
not O
affected O
by O
deletion B
of I
Kv I
1 I
. I
4 I
. O

6 O
. O

We O
investigated O
if O
the O
PPP O
2 O
R O
1 O
B O
gene O
was O
inactivated O
in O
ovarian O
cancer O
by O
single O
strand O
conformational O
polymorphism O
( O
SSCP O
) O
and O
heteroduplex O
( O
HD O
) O
analysis O
of O
99 O
% O
of O
the O
coding O
region O
. O

A O
germline O
G B
> I
A I
transition I
( I
GGC I
> I
GAC I
) I
in I
codon I
90 I
was O
detected O
in O
4 O
/ O
76 O
tumors O
. O

The O
codon B
90 I
Gly I
> I
Asp I
alteration O
may O
represent O
a O
non O
- O
pathological O
polymorphism O
and O
consequently O
the O
mutation O
frequency O
reported O
in O
lung O
cancers O
may O
have O
been O
overstated O
and O
the O
designation O
of O
PPP O
2 O
R O
1 O
B O
as O
a O
tumor O
suppressor O
gene O
should O
be O
regarded O
with O
caution O
. O

Novel O
amyloid O
precursor O
protein O
gene O
mutation B
( I
codon I
665 I
Asp I
) I
in O
a O
patient O
with O
late O
- O
onset O
Alzheimer O
' O
s O
disease O
. O

Amyloid O
plaques O
in O
Alzheimer O
' O
s O
disease O
contain O
beta O
- O
amyloid O
, O
encoded O
by O
portions O
of O
exons O
16 O
and O
17 O
of O
the O
amyloid O
precursor O
protein O
. O

We O
found O
a O
novel O
point O
mutation O
, O
substitution B
of I
cytosine I
for I
guanine I
, I
at I
nucleotide I
2119 I
( O
amyloid O
precursor O
protein O
770 O
messenger O
RNA O
transcript O
) O
in O
a O
patient O
with O
late O
- O
onset O
Alzheimer O
' O
s O
disease O
. O

This O
substitution O
deletes B
a I
Bgl I
II I
site I
and O
substitutes B
aspartate I
for I
glutamine I
at I
codon I
665 I
. O

An O
incompletely O
resolved O
paradox O
is O
that O
only O
some O
5 O
- O
HT O
( O
2 O
A O
) O
receptor O
agonists O
exhibit O
hallucinogenic O
activity O
, O
whereas O
structurally O
related O
agonists O
with O
comparable O
affinity O
and O
activity O
lack O
such O
a O
psychoactive O
activity O
. O

The O
mutation O
of O
Ser B
( I
280 I
) I
to I
aspartic I
acid I
( O
to O
mimic O
phosphorylation O
) O
reduced O
receptor O
desensitization O
by O
nonhallucinogenic O
agonists O
, O
whereas O
its O
mutation O
to O
alanine O
increased O
the O
ability O
of O
hallucinogens O
to O
desensitize O
the O
receptor O
. O

A O
* O
2406 O
and O
A O
* O
2413 O
both O
have O
two O
adjacent O
( O
but O
different O
) O
nucleotide O
substitutions B
in I
codon I
156 I
in I
exon I
3 I
compared O
to O
A O
* O
2402 O
, O
resulting O
in O
a O
single O
amino O
acid O
replacement O
in O
each O
allele O
. O

The O
South O
American O
A O
* O
2414 O
is O
apparently O
a O
hybrid O
between O
A O
2 O
and O
A O
24 O
with O
a O
segment O
of O
the O
A O
* O
24 O
sequence B
between I
codons I
95 I
and I
107 I
in I
exon I
3 I
replaced I
with I
the I
A I
* I
02 I
sequence I
. O

The O
single B
amino I
acid I
replacements I
in I
position I
156 I
of O
the O
two O
Australian O
Aboriginal O
A O
* O
24 O
alleles O
may O
also O
have O
significant O
functional O
effects O
. O

In O
particular O
, O
Trp B
replacing I
Gln I
in I
position I
156 I
( O
A O
* O
2406 O
) O
is O
predicted O
to O
markedly O
reduce O
the O
volume O
of O
the O
peptide O
binding O
cleft O
, O
influence O
the O
interaction O
of O
HLA O
pockets O
with O
peptide O
side O
chains O
, O
and O
therefore O
, O
cause O
major O
changes O
in O
peptide O
presentation O
. O

In O
the O
present O
study O
, O
the O
ASPA O
gene O
was O
analysed O
in O
22 O
unrelated O
non O
- O
Jewish O
patients O
with O
Canavan O
disease O
, O
and O
24 O
different O
mutations O
were O
found O
. O

Of O
these O
, O
14 O
are O
novel O
, O
including O
five O
missense O
mutations O
( O
E O
24 O
G O
, O
D O
68 O
A O
, O
D O
249 O
V O
, O
C O
152 O
W O
, O
H O
244 O
R O
) O
, O
two O
nonsense O
mutations O
( O
Q O
184 O
X O
, O
E O
214 O
X O
) O
, O
three O
deletions O
( O
923 O
del O
T O
, O
33 O
del O
13 O
, O
244 O
del O
A O
) O
, O
one B
insertion I
mutation I
( I
698 I
ins I
C I
) I
, O
two O
sequence O
variations O
in O
one O
allele O
( O
[ O
10 O
T O
> O
G O
; O
11 O
ins O
G O
] O
) O
, O
an O
elimination B
of I
the I
stop I
codon I
( I
941 I
A I
> I
G I
, I
TAG I
- I
- I
> I
TGG I
, O
X O
314 O
W O
) O
, O
and O
one O
splice O
acceptor O
site O
mutation O
( O
IVS O
1 O
- O
2 O
A O
> O
T O
) O
. O

The O
IVS O
1 O
- O
2 O
A O
> O
T O
mutation O
caused O
the O
retention B
of I
40 I
nucleotides I
of I
intron I
1 I
upstream I
of I
exon I
2 I
. O

Previously O
, O
a O
missense O
mutation O
in O
the O
human O
ABC O
7 O
gene O
was O
shown O
to O
be O
the O
defect O
in O
members O
of O
a O
family O
affected O
with O
X O
- O
linked O
sideroblastic O
anemia O
with O
cerebellar O
ataxia O
( O
XLSA O
/ O
A O
) O
. O

A O
single B
missense I
mutation I
was I
found I
in I
exon I
10 I
of O
the O
ABC O
7 O
gene O
in O
2 O
affected O
brothers O
with O
XLSA O
/ O
A O
. O

The O
mutation O
was O
a O
G B
- I
to I
- I
A I
transition I
at I
nucleotide I
1305 I
of O
the O
full O
- O
length O
c O
DNA O
, O
resulting O
in O
a O
charge O
inversion O
caused O
by O
the O
substitution B
of I
lysine I
for I
glutamate I
at I
residue I
433 I
C I
- I
terminal I
to I
the I
putative I
sixth I
transmembrane I
domain I
of O
ABC O
7 O
. O

Expression O
of O
normal O
ABC O
7 O
almost O
fully O
complemented O
the O
defect O
in O
the O
maturation O
of O
cytosolic O
Fe O
/ O
S O
proteins O
in O
a O
yeast O
strain O
in O
which O
the O
ATM B
1 I
gene I
had I
been I
deleted I
( O
Deltaatm O
1 O
cells O
) O
. O

Siiyama O
( O
serine B
53 I
( I
TCC I
) I
to I
phenylalanine I
53 I
( I
TTC I
) I
) O
. O

Although O
more O
than O
25 O
years O
have O
passed O
since O
a O
deficiency O
in O
the O
serum O
level O
of O
alpha O
1 O
AT O
was O
reported O
, O
it O
is O
only O
recently O
that O
the O
consequence O
of O
the O
amino O
acid O
replacement O
which O
leads O
to O
the O
deficient O
state O
has O
been O
discussed O
in O
terms O
of O
the O
crystallographic O
structure O
of O
alpha O
1 O
AT O
and O
the O
amino O
acid O
residues O
conserved O
in O
the O
superfamily O
to O
which O
it O
belongs O
. O

A O
single O
missense O
mutation O
, O
Ser B
53 I
( I
TCC I
) I
to I
Phe I
53 I
( O
TTC O
was O
identified O
in O
exon O
II O
of O
the O
proband O
' O
s O
alpha O
1 O
AT O
gene O
. O

The O
family O
was O
Catholic O
, O
and O
the O
father O
and O
the O
mother O
were O
of O
Irish O
and O
German O
descent O
, O
respectively O
. O

A O
hitherto O
undescribed O
single B
nucleotide I
transversion I
was I
found I
within I
exon I
11 I
( O
G O
1260 O
- O
- O
- O
- O
C O
; O
Trp O
420 O
- O
- O
- O
- O
Cys O
) O
. O

DNA O
analysis O
revealed O
a O
nucleotide O
transversion O
at O
codon B
123 I
( I
GAC I
- I
- I
> I
CAC I
) I
, O
causing O
Asp O
- O
- O
> O
His O
substitution O
( O
D O
123 O
H O
) O
. O

The O
detection O
of O
the O
D O
123 O
H O
mutation O
in O
three O
unaffected O
family O
members O
indicates O
that O
it O
has O
low O
penetrance O
for O
GCD O
. O

One O
novel O
cryptic O
splicing O
mutation O
of O
the O
BRCA O
1 O
gene O
, O
found O
in O
two O
unrelated O
families O
, O
was O
shown O
to O
be O
a O
deletion B
of I
10 I
bp I
near I
the I
branch I
site I
in I
intron I
7 I
. O

This O
mutation O
causes O
an O
insertion B
of I
59 I
nucleotides I
derived I
from I
intron I
7 I
and O
results O
in O
a O
frameshift O
, O
leading O
to O
premature O
translational O
termination O
of O
BRCA O
1 O
m O
RNA O
in O
exon O
8 O
. O

We O
show O
that O
mutation O
of O
the O
conserved B
Glu I
- I
165 I
beta I
in O
human O
ETF O
leads O
to O
drastically O
modulated O
rates O
of O
interprotein O
electron O
transfer O
with O
both O
medium O
chain O
acyl O
- O
Co O
A O
dehydrogenase O
and O
dimethylglycine O
dehydrogenase O
. O

One O
was O
detected O
in O
1 O
patient O
only O
and O
associated O
with O
an O
amino O
acid O
substitution O
( B
Val I
/ I
Met I
) I
at I
codon I
832 I
in O
the O
region O
essential O
for O
binding O
to O
beta O
- O
catenin O
. O

The O
M B
832 I
variant I
was O
detected O
not O
only O
in O
the O
proband O
but O
also O
in O
2 O
other O
gastric O
cancer O
patients O
in O
the O
family O
. O

However O
, O
no O
significant O
difference O
in O
the O
activity O
of O
beta O
- O
catenin O
binding O
was O
detected O
between O
the O
M B
832 I
variant I
and O
V O
832 O
wild O
- O
type O
E O
- O
cadherin O
in O
immunofluorescence O
and O
immunoprecipitation O
/ O
Western O
blot O
analyses O
. O

Thus O
, O
the O
M B
832 I
variant I
could O
be O
a O
germline O
mutation O
causative O
of O
familial O
aggregation O
of O
DGC O
, O
although O
further O
functional O
studies O
are O
needed O
to O
understand O
the O
pathogenic O
significance O
of O
this O
variant O
. O

Two O
naturally O
occurring O
amino O
acid O
substitutions O
in O
the O
human O
5 O
- O
HT O
1 O
A O
receptor O
: O
glycine B
22 I
to I
serine I
22 I
and O
isoleucine B
28 I
to I
valine I
28 I
. O

The O
human O
5 O
- O
HT O
1 O
A O
receptor O
was O
screened O
for O
naturally O
occurring O
mutations O
. O

The O
polymorphisms O
encode O
amino O
acid O
substitutions O
in O
the O
5 O
- O
HT O
1 O
A O
receptor O
of O
a O
glycine B
to I
serine I
at I
amino I
acid I
22 I
and O
an O
isoleucine B
to I
valine I
at I
amino I
acid I
28 I
, O
respectively O
. O

The O
2 O
predicted O
FANCD O
2 O
proteins O
differ O
in O
their O
carboxy O
terminal O
24 O
amino O
acids O
. O

A O
truncated O
FANCD O
2 O
protein O
( O
Exon O
44 O
- O
T O
) O
, O
lacking B
the I
carboxy I
terminal I
24 I
amino I
acids I
encoded I
by I
exon I
44 I
but O
retaining O
K O
561 O
, O
and O
another O
mutant O
FANCD O
2 O
protein O
, O
with O
a O
single B
amino I
acid I
substitution I
at I
a I
conserved I
residue I
within I
the I
C I
- I
terminal I
24 I
amino I
acids I
( O
D O
1428 O
A O
) O
, O
were O
monoubiquitinated O
. O

OBJECTIVE O
: O
Osteogenesis O
imperfecta O
( O
OI O
) O
is O
a O
congenital O
disease O
of O
connective O
tissue O
of O
increased O
bone O
fragility O
and O
low O
bone O
mass O
, O
most O
often O
caused O
by O
single O
amino O
acid O
substitution O
of O
glycine O
residues O
in O
the O
collagen O
, O
type O
I O
, O
alpha O
1 O
protein O
( O
COL O
1 O
A O
1 O
) O
gene O
or O
the O
collagen O
, O
type O
I O
, O
alpha O
2 O
protein O
( O
COL O
1 O
A O
2 O
) O
gene O
, O
encoding O
type O
I O
procollagen O
chains O
. O

RESULTS O
: O
We O
found O
a O
G B
and I
A I
heterozygosis I
mutation I
at I
the I
exon I
48 I
causing O
an O
a O
1 O
( O
I O
) O
p O
. O
G O
1157 O
D O
substitution O
in O
the O
proband O
and O
his O
sister O
who O
is O
also O
a O
sufferer O
of O
OI O
. O

Substituting B
Glu I
334 I
in I
motif I
I I
or I
Glu I
1086 I
in I
motif I
III I
with I
Lys I
produced O
mutant O
calcium O
channels O
that O
permeated O
sodium O
ions O
10 O
- O
fold O
more O
effectively O
than O
barium O
ions O
. O

More O
conservative O
changes O
such O
as O
substitution B
of I
Glu I
1086 I
with I
Gln I
or O
substitution B
of I
Glu I
1387 I
with I
Ala I
also O
increased O
sodium O
permeation O
through O
the O
mutant O
calcium O
channels O
. O

Ectopic O
expression O
of O
H O
2 O
B O
in O
which O
Ser B
36 I
was I
substituted I
by I
alanine I
reduced O
transcription O
and O
RNA O
polymerase O
II O
association O
to O
AMPK O
- O
dependent O
genes O
, O
and O
lowered O
cell O
survival O
in O
response O
to O
stress O
. O

The O
gene O
encoding O
the O
human O
C O
( O
27 O
) O
3 O
beta O
- O
HSD O
enzyme O
was O
isolated O
previously O
, O
and O
a O
2 B
- I
bp I
deletion I
in I
exon I
6 I
of O
HSD O
3 O
B O
7 O
was O
identified O
in O
a O
well O
characterized O
subject O
with O
this O
disorder O
. O

Ten O
mutations O
were O
studied O
in O
detail O
and O
shown O
to O
cause O
complete O
loss O
of O
enzyme O
activity O
and O
, O
in O
two O
cases O
, O
alterations O
in O
the O
size O
or O
amount O
of O
the O
transcribed O
m O
RNA O
. O

We O
have O
demonstrated O
that O
the O
protein O
subunit O
isolated O
from O
amyloid O
fibrils O
shows O
considerable O
sequence O
identity O
with O
gelsolin O
, O
an O
actin O
- O
binding O
protein O
. O

Sequence O
analysis O
shows O
that O
, O
in O
both O
cases O
, O
the O
amyloid O
subunit O
starts O
at O
position O
173 O
of O
the O
mature O
molecule O
; O
it O
has O
a O
heterogeneous O
N O
- O
terminus O
and O
contains O
one O
amino O
acid O
substitution O
, O
namely O
asparagine B
for I
aspartic I
acid I
, I
at I
position I
15 I
( O
gelsolin O
residue O
187 O
) O
, O
that O
is O
due O
to O
a O
guanine B
- I
to I
- I
adenine I
transversion I
corresponding I
to I
nucleotide I
- I
654 I
of O
human O
plasma O
gelsolin O
c O
DNA O
. O

Nucleotide O
sequences O
of O
alleles O
encoding O
four O
serologically O
defined O
splits O
of O
the O
HLA O
- O
A O
10 O
group O
, O
A O
26 O
. O
1 O
, O
A O
26 O
. O
3 O
, O
A O
26 O
. O
4 O
, O
and O
A O
10 O
SA O
, O
were O
determined O
. O

A O
26 O
. O
4 O
( O
A O
* O
2603 O
) O
was O
different B
from I
the I
other I
A I
26 I
splits I
at I
three I
positions I
: I
74 I
histidine I
, I
76 I
valine I
, I
and I
77 I
aspartate I
. O

A O
10 O
SA O
( O
A O
* O
2604 O
) O
was O
different O
from O
A O
26 O
. O
3 O
( O
A O
* O
2601 O
) O
by O
a O
single O
substitution B
of I
arginine I
by I
leucine I
at I
position I
163 I
. O

Antithrombin O
- O
III O
- O
Stockholm O
: O
a O
codon B
392 I
( I
Gly I
- I
- I
- I
- I
Asp I
) I
mutation O
with O
normal O
heparin O
binding O
and O
impaired O
serine O
protease O
reactivity O
. O

Only O
exon O
7 O
provided O
evidence O
for O
the O
presence O
of O
a O
mutation O
, O
with O
the O
second O
base O
of O
codon B
392 I
having I
a I
G I
- I
- I
- I
- I
A I
substitution I
. O

Experiments O
with O
AT O
- O
III O
from O
the O
proposita O
together O
with O
experiments O
with O
cell O
- O
free O
translated O
AT O
- O
III O
- O
Stockholm O
provided O
evidence O
that O
the O
mutant O
AT O
- O
III O
protein O
does O
not O
efficiently O
form O
a O
stable O
covalent O
inhibitory O
complex O
with O
alpha O
- O
thrombin O
, O
although O
it O
exhibits O
normal O
heparin O
affinity O
. O

In O
the O
present O
study O
, O
we O
evaluated O
the O
possible O
contribution O
of O
genetic O
variation O
of O
the O
serotonin O
5 O
- O
HT O
7 O
receptor O
to O
the O
development O
of O
schizophrenia O
and O
bipolar O
affective O
disorder O
. O

We O
detected O
two O
rare O
naturally O
occurring O
receptor O
variants O
( O
Pro O
- O
279 O
- O
Leu O
, O
Thr O
- O
92 O
- O
Lys O
) O
and O
a O
silent O
nucleotide O
substitution O
( B
A I
- I
- I
> I
G I
) I
at I
position I
+ I
1233 I
. O

In O
affected O
relatives O
, O
we O
found O
a O
previously O
unreported O
G B
to I
A I
transition I
in I
exon I
9 I
leading I
to I
a I
Gly I
to I
Arg I
substitution I
at I
amino I
acid I
position I
420 I
. O

G O
420 O
R O
has O
been O
reported O
previously O
with O
a O
G B
to I
C I
transversion I
. O

Aldolase O
A O
derived O
from O
a O
hemolytic O
anemia O
patient O
with O
aldolase O
A O
deficiency O
was O
shown O
to O
have O
an O
amino O
acid O
substitution O
of O
glycine B
for I
aspartic I
acid I
at I
the I
128 I
th I
position I
( O
Asp O
- O
128 O
) O
in O
the O
enzyme O
[ O
Kishi O
et O
al O
. O

Conversion O
of O
Asp B
to I
Gly I
at I
the I
128 I
th I
position I
in O
the O
enzyme O
rendered O
the O
enzyme O
thermolabile O
and O
susceptible O
to O
tryptic O
digestion O
. O

CD O
spectra O
analysis O
also O
revealed O
that O
the O
mutant O
enzyme O
had O
a O
remarkable O
conformation O
change O
with O
a O
decrease O
of O
regular O
form O
in O
the O
molecule O
. O

The O
deficiency O
is O
assigned O
to O
the O
XP O
- O
D O
complementation O
group O
, O
and O
we O
have O
identified O
two O
causative O
mutations O
in O
the O
XPD O
gene O
: O
a B
gly I
- I
- I
> I
arg I
change I
at I
amino I
acid I
675 I
in O
the O
allele O
inherited O
from O
the O
patient O
' O
s O
mother O
and O
a O
- B
1 I
frameshift I
at I
amino I
acid I
669 I
in O
the O
allele O
inherited O
from O
his O
father O
. O

To O
investigate O
the O
function O
of O
LNX O
, O
we O
tested O
its O
RING O
finger O
domain O
for O
ubiquitin O
ligase O
activity O
. O

The O
isolated O
RING O
finger O
domain O
was O
able O
to O
function O
as O
an O
E O
2 O
- O
dependent O
, O
E O
3 O
ubiquitin O
ligase O
in O
vitro O
and O
mutation B
of I
a I
conserved I
cysteine I
residue I
within I
the I
RING I
domain I
abolished O
its O
activity O
, O
indicating O
that O
LNX O
is O
the O
first O
described O
PDZ O
domain O
- O
containing O
member O
of O
the O
E O
3 O
ubiquitin O
ligase O
family O
. O

Direct O
sequencing O
revealed O
hemizygosity O
in O
the O
brothers O
and O
heterozygosity O
in O
the O
mother O
for O
a O
G B
- I
- I
> I
C I
transversion I
at I
position I
1299 I
of O
the O
published O
c O
DNA O
. O

An O
uncle O
affected O
by O
ataxia O
also O
carried O
this O
mutation O
. O

Immunoblot O
analysis O
of O
mutant O
AADACs O
that O
contained O
an O
asparagine B
( I
N I
, I
Asn I
) I
to I
glutamine I
( I
Q I
, I
Gln I
) I
substitution I
at I
either I
residue I
78 I
or I
282 I
( O
N O
78 O
Q O
or O
N O
282 O
Q O
) O
showed O
a O
different O
migration O
compared O
with O
the O
wild O
- O
type O
protein O
. O

A O
mutant O
AADAC O
that O
contained O
N B
to I
Q I
substitutions I
at I
both I
residue I
78 I
and I
282 I
( O
N O
78 O
Q O
/ O
N O
282 O
Q O
) O
showed O
a O
similar O
migration O
to O
AADAC O
in O
human O
liver O
microsomes O
( O
HLM O
) O
treated O
with O
endoglycosidase O
H O
( O
Endo O
H O
) O
, O
which O
produces O
deglycosylated O
proteins O
. O

This O
result O
indicated O
that O
AADAC O
was O
glycosylated O
at O
both O
N O
78 O
and O
N O
282 O
. O

Thr B
308 I
and I
/ I
or I
Ser I
473 I
were I
mutated I
to I
Ala I
or I
Asp I
and O
activities O
of O
mutant O
PKBalpha O
molecules O
were O
analysed O
after O
transfection O
into O
293 O
cells O
. O

Genetic O
sequencing O
studies O
of O
the O
entire O
coding O
( O
exon O
) O
sequences O
of O
ATP O
8 O
B O
1 O
and O
ABCB O
11 O
uncovered O
a O
novel O
heterozygous B
missense I
3035 I
G I
> I
T I
mutation O
( O
S O
1012 O
I O
) O
and O
a O
synonymous B
696 I
T I
> I
C I
mutation O
in O
ATP O
8 O
B O
1 O
. O

In O
non O
- O
Jewish O
patients O
of O
European O
origin O
, O
one O
mutation O
( O
914 O
C O
> O
A O
) O
is O
found O
in O
50 O
% O
of O
the O
alleles O
, O
the O
other O
alleles O
representing O
all O
kinds O
of O
different O
mutations O
. O

A O
deletion B
of I
exon I
4 I
, O
which O
until O
now O
had O
only O
been O
described O
once O
, O
was O
revealed O
in O
all O
five O
alleles O
of O
Turkish O
origin O
tested O
, O
indicating O
that O
this O
is O
a O
founder O
effect O
in O
the O
Turkish O
population O
. O

In O
addition O
to O
the O
previously O
identified O
c O
- O
kit O
gene O
product O
( O
Kit O
+ O
) O
, O
a O
second O
normal O
Kit O
isoform O
( O
Kit O
A O
+ O
) O
containing O
an O
in B
- I
frame I
insertion I
, I
Gly I
- I
Asn I
- I
Asn I
- I
Lys I
, I
within I
the I
extracellular I
domain I
, O
was O
detected O
in O
murine O
mast O
cell O
cultures O
and O
mid O
- O
gestation O
placenta O
. O

No O
association O
or O
increase O
in O
phosphorylation O
of O
GAP O
and O
two O
GAP O
- O
associated O
proteins O
, O
p O
62 O
and O
p O
190 O
, O
was O
observed O
. O

By O
analysis O
of O
Ba O
/ O
F O
3 O
cells O
retrovirally O
transduced O
to O
express O
c O
- O
Kit O
receptors O
, O
phenylalanine B
substitution I
of I
c I
- I
Kit I
tyrosine I
residue I
569 I
was O
shown O
to O
be O
associated O
with O
disruption O
of O
c O
- O
Kit O
- O
SHP O
- O
1 O
binding O
and O
induction O
of O
hyperproliferative O
responses O
to O
stem O
cell O
factor O
. O

Although O
phenylalanine B
substitution I
of I
c I
- I
Kit I
tyrosine I
residue I
567 I
in O
the O
Ba O
/ O
F O
3 O
- O
c O
- O
Kit O
cells O
did O
not O
alter O
SHP O
- O
1 O
binding O
to O
c O
- O
Kit O
, O
the O
capacity O
of O
a O
second O
c O
- O
Kit O
- O
binding O
tyrosine O
phosphatase O
, O
SHP O
- O
2 O
, O
to O
associate O
with O
c O
- O
Kit O
was O
markedly O
reduced O
, O
and O
the O
cells O
again O
showed O
hyperproliferative O
responses O
to O
stem O
cell O
factor O
. O

Assuming O
autosomal O
- O
recessive O
mode O
of O
inheritance O
, O
whole O
- O
genome O
linkage O
analysis O
, O
on O
DNA O
samples O
from O
four O
affected O
individuals O
, O
was O
undertaken O
. O

Sanger O
sequence O
analysis O
revealed O
a O
missense O
mutation O
, O
causing O
a O
substitution B
of I
valine I
( I
Val I
) I
to I
methionine I
( I
Met I
) I
at I
position I
71 I
. O

Importantly O
, O
human O
cells O
depleted O
of O
P O
4 O
H O
- O
alpha O
( O
I O
) O
or O
P O
4 O
H O
- O
beta O
by O
short O
hairpin O
RNA O
and O
P O
4 O
H O
- O
alpha O
( O
I O
) O
null O
mouse O
embryonic O
fibroblast O
cells O
showed O
reduced O
stability O
of O
Ago O
2 O
and O
impaired O
short O
interfering O
RNA O
programmed O
RISC O
activity O
. O

Furthermore O
, O
mutation B
of I
proline I
700 I
to I
alanine I
also O
resulted O
in O
destabilization O
of O
Ago O
2 O
, O
thus O
linking O
Ago O
2 O
P O
700 O
and O
hydroxylation O
at O
this O
residue O
to O
its O
stability O
regulation O
. O

In O
this O
study O
, O
a O
Thr O
278 O
Ile O
mutation O
was O
identified O
in O
helix O
9 O
of O
the O
modelled O
protein O
structure O
. O

The O
alteration B
of I
residue I
Thr I
278 I
is O
predicted O
to O
have O
a O
small O
but O
significant O
effect O
on O
the O
gamma O
1 O
actin O
structure O
owing O
to O
its O
close O
proximity O
to O
a O
methionine O
residue O
at O
position O
313 O
in O
helix O
11 O
. O

We O
describe O
a O
highly O
disabling O
congenital O
myasthenic O
syndrome O
( O
CMS O
) O
associated O
with O
rapidly O
decaying O
, O
low O
- O
amplitude O
synaptic O
currents O
, O
and O
trace O
its O
cause O
to O
a O
valine B
to I
leucine I
mutation I
in I
the I
signature I
cystine I
loop I
( I
cys I
- I
loop I
) I
of O
the O
ACh O
R O
alpha O
subunit O
. O

The O
overall O
findings O
reveal O
functional O
asymmetry O
between O
cys O
- O
loops O
of O
the O
different O
ACh O
R O
subunits O
in O
contributing O
to O
ACh O
binding O
and O
channel O
gating O
. O

We O
report O
here O
the O
sequence O
of O
the O
PI O
Mmalton O
allele O
, O
which O
contains O
a O
3 B
- I
bp I
deletion I
coding I
for I
one I
of I
two I
adjacent I
phenylalanine I
residues I
( I
amino I
acid I
51 I
or I
52 I
of O
the O
mature O
protein O
) O
. O

To O
judge O
on O
the O
basis O
of O
X O
- O
ray O
crystallography O
data O
for O
the O
normal O
alpha O
1 O
AT O
protein O
, O
the O
deletion B
of I
aa I
51 I
/ I
52 I
would O
shorten O
one O
strand O
of O
the O
beta O
sheet O
, O
B O
6 O
, O
apparently O
preventing O
normal O
processing O
and O
secretion O
. O

Reverse O
- O
polarity O
PAGE O
revealed O
that O
serine O
- O
43 O
and O
threonine O
- O
48 O
within O
the O
DNA O
binding O
domain O
of O
BATF O
are O
phosphorylated O
. O

To O
model O
phosphorylation O
of O
the O
BATF O
DNA O
binding O
domain O
, O
serine B
- I
43 I
was I
replaced I
by I
an I
aspartate I
residue I
. O

Recent O
studies O
have O
implicated O
mutations O
in O
ABCA O
1 O
as O
the O
cause O
of O
Tangier O
disease O
( O
TD O
) O
and O
familial O
hypoalphalipoproteinemia O
( O
FHA O
) O
. O

The O
proband O
and O
affected O
individuals O
were O
heterozygotes O
for O
C O
254 O
T O
with O
proline B
converted I
to I
leucine I
( I
P I
85 I
L I
) I
. O

The O
entire O
acid O
sphingomyelinase O
coding O
region O
from O
an O
Ashkenazi O
Jewish O
Type O
B O
patient O
was O
polymerase O
chain O
reaction O
- O
amplified O
, O
subcloned O
, O
and O
completely O
sequenced O
. O

A O
three B
- I
base I
deletion I
was I
identified I
of I
nucleotides I
1821 I
- I
1823 I
in O
the O
c O
DNA O
which O
predicted O
the O
removal B
of I
an I
arginine I
residue I
from I
position I
608 I
of O
the O
acid O
sphingomyelinase O
polypeptide O
( O
delta O
R O
608 O
) O
. O

Replacement B
of I
three I
arginine I
residues I
unique I
to I
the I
HA I
- I
stretch I
of O
the O
5 O
- O
HT O
3 O
A O
subunit O
by O
their O
5 O
- O
HT O
3 O
B O
subunit O
counterparts O
increased O
single O
- O
channel O
conductance O
28 O
- O
fold O
. O

Our O
findings O
solve O
the O
conundrum O
of O
the O
anomalously O
low O
conductance O
of O
homomeric O
5 O
- O
HT O
3 O
A O
receptors O
and O
indicate O
an O
important O
function O
for O
the O
HA O
- O
stretch O
in O
Cys O
- O
loop O
transmitter O
- O
gated O
ion O
channels O
. O

The O
structure O
shows O
that O
the O
residues O
forming O
the O
putative O
B O
1 O
, O
P O
1 O
, O
and O
B O
2 O
RNA O
- O
binding O
subsites O
occupy O
positions O
similar O
to O
their O
h O
Ang O
counterparts O
. O

In O
the O
putative O
cell O
- O
binding O
segment O
, O
the O
replacement B
of I
Lys I
59 I
with I
Asn I
( O
its O
counterpart O
at O
position O
61 O
of O
h O
Ang O
) O
does O
not O
abrogate O
enzymatic O
activity O
but O
abolishes O
angiogenic O
activity O
, O
the O
reason O
for O
which O
is O
unclear O
. O

We O
found O
a O
somatic O
mutation O
and O
a O
gene O
variation O
in O
human O
lung O
cancer O
cells O
that O
change B
glycine I
to I
cysteine I
in I
the I
DGR I
domain I
, O
introducing O
local O
conformational O
changes O
that O
reduce O
Keap O
1 O
' O
s O
affinity O
for O
Nrf O
2 O
. O

We O
report O
a O
mutation O
at O
a O
novel O
site O
in O
APP O
in O
a O
three O
- O
generation O
Iowa O
family O
with O
autosomal O
dominant O
dementia O
beginning O
in O
the O
sixth O
or O
seventh O
decade O
of O
life O
. O

The O
affected O
brothers O
shared O
a O
missense O
mutation O
in O
APP O
, O
resulting O
in O
substitution O
of O
asparagine B
for I
aspartic I
acid I
at I
position I
694 I
. O

A O
chimeric O
protein O
MTH O
1 O
- O
Ec O
, O
in O
which O
the O
23 B
- I
residue I
sequence I
of I
MTH I
1 I
was I
replaced I
with I
that I
of I
Mut I
T I
, O
retains O
its O
capability O
to O
hydrolyze O
8 O
- O
oxo O
- O
d O
GTP O
, O
thereby O
indicating O
that O
the O
23 O
- O
residue O
sequences O
of O
MTH O
1 O
and O
Mut O
T O
are O
functionally O
and O
structurally O
equivalent O
and O
constitute O
functional O
modules O
. O

For O
the O
other O
9 O
residues O
( O
40 O
, O
42 O
, O
44 O
, O
46 O
, O
47 O
, O
49 O
, O
50 O
, O
54 O
, O
and O
58 O
) O
, O
positive O
mutants O
were O
obtained O
, O
and O
Arg B
( I
50 I
) I
can I
be I
replaced I
with I
hydrophobic I
residues I
( I
Val I
, I
Leu I
, I
or I
Ile I
) I
, O
with O
a O
greater O
stability O
and O
higher O
specific O
activity O
of O
the O
enzyme O
. O

We O
identified O
five O
novel O
mutations O
in O
nine O
families O
with O
P O
5 O
N O
- O
I O
deficiency O
: O
two B
missense I
mutations I
( I
425 I
C I
, I
721 I
C I
) I
, I
one B
splice I
mutation I
( I
339 I
C I
) I
, O
one B
1 I
- I
bp I
insertion I
( I
251 I
- I
ins I
A I
- I
252 I
) I
and O
one O
9 B
- I
bp I
deletion I
( I
del I
192 I
- I
200 I
) I
. O

The O
mutant O
P O
5 O
N O
was O
then O
expressed O
in O
Cos O
- O
7 O
. O

In O
contrast O
, O
the O
substitution B
of I
residues I
at I
position I
Trp I
- I
117 I
and O
Asp O
- O
119 O
of O
MTH O
1 O
, O
which O
showed O
apparent O
chemical O
shift O
perturbations O
with O
8 O
- O
oxo O
- O
d O
GDP O
in O
NMR O
analyses O
but O
are O
not O
conserved O
in O
Mut O
T O
, O
affected O
the O
substrate O
specificity O
. O

Compared O
with O
wild O
- O
type O
JAK O
2 O
, O
which O
is O
constitutively O
active O
when O
overexpressed O
, O
JAK O
2 O
lacking B
tyrosine I
868 I
, I
966 I
, I
or I
972 I
has O
substantially O
reduced O
activity O
. O

The O
three O
mutated O
JAK O
2 O
s O
also O
mediate O
GH O
activation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
( O
Stat O
3 O
) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
5 O
b O
( O
Stat O
5 O
b O
) O
and O
ERK O
1 O
, O
but O
at O
reduced O
levels O
. O

Understanding O
molecular O
underpinnings O
of O
these O
properties O
requires O
identification O
and O
characterization O
of O
additional O
factors O
that O
act O
in O
conjunction O
with O
these O
key O
factors O
in O
ESCs O
. O

In O
particular O
, O
we O
demonstrated O
that O
deletion B
of I
Zfp O
281 O
resulted O
in O
upregulation O
of O
Nanog O
at O
both O
the O
transcript O
and O
protein O
levels O
with O
concomitant O
compromised O
differentiation O
of O
ESCs O
during O
embryoid O
body O
culture O
. O

BTK O
* O
results O
from O
a O
single O
point O
mutation O
in O
the O
pleckstrin O
homology O
( O
PH O
) O
domain O
, O
where O
a O
Glu B
is I
replaced I
by I
Lys I
at I
residue I
41 I
. O

Mutation O
of O
the O
SH O
2 O
or O
SH O
3 O
domains O
did O
not O
affect O
the O
activity O
of O
BTK O
* O
. O

Two O
mutations O
( O
a O
termination B
codon I
in I
exon I
4 I
and I
a I
large I
genomic I
deletion I
extending I
3 I
' I
of I
intron I
8 I
) O
did O
not O
produce O
a O
stable O
ENG O
transcript O
in O
lymphocytes O
. O

These O
data O
suggest O
that O
the O
molecular O
mechanism O
by O
which O
ENG O
mutations O
cause O
HHT O
is O
haploinsufficiency O
. O

The O
first O
patient O
was O
homozygous O
for O
double O
deletions O
of O
1221 B
bp I
between I
intron I
12 I
and I
14 I
and O
19 B
. I
9 I
kb I
between I
intron I
16 I
and I
31 I
. O

The O
second O
patient O
was O
homozygous O
for O
a O
novel B
mutation I
of I
A I
3198 I
C I
in I
exon I
19 I
, O
resulting O
in O
Asn O
935 O
His O
. O

The O
murine O
white O
spotting O
locus O
( O
W O
) O
is O
allelic O
with O
the O
proto O
- O
oncogene O
c O
- O
kit O
, O
which O
encodes O
a O
transmembrane O
tyrosine O
protein O
kinase O
receptor O
for O
an O
unknown O
ligand O
. O

Nucleotide O
sequence O
analysis O
of O
mutant O
complementary O
DNAs O
revealed O
a O
missense B
mutation I
that I
replaces I
aspartic I
acid I
with I
asparagine I
at I
position I
790 I
in O
the O
c O
- O
kit O
protein O
product O
. O

ALK O
- O
1 O
levels O
were O
specifically O
reduced O
in O
three O
HUVEC O
with O
ALK O
- O
1 O
missense O
mutant O
codons O
, O
and O
normal O
in O
two O
newborns O
not O
carrying O
the O
missense O
mutations O
present O
in O
the O
clinically O
affected O
relatives O
. O

Levels O
were O
also O
normal O
in O
a O
HUVEC O
with O
deletion B
of I
S I
232 I
in O
the O
ATP O
binding O
site O
of O
ALK O
- O
1 O
. O

A O
single B
A I
to I
G I
nucleotide I
replacement I
which I
resulted I
in I
lysine I
329 I
- I
to I
- I
glutamic I
acid I
329 I
substitution I
of O
the O
MCAD O
protein O
was O
identified O
in O
all O
cultures O
. O

The O
Vmunich O
allele O
differed O
from O
the O
common O
normal O
M O
1 O
( O
Val B
213 I
) I
alpha I
1 I
AT I
allele I
by I
a I
single I
nucleotide I
substitution I
of I
cytosine I
for I
adenosine I
, O
with O
the O
resultant O
amino B
acid I
change I
Asp I
2 I
GAT I
- I
- I
- I
- I
Ala I
GCT I
. O

The O
Asp B
2 I
- I
- I
- I
- I
Ala I
mutation I
explains O
the O
cathodal O
position O
of O
the O
Vmunich O
protein O
on O
IEF O
, O
as O
there O
is O
a O
substitution O
of O
a O
negatively O
charged O
amino O
acid O
by O
a O
neutral O
one O
. O

One O
was O
transition B
from I
guanine I
to I
adenine I
at I
nucleotide I
position I
1002 I
, O
resulting O
in O
substitution B
of I
aspartate I
for I
asparagine I
at I
codon I
103 I
, O
and O
the O
other O
was O
transition B
from I
cytosine I
to I
thymine I
at I
nucleotide I
1104 I
, O
leading B
to I
substitution I
of I
arginine I
for I
tryptophan I
at I
codon I
137 I
. O

Act O
R O
- O
IIB O
are O
phosphoproteins O
with O
demonstrable O
affinity O
for O
each O
other O
. O

Mutation B
of I
conserved I
serines I
and I
threonines I
in I
the I
GS I
domain I
, I
a I
region I
just I
upstream I
of I
the I
kinase I
domain I
in O
Act O
R O
- O
IB O
, O
abrogates O
both O
phosphorylation O
and O
signal O
propagation O
, O
suggesting O
that O
this O
domain O
contains O
phosphorylation O
sites O
required O
for O
signalling O
. O

Act O
R O
- O
IB O
activation O
can O
be O
mimicked O
by O
mutation B
of I
Thr I
- I
206 I
to I
aspartic I
acid I
, O
which O
yields O
a O
construct O
, O
Act O
R O
- O
IB O
( O
T O
206 O
D O
) O
, O
that O
signals O
in O
the O
absence O
of O
ligand O
. O

Patients O
with O
pyridoxine O
dependent O
epilepsy O
( O
PDE O
) O
present O
with O
early O
- O
onset O
seizures O
resistant O
to O
common O
anticonvulsants O
. O

Furthermore O
, O
a O
novel B
deletion I
of I
exon I
7 I
was O
identified O
. O

Mutation B
in I
codon I
713 I
of O
the O
beta O
amyloid O
precursor O
protein O
gene O
presenting O
with O
schizophrenia O
. O

Following O
reports O
of O
mutations B
of I
codon I
717 I
in I
exon I
17 I
of O
the O
amyloid O
precursor O
protein O
( O
APP O
) O
gene O
in O
early O
- O
onset O
familial O
Alzheimer O
' O
s O
disease O
, O
we O
screened O
exon O
17 O
for O
new O
mutations O
in O
presenile O
dementia O
. O

Sequencing O
revealed O
a O
C B
to I
T I
nucleotide I
substitution I
which I
produces I
an I
alanine I
to I
valine I
change I
at I
codon I
713 I
. O

In O
a O
large O
family O
with O
multiple O
branches O
, O
we O
identified O
biallelic O
variants O
in O
DCPS O
in O
three O
affected O
individuals O
; O
a O
splice O
site O
variant O
( O
c O
. O
636 O
+ O
1 O
G O
> O
A O
) O
that O
results O
in O
an O
in B
- I
frame I
insertion I
of I
45 I
nucleotides I
and O
a O
missense O
variant O
( O
c O
. O
947 O
C O
> O
T O
; O
p O
. O
Thr O
316 O
Met O
) O
. O

In O
vitro O
decapping O
assays O
showed O
an O
ablation O
of O
decapping O
function O
for O
both O
variants O
in O
DCPS O
. O

OBJECTIVE O
: O
To O
report O
the O
spectrum O
of O
ophthalmic O
findings O
in O
patients O
with O
Stargardt O
dystrophy O
or O
fundus O
flavimaculatus O
who O
have O
a O
specific O
sequence O
variation O
in O
the O
ABCR O
gene O
. O

In O
phenotype O
I O
, O
9 O
of O
12 O
patients O
had O
a O
sequence O
change O
in B
exon I
42 I
of I
the I
ABCR I
gene I
in I
which I
the I
amino I
acid I
glutamic I
acid I
was I
substituted I
for I
glycine I
( O
Gly O
1961 O
Glu O
) O
. O

One O
patient O
showed O
the O
Gly O
1961 O
Glu O
change O
. O

We O
found O
that O
the O
expression O
patterns O
of O
the O
Notch O
ligand O
delta O
- O
like O
1 O
( O
Dll O
1 O
) O
and O
of O
the O
active O
form O
of O
Notch O
1 O
were O
mutually O
exclusive O
and O
segregated O
into O
distinct O
NPC O
subpopulations O
in O
the O
ventricular O
zone O
of O
the O
telencephalon O
. O

Importantly O
, O
conditional O
deletion B
of I
the O
Dll O
1 O
gene O
in O
a O
small O
proportion O
of O
NPCs O
reduced O
neurogenesis O
in O
vivo O
, O
whereas O
deletion O
in O
a O
large O
proportion O
promoted O
premature O
neurogenesis O
. O

Although O
the O
linkage O
of O
polyglutamine O
( O
poly O
- O
Q O
) O
repeat O
expansion O
in O
the O
androgen O
receptor O
( O
AR O
) O
to O
Kennedy O
' O
s O
disease O
( O
X O
- O
linked O
spinal O
and O
bulbar O
muscular O
atrophy O
) O
was O
a O
major O
step O
forward O
, O
the O
detailed O
molecular O
mechanism O
of O
how O
the O
change O
in O
poly O
- O
Q O
length O
contributes O
to O
the O
disease O
remains O
unclear O
. O

Deletion B
of I
the I
acidic I
hexapeptide I
( I
DEDDDL I
) I
at I
the I
C I
terminus I
of O
ARA O
24 O
further O
enhances O
its O
AR O
coactivation O
. O

Autosomal O
dominant O
nocturnal O
frontal O
lobe O
epilepsy O
( O
ADNFLE O
) O
is O
a O
partial O
epilepsy O
causing O
frequent O
, O
violent O
, O
brief O
seizures O
at O
night O
, O
usually O
beginning O
in O
childhood O
. O

We O
screened O
affected O
family O
members O
for O
mutations O
within O
CHRNA O
4 O
and O
found O
a O
missense B
mutation I
that I
replaces I
serine I
with I
phenylalanine I
at I
codon I
248 I
, O
a O
strongly O
conserved O
amino O
acid O
residue O
in O
the O
second O
transmembrane O
domain O
. O

We O
report O
here O
five O
mutations O
identified O
in O
four O
patients O
: O
a O
135 B
- I
bp I
deletion I
encompassing I
bases I
343 I
- I
477 I
, O
a B
C I
- I
1837 I
- I
to I
- I
T I
transition O
( O
R O
613 O
W O
) O
, O
3 B
- I
bp I
deletions I
at I
the I
nucleotide I
positions I
388 I
- I
390 I
( I
E I
130 I
del I
) I
and O
895 O
- O
897 O
( O
K O
299 O
del O
) O
, O
and O
an O
A O
- O
1144 O
- O
to O
- O
C O
transversion O
( O
K O
382 O
Q O
) O
. O

Sequencing O
of O
genomic O
DNA O
amplified O
by O
PCR O
revealed O
a O
135 B
- I
bp I
deletion I
caused I
by I
exon I
skipping I
due I
to I
a I
1 I
- I
bp I
deletion I
in I
a I
3 I
' I
splice I
site I
of I
an I
intron I
. O

In O
c O
DNA O
expression O
experiments O
using O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
, O
we O
found O
that O
each O
of O
the O
m O
RNAs O
derived O
from O
E O
130 O
del O
and O
K O
299 O
del O
clones O
were O
unstable O
and O
that O
translation O
products O
from O
R O
613 O
W O
, O
E O
130 O
del O
, O
K O
299 O
del O
, O
and O
K O
382 O
Q O
clones O
were O
labile O
. O

Recessive O
mutations O
of O
sulfonylurea O
receptor O
1 O
( O
SUR O
1 O
) O
and O
potassium O
inward O
rectifier O
6 O
. O
2 O
( O
Kir O
6 O
. O
2 O
) O
, O
the O
two O
adjacent O
genes O
on O
chromosome O
11 O
p O
that O
comprise O
the O
beta O
- O
cell O
plasma O
membrane O
ATP O
- O
sensitive O
K O
( O
+ O
) O
( O
K O
( O
ATP O
) O
) O
channels O
, O
are O
responsible O
for O
the O
most O
common O
form O
of O
congenital O
hyperinsulinism O
in O
children O
. O

Mutation O
analysis O
identified O
a O
novel O
trinucleotide B
deletion I
in I
SUR I
1 I
exon I
34 I
that I
results I
in I
the I
loss I
of I
serine I
1387 I
. O

Sequence O
analysis O
reveals O
that O
the O
amino B
acid I
substitution I
occurs I
at I
position I
7 I
of I
the I
largest I
CNBr I
fragment I
, I
corresponding I
to I
position I
47 I
of I
the I
whole I
protein I
chain I
. O

The O
histidine B
/ I
arginine I
- I
47 I
mutational I
replacement I
corresponds O
to O
a O
position O
that O
binds O
the O
pyrophosphate O
group O
of O
the O
coenzyme O
NAD O
( O
H O
) O
; O
this O
explains O
the O
functional O
differences O
between O
the O
beta O
1 O
beta O
1 O
and O
beta O
2 O
beta O
2 O
isozymes O
, O
including O
both O
a O
lower O
p O
H O
optimum O
and O
higher O
turnover O
number O
of O
beta O
2 O
beta O
2 O
, O
which O
is O
likely O
to O
be O
the O
mutant O
form O
. O

We O
also O
observed O
silent O
sequence O
variants O
in O
the O
FALDH O
gene O
and O
a O
base B
pair I
substitution I
in I
exon I
5 I
that I
alters I
aspartic I
acid I
to I
asparagine I
, O
all O
of O
which O
are O
considered O
polymorphisms O
. O

Four O
of O
these O
sequence O
variations O
have O
not O
been O
described O
previously O
. O

However O
, O
IVS B
6 I
+ I
31 I
C I
> I
T I
, O
IVS B
6 I
+ I
40 I
C I
> I
A I
, O
and O
1386 O
T O
> O
C O
were O
solely O
detected O
in O
bipolar O
affective O
patients O
and O
in O
none O
of O
the O
controls O
. O

We O
have O
identified O
a O
single B
point I
mutation I
between I
M I
1 I
Val I
213 I
and I
M I
3 I
at I
codon I
position I
376 I
which I
is I
a I
GAA I
( I
Glu I
) I
to I
GAC I
( I
Asp I
) I
transversion I
. O

The O
patients O
carried O
a O
homozygous O
missense O
mutation O
converting O
Asn B
100 I
to I
Ser I
in O
exon O
3 O
of O
his O
type O
II O
3 O
beta O
HSD O
gene O
. O

Except O
for O
the O
hypothetical O
effect O
of O
local O
factors O
, O
these O
findings O
suggest O
that O
a O
very O
weak O
residual O
activity O
of O
the O
normal O
type O
II O
3 O
beta O
HSD O
enzyme O
could O
prevent O
salt O
loss O
, O
but O
it O
was O
insufficient O
for O
normal O
male O
sex O
differentiation O
. O

At B
amino I
acid I
position I
389 I
, I
Gly I
or I
Arg I
can I
be I
found I
( O
allele O
frequencies O
0 O
. O
26 O
and O
0 O
. O

Taken O
together O
, O
these O
data O
indicate O
that O
this O
polymorphic O
variation O
of O
the O
human O
beta O
1 O
AR O
results O
in O
alterations O
of O
receptor O
- O
Gs O
interaction O
with O
functional O
signal O
transduction O
consequences O
, O
consistent O
with O
its O
localization O
in O
a O
putative O
G O
- O
protein O
binding O
domain O
. O

Sequence O
analysis O
revealed O
13 O
nucleotide O
changes O
in O
the O
Aldh O
3 O
a O
1 O
c O
allele O
. O

Replacement B
of I
Arg I
with I
the I
more I
ionizable I
His I
at I
position I
305 I
of O
a O
beta O
strand O
might O
directly O
affect O
catalytic O
activity O
of O
the O
enzyme O
. O

ATM O
- O
and O
Rad O
3 O
- O
related O
also O
phosphorylates O
Thr O
68 O
in O
addition O
to O
Thr O
26 O
and O
Ser O
50 O
, O
which O
are O
not O
phosphorylated O
to O
a O
significant O
extent O
by O
ATM O
in O
vitro O
. O

Substitution O
of O
Thr B
68 I
with I
Ala I
reduced O
the O
extent O
of O
phosphorylation O
and O
activation O
of O
Chk O
2 O
in O
response O
to O
IR O
, O
and O
mutation O
of O
all O
seven O
SQ O
/ O
TQ O
moti O
fs O
blocked O
all O
phosphorylation O
and O
activation O
of O
Chk O
2 O
after O
IR O
. O

Circulating O
concentrations O
of O
delta O
5 O
steroids O
and O
delta O
5 O
urinary O
steroid O
metabolites O
were O
elevated O
and O
remained O
elevated O
after O
orchidectomy O
. O

A O
mutation O
in O
the O
gene O
for O
3 O
beta O
- O
HSD O
type O
II O
was O
observed O
at O
codon B
173 I
( I
CTA I
- I
- I
> I
CGA I
) I
, O
leading O
in O
the O
affected O
patient O
to O
a O
homozygous O
substitution O
in O
which O
the O
leucine B
at I
residue I
173 I
was I
altered I
to I
an I
arginine I
( O
L O
173 O
R O
) O
. O

The O
latter O
polymorphisms B
were I
located I
88 I
bp I
apart I
at I
the I
3 I
' I
end I
of I
the I
type I
I I
coding I
sequence I
and O
could O
be O
physically O
resolved O
as O
haplotypes O
using O
DGGE O
. O

Sequence O
analysis O
of O
c O
- O
kit O
c O
DNA O
from O
Wads O
( O
m O
/ O
m O
) O
revealed O
a O
unique O
T O
- O
to O
- O
C O
transition O
mutation O
that O
resulted O
in O
Phe B
- I
to I
- I
Ser I
substitution I
at I
amino I
acid I
856 I
within O
a O
highly O
conserved O
tyrosine O
kinase O
domain O
. O

Compared O
with O
other O
c O
- O
kit O
mutants O
, O
Wads O
may O
present O
a O
novel O
loss O
- O
of O
- O
function O
or O
hypomorphic O
mutation O
. O

By O
positional O
cloning O
, O
we O
demonstrate O
that O
a O
novel O
spontaneous O
mutation O
ringelschwanz O
( O
rs O
) O
in O
the O
mouse O
is O
caused O
by O
a O
point O
mutation O
in O
Lrp O
6 O
, O
leading B
to I
an I
amino I
acid I
substitution I
of I
tryptophan I
for I
the I
evolutionarily I
conserved I
residue I
arginine I
at I
codon I
886 I
( O
R O
886 O
W O
) O
. O

Furthermore O
, O
the O
Lrp O
6 O
dysfunction O
in O
rs O
leads O
to O
delayed O
ossification O
at O
birth O
and O
to O
a O
low O
bone O
mass O
phenotype O
in O
adults O
. O

Six O
patients O
were O
compound O
heterozygotes O
; O
7 O
of O
10 O
mutations O
found O
were O
novel O
, O
including O
one O
deletion O
( O
delta O
1019 O
- O
1020 O
) O
, O
three B
missense I
( I
Arg I
156 I
> I
His I
, O
Arg O
101 O
> O
Leu O
, O
Val O
177 O
> O
Met O
) O
, O
and O
three O
splicing O
defects O
( O
IVS B
5 I
, I
5 I
' I
ss I
T I
+ I
6 I
> I
A I
; O
IVS B
10 I
, I
5 I
' I
ss I
G I
+ I
1 I
> I
A I
; O
IVS B
10 I
, I
3 I
' I
ss I
G I
- I
34 I
> I
A I
) O
. O

Four O
of O
the O
mutations O
generated O
stop O
signals O
at O
codons O
131 O
, O
321 O
, O
334 O
, O
and O
348 O
; O
transcripts O
of O
all O
but O
the O
last O
, O
due O
to O
delta O
1019 O
- O
1020 O
, O
were O
severely O
reduced O
. O

The O
oldest O
patient O
diagnosed O
was O
homozygous O
for O
a O
single B
base I
change I
in I
intron I
10 I
, O
which O
activates O
a O
cryptic O
splice O
acceptor O
, O
resulting O
in O
a O
protein O
with O
100 O
extra O
amino O
acids O
. O

Protein O
- O
protein O
interaction O
assays O
reveal O
association O
of O
TIP O
5 O
with O
the O
histone O
deacetylase O
HDAC O
1 O
in O
vivo O
and O
in O
vitro O
. O

Deletion B
of I
the I
C I
- I
terminal I
PHD I
finger I
and O
bromodomain O
abolishes O
the O
interaction O
of O
TIP O
5 O
and O
HDAC O
1 O
, O
and O
abrogates O
transcriptional O
repression O
. O

The O
deduced O
Lyso O
PLA O
I O
sequence O
contains O
a O
well O
conserved O
GXSXG O
motif O
found O
in O
the O
active O
site O
of O
many O
serine O
enzymes O
, O
and O
the O
activity O
of O
the O
Lyso O
PLA O
I O
was O
irreversibly O
inhibited O
by O
the O
classical O
serine O
protease O
inhibitor O
diisopropyl O
fluorophosphate O
. O

Furthermore O
, O
site O
- O
directed O
mutagenesis O
was O
employed O
to O
change B
Ser I
- I
119 I
in I
the I
GXSXG I
motif I
to I
an I
Ala I
. O

To O
probe O
function O
of O
automethylation O
, O
we O
mutated O
arginine B
551 I
to I
lysine I
to O
create O
an O
automethylation O
- O
deficient O
CARM O
1 O
. O

These O
results O
strongly O
imply O
that O
automethylation O
of O
CARM O
1 O
provides O
a O
direct O
link O
to O
couple O
transcription O
and O
pre O
- O
m O
RNA O
splicing O
in O
a O
manner O
differing O
from O
the O
other O
steroid O
receptor O
coactivators O
. O

Molecular O
analysis O
of O
alpha O
1 O
- O
antitrypsin O
( O
alpha O
1 O
AT O
) O
Wbethesda O
revealed O
that O
it O
differs O
from O
the O
normal O
M O
1 O
( B
Ala I
213 I
) I
allele I
by I
a I
single I
base I
mutation I
causing I
an I
amino I
acid I
substitution I
Ala I
336 I
GCT I
- I
- I
- I
- I
Thr I
ACT I
. O

Comparison O
of O
this O
sequence O
to O
the O
ADH O
2 O
( O
1 O
) O
nucleotide O
sequence O
revealed O
only O
a O
single O
difference O
that O
results O
in O
an O
amino O
acid O
change O
, O
thus O
proving O
that O
the O
significant O
kinetic O
differences O
between O
these O
two O
isozymes O
is O
due O
to O
the O
Cys B
for I
Arg I
substitution I
at I
position I
369 I
. O

Here O
we O
present O
a O
second O
novel O
allele O
from O
this O
population O
: O
A O
* O
6817 O
, O
which O
differs O
from O
its O
closest O
neighbour O
A O
* O
68012 O
by O
a O
single B
substitution I
at I
nucleotide I
419 I
. O

This O
substitution B
of I
adenosine I
419 I
A I
* I
68012 I
for I
thymidine I
in O
A O
* O
6817 O
results O
in O
a O
novel O
amino O
acid O
change O
( B
aspartate I
to I
valine I
) I
at I
residue I
116 I
. O

Based O
on O
haplotypes O
, O
we O
previously O
identified O
, O
in O
eight O
patients O
, O
five O
different O
null O
alleles O
, O
four O
of O
which O
had O
been O
previously O
sequenced O
. O

We O
have O
cloned O
and O
sequenced O
one O
of O
these O
, O
PI O
* O
QOludwigshafen O
, O
which O
has O
a O
base B
substitution I
in I
exon I
II I
, I
replacing I
isoleucine I
92 I
in I
the I
normal I
sequence I
with I
an I
asparagine I
. O

Scd O
1 O
ab O
- O
Xyk O
: O
a O
new O
asebia O
allele O
characterized O
by O
a O
CCC B
trinucleotide I
insertion I
in I
exon I
5 I
of O
the O
stearoyl O
- O
Co O
A O
desaturase O
1 O
gene O
in O
mouse O
. O

By O
haplotype O
analysis O
and O
direct O
sequencing O
of O
PCR O
products O
, O
we O
show O
that O
this O
mutation O
is O
a O
new O
allele O
of O
the O
asebia O
locus O
with O
a O
naturally O
occurring O
mutation O
in O
the O
Scd O
1 O
gene O
( O
a B
CCC I
insertion I
at I
nucleotide I
position I
835 I
in I
exon I
5 I
) O
, O
which O
codes O
for O
stearoyl O
- O
Co O
A O
desaturase O
1 O
. O

This O
mutation O
introduces O
an O
extra B
proline I
residue I
at I
position I
279 I
in O
the O
Scd O
1 O
protein O
. O

This O
new O
mouse O
mutant O
is O
a O
good O
model O
not O
only O
for O
the O
study O
of O
scarring O
alopecias O
in O
humans O
, O
which O
are O
characterized O
by O
hypoplasic O
sebaceous O
glands O
, O
but O
also O
for O
studying O
the O
structure O
and O
function O
of O
the O
Scd O
1 O
protein O
. O

Understanding O
the O
regulation O
of O
Akt O
has O
been O
of O
major O
interest O
for O
elucidating O
the O
control O
of O
normal O
cellular O
physiology O
as O
well O
as O
malignant O
transformation O
. O

Substitution B
of I
Tyr I
- I
474 I
with I
phenylalanine I
abolished O
tyrosine O
phosphorylation O
of O
Akt O
and O
resulted O
in O
up O
to O
55 O
% O
inhibition O
of O
Akt O
activation O
, O
indicating O
phosphorylation O
at O
Tyr O
- O
474 O
is O
required O
for O
full O
activation O
of O
the O
kinase O
. O

Changing O
Asp B
295 I
to I
a I
glutamate I
decreases O
the O
kcat O
but O
does O
not O
alter O
the O
Km O
for O
adenosine O
, O
confirming O
the O
importance O
of O
this O
residue O
in O
the O
catalytic O
process O
and O
its O
minimal O
role O
in O
substrate O
binding O
. O

In O
contrast O
, O
Asp B
296 I
mutants I
exhibit O
markedly O
increased O
Km O
values O
, O
establishing O
this O
residue O
' O
s O
critical O
role O
in O
substrate O
binding O
. O

The O
structure O
of O
the O
D O
296 O
A O
mutant O
shows O
that O
the O
impaired O
binding O
of O
substrate O
is O
caused O
by O
the O
loss O
of O
a O
single O
hydrogen O
bond O
between O
a O
carboxylate O
oxygen O
and O
N O
7 O
of O
the O
purine O
ring O
. O

Constitutive O
activation O
of O
MAPKAP O
kinase O
2 O
is O
obtained O
by O
replacement B
of I
both I
of I
these I
threonine I
residues I
by I
glutamic I
acid I
. O

A O
constitutively O
active O
form O
of O
MAPKAP O
kinase O
2 O
is O
also O
obtained O
by O
deletion B
of I
a I
carboxyl I
- I
terminal I
region I
containing I
Thr I
- I
317 I
and I
the I
A I
- I
helix I
motif I
or O
by O
replacing B
the I
conserved I
residues I
of I
the I
A I
- I
helix I
. O

She O
and O
her O
father O
were O
both O
PI O
M O
1 O
Zbristol O
heterozygotes O
. O

The O
Zbristol O
mutation O
was O
found O
to O
be O
a O
C B
to I
T I
transition I
at I
codon I
85 I
changing I
ACG I
( I
Thr I
) I
to I
ATG I
( I
Met I
) I
. O

OBJECTIVE O
: O
Persistent O
hyperinsulinaemic O
hypoglycaemia O
of O
infancy O
( O
PHHI O
) O
is O
a O
disorder O
of O
glucose O
metabolism O
that O
is O
characterized O
by O
dysregulated O
secretion O
of O
insulin O
from O
pancreatic O
beta O
- O
cells O
. O

In O
Kir O
6 O
. O
2 O
gene O
screening O
, O
one O
patient O
was O
found O
to O
be O
a O
compound O
heterozygote O
of O
a O
missense O
mutation O
( O
R O
34 O
H O
) O
and O
a O
one B
- I
base I
deletion I
( I
C I
344 I
fs I
/ I
ter I
) I
. O

Phosphorylation O
was O
not O
observed O
in O
endothelial O
cells O
overexpressing O
a O
mutant O
form O
of O
ACE O
( O
ACEDelta B
S I
, I
all I
five I
cytoplasmic I
serine I
residues I
replaced I
by I
alanine I
) O
. O

Mutation B
of I
serine I
( I
1270 I
) I
within I
the I
CK I
2 I
consensus I
sequence I
almost O
abolished O
ACE O
phosphorylation O
. O

In O
ACE O
- O
overexpressing O
endothelial O
cells O
, O
ACE O
was O
mostly O
localized O
to O
the O
plasma O
membrane O
. O

Residues O
identified O
as O
potential O
catalytic O
triad O
members O
( B
S I
162 I
, I
D I
247 I
, I
and I
H I
279 I
) I
through I
sequence I
motif I
and I
homology I
modeling I
were I
mutated I
to I
alanine I
to O
probe O
their O
contributions O
to O
enzyme O
activity O
. O

The O
single O
mutants O
( O
S O
162 O
A O
, O
D O
247 O
A O
, O
and O
H O
279 O
A O
) O
lost O
essentially O
all O
( O
> O
99 O
% O
) O
activity O
. O

One O
non O
- O
synonymous O
AC O
9 O
polymorphism O
has O
been O
identified O
, O
which O
results O
in O
substitution O
of O
Met B
for I
Ile I
at I
amino I
acid I
772 I
. O

Met O
772 O
carriers O
on O
budesonide O
showed O
a O
significant O
improvement O
in O
forced O
expiratory O
volume O
in O
1 O
s O
( O
P O
= O
0 O
. O
005 O
) O
. O

Different O
inactivating O
germline O
mutations O
of O
the O
PRKAR O
1 O
A O
gene O
were O
found O
in O
the O
five O
patients O
. O

A O
somatic B
16 I
- I
bp I
deletion I
of O
PRKAR O
1 O
A O
gene O
was O
also O
found O
in O
this O
macronodule O
. O

Primary O
structure O
of O
c O
- O
kit O
: O
relationship O
with O
the O
CSF O
- O
1 O
/ O
PDGF O
receptor O
kinase O
family O
- O
- O
oncogenic O
activation O
of O
v O
- O
kit O
involves O
deletion B
of I
extracellular I
domain I
and I
C I
terminus I
. O

wt O
of O
109 O
. O
001 O
kd O
. O

N B
- I
terminal I
sequences I
which I
include I
the I
extracellular I
domain I
and O
the O
transmembrane B
domain I
as I
well I
as I
50 I
amino I
acids I
from I
the I
C I
- I
terminus I
of I
c I
- I
kit I
are I
deleted I
in I
v I
- I
kit I
. O

The O
mutation O
consists O
of O
a O
C B
- I
to I
- I
T I
exchange I
at I
nucleotide I
position I
943 I
in O
the O
c O
DNA O
. O

The O
mutation O
was O
found O
in O
49 O
out O
of O
58 O
affected O
chromosomes O
and O
could O
be O
the O
most O
widely O
spread O
SLS O
mutation O
in O
the O
world O
. O

Association O
of O
SHP O
- O
1 O
and O
SHP O
- O
2 O
to O
other O
receptors O
can O
involve O
recruitment O
to O
either O
a O
single O
receptor O
ITIM O
or O
to O
two O
receptor O
ITIMs O
. O

For O
human O
BTLA O
, O
mutations B
of I
either I
Y I
257 I
or I
Y I
282 I
, I
but I
not I
Y I
226 I
, O
abrogated O
association O
with O
both O
SHP O
- O
1 O
and O
SHP O
- O
2 O
. O

For O
murine O
BTLA O
, O
mutation B
of I
either I
Y I
274 I
or I
Y I
299 I
, I
but I
not I
Y I
245 I
, O
also O
abrogated O
association O
with O
both O
SHP O
- O
1 O
and O
SHP O
- O
2 O
. O

In O
this O
study O
we O
describe O
a O
9 B
- I
bp I
deletion I
in I
exon I
2 I
of O
the O
amelogenin O
gene O
( O
AMGX O
) O
causing O
X O
- O
linked O
hypoplastic O
amelogenesis O
imperfecta O
, O
a O
disease O
characterized O
by O
defective O
enamel O
. O

The O
mutation B
results I
in I
the I
loss I
of I
3 I
amino I
acids I
and O
exchange B
of I
1 I
in I
the I
signal I
peptide I
of O
the O
amelogenin O
protein O
. O

A O
Pro B
- I
- I
- I
- I
Leu I
substitution I
in I
codon I
369 I
of O
the O
alpha O
- O
1 O
- O
antitrypsin O
deficiency O
variant O
PI O
MHeerlen O
. O

The O
nucleotide O
sequence O
of O
the O
exons O
, O
intron O
/ O
exon O
junctions O
, O
and O
a O
part O
of O
the O
promoter O
region O
is O
similar O
to O
that O
of O
a O
PI O
M O
1 O
( O
Ala O
213 O
) O
gene O
except O
for O
an O
C B
- I
- I
- I
- I
T I
mutation I
in I
codon I
369 I
, O
causing O
a O
Pro B
- I
- I
- I
- I
Leu I
substitution I
. O

It O
is O
most O
likely O
that O
the O
Pro B
369 I
- I
- I
- I
- I
Leu I
substitution I
is O
responsible O
for O
the O
low O
serum O
alpha O
- O
1 O
- O
antitrypsin O
concentration O
of O
the O
patient O
because O
this O
mutation O
is O
solely O
confined O
to O
the O
PI O
MHeerlen O
allele O
and O
no O
other O
relevant O
mutations O
could O
be O
revealed O
. O

Mutant O
animals O
had O
dramatically O
reduced O
body O
weight O
and O
fat O
mass O
, O
and O
low O
basal O
insulin O
and O
glucose O
levels O
relative O
to O
unaffected O
controls O
. O

The O
phenotype O
was O
genetically O
linked O
to O
a O
5 O
. O
7 O
- O
Mb O
interval O
on O
chromosome O
12 O
, O
and O
sequencing O
of O
the O
entire O
interval O
identified O
a O
single O
coding O
mutation O
, O
predicted O
to O
cause O
a O
methionine B
- I
to I
- I
isoleucine I
substitution I
at I
position I
279 I
of O
the O
Adcy O
3 O
protein O
( O
Adcy O
3 O
M O
279 O
I O
, O
henceforth O
referred O
to O
as O
Adcy O
3 O
Jll O
) O
. O

We O
identified O
a O
novel O
C B
- I
to I
- I
T I
substitution I
in I
exon I
8 I
of I
the I
delta I
- I
subunit I
that O
results O
in O
a O
serine B
to I
phenylalanine I
mutation I
in I
the I
region I
encoding I
the I
second I
transmembrane I
domain I
that I
lines I
the I
ion I
channel I
. O

Finally O
, O
we O
used O
serial O
morphometric O
analysis O
of O
electron O
micrographs O
to O
explore O
the O
basis O
for O
the O
progressive O
weakness O
and O
decline O
of O
amplitude O
of O
endplate O
currents O
over O
a O
period O
of O
14 O
years O
. O

The O
mouse O
agouti O
- O
related O
protein O
( O
AGRP O
) O
is O
a O
powerful O
appetite O
effector O
that O
results O
in O
hyperphagia O
and O
the O
development O
of O
obesity O
when O
administered O
intracerebroventricularly O
or O
when O
overexpressed O
in O
transgenic O
mice O
. O

A O
polymorphism O
was O
identified O
in O
the O
third O
exon O
of O
h O
AGRP O
, O
c O
. O
199 O
G O
- O
- O
> O
A O
, O
that O
resulted O
in O
a O
nonconservative B
amino I
acid I
substitution I
, I
Ala I
( I
67 I
) I
Thr I
. O

Previous O
studies O
have O
shown O
that O
ACK O
1 O
interacts O
with O
clathrin O
heavy O
chain O
and O
is O
involved O
in O
clathrin O
- O
coated O
vesicle O
endocytosis O
. O

Overexpression O
of O
the O
Uba B
domain I
- I
deletion I
mutant O
of O
ACK O
1 O
blocked O
the O
ligand O
- O
dependent O
degradation O
of O
EGFR O
, O
suggesting O
that O
ACK O
1 O
regulates O
EGFR O
degradation O
via O
its O
Uba O
domain O
. O

Deletion B
mutagenesis I
of I
the I
p I
75 I
( I
NTR I
) I
- I
luciferase I
reporter I
identified O
the O
- O
1039 O
conserved O
E O
- O
box O
necessary O
for O
the O
regulation O
of O
p O
75 O
( O
NTR O
) O
by O
CLOCK O
and O
BMAL O
1 O
. O

Oscillation O
of O
p O
75 O
( O
NTR O
) O
is O
disrupted O
in O
Clock O
- O
deficient O
and O
mutant O
mice O
, O
is O
E O
- O
box O
dependent O
, O
and O
is O
in O
phase O
with O
clock O
genes O
, O
such O
as O
Per O
1 O
and O
Per O
2 O
. O

Moreover O
, O
deletion B
of I
p I
75 I
( I
NTR I
) I
also O
alters O
the O
circadian O
oscillation O
of O
glucose O
and O
lipid O
homeostasis O
genes O
. O

We O
have O
studied O
the O
functional O
consequences O
of O
these O
polymorphisms O
by O
site O
- O
directed O
mutagenesis O
and O
the O
recombinant O
expression O
of O
these O
receptors O
in O
Chinese O
hamster O
fibroblasts O
. O

The O
polymorphisms O
consist O
of O
substitutions B
of I
Gly I
for I
Arg I
at I
amino I
acid I
16 I
( O
Arg O
16 O
- O
- O
> O
Gly O
) O
, O
Glu B
for I
Gln I
at I
amino I
acid I
27 I
( O
Gln O
27 O
- O
- O
> O
Glu O
) O
, O
and O
a O
combination O
of O
both O
substitutions O
. O

In O
addition O
, O
we O
showed O
that O
the O
removal B
of I
the I
pro I
- I
domain I
from O
the O
ADAMTS O
- O
1 O
precursor O
is O
impaired O
in O
the O
furin O
- O
deficient O
cell O
line O
, O
Lo O
Vo O
, O
and O
that O
the O
processing O
ability O
of O
the O
cells O
is O
restored O
by O
the O
co O
- O
expression O
of O
the O
furin O
c O
DNA O
. O

These O
data O
provide O
evidence O
that O
the O
ADAMTS O
- O
1 O
precursor O
is O
processed O
in O
vivo O
by O
furin O
endopeptidase O
in O
the O
secretory O
pathway O
. O

Currently O
more O
than O
200 O
genotypes O
have O
been O
identified O
, O
including O
several O
aberrant O
splicing O
. O

We O
verified O
that O
a O
weak O
cryptic O
site O
( O
SSS O
= O
0 O
. O
09 O
) O
14 O
nucleotides O
downstream O
was O
activated O
and O
resulted O
in O
an O
insertion B
of I
14 I
bp I
and I
a I
frameshift I
stop I
at I
codon I
106 I
. O

We O
describe O
the O
genetic O
and O
kinetic O
defects O
in O
a O
congenital O
myasthenic O
syndrome O
due O
to O
the O
mutation B
epsilon I
A I
411 I
P I
in O
the O
amphipathic O
helix O
of O
the O
acetylcholine O
receptor O
( O
ACh O
R O
) O
epsilon O
subunit O
. O

We O
expressed O
human O
ACh O
Rs O
containing O
wild O
- O
type O
or O
A O
411 O
P O
epsilon O
subunits O
in O
293 O
HEK O
cells O
, O
recorded O
single O
channel O
currents O
at O
high O
bandwidth O
, O
and O
determined O
microscopic O
rate O
constants O
for O
individual O
channels O
using O
hidden O
Markov O
modeling O
. O

Prolines B
engineered I
into I
positions I
flanking I
residue I
411 I
of I
the I
epsilon I
subunit I
greatly O
increase O
the O
range O
of O
activation O
kinetics O
similar O
to O
epsilon O
A O
411 O
P O
, O
whereas O
prolines B
engineered I
into I
positions I
equivalent I
to I
epsilon I
A I
411 I
in I
beta I
and I
delta I
subunits I
are O
without O
effect O
. O

PKA O
is O
known O
to O
phosphorylate O
Ins O
P O
( O
3 O
) O
R O
2 O
, O
but O
the O
molecular O
determinants O
of O
this O
effect O
are O
not O
known O
. O

The O
enhancing O
effects O
of O
PKA O
activation O
on O
this O
isoform O
required O
the O
phosphorylation O
of O
Ser B
( I
937 I
) I
, I
since I
replacing I
this I
residue I
with I
alanine I
eliminated O
the O
positive O
effects O
of O
PKA O
activation O
. O

Here O
, O
we O
show O
that O
the O
Duffy O
antigen O
/ O
chemokine O
receptor O
gene O
( O
DARC O
) O
is O
composed O
of O
a O
single O
exon O
and O
that O
most O
Duffy O
- O
negative O
blacks O
carry O
a O
silent O
FY O
* O
B O
allele O
with O
a O
single B
T I
to I
C I
substitution I
at I
nucleotide I
- I
46 I
. O

Here O
, O
we O
characterize O
the O
population O
genomics O
and O
signalling O
effects O
of O
a O
polymorphism O
within O
the O
coding O
region O
of O
the O
AC O
9 O
gene O
that O
results O
in O
an O
Ile B
to I
Met I
substitution I
at I
amino I
acid I
772 I
within O
the O
C O
1 O
b O
region O
of O
the O
enzyme O
. O

Allele O
frequencies O
were O
0 O
. O
300 O
and O
0 O
. O
375 O
in O
Caucasians O
and O
Asians O
but O
were O
lower O
in O
African O
- O
Americans O
( O
0 O
. O
163 O
) O
. O

The O
functional O
effects O
were O
studied O
in O
stably O
transfected O
HEK O
293 O
cells O
recombinantly O
expressing O
equivalent O
levels O
of O
wild B
- I
type I
( I
Ile I
772 I
) I
and I
polymorphic I
( I
Met I
772 I
) I
AC O
9 O
. O

SUMO O
- O
1 O
modification B
of I
the I
C I
- I
terminal I
KVEKVD I
of O
Axin O
is O
required O
for O
JNK O
activation O
but O
has O
no O
effect O
on O
Wnt O
signaling O
. O

Deletion B
of I
the I
C I
- I
terminal I
six I
amino I
acids I
drastically O
reduced O
sumoylation O
, O
indicating O
that O
the O
C O
- O
terminal O
six O
amino O
acids O
stretch O
is O
the O
main O
sumoylation O
site O
for O
Axin O
. O

Taken O
together O
, O
we O
demonstrate O
that O
sumoylation O
plays O
a O
role O
for O
Axin O
to O
function O
in O
the O
JNK O
pathway O
. O

OBJECTIVE O
: O
To O
identify O
the O
mutation O
responsible O
for O
autosomal O
dominant O
nocturnal O
frontal O
lobe O
epilepsy O
( O
ADNFLE O
) O
in O
a O
nonwhite O
family O
. O

RESULTS O
: O
A O
C B
- I
to I
- I
T I
exchange I
( I
C I
755 I
T I
) I
was I
found I
in I
exon I
5 I
of O
the O
CHRNA O
4 O
gene O
on O
one O
allele O
of O
affected O
individuals O
. O

Northern O
blot O
analysis O
of O
selected O
mouse O
tissues O
revealed O
that O
ADAM O
28 O
is O
expressed O
highly O
and O
in O
alternatively O
spliced O
forms O
in O
the O
epididymis O
, O
suggesting O
a O
possible O
role O
in O
sperm O
maturation O
, O
and O
at O
lower O
levels O
in O
lung O
. O

A O
mutation O
converting B
the I
catalytic I
- I
site I
glutamate I
residue I
into I
alanine I
abolishes O
pro O
- O
domain O
removal O
, O
even O
though O
this O
mutant O
form O
of O
ADAM O
28 O
can O
be O
transported O
to O
the O
cell O
surface O
in O
a O
manner O
similar O
to O
the O
wild O
- O
type O
protein O
. O

This O
is O
in O
contrast O
with O
several O
other O
ADAMs O
, O
for O
which O
furin O
- O
like O
proprotein O
convertases O
are O
involved O
in O
pro O
- O
domain O
removal O
, O
and O
in O
which O
a O
glutamate B
- I
to I
- I
alanine I
mutation I
in I
the I
catalytic I
site I
does O
not O
alter O
pro O
- O
domain O
removal O
. O

Moreover O
, O
C O
122 O
A O
CTLA O
- O
4 O
partitioned O
within O
lipid O
rafts O
, O
colocalized O
with O
the O
TCR O
in O
the O
immunological O
synapse O
, O
and O
inhibited O
T O
cell O
activation O
. O

C O
122 O
- O
independent O
dimerization O
of O
CTLA O
- O
4 O
involved O
N O
- O
glycosylation O
, O
because O
further O
mutation B
of I
the I
N I
78 I
and I
N I
110 I
glycosylation O
sites O
abrogated O
dimerization O
. O

A O
serine B
- I
to I
- I
alanine I
mutation I
at I
position I
121 I
of O
ATF O
- O
2 O
represses O
the O
c O
- O
Jun O
- O
dependent O
transcription O
of O
AP O
- O
1 O
/ O
cyclic O
AMP O
- O
response O
element O
reporter O
genes O
and O
also O
the O
p O
300 O
- O
mediated O
activation O
of O
a O
Gal O
4 O
- O
reporter O
gene O
in O
response O
to O
TPA O
. O

Mutation B
of I
this I
site I
( I
Ala I
( I
345 I
, I
346 I
) I
beta O
( O
2 O
) O
AR O
) O
significantly O
reduced O
the O
rate O
and O
extent O
of O
the O
rapid O
desensitization O
promoted O
by O
sustained O
treatment O
with O
the O
agonist O
isoproterenol O
. O

The O
direct O
contribution O
of O
Ser O
( O
345 O
, O
346 O
) O
in O
desensitization O
was O
then O
studied O
by O
mutating O
all O
other O
putative O
PKA O
and O
beta O
ARK O
phosphorylation O
sites O
( O
Ala O
( O
261 O
, O
262 O
) O
beta O
ARK O
( O
- O
) O
beta O
( O
2 O
) O
AR O
) O
. O

Taken O
with O
the O
observation O
that O
mutation B
of I
either I
Ser I
( I
345 I
, I
346 I
) I
or O
of O
the O
beta O
ARK O
phosphorylation O
sites O
prevented O
both O
the O
hyper O
- O
phosphorylation O
and O
constitutive O
desensitization O
of O
a O
palmitoylation B
- I
less I
mutant I
( I
Gly I
( I
341 I
) O
beta O
( O
2 O
) O
AR O
) O
, O
our O
data O
suggest O
a O
concerted O
/ O
synergistic O
action O
of O
the O
two O
kinases O
that O
depends O
on O
the O
palmitoylation O
state O
of O
the O
receptor O
. O

A O
single O
substitution O
in O
hp O
32 O
of O
Gly B
35 I
to I
Asp I
35 I
, O
which O
is O
found O
in O
mp O
32 O
, O
abrogates O
this O
activity O
. O

Coexpressed O
hu O
UBC O
9 O
did O
not O
affect O
the O
ETS O
- O
1 O
protein O
level O
, O
and O
moreover O
, O
a O
point B
mutation I
at I
Cys I
93 I
, O
an O
amino O
acid O
known O
to O
be O
essential O
for O
ubiquitination O
, O
did O
not O
abolish O
the O
stimulation O
of O
the O
ETS O
- O
1 O
transcriptional O
activity O
. O

Our O
results O
indicate O
that O
the O
modulation O
of O
ETS O
- O
1 O
activity O
by O
hu O
UBC O
9 O
results O
from O
processes O
other O
than O
ubiquitination O
and O
ETS O
- O
1 O
stabilization O
. O

This O
mutation O
, O
G B
to I
A I
at I
nucleotide I
6651 I
, O
may O
create O
a O
new O
splicing O
junction O
and O
affect O
the O
normal O
splicing O
of O
the O
messenger O
ribonucleic O
acid O
. O

In O
the O
other O
allele O
of O
both O
siblings O
, O
a O
missense O
mutation O
from O
GGG B
( I
Gly I
) I
to I
AGG I
( I
Arg I
) I
at I
codon I
129 I
( O
G O
129 O
R O
) O
in O
exon O
IV O
was O
found O
. O

Using O
homogenates O
from O
transfected O
cells O
, O
the O
G O
129 O
R O
3 O
beta O
HSD O
enzyme O
showed O
a O
Km O
value O
for O
pregnenolone O
of O
10 O
+ O
/ O
- O
2 O
mumol O
/ O
L O
compared O
with O
1 O
. O
00 O
+ O
/ O
- O
0 O
. O
03 O
mumol O
/ O
L O
for O
the O
wild O
- O
type O
type O
II O
3 O
beta O
HSD O
enzyme O
. O

In O
the O
present O
study O
, O
the O
AAT O
gene O
was O
characterized O
in O
an O
Indian O
sample O
. O

Nucleotide O
sequence O
comparison O
with O
the O
human O
genome O
and O
the O
AAT O
sequences O
available O
in O
the O
Gen O
Bank O
( O
NCBI O
) O
demonstrated O
four O
unique O
variations O
- O
- O
( O
i O
) O
an O
A B
to I
G I
variation I
at I
position I
286 I
( I
Thr I
96 I
Ala I
) I
, O
( O
ii O
) O
an O
A B
to I
G I
variation I
at I
position I
839 I
( I
Asp I
280 I
Gly I
) I
, O
( O
iii O
) O
a O
T B
to I
C I
variation I
at I
position I
1182 I
that I
did I
not I
result I
in I
any I
change I
in I
the I
protein I
sequence I
( I
TTT I
to I
TTC I
both I
code I
for I
Phe I
) I
and O
( O
iv O
) O
an O
A B
to I
C I
variation I
at I
position I
1200 I
( I
Glu I
400 I
Asp I
) I
that O
resulted O
in O
replacement O
by O
an O
amino O
acid O
of O
similar O
nature O
. O

Other O
variations O
found O
were O
T B
to I
C I
at I
position I
710 I
( I
Val I
273 I
Ala I
) I
and O
T B
to I
C I
position I
863 I
( I
Val I
288 I
Glu I
) I
, O
which O
were O
also O
reported O
earlier O
. O

Sequence O
analysis O
revealed O
that O
Osaka O
- O
12 O
is O
a O
compound O
heterozygote O
for O
a O
single B
( I
521 I
) I
T I
> I
C I
substitution I
leading I
to I
a I
Tyr I
143 I
His I
substitution O
in O
alpha O
( O
IIb O
) O
and O
for O
the O
null O
expression O
of O
alpha O
( O
IIb O
) O
m O
RNA O
from O
the O
maternal O
allele O
. O

Given O
that O
Tyr O
143 O
is O
located O
in O
the O
W O
3 O
4 O
- O
1 O
loop O
of O
the O
beta O
- O
propeller O
domain O
of O
alpha O
( O
IIb O
) O
, O
we O
examined O
the O
effects O
of O
Tyr O
143 O
His O
or O
Tyr O
143 O
Ala O
substitution O
on O
the O
expression O
and O
function O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
and O
compared O
them O
with O
KO O
( O
Arg B
- I
Thr I
insertion I
between I
160 I
and I
161 I
residues I
of O
alpha O
( O
IIb O
) O
) O
and O
with O
the O
Asp O
163 O
Ala O
mutation O
located O
in O
the O
same O
loop O
by O
using O
293 O
cells O
. O

Because O
immobilized O
fibrinogen O
and O
fibrin O
are O
higher O
affinity O
/ O
avidity O
ligands O
for O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
, O
we O
performed O
cell O
adhesion O
and O
clot O
retraction O
assays O
. O

Fibrinogen O
Lima O
: O
a O
homozygous O
dysfibrinogen O
with O
an O
A O
alpha O
- O
arginine B
- I
141 I
to I
serine I
substitution I
associated O
with O
extra O
N O
- O
glycosylation O
at O
A O
alpha O
- O
asparagine O
- O
139 O
. O

An O
A O
alpha O
- O
arginine B
- I
141 I
to I
serine I
substitution I
has O
been O
identified O
in O
a O
homozygous O
dysfibrinogen O
, O
fibrinogen O
Lima O
, O
associated O
with O
impaired O
fibrin O
polymerization O
. O

This O
type O
of O
glycosylation O
sequence O
is O
unique O
for O
human O
fibrinogen O
, O
because O
the O
sequences O
shown O
for O
normal O
and O
abnormal O
fibrinogens O
are O
all O
asparagine O
- O
X O
- O
threonine O
types O
. O

Here O
, O
we O
report O
the O
identification O
of O
a O
novel O
truncated O
GLI O
1 O
splice O
variant O
, O
t O
GLI O
1 O
, O
with O
an O
in B
- I
frame I
deletion I
of I
123 I
bases I
( I
41 I
codons I
) I
spanning I
the I
entire I
exon I
3 I
and I
part I
of I
exon I
4 I
of O
the O
GLI O
1 O
gene O
. O

Expression O
of O
t O
GLI O
1 O
is O
undetectable O
in O
normal O
cells O
but O
is O
high O
in O
glioblastoma O
multiforme O
( O
GBM O
) O
and O
other O
cancer O
cells O
. O

Substitution B
of I
Ser I
58 I
to I
Ala I
completely O
abolished O
phosphorylation O
of O
14 O
- O
3 O
- O
3 O
zeta O
by O
PKA O
. O

A O
phospho O
- O
mimic O
mutant O
of O
14 O
- O
3 O
- O
3 O
zeta O
, O
Ser B
58 I
to I
Glu I
substitution I
, O
failed O
to O
form O
homodimers O
, O
showed O
reduced O
interaction O
with O
14 O
- O
3 O
- O
3 O
epsilon O
and O
p O
53 O
, O
and O
could O
not O
enhance O
transcriptional O
activity O
of O
p O
53 O
. O

Moreover O
, O
activation O
of O
PKA O
decreases O
and O
inhibition O
of O
PKA O
increases O
the O
dimerization O
of O
14 O
- O
3 O
- O
3 O
zeta O
and O
the O
functional O
interaction O
of O
14 O
- O
3 O
- O
3 O
zeta O
with O
p O
53 O
. O

The O
eight O
novel O
mutations O
identified O
included O
1 O
- O
and O
4 B
- I
bp I
deletions I
( I
32 I
delta I
T I
and O
876 O
delta O
AGAA O
, O
respectively O
) O
and O
I O
16 O
T O
, O
G O
27 O
R O
, O
D O
114 O
E O
, O
G O
123 O
E O
, O
C O
152 O
Y O
, O
and O
R O
168 O
C O
missense O
mutations O
. O

The O
homozygous O
32 O
delta B
T I
deletion I
was O
identified O
in O
the O
only O
known O
patient O
of O
African O
- O
American O
origin O
with O
Canavan O
disease O
. O

A O
PCR O
- O
based O
protocol O
is O
described O
that O
was O
used O
to O
introduce O
mutations O
in O
wild O
- O
type O
c O
DNA O
. O

Transcription O
assays O
with O
HP B
1 I
box I
deletion I
or O
HP O
1 O
alpha O
knockdown B
indicated O
that O
HP O
1 O
alpha O
is O
required O
for O
ASXL O
1 O
- O
mediated O
repression O
. O

Furthermore O
, O
we O
found O
a O
direct O
interaction O
of O
ASXL O
1 O
with O
histone O
H O
3 O
demethylase O
LSD O
1 O
through O
the O
N O
- O
terminal O
region O
nearby O
the O
HP O
1 O
- O
binding O
site O
. O

This O
possibility O
was O
supported O
by O
chromatin O
immunoprecipitation O
assays O
followed O
by O
ASXL O
1 O
overexpression O
or O
knockdown B
. O

Its O
ability O
to O
activate O
progelatinase O
A O
is O
dependent O
on O
its O
proteolytic O
activity O
since O
a O
mutation B
converting I
Glu I
to I
Ala I
in I
the I
zinc I
binding I
motif I
HE I
255 I
LGH I
renders O
MT O
5 O
- O
MMP O
inactive O
against O
progelatinase O
A O
. O

In O
contrast O
to O
other O
MT O
- O
MMPs O
, O
MT O
5 O
- O
MMP O
tends O
to O
shed O
from O
cell O
surface O
as O
soluble O
proteinases O
, O
thus O
offering O
flexibility O
as O
both O
a O
cell O
bound O
and O
soluble O
proteinase O
for O
extracellular O
matrix O
remodeling O
processes O
. O

In O
electrophysiological O
recordings O
of O
cells O
transfected O
with O
Ca O
( O
v O
) O
1 O
. O
3 O
and O
Ca O
BP O
4 O
, O
mutation O
of O
the O
serine B
37 I
to I
alanine I
abolished O
the O
effect O
of O
Ca O
BP O
4 O
in O
prolonging O
the O
Ca O
2 O
+ O
current O
through O
Ca O
( O
v O
) O
1 O
. O
3 O
channel O
, O
whereas O
inactivating O
mutations O
in O
the O
Ca O
BP O
4 O
Ca O
2 O
+ O
- O
binding O
sites O
strengthened O
Ca O
( O
v O
) O
1 O
. O
3 O
modulation O
. O

These O
findings O
demonstrate O
how O
light O
- O
stimulated O
changes O
in O
Ca O
BP O
4 O
phosphorylation O
and O
Ca O
2 O
+ O
binding O
may O
regulate O
presynaptic O
Ca O
2 O
+ O
signals O
in O
photoreceptors O
. O

We O
examined O
the O
gene O
encoding O
the O
beta O
2 O
AR O
to O
assess O
the O
frequency O
of O
polymorphisms O
in O
51 O
patients O
with O
moderate O
to O
severe O
asthma O
and O
56 O
normal O
subjects O
. O

Nine B
different I
point I
mutations I
were I
found I
in I
both I
heterozygous I
and I
homozygous I
forms I
at I
nucleic I
acid I
residues I
46 I
, I
79 I
, I
100 I
, I
252 I
, I
491 I
, I
523 I
, I
1053 I
, I
1098 I
, I
and I
1239 I
. O

Of O
these O
nine O
polymorphisms O
, O
four O
were O
found O
to O
cause B
changes I
in I
the I
encoded I
amino I
acids I
at I
residues I
16 I
, I
27 I
, I
34 I
, I
and I
164 I
. O

The O
most O
frequent O
polymorphisms O
were O
arginine B
16 I
to I
glycine I
( O
Arg O
16 O
- O
- O
> O
Gly O
) O
and O
glutamine B
27 I
to I
glutamic I
acid I
( O
Gln O
27 O
- O
- O
> O
Glu O
) O
. O

The O
other O
two O
polymorphisms O
, O
valine B
34 I
to I
methionine I
, O
and O
threonine B
164 I
to I
isoleucine I
, O
occurred O
in O
only O
four O
subjects O
. O

The O
familial B
mutation I
substitutes I
a I
proline I
for I
a I
highly I
conserved I
alanine I
at I
position I
114 I
in O
the O
ANT O
1 O
protein O
. O

The O
1 O
- O
kb O
fragment O
upstream O
from O
the O
start O
codon O
was O
rich O
in O
GC O
, O
lacked O
consensus O
TATA O
or O
CAAT O
box O
, O
but O
contained O
several O
Sp O
1 O
- O
binding O
sites O
. O

Interestingly O
, O
the O
G B
/ I
C I
substitution I
at I
position I
- I
98 I
relative I
to I
the I
start I
codon I
was O
common O
and O
in O
complete O
linkage O
with O
a O
previously O
identified O
insertion O
/ O
deletion O
polymorphism O
in O
the O
coding O
region O
which O
was O
showed O
to O
affect O
alpha O
2 O
B O
- O
adrenergic O
receptor O
function O
. O

Based O
on O
transfection O
data O
and O
computer O
- O
assisted O
sequence O
analysis O
, O
the O
- B
98 I
G I
/ I
C I
single I
nucleotide I
polymorphism I
was O
located O
within O
a O
portion O
of O
the O
5 O
' O
- O
UTR O
( O
- O
127 O
/ O
+ O
3 O
) O
affecting O
luciferase O
activity O
and O
it O
created O
additional O
putative O
binding O
site O
for O
Sp O
1 O
. O

Sequencing O
of O
the O
gene O
- O
specific O
PCR O
products O
showed O
that O
the O
three O
common O
ORM O
1 O
alleles O
result O
from O
A B
- I
- I
> I
G I
transitions I
at I
the I
codons I
for I
amino I
acid I
positions I
20 I
in I
exon I
1 I
and O
156 B
in I
exon I
5 I
of O
the O
AGP O
1 O
gene O
: O
ORM B
1 I
* I
F I
1 I
was I
characterized I
by I
CAG I
( I
Gln I
) I
and I
GTG I
( I
Val I
) I
, O
ORM B
1 I
* I
F I
2 I
, I
by I
CAG I
( I
Gln I
) I
and I
ATG I
( I
Met I
) I
, O
and O
ORM B
1 I
* I
S I
, I
by I
CGG I
( I
Arg I
) I
and I
GTG I
( I
Val I
) I
. O

Chemokine O
receptor O
CXCR O
7 O
is O
essential O
for O
normal O
development O
, O
and O
this O
receptor O
promotes O
initiation O
and O
progression O
of O
diseases O
including O
cancer O
and O
autoimmunity O
. O

While O
wild O
- O
type O
CXCR O
7 O
predominantly O
localized O
to O
intracellular O
vesicles O
, O
progressive O
deletion B
of I
the I
carboxy I
terminus I
redistributed O
the O
receptor O
to O
the O
plasma O
membrane O
. O

Using O
a O
firefly O
luciferase O
complementation O
system O
, O
we O
established O
that O
deletions B
of I
the I
carboxy I
terminus I
decreased O
basal O
interactions O
and O
eliminated O
ligand O
- O
dependent O
recruitment O
of O
the O
scaffolding O
protein O
β O
- O
arrestin O
- O
2 O
to O
receptors O
. O

Deleting B
the I
carboxy I
terminus I
of O
CXCR O
7 O
impaired O
constitutive O
internalization O
of O
the O
receptor O
and O
reduced O
activation O
of O
ERK O
1 O
/ O
2 O
by O
CXCL O
12 O
- O
CXCR O
7 O
. O

Human O
MTH O
1 O
( O
mut O
T O
homologue O
1 O
) O
has O
8 O
- O
oxo O
- O
7 O
, O
8 O
- O
dihydrodeoxyguanosine O
triphosphatase O
activity O
, O
which O
repairs O
oxidized O
forms O
of O
d O
GTP O
. O

The O
Met B
/ I
Met I
genotype I
at I
codon I
83 I
was O
very O
rare O
in O
both O
control O
and O
patient O
groups O
. O

Val B
/ I
Met I
genotype I
tended O
to O
be O
more O
frequent O
in O
the O
whole O
type O
1 O
diabetic O
patients O
than O
in O
controls O
. O

On O
the O
other O
hand O
, O
in O
female O
type O
1 O
diabetic O
patients O
, O
the O
Val B
/ I
Met I
genotype I
was O
more O
frequent O
than O
in O
female O
controls O
( O
corrected O
P O
= O
0 O
. O
102 O
) O
. O

Impaired O
cholesterol O
efflux O
from O
macrophages O
leads O
to O
the O
presence O
of O
foam O
cells O
throughout O
the O
body O
, O
which O
may O
explain O
the O
increased O
risk O
of O
coronary O
heart O
disease O
in O
some O
TD O
families O
. O

In O
the O
first O
pedigree O
, O
a O
1 B
- I
bp I
deletion I
in I
exon I
13 I
, O
resulting O
in O
truncation O
of O
the O
predicted O
protein O
to O
approximately O
one O
- O
fourth O
of O
its O
normal O
size O
, O
co O
- O
segregated O
with O
the O
disease O
phenotype O
. O

An O
in B
- I
frame I
insertion I
- I
deletion I
in I
exon I
12 I
was O
found O
in O
the O
second O
family O
. O

The O
sequence O
of O
the O
c O
DNA O
clone O
coding O
for O
the O
variant O
differed O
from O
that O
coding O
for O
the O
wild O
- O
type O
DD O
by O
two O
nucleotides O
( O
substitutions B
of I
C I
with I
G I
at I
positions I
434 I
and I
931 I
) O
which O
caused O
two O
amino O
acid O
replacements O
, O
Ser B
145 I
to I
Cys I
( I
S I
145 I
C I
) I
and O
Leu B
311 I
to I
Val I
( O
L O
311 O
V O
) O
. O

The O
results O
substantiate O
the O
existence O
of O
polymorphic O
forms O
for O
human O
liver O
DD O
, O
and O
also O
suggest O
the O
importance O
of O
the O
residue O
at O
position O
311 O
for O
substrate O
binding O
to O
the O
enzyme O
. O

All O
AR O
genes O
from O
the O
five O
patients O
had O
single O
- O
nucleotide O
substitutions O
, O
which O
introduced B
a I
premature I
termination I
codon I
in I
three I
patients I
( I
Gln I
640 I
, I
Arg I
752 I
, I
and I
Gln I
640 I
and I
Trp I
751 I
) I
, O
and O
a O
single O
amino O
acid O
substitution O
in O
two O
patients O
( O
Arg B
831 I
to I
Gln I
, O
and O
Leu B
812 I
to I
Phe I
) I
. O

Molecular O
characterisation O
of O
three O
alpha O
- O
1 O
- O
antitrypsin O
deficiency O
variants O
: O
proteinase O
inhibitor O
( O
Pi O
) O
nullcardiff O
( O
Asp O
256 O
- O
- O
- O
- O
Val O
) O
; O
Pi O
Mmalton O
( O
Phe B
51 I
- I
- I
- I
- I
deletion I
) O
and O
Pi O
I O
( O
Arg O
39 O
- O
- O
- O
- O
Cys O
) O
. O

In O
the O
Pi O
( O
proteinase O
- O
inhibitor O
) O
nullcardiff O
gene O
, O
the O
codon B
for I
aspartate I
at I
position I
256 I
has I
mutated I
to I
encode I
valine I
. O

In O
Pi O
Mmalton O
and O
Pi O
I O
, O
the O
respective O
mutations O
are O
the O
deletion B
of I
the I
codon I
for I
a I
phenylalanine I
residue I
at I
position I
51 I
or I
52 I
, O
and O
a O
single B
base I
substitution I
resulting I
in I
arginine I
being I
replaced I
by I
cysteine I
at I
position I
39 I
. O

It O
occurs O
also O
in O
the O
Manobos O
, O
the O
Mongoloid O
indigenous O
inhabitants O
of O
the O
same O
district O
, O
although O
the O
frequency O
is O
low O
( O
. O
019 O
+ O
/ O
- O
. O
008 O
) O
. O

Furthermore O
, O
amino O
acid O
analyses O
of O
the O
tryptic O
peptides O
indicated O
that O
CA O
1 O
3 O
N O
is O
characterized O
by O
the O
substitution B
253 I
Gly I
leads I
to I
Arg I
, O
confirming O
the O
identity O
of O
this O
variant O
with O
CA O
1 O
Guam O
. O

We O
did O
not O
detect O
any O
mutation O
in O
the O
type O
I O
3 O
beta O
- O
HSD O
gene O
, O
but O
we O
found O
two O
different O
missense O
mutations O
in O
exon O
IV O
of O
the O
type O
II O
3 O
beta O
- O
HSD O
gene O
of O
the O
patient O
; O
a O
conversion O
of O
codon O
Leu B
108 I
into I
a I
Trp I
( O
L O
108 O
W O
) O
inherited O
from O
his O
mother O
and O
a O
conversion O
of O
codon O
Pro B
186 I
into I
a I
Leu I
( O
P O
186 O
L O
) O
inherited O
from O
his O
father O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

A O
cohort O
of O
> O
1 O
, O
000 O
individuals O
of O
Chinese O
and O
Japanese O
descent O
, O
from O
nuclear O
families O
, O
was O
genotyped O
for O
two O
polymorphisms O
, O
resulting O
in O
a O
serine B
/ I
glycine I
substitution I
at I
amino I
acid I
49 I
( O
Ser O
49 O
Gly O
) O
and O
an O
arginine B
/ I
glycine I
substitution I
at I
residue I
389 I
( O
Arg O
389 O
Gly O
) O
, O
in O
the O
beta O
1 O
adrenergic O
receptor O
. O

Neither O
the O
Arg O
389 O
Gly O
polymorphism O
in O
the O
beta O
1 O
adrenergic O
receptor O
nor O
polymorphisms O
in O
the O
beta O
2 O
and O
beta O
3 O
adrenergic O
receptors O
were O
associated O
with O
resting O
heart O
rate O
. O

The O
PI O
Y O
barcelona O
allele O
differs O
from O
the O
normal O
M O
1 O
( B
Val I
213 I
) I
allele I
sequence I
by I
two I
point I
substitutions I
: I
a I
transversion I
of I
GAT I
TO I
GTT I
in I
exon I
III I
in I
the I
codon I
for I
residue I
256 I
, O
resulting B
in I
the I
amino I
acid I
change I
of I
Asp I
256 I
to I
Val I
256 I
, O
and O
a O
transversion B
of I
CCC I
to I
CAC I
in I
exon I
V I
in I
the I
codon I
for I
residue I
391 I
, O
resulting O
in O
the O
amino O
acid O
substitution O
of O
Pro B
391 I
to I
His I
391 I
. O

The O
index O
case O
, O
diagnosed O
with O
severe O
obstructive O
pulmonary O
disease O
, O
initially O
phenotyped O
a O
PI O
ZZ O
, O
was O
homozygous O
for O
PI O
Y O
barcelona O
. O

Amino B
acid I
substitution I
in I
postion I
391 I
occurs O
in O
the O
C O
- O
terminal O
peptide O
region O
, O
which O
shows O
a O
high O
degree O
of O
homology O
with O
the O
family O
of O
serpins O
. O

Thus O
we O
have O
addressed O
the O
role O
of O
AMP O
- O
activated O
protein O
kinase O
in O
adipose O
tissue O
by O
modulating O
AMP O
- O
activated O
protein O
kinase O
activity O
in O
primary O
rodent O
adipocytes O
using O
pharmacological O
activators O
or O
by O
adenoviral O
expression O
of O
dominant O
negative O
or O
constitutively O
active O
forms O
of O
the O
kinase O
. O

Finally O
, O
we O
analyzed O
the O
consequences O
of O
a O
genetic O
deletion B
of I
AMP O
- O
activated O
protein O
kinase O
in O
mouse O
adipocytes O
. O

Conversely O
, O
when O
AMP O
- O
activated O
protein O
kinase O
activity O
is O
decreased O
either O
by O
a O
dominant O
negative O
form O
or O
in O
AMP O
- O
activated O
protein O
kinase O
alpha O
( O
1 O
) O
knock B
- I
out I
mice O
, O
lipolysis O
is O
increased O
. O

A O
locus O
for O
HI O
was O
assigned O
by O
linkage O
analyses O
to O
human O
chromosome O
11 O
p O
15 O
. O
1 O
. O

In O
this O
study O
, O
we O
evaluated O
disease O
- O
associated O
chromosomes O
from O
41 O
Ashkenazi O
Jewish O
and O
2 O
non O
- O
Jewish O
HI O
patients O
carrying O
the O
3992 B
- I
9 I
g I
- I
- I
> I
a I
mutation I
by O
assessing O
haplotypes O
defined O
by O
nine O
common O
single O
nucleotide O
polymorphisms O
( O
SNPs O
) O
, O
six O
in O
the O
SUR O
1 O
gene O
, O
and O
three O
in O
the O
KIR O
6 O
. O
2 O
gene O
. O

Our O
results O
indicate O
that O
all B
54 I
chromosomes I
carrying I
the I
3992 I
- I
9 I
g I
- I
- I
> I
a I
mutation I
in O
the O
Jewish O
patients O
appear O
to O
have O
originated O
from O
one O
founder O
mutation O
, O
whereas O
the O
same O
mutation O
on O
chromosomes O
from O
non O
- O
Jewish O
patients O
originated O
independently O
. O

The O
codons O
corresponding O
to O
His B
- I
295 I
, I
His I
- I
299 I
, I
or I
Glu I
- I
318 I
were I
replaced I
by I
codons I
encoding I
tyrosine I
, I
tyrosine I
, I
and I
glutamine I
, O
respectively O
. O

The O
mutated O
c O
DNAs O
were O
expressed O
in O
Escherichia O
coli O
, O
and O
the O
three O
mutated O
proteins O
were O
purified O
to O
apparent O
homogeneity O
. O

Codons B
encoding I
His I
- I
295 I
, I
His I
- I
299 I
, I
and I
Glu I
- I
318 I
were I
replaced I
by I
ones I
encoding I
tyrosine I
, I
leucine I
, I
and I
alanine I
, O
respectively O
, O
and O
the O
three O
mutants O
were O
expressed O
in O
E O
. O
coli O
. O

Heterozygosity O
for O
a O
G B
- I
- I
> I
A I
mutation I
converting I
Val I
384 I
( I
GTG I
) I
to I
Met I
( I
ATG I
) I
associated O
with O
plasmin O
inhibitor O
( O
alpha O
2 O
- O
antiplasmin O
) O
deficiency O
was O
identified O
in O
three O
family O
members O
with O
bleeding O
tendency O
. O

The O
mutation O
was O
not O
present O
in O
the O
non O
- O
affected O
family O
member O
or O
30 O
blood O
donors O
. O

In O
addition O
to O
the O
Val B
384 I
Met I
mutation I
two I
new I
polymorphisms I
Ala I
- I
26 I
( I
GCG I
) I
/ I
Val I
( I
GTG I
) I
and O
Arg O
407 O
( O
AGG O
) O
/ O
Lys O
( O
AAG O
) O
and O
one O
previously O
reported O
polymorphism O
Arg O
6 O
( O
CGG O
) O
/ O
Trp O
( O
TGG O
) O
were O
identified O
in O
the O
plasmin O
inhibitor O
gene O
of O
the O
family O
. O

The O
allelic O
frequencies O
among O
30 O
blood O
donors O
with O
normal O
values O
of O
plasma O
plasmin O
inhibitor O
( O
functional O
) O
were O
0 O
. O
84 O
/ O
0 O
. O
16 O
for O
C O
/ O
T O
in O
codon O
- O
26 O
, O
0 O
. O
81 O
/ O
0 O
. O
19 O
for O
C O
/ O
T O
in O
codon O
6 O
and O
0 O
. O
83 O
/ O
0 O
. O
17 O
for O
G B
/ I
A I
in I
codon I
407 I
. O

In O
a O
four O
- O
generation O
Chinese O
family O
with O
congenital O
nuclear O
pulverulent O
and O
posterior O
polar O
cataracts O
, O
we O
detected O
a O
heterozygous O
c O
. O
5 O
G O
> O
A O
transition O
in O
the O
second O
exon O
of O
GJA O
3 O
, O
resulting O
in O
the O
substitution O
of O
a O
highly O
conserved O
glycine B
with I
aspartic I
acid I
( I
p I
. I
G I
2 I
D I
) I
at I
the I
N I
- I
terminus I
of O
the O
connexin O
46 O
( O
Cx O
46 O
) O
protein O
. O

Using O
developmental O
stage O
- O
specific O
deletion B
of I
Arl O
13 O
b O
in O
mouse O
cortical O
progenitors O
, O
we O
found O
that O
early O
neuroepithelial O
deletion B
of I
ciliary O
Arl O
13 O
b O
led O
to O
a O
reversal O
of O
the O
apical O
- O
basal O
polarity O
of O
radial O
progenitors O
and O
aberrant O
neuronal O
placement O
. O

Our O
findings O
indicate O
that O
Arl O
13 O
b O
signaling O
in O
primary O
cilia O
is O
crucial O
for O
the O
initial O
formation O
of O
a O
polarized O
radial O
glial O
scaffold O
and O
suggest O
that O
disruption O
of O
this O
process O
may O
contribute O
to O
aberrant O
neurodevelopment O
and O
brain O
abnormalities O
in O
Joubert O
syndrome O
- O
related O
ciliopathies O
. O

In O
this O
article O
we O
report O
that O
pcd O
5 O
J O
results O
from O
the O
insertion B
of I
a I
single I
GAC I
triplet I
encoding I
an I
aspartic I
acid I
residue I
at I
position I
775 I
of O
Nna O
1 O
. O

Pulse O
- O
chase O
experiments O
reveal O
that O
the O
aspartic O
acid O
insertion O
dramatically O
destabilizes O
Nna O
1 O
pcd O
- O
5 O
J O
protein O
, O
accounting O
for O
the O
observation O
that O
pcd O
5 O
J O
is O
a O
severe O
allele O
. O

The O
other O
mutation O
, O
a O
3 B
- I
codon I
deletion I
( I
beta I
426 I
del I
EQE I
) I
in I
the I
long I
cytoplasmic I
loop I
between I
the I
M I
3 I
and I
M I
4 I
domains I
, O
curtails O
but O
does O
not O
abolish O
expression O
. O

Only O
the O
human O
cyclin O
T O
1 O
protein O
efficiently O
formed O
a O
complex O
with O
Tat O
bound O
to O
TAR O
RNA O
. O

A O
mouse O
cyclin O
T O
1 O
protein O
containing O
a O
substitution O
of O
tyrosine B
residue I
261 I
with I
a I
cysteine I
residue I
, O
was O
able O
to O
interact O
with O
Tat O
and O
stimulate O
tat O
- O
transactivation O
in O
rodent O
cells O
. O

Likewise O
, O
substitution O
of O
a O
cysteine B
residue I
for I
an I
asparagine I
residue I
at I
position I
260 I
of O
the O
cyclin O
T O
2 O
a O
and O
T O
2 O
b O
proteins O
also O
resulted O
in O
their O
ability O
to O
interact O
with O
Tat O
and O
stimulate O
tat O
- O
activation O
in O
rodent O
cells O
. O

It O
is O
predicted O
that O
the O
missense O
mutation O
, O
causing O
the O
change O
of O
the O
highly O
conserved O
serine B
to I
arginine I
at I
the I
codon I
113 I
( O
p O
. O
S O
113 O
R O
) O
, O
disrupts O
the O
second O
transmembrane O
domain O
in O
the O
transporter O
and O
reverses O
the O
orientation O
of O
all O
of O
the O
descending O
domains O
. O

Knockdown B
of O
Slc O
33 O
a O
1 O
in O
zebrafish O
caused O
a O
curve O
- O
shaped O
tail O
and O
defective O
axon O
outgrowth O
from O
the O
spinal O
cord O
. O

Thus O
, O
our O
study O
illustrated O
a O
critical O
role O
of O
acetyl O
- O
Co O
A O
transporter O
in O
motor O
- O
neuron O
development O
and O
function O
. O

Dry O
earwax O
is O
frequent O
in O
East O
Asians O
, O
whereas O
wet O
earwax O
is O
common O
in O
other O
populations O
. O

A O
27 B
- I
bp I
deletion I
in I
ABCC I
11 I
exon I
29 I
was O
also O
found O
in O
a O
few O
individuals O
of O
Asian O
ancestry O
. O

To O
test O
the O
physiological O
importance O
of O
these O
sites O
, O
we O
generated O
a O
transgenic O
mouse O
model O
in O
which O
all O
three O
conserved O
ATM O
serine B
autophosphorylation I
sites I
( I
S I
367 I
/ I
1899 I
/ I
1987 I
) I
have I
been I
replaced I
with I
alanine I
. O

Switch O
of O
coenzyme O
specificity O
of O
mouse O
lung O
carbonyl O
reductase O
by O
substitution O
of O
threonine B
38 I
with I
aspartic I
acid I
. O

Using O
site O
- O
directed O
mutagenesis O
, O
we O
constructed O
a O
mutant O
mouse O
lung O
carbonyl O
reductase O
in O
which O
Thr B
- I
38 I
was I
replaced I
by I
Asp I
( O
T O
38 O
D O
) O
, O
and O
we O
compared O
kinetic O
properties O
of O
the O
mutant O
and O
wild O
- O
type O
enzymes O
in O
both O
forward O
and O
reverse O
reactions O
. O

Changing O
Thr B
- I
38 I
to I
Asp I
destabilized O
the O
binding O
energies O
of O
NADP O
( O
H O
) O
by O
3 O
. O
9 O
- O
4 O
. O
5 O
kcal O
/ O
mol O
and O
stabilized O
those O
of O
NAD O
( O
H O
) O
by O
1 O
. O
2 O
- O
1 O
. O
4 O
kcal O
/ O
mol O
. O

These O
results O
indicate O
a O
significant O
role O
of O
Thr O
- O
38 O
in O
NADP O
( O
H O
) O
binding O
for O
the O
mouse O
lung O
enzyme O
and O
provide O
further O
evidence O
for O
the O
key O
role O
of O
Asp O
at O
this O
position O
in O
NAD O
( O
H O
) O
specificity O
of O
the O
SDR O
family O
proteins O
. O

BACKGROUND O
: O
The O
low O
incidence O
RBC O
antigen O
Fr O
( O
a O
) O
has O
been O
excluded O
from O
17 O
of O
the O
25 O
established O
blood O
group O
systems O
. O

DNA O
sequencing O
revealed O
a O
GAG B
- I
- I
> I
AAG I
mutation I
that O
underlies O
a O
Glu O
480 O
Lys O
substitution O
in O
RBC O
band O
3 O
. O

Cloning O
and O
sequencing O
of O
the O
two O
exons O
that O
encode O
the O
amyloid O
protein O
from O
two O
patients O
with O
this O
amyloidosis O
revealed O
a O
cytosine O
- O
to O
- O
guanine O
transversion O
, O
a O
mutation O
that O
caused O
a O
single O
amino O
acid O
substitution O
( B
glutamine I
instead I
of I
glutamic I
acid I
) I
at I
position I
22 I
of O
the O
amyloid O
protein O
. O

Characterization O
of O
the O
m O
RNA O
encoding O
MCAD O
in O
a O
Dutch O
MCAD O
- O
deficient O
patient O
revealed O
an O
A B
- I
- I
- I
- I
G I
change I
at I
nucleotide I
position I
985 I
of O
the O
MCAD O
m O
RNA O
coding O
region O
. O

This O
point O
mutation O
results O
in O
the O
substitution O
of O
a O
glutamic B
acid I
for I
a I
lysine I
at I
amino I
acid I
position I
304 I
of O
the O
mature O
protein O
. O

A O
mutant O
allele O
- O
specific O
oligonucleotide O
probe O
was O
used O
in O
a O
hybridization O
analysis O
of O
amplified O
genomic O
DNA O
of O
MCAD O
- O
deficient O
family O
members O
, O
a O
carrier O
, O
and O
normal O
individuals O
. O

Identification O
, O
expression O
, O
and O
pharmacology O
of O
a O
Cys B
23 I
- I
Ser I
23 I
substitution I
in O
the O
human O
5 O
- O
HT O
2 O
c O
receptor O
gene O
( O
HTR O
2 O
C O
) O
. O

Thus O
, O
it O
is O
important O
to O
identify O
polymorphisms O
and O
functional O
variants O
within O
this O
gene O
. O

Using O
SSCP O
analysis O
, O
we O
identified O
a O
Cys B
23 I
- I
Ser I
23 I
substitution I
( O
designated O
5 O
- O
HT O
2 O
Ccys O
and O
5 O
- O
HT O
2 O
Cser O
) O
in O
the O
first O
hydrophobic O
region O
of O
the O
human O
5 O
- O
HT O
2 O
C O
receptor O
. O

Sequencing O
of O
the O
ACTA O
1 O
gene O
showed O
a O
" B
de I
novo I
" I
missense I
heterozygous I
mutation I
a I
> I
g I
in I
exon I
7 I
( O
Lys O
336 O
Glu O
) O
. O

Expression O
constructs O
carrying O
the O
c O
DNAs O
for O
the O
two O
12 O
- O
lipoxygenase O
forms O
were O
introduced O
into O
human O
embryonic O
kidney O
293 O
cells O
. O

Mutagenesis O
and O
deletion B
of I
the I
highly I
conserved I
lipoxygenase I
C I
- I
terminal I
isoleucine I
( I
Ile I
663 I
) I
, O
a O
residue O
believed O
to O
be O
involved O
in O
the O
non O
- O
heme O
iron O
atom O
coordination O
of O
all O
lipoxygenases O
, O
was O
performed O
. O

Deletion B
of I
Ile I
663 I
and O
substitution O
with O
most O
amino O
acids O
abolished O
enzyme O
activity O
. O

Sequence O
analysis O
of O
the O
ABCA O
1 O
gene O
from O
the O
patients O
with O
TD O
revealed O
a O
homozygous B
G I
to I
A I
transition I
at I
nucleotide I
3805 I
of O
the O
c O
DNA O
resulting O
in O
the O
substitution B
of I
Asp I
1229 I
with I
Asn I
in I
exon I
27 I
, O
and O
a O
C B
to I
T I
at I
nucleotide I
6181 I
resulting O
in O
the O
substitution B
of I
Arg I
2021 I
with I
Trp I
in I
exon I
47 I
. O

Sequence O
analysis O
of O
the O
ABCA O
1 O
gene O
from O
the O
FHA O
patient O
revealed O
a O
homozygous B
4 I
bp I
CGCC I
deletion I
from I
nucleotide I
3787 I
to I
3790 I
resulting O
in O
premature B
termination I
by I
frameshift I
at I
codon I
1224 I
. O

Here O
we O
report O
on O
the O
isolation O
of O
a O
splice O
variant O
( O
gas O
6 O
SV O
) O
characterised O
by O
an O
in B
- I
frame I
129 I
bp I
insertion I
between I
the I
fourth I
EGF I
domain I
and I
the I
D I
domain I
. O

Here O
we O
describe O
a O
new O
class O
of O
histone O
modification O
, O
methylation B
of I
glutamine I
, I
occurring I
on I
yeast I
histone I
H I
2 I
A I
at I
position I
105 I
( I
Q I
105 I
) I
and O
human O
H O
2 O
A O
at O
Q O
104 O
. O

Methylation B
of I
Q I
105 I
or I
its I
substitution I
to I
alanine I
disrupts O
binding O
to O
FACT O
in O
vitro O
. O

A O
yeast O
strain O
mutated O
at O
Q O
105 O
shows O
reduced O
histone O
incorporation O
and O
increased O
transcription O
at O
the O
ribosomal O
DNA O
locus O
. O

The O
ability O
of O
insulin O
to O
promote O
phosphorylation O
of O
the O
human O
beta O
2 O
- O
adrenergic O
receptor O
( O
beta O
2 O
AR O
) O
was O
assessed O
in O
Chinese O
hamster O
fibroblasts O
transfected O
with O
beta O
2 O
AR O
c O
DNA O
. O

Substitution B
of I
a I
phenylalanine I
residue I
for I
tyrosine I
- I
141 I
completely O
prevented O
both O
the O
increased O
tyrosine O
phosphorylation O
and O
the O
enhanced O
responsiveness O
of O
the O
beta O
2 O
AR O
promoted O
by O
insulin O
treatment O
. O

The O
examination O
of O
the O
ALDH O
3 O
locus O
of O
three O
additional O
SLS O
patients O
showed O
that O
two O
are O
heterozygous B
with I
C I
- I
- I
> I
G I
at I
nt I
985 I
( O
Pro B
- I
- I
> I
Ala I
at I
protein I
position I
329 I
) O
. O

Isoelectric O
focusing O
analysis O
indicated O
that O
ALDH O
3 O
is O
hardly O
expressed O
in O
normal O
as O
well O
as O
patients O
' O
fibroblast O
cells O
, O
while O
ALDH O
10 O
expressed O
in O
the O
normal O
cells O
is O
diminished O
in O
the O
three O
patients O
' O
cells O
. O

The O
examination O
of O
the O
ALDH O
10 O
locus O
revealed O
the O
existence O
of O
a O
3 B
base I
deletion I
coupled I
with I
a I
21 I
base I
insertion I
at I
intron I
6 I
/ I
exon I
7 I
junction O
in O
one O
patient O
. O

One O
patient O
is O
associated O
with O
a O
2 B
base I
deletion I
at I
nt I
1297 I
and O
consequent B
premature I
chain I
termination I
at I
protein I
position I
434 I
. O

Another O
patient O
is O
a O
compound O
heterozygote O
for O
the O
same O
2 B
base I
deletion I
at I
nt I
1297 I
and O
a O
5 B
base I
insertion I
at I
nt I
1311 I
and O
premature B
chain I
termination I
at I
protein I
position I
457 I
. O

Deletion B
of I
amino I
acids I
Asp I
487 I
- I
Ser I
488 I
- I
Phe I
489 I
in O
human O
cytochrome O
P O
450 O
c O
17 O
causes O
severe O
17 O
alpha O
- O
hydroxylase O
deficiency O
. O

Analysis O
of O
her O
P O
450 O
c O
17 O
gene O
by O
polymerase O
chain O
reaction O
amplification O
and O
sequencing O
showed O
a O
nine O
- O
base O
deletion O
, O
eliminating B
codons I
487 I
- I
489 I
( I
Asp I
- I
Ser I
- I
Phe I
) I
near O
the O
carboxy O
- O
terminus O
of O
P O
450 O
c O
17 O
. O

This O
deletion O
creates O
a O
Bcl O
I O
site O
in O
the O
mutant O
DNA O
, O
permitting O
accurate O
demonstration O
that O
the O
patient O
was O
homozygous O
for O
this O
lesion O
, O
whereas O
one O
parent O
and O
two O
siblings O
were O
heterozygous O
. O

Sequence O
analysis O
revealed O
a O
novel O
mutation O
G O
617 O
T O
in O
exon O
8 O
resulting O
in O
an O
arginine B
to I
leucine I
substitution I
at I
codon I
206 I
( I
R I
206 I
L I
) I
. O

Characterization O
of O
the O
alpha O
1 O
AT O
Mmineral O
springs O
gene O
demonstrated O
that O
it O
differed O
from O
the O
common O
normal O
M O
1 O
( B
Ala I
213 I
) I
allele I
by I
a I
single I
- I
base I
substitution I
causing I
the I
amino I
acid I
substitution I
Gly I
- I
67 I
( I
GGG I
) I
- I
- I
- I
- I
Glu I
- I
67 I
( I
GAG I
) I
. O

To O
characterize O
the O
posttranslational O
events O
causing O
the O
alpha O
1 O
AT O
- O
secretory O
defect O
associated O
with O
the O
alpha O
1 O
AT O
Mmineral O
springs O
gene O
, O
retroviral O
gene O
transfer O
was O
used O
to O
establish O
polyclonal O
populations O
of O
murine O
fibroblasts O
containing O
either O
a O
normal O
human O
M O
1 O
alpha O
1 O
AT O
c O
DNA O
or O
an O
Mmineral O
springs O
alpha O
1 O
AT O
c O
DNA O
and O
expressing O
comparable O
levels O
of O
human O
alpha O
1 O
AT O
m O
RNA O
transcripts O
. O

The O
latter O
would O
be O
predicted O
to O
cause O
a O
C B
- I
terminal I
one I
- I
amino I
acid I
( I
glutamine I
) I
extension I
. O

COS O
7 O
cells O
expressing O
AADAC O
. O
1 O
( O
wild O
- O
type O
) O
exhibited O
flutamide O
, O
phenacetin O
, O
and O
rifampicin O
hydrolase O
activities O
with O
intrinsic O
clearance O
( O
CLint O
) O
values O
of O
1 O
. O
31 O
± O
0 O
. O
06 O
, O
1 O
. O
00 O
± O
0 O
. O
02 O
, O
and O
0 O
. O
39 O
± O
0 O
. O
02 O
μ O
l O
x O
min O
( O
- O
1 O
) O
x O
unit O
( O
- O
1 O
) O
, O
respectively O
. O

In O
humans O
, O
the O
non B
- I
conservative I
amino I
acid I
substitution I
Alanine I
( I
Ala I
) I
67 I
Threonine I
( I
Thr I
) I
has O
been O
associated O
with O
Anorexia O
Nervosa O
and O
with O
leanness O
. O

later O
age O
at O
onset O
of O
first O
symptoms O
, O
elbow O
contractures O
, O
ankle O
contractures O
, O
upper O
limb O
weakness O
and O
lower O
limb O
weakness O
, O
but O
there O
is O
no O
difference O
for O
the O
age O
at O
onset O
of O
cardiac O
involvement O
. O

In O
C O
57 O
BL O
/ O
10 O
Sc O
Cr O
mice O
the O
gene B
is I
deleted I
, O
yielding O
a O
recessive O
abolition O
of O
the O
LPS O
response O
. O

Deleterious B
mutations I
of O
TLR O
4 O
might O
reasonably O
be O
sought O
in O
individuals O
who O
have O
developed O
serious O
Gram O
- O
negative O
infections O
, O
on O
the O
premise O
that O
mice O
with O
deleterious O
mutations O
of O
Tlr O
4 O
are O
rendered O
susceptible O
to O
such O
infections O
. O

Beyond O
this O
, O
it O
may O
be O
assumed O
, O
given O
the O
powerful O
pro O
- O
inflammatory O
activity O
of O
the O
receptor O
, O
that O
germline O
or O
somatic B
mutations I
of O
TLR O
4 O
could O
in O
some O
instances O
cause O
constitutive O
signal O
transduction O
( O
as O
observed O
with O
the O
Drosophila O
Toll O
locus O
[ O
31 O
] O
) O
. O

The O
three O
principal O
exons O
of O
Tlr O
4 O
were O
amplified O
independently O
from O
mouse O
genomic O
DNA O
samples O
, O
leaving O
a O
margin O
of O
approximately O
50 O
bp O
to O
each O
side O
of O
the O
exons O
so O
as O
to O
indentify O
intronic B
mutations I
that O
might O
alter O
splicing O
. O

( O
The O
N O
- O
terminal O
sequences O
of O
the O
APE O
1 O
mutants O
are O
listed O
in O
Table O
1 O
, O
and O
the O
intensities O
of O
EGFP O
in O
nuclei O
versus O
total O
intensities O
were O
calculated O
for O
the O
APE O
1 O
- O
EGFP O
constructs O
in O
this O
study O
, O
and O
are O
shown O
in O
Table O
2 O
) O
. O

To O
further O
define O
the O
sequence O
responsible O
for O
the O
nuclear O
targeting O
, O
the O
cells O
were O
transfected O
with O
ND O
20 O
APE O
1 O
- O
EGFP O
, O
deleting B
the I
N I
- I
terminal I
20 I
amino I
acid I
residues I
( O
Figure O
1 O
D O
and O
Table O
2 O
) O
. O

Mutations O
in O
GPR O
143 O
were O
identified O
in O
each O
of O
the O
six O
families O
: O
c O
. O
849 O
del O
T O
( O
p O
. O
Val O
284 O
Ser O
fs O
X O
15 O
) O
; O
c O
. O
238 O
_ O
240 O
del O
CTC O
( O
p O
. O
Leu O
80 O
del O
) O
; O
c O
. O
658 O
+ O
1 O
G O
> O
A O
, O
c O
. O
353 O
G O
> O
A O
( O
p O
. O
Gly O
118 O
Glu O
) O
; O
g O
. O
1103 O
_ O
7266 O
del O
6164 O
( O
p O
. O
Gly O
84 O
Ala O
fs O
X O
65 O
) O
, O
which O
resulted O
in O
a O
deletion O
of O
exons O
2 O
and O
3 O
; O
and O
g O
. O
25985 O
_ O
26546 O
del O
562 O
( O
p O
. O
Gly O
296 O
Val O
fs O
X O
26 O
) O
, O
which O
resulted O
in O
a O
deletion B
of I
exon I
8 I
. I

The O
c O
. O
238 O
_ O
240 O
del O
CTC O
mutation O
resulted O
in O
a O
leucine O
deletion O
in O
the O
80 O
th O
amino O
acid O
position O
, O
and O
the O
c O
. O
353 O
G O
> O
A O
mutation O
resulted O
in O
a O
replacement O
of O
glutamic B
acid I
with I
glycine I
in I
the I
118 I
th I
amino I
acid I
positions O
. O

Of O
the O
six O
mutations O
in O
our O
OA O
1 O
patients O
, O
there O
were O
four O
deletion O
mutations O
, O
one O
missense O
mutation O
, O
and O
one O
splice O
site O
mutation O
. O

The O
c O
. O
353 O
G O
> O
A O
( O
p O
. O
Gly O
118 O
Glu O
) O
mutation O
, O
resulting O
in O
the O
replacement O
of O
glutamic B
acid I
with I
glycine I
at I
the I
118 I
th I
amino I
acid I
position O
, O
has O
been O
identified O
in O
Caucasian O
populations O
[ O
3 O
] O
and O
patients O
from O
the O
Netherlands O
[ O
23 O
] O
. O

Reduced O
levels O
of O
V O
( O
1 O
) O
V O
( O
o O
) O
and O
V O
( O
o O
) O
complexes O
at O
T O
202 O
A O
membranes O
suggest O
that O
the O
balance O
between O
V O
( O
1 O
) O
V O
( O
o O
) O
and O
V O
( O
o O
) O
was O
not O
perturbed O
; O
instead O
, O
cells O
adjusted O
the O
amount O
of O
assembled O
V O
- O
ATPase O
complexes O
in O
order O
to O
compensate O
for O
the O
enhanced O
activity O
. O

These O
results O
indicated O
communication O
between O
subunit O
E O
and O
the O
catalytic O
sites O
at O
the O
A O
( O
3 O
) O
B O
( O
3 O
) O
hexamer O
and O
suggest O
potential O
regulatory O
roles O
for O
the O
carboxyl O
end O
of O
subunit O
E O
. O
At O
the O
carboxyl O
end O
, O
alanine B
substitution I
of I
Asp I
- I
233 I
significantly O
reduced O
ATP O
hydrolysis O
, O
although O
the O
truncation B
229 I
- I
233 I
Delta I
and O
the O
point O
mutation O
K O
230 O
A O
did O
not O
affect O
assembly O
and O
activity O
. O

In O
FZD O
7 O
, O
we O
observed O
two O
synonymous O
variants O
, O
L O
23 O
L O
and O
L O
26 O
L O
, O
which O
are O
both O
in O
close O
proximity O
to O
a O
common O
SNP B
in I
codon I
24 I
that O
results O
in O
a O
conservative O
shift O
from O
glycine O
to O
arginine O
. O

All O
Nijmegen O
samples O
were O
analysed O
using O
SNP O
microarray O
analysis O
prior O
to O
exome O
sequencing O
and O
this O
had O
excluded O
larger O
CNVs O
in O
all O
patients O
apart O
from O
one O
deletion B
of I
exons I
81 I
– I
83 I
identified O
in O
patient O
JATD O
- O
6 O
, O
who O
additionally O
carried O
two O
heterozygous O
missense O
changes O
identified O
by O
Sanger O
sequencing O
. O

JATD O
- O
6 O
carried O
the O
common O
mutation O
p O
. O
D O
3015 O
G O
, O
and O
a O
large O
deletion B
p I
. I
G I
3891 I
_ I
Q I
4020 I
; O
the O
third O
variant O
is O
a O
heterozygous O
missense O
change O
p O
. O
R O
3813 O
C O
. O

Recently O
reported O
were O
two O
infantile O
RDP O
patients O
with O
ATP O
1 O
A O
3 O
mutations O
( O
R O
756 O
H O
and O
D O
923 O
N O
) O
; O
onset O
began O
for O
one O
of O
them O
at O
11 O
months O
and O
for O
the O
other O
at O
4 O
years O
of O
age O
. O

The O
position B
42474557 I
of I
chromosome I
19 I
, I
where I
the I
G I
to I
A I
transversion I
resulted O
in O
D O
801 O
N O
identified O
by O
our O
exome O
sequencing O
, O
had O
been O
registered O
as O
the O
nucleotide O
where O
the O
G O
to O
T O
transition O
is O
identified O
in O
rapid O
- O
onset O
dystonia O
- O
parkinsonism O
. O

Examination O
of O
PCR O
fragments O
corresponding O
to O
exons O
3 O
- O
4 O
and O
exons O
51 O
- O
53 O
revealed O
heteroduplexes O
. O

Direct O
sequencing O
of O
the O
PCR O
fragment O
containing O
exon O
3 O
revealed O
a O
previously O
reported O
A B
- I
to I
- I
G I
transition I
in I
the I
5 I
' I
donor I
splice I
site I
of I
exon I
3 I
in O
the O
proband O
and O
in O
the O
clinically O
unaffected O
father O
, O
while O
direct O
sequencing O
of O
the O
PCR O
fragment O
containing O
exon O
53 O
revealed O
a O
novel O
glycine O
substitution O
G O
1652 O
R O
in O
the O
proband O
and O
in O
the O
clinically O
unaffected O
mother O
. O

In O
six O
pedigrees O
, O
we O
detected O
two O
pathogenic O
mutations O
that O
segregated O
under O
an O
autosomal O
recessive O
model O
( O
Fig O
. O

Additionally O
, O
family O
F O
51426 O
carried O
a O
heterozygous O
W O
150 O
R O
change O
shown O
to O
be O
functionally O
null O
in O
the O
in O
vivo O
zebrafish O
rescue O
assay O
, O
and O
a O
splice O
variant O
predicted O
to O
result O
in O
a O
54 B
- I
amino I
acid I
deletion I
( O
Fig O
. O

This O
article O
reports O
the O
positional O
cloning O
and O
mutation O
analysis O
of O
the O
rat O
PKD O
gene O
, O
which O
revealed O
a O
C O
to O
T O
transition O
that O
replaces O
an O
arginine B
by I
a I
tryptophan I
at I
amino I
acid I
823 I
in O
the O
protein O
sequence O
. O

The O
characterization O
of O
this O
protein O
, O
which O
does O
not O
share O
structural O
homologies O
with O
known O
polycystins O
, O
may O
give O
new O
insights O
into O
the O
pathophysiology O
of O
renal O
cyst O
development O
in O
patients O
. O

Although O
the O
first B
Glu I
in I
the I
common I
motif I
is I
replaced I
by I
Gln I
( I
Q I
207 I
EEVLIP O
) O
in O
rat O
T O
lymphocyte O
alloantigens O
RT O
6 O
. O
1 O
and O
RT O
6 O
. O
2 O
, O
the O
two O
RT O
6 O
s O
appear O
to O
have O
both O
activities O
of O
NAD O
+ O
glycohydrolase O
and O
ADP O
- O
ribosyltransferase O
to O
a O
lesser O
extent O
. O

To O
investigate O
the O
significance O
of O
the O
Glu O
- O
rich O
motif O
in O
the O
two O
enzyme O
activities O
, O
we O
produced O
a O
mutant O
RT O
6 O
. O
1 O
( O
Q O
207 O
E O
) O
, O
in O
which O
Gln B
207 I
was I
replaced I
by I
Glu I
, O
together O
with O
wild O
- O
type O
RT O
6 O
s O
, O
in O
Escherichia O
coli O
. O

In O
contrast O
, O
much O
greater O
auto O
- O
modification O
was O
observed O
for O
the O
Q O
207 O
E O
mutant O
. O

Coenzyme O
Q O
( O
10 O
) O
( O
Co O
Q O
( O
10 O
) O
) O
plays O
a O
pivotal O
role O
in O
oxidative O
phosphorylation O
( O
OXPHOS O
) O
in O
that O
it O
distributes O
electrons O
between O
the O
various O
dehydrogenases O
and O
the O
cytochrome O
segments O
of O
the O
respiratory O
chain O
. O

Various O
missense O
mutations O
( O
R O
213 O
W O
, O
G O
272 O
V O
, O
G O
272 O
D O
, O
and O
E O
551 O
K O
) O
modifying O
highly O
conserved O
amino O
acids O
of O
the O
protein O
and O
a O
1 B
bp I
frameshift I
insertion I
c I
. I
[ I
1812 I
_ I
1813 I
ins I
G I
] I
were O
identified O
. O

A O
point O
mutation O
of O
YPD O
1 O
that O
led O
to O
a O
substitution B
of I
the I
74 I
th I
glycine I
( I
Gly I
74 I
) I
to I
cysteine I
( I
Cys I
) I
was O
identified O
in O
a O
mutant O
strain O
NH O
1 O
. O

It O
was O
therefore O
suggested O
that O
the O
substitution B
of I
Gly I
74 I
to I
Cys I
altered O
the O
Ypd O
1 O
structure O
, O
which O
resulted O
in O
the O
resistance O
to O
pradimicin O
. O

The O
G O
→ O
A O
point O
mutation O
that O
results O
in O
the O
substitution B
of I
lysine I
for I
glutamic I
acid I
at I
amino I
acid I
17 I
was O
introduced O
using O
Quick O
- O
Change O
Site O
- O
Directed O
Mutagenesis O
( O
Stratagene O
, O
La O
Jolla O
, O
CA O
, O
USA O
) O
. O

An O
in O
vitro O
splicing O
assay O
revealed O
that O
the O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
mutation O
causes O
a O
4 B
amino I
acid I
deletion I
( O
p O
. O
T O
159 O
_ O
Q O
162 O
del O
) O
. O

The O
17 B
p I
11 I
. I
2 I
duplication I
or I
deletion I
, O
and O
mutations O
in O
PMP O
22 O
, O
CX O
32 O
and O
its O
promoter O
, O
and O
TTR O
had O
been O
excluded O
first O
by O
DNA O
analysis O
of O
the O
proband O
in O
each O
family O
. O

Analysis O
of O
abnormal O
splicing O
at O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
, O
the O
splice B
acceptor I
mutation I
in O
MFN O
2 O
intron O
5 O
, O
using O
the O
minigene O
method O

( O
A O
) O
Sense O
strand O
electropherogram O
of O
patient O
and O
control O
genomic O
DNA O
, O
showing O
the O
heterozygous O
AARS O
mutation O
c O
. O
211 O
A O
> O
T O
in O
the O
patient O
DNA O
, O
corresponding O
to O
the O
amino B
acid I
substitution I
N I
71 I
Y I
. O

( O
A O
) O
Sense O
strand O
electropherogram O
of O
patient O
and O
control O
genomic O
DNA O
, O
showing O
the O
heterozygous O
HSPB O
1 O
mutation O
c O
. O
490 O
A O
> O
G O
in O
the O
patients O
DNA O
, O
corresponding O
to O
the O
amino B
acid I
substitution I
T I
164 I
A I
. O

The O
minigene O
assay O
showed O
that O
the O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
mutation O
, O
which O
affects O
the O
AG O
splice O
acceptor O
site O
, O
results O
in O
a O
deletion B
of I
12 I
nucleotides I
in I
the I
m I
RNA I
( O
c O
. O
475 O
_ O
486 O
del O
ACTGTGAACCAG O
) O
, O
corresponding O
to O
the O
loss O
of O
4 O
amino O
acid O
residues O
in O
the O
protein O
( O
p O
. O
T O
159 O
_ O
Q O
162 O
del O
; O
Figure O
4 O
) O
. O

The O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
splice O
acceptor O
site O
mutation O
resulting O
in O
a O
4 B
- I
amino I
acid I
deletion I
. O

( O
C O
) O
RT O
- O
PCR O
amplification O
of O
the O
minigene O
constructs O
( O
expressed O
in O
293 O
T O
and O
He O
La O
cells O
) O
using O
primers O
that O
are O
specific O
for O
MFN O
2 O
exons O
5 O
and O
7 O
( O
E O
5 O
F O
and O
E O
7 O
R O
) O
. O

The O
wild O
type O
construct O
( O
WT O
) O
is O
correctly O
spliced O
, O
whereas O
the O
mutant O
construct O
( O
Mut O
) O
containing O
the O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
is O
aberrantly O
spliced O
, O
leading O
to O
a O
12 B
- I
bp I
c I
DNA I
fragment I
deletion I
. O

The O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
splice O
acceptor O
site O
mutation O
causes O
a O
12 B
- I
bp I
deletion I
in I
the I
c I
DNA I
( O
c O
. O
475 O
_ O
486 O
del O
ACTGTGAACCAG O
) O
and O
putatively O
a O
deletion B
of I
4 I
amino I
acids I
in O
the O
MFN O
2 O
protein O
( O
p O
. O
T O
159 O
_ O
Q O
162 O
del O
) O
. O

We O
also O
used O
the O
minigene O
assay O
to O
demonstrate O
that O
the O
MFN O
2 O
splice O
acceptor O
site O
mutation O
c O
. O
475 O
- O
1 O
G O
> O
T O
may O
cause O
abnormal O
m O
RNA O
splicing O
and O
result O
in O
a O
4 B
- I
amino I
acid I
deletion I
( O
p O
. O
T O
159 O
_ O
Q O
162 O
del O
) O
. O

A O
single O
mutation B
in I
the I
helical I
domain I
of I
Ala I
RS I
( O
p O
. O
R O
329 O
H O
) O
was O
recently O
described O
in O
two O
families O
with O
autosomal O
dominant O
axonal O
CMT O
( O
CMT O
2 O
N O
) O
[ O
16 O
] O
. O

Indeed O
, O
recent O
functional O
analyses O
( O
Dr O
. O
Anthony O
Antonellis O
, O
personal O
communication O
, O
manuscript O
in O
preparation O
) O
demonstrated O
that O
N O
71 O
Y O
Ala O
RS O
severely O
impairs O
enzyme O
activity O
in O
vitro O
and O
in O
vivo O
. O

Patient O
10 O
carries O
a O
rare O
, O
novel O
MFN O
2 O
acceptor O
splice O
site O
mutation O
, O
that O
alters B
the I
consensus I
acceptor I
splice I
site I
of I
intron I
5 I
from I
AG I
to I
AT I
and O
affects O
MFN O
2 O
splicing O
and O
expression O
. O

Functional O
analysis O
revealed O
that O
this O
splice O
site O
mutation O
might O
lead O
to O
four O
aberrant O
m O
RNA O
transcripts O
, O
which O
are O
predicted O
to O
result O
in O
two O
different O
truncating O
frameshift O
mutations O
with O
two O
approximate O
260 O
- O
amino O
acid O
deletions O
, O
one O
mutation O
with O
a O
15 B
- I
amino I
acid I
insertion I
and O
one O
mutation O
with O
a O
4 B
- I
amino I
acid I
deletion I
[ O
28 O
] O
. O

The O
MFN O
2 O
c O
. O
475 O
- O
1 O
G O
> O
T O
, O
which O
is O
carried O
by O
Patient O
10 O
, O
was O
found O
to O
cause O
a O
deletion B
of I
4 I
amino I
acids I
( O
p O
. O
T O
159 O
_ O
Q O
162 O
del O
) O
, O
and O
this O
may O
explain O
his O
relatively O
mild O
polyneuropathy O
. O

This O
suggests O
that O
E O
396 O
is O
a O
hot O
- O
spot O
for O
this O
spontaneous O
mutation O
in O
the O
NEFL O
gene O
. O

Methylation B
and I
deamination I
of I
cytosine I
within I
a I
Cp I
G I
dinucleotide I
, O
which O
results O
in O
transitions O
of O
cytosine O
to O
thymine O
[ O
44 O
] O
, O
may O
play O
an O
important O
role O
in O
the O
recurrent O
mutations O
of O
NEFL O
p O
. O
E O
396 O
K O
( O
c O
. O
1186 O
G O
> O
A O
, O
which O
causes O
ggc O
GAG O
> O
ggc O
AAG O
) O
, O
MFN O
2 O
R O
364 O
W O
( O
c O
. O
1090 O
C O
> O
T O
, O
which O
causes O
CGG O
> O
TGG O
) O
, O
and O
MFN O
2 O
R O
364 O
P O
( O
c O
. O
1091 O
G O
> O
A O
, O
which O
causes O
CGG O
> O
TAG O
) O
, O
as O
they O
each O
occur O
at O
the O
cytosine O
residue O
of O
a O
Cp O
G O
dinucleotide O
in O
the O
sense O
or O
antisense O
strand O
. O

Instead O
, O
the O
crucial O
elements O
of O
the O
methylated O
lysine O
- O
binding O
aromatic O
cage O
seen O
in O
ING O
2 O
and O
BPTF O
( O
supplementary O
Fig O
S O
6 O
online O
) O
are O
substituted B
by I
negatively I
charged I
( I
D I
297 I
) I
and O
small O
hydrophobic O
( O
A O
317 O
) O
residues O
in O
AIRE O
– O
PHD O
1 O
. O

Recently O
, O
the O
PHD O
finger O
of O
BHC O
80 O
and O
the O
cysteine O
- O
rich O
domain O
of O
DNMT O
3 O
L O
were O
shown O
to O
recognize O
H O
3 O
K O
4 O
me O
0 O
by O
an O
analogous O
mechanism O
, O
in O
which O
the O
H O
3 O
peptide O
binds O
to O
the O
surface O
of O
the O
domain O
, O
forming O
an O
additional O
β O
- O
strand O
that O
is O
anchored O
by O
the O
side O
chain O
and O
N O
- O
amine O
group O
of O
H O
3 O
A O
1 O
. O

The O
first O
mutation O
at O
the O
codon O
347 O
cause O
a O
change B
in I
reading I
frame I
after I
Ala I
- I
347 I
and I
premature I
termination I
of I
translation I
in I
amino I
acid I
400 I
, O
which O
has O
been O
previously O
reported O
in O
Italian O
family O
with O
GSD O
- O
1 O
b O
( O
6 O
) O
. O

The O
second O
mutation B
at I
the I
codon I
148 I
, O
novel O
mutation O
was O
a O
missence O
mutation O
from O
alanine B
to I
valine I
at I
codon I
148 I
. O

( O
F O
) O
Aprataxin O
FHA O
GST O
pull O
downs O
from O
He O
La O
cells O
expressing O
wild O
- O
type O
GFP O
- O
MDC O
1 O
, O
a O
mutant O
containing O
a O
deletion B
of I
the I
SDTD I
region I
( O
Δ O
SDTD O
) O
, O
and O
a O
mutant O
where O
the O
Thr B
residues I
contained I
in I
the I
SDTD I
sequence I
were I
replaced I
by I
Ala I
( O
SDAD O
) O
2 O
. O

( O
A O
) O
Substitution B
of I
Arg I
29 I
and O
Lys B
38 I
to I
Ala I
abrogated O
the O
interaction O
between O
aprataxin O
and O
MDC O
1 O
as O
determined O
by O
pull O
- O
down O
assays O
as O
described O
earlier O
. O

Carnitine O
palmitoyltransferase O
I O
( O
CPT O
I O
) O
and O
carnitine O
octanoyltransferase O
( O
COT O
) O
catalyze O
the O
conversion O
of O
long O
- O
and O
medium O
- O
chain O
acyl O
- O
Co O
A O
to O
acylcarnitines O
in O
the O
presence O
of O
carnitine O
. O

When O
the O
critical O
histidine B
residue I
473 I
in I
CPT I
I I
( I
327 I
in I
COT I
) I
, I
localized I
in I
the I
acyl I
- I
Co I
A I
pocket I
in I
the I
model I
, I
was I
mutated I
to I
alanine I
, O
the O
catalytic O
activity O
was O
abolished O
. O

Mutation B
of I
the I
conserved I
alanine I
residue I
to I
aspartic I
acid I
, O
A O
381 O
D O
( O
in O
CPT O
I O
) O
and O
A O
238 O
D O
( O
in O
COT O
) O
, O
which O
are O
92 O
/ O
89 O
amino O
acids O
far O
from O
the O
catalytic O
histidine O
, O
respectively O
( O
but O
very O
close O
to O
the O
acyl O
- O
Co O
A O
pocket O
in O
the O
structural O
model O
) O
, O
decreased O
the O
activity O
by O
86 O
and O
80 O
% O
, O
respectively O
. O

Point O
mutations O
in O
awd O
Kpn O
which O
revert O
the O
prune O
/ O
Killer B
of I
prune I
lethal O
interaction O
affect O
conserved O
residues O
that O
are O
involved O
in O
nucleoside O
diphosphate O
kinase O
substrate O
binding O
and O
catalysis O
. O

The O
awd O
gene O
of O
Drosophila O
melanogaster O
encodes O
a O
nucleoside O
diphosphate O
kinase O
. O

Killer B
of I
prune I
( O
Kpn O
) O
is O
a O
mutation O
in O
the O
awd O
gene O
which O
substitutes O
Ser B
for I
Pro I
at I
position I
97 I
and O
causes O
dominant O
lethality O
in O
individuals O
that O
do O
not O
have O
a O
functional O
prune O
gene O
. O

In O
order O
to O
understand O
why O
the O
prune O
/ O
Killer B
of I
prune I
combination O
is O
lethal O
, O
even O
in O
the O
presence O
of O
an O
adequate O
NDP O
kinase O
specific O
activity O
level O
, O
and O
to O
understand O
the O
biochemical O
basis O
for O
the O
conditional O
lethality O
of O
the O
awd O
Kpn O
mutation O
, O
we O
generated O
second O
site O
mutations O
which O
revert O
this O
lethal O
interaction O
. O

Two O
sequence O
changes O
would O
result O
in O
protein O
alterations O
: O
a O
substitution B
of I
threonine I
by I
asparagine I
at I
position I
25 I
( O
Thr O
25 O
Asn O
) O
, O
and O
a O
substitution B
of I
histidine I
by I
tyrosine I
at I
position I
452 I
( O
His O
452 O
Tyr O
) O
. O

The O
two O
amino O
acid O
substitutions O
are O
found O
with O
similar O
frequencies O
in O
patients O
and O
controls O
, O
indicating O
that O
the O
presence O
of O
these O
variants O
is O
not O
causally O
related O
to O
the O
development O
of O
schizophrenia O
. O

The O
Vif O
( O
virion O
infectivity O
factor O
) O
protein O
of O
human O
immunodeficiency O
virus O
1 O
( O
HIV O
- O
1 O
) O
acts O
by O
overcoming O
the O
antiviral O
activity O
of O
APOBEC O
3 O
G O
( O
CEM O
15 O
) O
, O
a O
cytidine O
deaminase O
that O
induces O
G O
to O
A O
hypermutation O
in O
newly O
synthesized O
viral O
DNA O
. O

A O
mutation B
of I
highly I
conserved I
cysteines I
or O
the O
deletion B
of I
a I
conserved I
SLQ I
( I
Y I
/ I
F I
) I
LA I
motif O
in O
Vif O
results O
in O
mutants O
that O
fail O
to O
induce O
APOBEC O
3 O
G O
degradation O
and O
produce O
non O
- O
infectious O
HIV O
- O
1 O
; O
however O
, O
mutations B
of I
conserved I
phosphorylation I
sites I
in O
Vif O
that O
impair O
viral O
replication O
do O
not O
affect O
APOBEC O
3 O
G O
degradation O
, O
suggesting O
that O
Vif O
is O
important O
for O
other O
functions O
in O
addition O
to O
inducing O
proteasomal O
degradation O
of O
APOBEC O
3 O
G O
. O

Mutation O
analysis O
of O
ESRRB O
, O
a O
candidate O
gene O
in O
the O
overlapping O
region O
, O
revealed O
a O
homozygous B
7 I
bp I
duplication I
in I
exon I
8 I
in O
all O
affected O
individuals O
. O

Sequence O
analysis O
of O
the O
ESRRB O
gene O
in O
the O
affected O
individuals O
of O
the O
original O
DFNB O
35 O
family O
and O
in O
three O
other O
DFNB O
35 O
- O
linked O
consanguineous O
families O
from O
Pakistan O
revealed O
four O
missense O
mutations O
. O

Patient O
1 O
was O
shown O
to O
have O
a O
14 O
. O
83 O
Mb O
deletion O
which O
extended O
from O
FREM O
1 O
intron O
9 O
to O
the O
chromosome O
9 O
p O
telomere O
, O
deleting B
exons I
10 I
- I
37 I
of O
FREM O
1 O
. O

Patient O
2 O
had O
a O
complex O
chromosome B
9 I
deletion I
- I
duplication I
mutation O
with O
a O
breakpoint O
within O
FREM O
1 O
. O

The O
deletion O
component O
of O
this O
re O
- O
arrangement O
extended O
from O
FREM O
1 O
intron O
6 O
to O
the O
9 O
p O
telomere O
, O
deleting B
exons I
7 I
- I
37 I
of O
FREM O
1 O
. O

The O
third O
CNV O
was O
a O
15 B
. I
32 I
Mb I
deletion I
in O
Patient O
3 O
which O
extended O
from O
the O
chromosome O
9 O
p O
telomere O
to O
the O
intergenic O
region O
between O
TTC O
39 O
B O
and O
SNAPC O
3 O
resulting O
in O
the O
deletion B
of I
the I
entire I
FREM O
1 O
locus O
. O

Patient O
4 O
had O
the O
smallest O
CNV O
; O
a O
2 B
. I
14 I
Mb I
interstitial I
9 I
p I
deletion I
between I
genomic I
co I
- I
ordinates I
14 I
. I
20 I
and I
16 I
. I
34 I
Mb I
[ O
hg O
18 O
] O
which O
involved O
only O
9 O
genes O
. O

This O
region O
extends O
from O
NFIB O
intron O
2 O
to O
the O
intergenic O
region O
between O
C O
9 O
orf O
93 O
and O
BNC O
2 O
also O
deleting B
FREM O
1 O
. O

In O
summary O
, O
morphometric O
analysis O
of O
skulls O
from O
bat O
homozygous O
and O
heterozygous O
mice O
identified O
craniofacial O
malformations O
consistent O
with O
the O
craniofacial O
features O
, O
in O
particular O
MC O
and O
midfacial O
asymmetry O
/ O
hypoplasia O
, O
seen O
in O
the O
9 B
p I
22 I
deletion I
syndrome O
, O
with O
the O
penetrance O
of O
the O
phenotypes O
in O
mice O
correlated O
to O
mutant O
gene O
dosage O
. O

To O
investigate O
whether O
either O
of O
the O
two O
remaining O
genes O
within O
the O
refined O
critical O
interval O
might O
also O
contribute O
to O
the O
craniofacial O
phenotype O
of O
the O
9 B
p I
22 I
deletion I
syndrome O
, O
we O
first O
analyzed O
a O
small O
number O
of O
Zdhhc O
21 O
dep O
/ O
dep O
homozygotes O
. O

A O
T O
515 O
C O
transition O
led O
to O
the O
replacement B
of I
isoleucine I
by I
threonine I
at I
amino I
acid I
position I
172 I
( O
I O
172 O
T O
) O
in O
a O
region O
of O
cryopyrin O
flanking O
the O
PYRIN O
and O
NACHT O
domains O
. O

CSF O
cytokine O
levels O
decreased O
to O
normal O
under O
corticosteroid O
and O
intrathecal O
methotrexate O
therapy O
. O

We O
have O
thus O
directly O
sequenced O
DNA O
fragments O
generated O
by O
PCR O
amplification O
of O
the O
four O
exons O
, O
exon O
- O
intron O
boundaries O
, O
and O
the O
5 O
' O
- O
flanking O
regions O
of O
the O
HSD O
3 O
B O
2 O
gene O
. O

Sequencing O
of O
exon O
II O
revealed O
the O
presence O
of O
a O
C B
to I
A I
transversion I
in I
both I
alleles I
of I
these I
two I
cases I
, O
thus O
converting B
codon I
10 I
( I
GCA I
) I
, I
which I
codes I
for I
Ala I
, I
into I
GAA I
, I
encoding I
Glu I
. O

Both O
mutant O
arginases O
were O
trimeric O
by O
gel O
filtration O
, O
but O
the O
control O
G O
235 O
A O
mutant O
had O
56 O
% O
of O
wild O
- O
type O
activity O
and O
the O
G O
235 O
R O
mutant O
had O
less O
than O
0 O
. O
03 O
% O
activity O
compared O
to O
the O
wild O
- O
type O
enzyme O
. O

Molecular O
modeling O
indicates O
that O
the O
introduction B
of I
an I
arginine I
residue I
at I
position I
235 I
results O
in O
a O
major O
rearrangement O
of O
the O
metal O
ligands O
that O
compromise O
Mn O
( O
II O
) O
binding O
. O

Osteogenesis O
imperfecta O
( O
OI O
) O
is O
a O
genetic O
disorder O
of O
connective O
tissue O
characterized O
by O
bone O
fragility O
and O
alteration O
in O
synthesis O
and O
posttranslational B
modification I
of I
type I
I I
collagen I
. O

Autosomal O
dominant O
OI O
is O
caused O
by O
mutations O
in O
the O
genes O
( O
COL O
1 O
A O
1 O
or O
COL O
1 O
A O
2 O
) O
encoding O
the O
chains O
of O
type O
I O
collagen O
. O

Recently O
, O
the O
molecular O
spectrum O
of O
OI O
has O
been O
expanded O
with O
the O
description O
of O
the O
basis O
of O
a O
unique O
posttranslational B
modification I
of I
type I
I I
procollagen I
, O
that O
is O
, O
3 O
- O
prolyl O
- O
hydroxylation O
. O

Mutations B
in I
genes I
encoding I
type I
I I
procollagen I
or O
proteins O
responsible O
for O
posttranslational O
modifications O
of O
the O
type O
I O
collagen O
heterotrimer O
may O
result O
in O
the O
brittle O
bone O
disorder O
osteogenesis O
imperfecta O
( O
OI O
) O
. O

This O
is O
followed O
shortly O
by O
interchain O
disulfide O
bond O
formation O
by O
protein O
- O
disulfide O
isomerase O
( O
PDI O
) O
. O

( O
1 O
– O
4 O
) O
Furthermore O
, O
mutations O
in O
all O
three O
proteins O
now O
have O
been O
shown O
to O
cause O
recessive O
forms O
of O
OI O
in O
part O
by O
leading O
to O
loss B
of I
hydroxylation I
at I
proline I
residue I
986 I
of I
the I
α I
1 I
( O
I O
) O
triple O
- O
helical O
domain O
and O
subsequent O
collagen O
overmodification O
. O

Figure O
depicts O
proteins O
involved O
in O
posttranslational B
modification I
of I
type I
I I
collagen I
and O
mutated O
in O
osteogenesis O
imperfecta O
( O
OI O
) O
or O
Bruck O
syndrome O
. O

These O
proteins O
modify B
collagen I
by I
3 I
- I
prolyl I
- I
hydroxylation I
and O
serve O
as O
endoplasmic O
reticulum O
chaperones O
, O
respectively O
. O

( O
18 O
) O
Loss O
of O
the O
FKBP O
10 O
/ O
SERPINH O
1 O
complex O
owing O
to O
deletion B
of O
the O
SERPINH O
1 O
gene O
was O
shown O
originally O
to O
cause O
recessive O
OI O
in O
a O
dachshund O
model O
. O

( O
19 O
) O
However O
, O
SERPINH O
1 O
mutations O
in O
humans O
had O
not O
been O
identified O
until O
the O
very O
recent O
report O
of O
a O
single O
child O
with O
the O
phenotype O
of O
OI O
type O
3 O
. O

The O
child O
was O
found O
to O
have O
a O
homozygous B
missense I
mutation I
in O
the O
coding O
region O
of O
SERPINH O
1 O
. O

Finally O
, O
with O
the O
discovery O
of O
disease O
- O
causing O
FKBP O
10 O
and O
SERPINH O
1 O
mutations O
, O
defects B
in I
ER I
chaperone I
protein I
complexes I
have O
been O
noted O
to O
cause O
recessive O
OI O
. O

The O
first O
change O
( O
left O
) O
is O
a O
single B
- I
nucleotide I
base I
- I
pair I
duplication I
( O
c O
. O
831 O
dup O
) O
that O
results O
in O
a O
frameshift O
mutation O
. O

The O
second O
( O
right O
) O
is O
a O
single B
- I
nucleotide I
base I
pair I
duplication I
( O
c O
. O
1276 O
dup O
) O
that O
results O
in O
a O
frameshift O
mutation O
. O

The O
OI O
phenotype O
in O
all O
patients O
with O
FKBP O
10 O
mutations O
reported O
so O
far O
is O
milder O
than O
the O
severe O
- O
to O
- O
lethal O
recessive O
OI O
phenotypes O
caused O
by O
mutations B
in I
the I
genes I
of I
the I
prolyl I
- I
3 I
- I
hydroxylation I
complex I
( O
CRTAP O
, O
LEPRE O
1 O
, O
or O
PPIB O
) O
. O

Deletion B
of I
ZF I
1 I
- I
2 I
caused O
cytoplasmic O
accumulation O
of O
ZNF O
24 O
. O

Co O
- O
immunoprecipitation O
demonstrated O
that O
ZNF O
24 O
interacted O
with O
importin O
- O
β O
and O
this O
interaction O
required O
the O
ZF O
moti O
fs O
. O

( O
A O
) O
Schematic O
of O
full O
- O
length O
and O
deletion B
ZNF O
24 O
- O
GFP O
constructs O
used O
in O
this O
study O
( O
not O
to O
scale O
) O
. O

All O
deletion O
constructs O
were O
fused O
to O
the O
N O
terminus O
of O
the O
GFP O
. O

Deletion B
of I
the I
ZF I
4 I
( I
p I
1 I
- I
329 I
- I
GFP I
) I
or I
the I
ZF I
3 I
- I
4 I
( I
p I
1 I
- I
301 I
- I
GFP I
) I
had O
no O
effect O
on O
the O
nuclear O
localization O
of O
ZNF O
24 O
( O
Figure O
2 O
B O
) O
. O

However O
, O
deletion B
of I
the I
ZF I
2 I
- I
4 I
( O
p O
1 O
- O
273 O
- O
GFP O
) O
led O
to O
both O
nuclear O
and O
cytoplasmic O
localization O
with O
brighter O
staining O
intensity O
in O
the O
nucleus O
. O

Deletion B
of I
whole I
ZF I
region I
( O
p O
1 O
- O
250 O
- O
GFP O
) O
led O
to O
diffusively O
present O
throughout O
the O
cell O
with O
similar O
staining O
intensity O
in O
the O
nucleus O
and O
cytoplasm O
( O
Figure O
2 O
B O
) O
. O

These O
data O
suggest O
that O
ZF O
1 O
- O
2 O
( O
aa O
251 O
to O
301 O
) O
is O
necessary O
for O
efficient O
nuclear O
localization O
of O
ZNF O
24 O
. O

To O
further O
verify O
this O
notion O
, O
we O
made O
an O
internal O
deletion B
of I
the I
ZF I
1 I
- I
2 I
region I
( O
Figure O
2 O
A O
, O
d O
ZF O
1 O
- O
2 O
) O
and O
found O
that O
indeed O
all O
of O
the O
cells O
showed O
both O
nuclear O
and O
cytoplasmic O
localization O
of O
the O
mutant O
protein O
( O
Figure O
2 O
B O
, O
d O
ZF O
1 O
- O
2 O
) O
. O

We O
therefore O
sequentially O
replaced B
each I
lysine I
and I
arginine I
in I
ZF I
1 I
and I
ZF I
2 I
with I
alanine I
to O
investigate O
which O
amino O
acid O
residues O
are O
essential O
for O
the O
ZNF O
24 O
NLS O
. O

The O
mutation O
of O
basic O
residues B
286 I
or I
290 I
to I
alanine I
( O
K O
286 O
A O
or O
R O
290 O
A O
) O
resulted O
in O
a O
partial O
mislocalization O
of O
the O
protein O
to O
the O
cytoplasm O
, O
whereas O
the O
nuclear O
localization O
of O
the O
other O
mutants O
did O
not O
significantly O
change O
( O
Figure O
5 O
B O
) O
. O

Figure O
5 O
C O
quantifies O
the O
Fn O
/ O
c O
ratios O
of O
these O
mutants O
and O
confirms O
the O
visual O
phenotypes O
seen O
in O
Figure O
5 O
B O
. O

To O
further O
identify O
critical O
residues O
within O
the O
ZF O
1 O
and O
ZF O
2 O
region O
, O
we O
further O
mutated O
the O
serine O
, O
threonine O
or O
tyrosine B
residues I
within I
this I
region I
( O
Figure O
5 O
A O
) O
, O
since O
these O
residues O
were O
potential O
targets O
for O
posttranslational O
modifications O
or O
interaction O
with O
importins O
that O
would O
contribute O
to O
nuclear O
transport O
[ O
25 O
, O
33 O
, O
34 O
] O
. O

The O
first O
and O
second O
ZFs O
are O
necessary O
for O
efficient O
nuclear O
localization O
; O
deletion B
of I
ZF I
1 I
or I
ZF I
2 I
results O
in O
partial O
loss O
of O
nuclear O
targeting O
( O
Figure O
2 O
B O
) O
, O
whereas O
deletion B
of I
ZF I
1 I
- I
2 I
resulted O
in O
the O
nuclear O
and O
cytoplasmic O
localization O
( O
Figure O
2 O
B O
) O
. O

For O
example O
, O
the O
NLS O
of O
ZIC O
3 O
was O
delimited O
to O
the O
second O
and O
third O
( O
of O
three O
) O
ZFs O
[ O
35 O
] O
, O
whereas O
the O
first O
and O
second O
( O
of O
three O
) O
ZFs O
of O
KLF O
8 O
was O
sufficient O
for O
nuclear O
localization O
[ O
28 O
] O
. O

Our O
results O
suggest O
that O
the O
presence O
of O
ZF O
1 O
- O
2 O
is O
required O
for O
the O
nuclear O
localization O
of O
ZNF O
24 O
, O
since O
removal B
of I
ZF I
1 I
- I
2 I
inhibited O
the O
nuclear O
localization O
of O
ZNF O
24 O
and O
removal B
of I
ZF I
3 I
or I
ZF I
4 I
did O
not O
affect O
the O
nuclear O
localization O
of O
ZNF O
24 O
. O

We O
report O
the O
molecular O
analysis O
of O
four O
PMD O
patients O
in O
three O
unrelated O
families O
and O
describe O
a O
point O
mutation O
( O
G B
- I
- I
> I
A I
transition I
) I
in I
exon I
V I
which O
leads O
to O
the O
substitution B
of I
Gly I
216 I
by I
a I
serine I
residue O
in O
a O
highly O
conserved O
extracytosolic O
domain O
and O
a O
Mae O
I O
RFLP O
. O

The O
CAPN O
5 O
gene O
harbors O
mutations B
in I
exon I
6 I
of O
ADNIV O
subjects O
. O

A O
. O

Secondary O
structure O
modeling O
shows O
that O
the O
two B
mutations I
are I
within I
a I
putative I
alpha I
helical I
domain I
. O

In O
contrast O
, O
the O
disease O
- O
causing O
mutation O
at O
this O
codon O
introduces B
a I
new I
proline I
bend I
within I
a I
putative I
alpha I
helix I
. O

The O
differences O
in O
these O
diseases O
are O
also O
noteworthy O
. O

Capn O
5 O
knockout B
mice O
have O
no O
observable O
phenotype O
[ O
32 O
] O
, O
and O
several O
human O
neurological O
disorders O
have O
been O
associated O
with O
excess O
calpain O
activity O
[ O
17 O
] O
, O
[ O
33 O
] O
, O
including O
photoreceptor O
degeneration O
[ O
34 O
] O
. O

Site O
- O
directed O
mutagenesis O
at B
amino I
acid I
728 I
generated I
one I
allele I
, O
pcf O
1 O
- O
4 O
, O
with O
a O
stronger O
phenotype O
than O
pcf O
1 O
- O
3 O
. O

Extracts O
from O
pcf O
1 O
- O
3 O
and O
pcf O
1 O
- O
4 O
strains O
increase O
pol O
III O
transcription O
two O
- O
to O
threefold O
and O
ninefold O
, O
respectively O
, O
over O
wild O
- O
type O
under O
conditions O
that O
permit O
either O
single O
or O
multiple O
rounds O
of O
initiation O
. O

Deletion B
of I
the I
N I
- I
terminal I
Atg O
5 O
binding O
domain O
( O
1 O
– O
78 O
aa O
) O
or O
C O
- O
terminal O
WD O
domain O
( O
266 O
– O
623 O
aa O
) O
had O
no O
effect O
on O
the O
Atg O
16 O
L O
1 O
- O
WIPI O
2 O
b O
interaction O
in O
GFP O
pull O
- O
down O
experiments O
( O
Figure O
2 O
B O
) O
. O

We O
refined O
the O
interaction O
site O
using O
truncation O
mutants O
of O
FLAG O
- O
Atg O
16 O
L O
1 O
constructs O
, O
with O
GFP O
and O
CFP O
- O
Atg O
5 O
as O
controls O
, O
and O
GFP O
- O
WIPI O
1 O
a O
or O
GFP O
- O
WIPI O
2 O
b O
( O
Figures O
2 O
C O
and O
S O
2 O
C O
) O
. O

Mutation B
of I
either I
residue I
E I
226 I
or I
E I
230 I
to I
arginine I
( O
E O
226 O
R O
and O
E O
230 O
R O
) O
abolished O
binding O
of O
Atg O
16 O
L O
1 O
to O
WIPI O
2 O
b O
, O
and O
E O
208 O
R O
or O
D O
212 O
R O
mutants O
reproducibly O
showed O
reduced O
binding O
. O

However O
, O
the O
Atg O
16 O
L O
1 O
point B
mutations I
from I
E I
235 I
to I
E I
241 I
bound O
very O
weakly O
or O
not O
at O
all O
to O
FIP O
200 O
. O

Recent O
data O
suggest O
that O
the O
FIP O
200 O
binding O
site O
on O
Atg O
16 O
L O
1 O
encompasses O
residue O
246 O
( O
Fujita O
et O
al O
. O
, O
2013 O
) O
, O
so O
we O
extended O
residue O
mapping O
to O
E O
249 O
and O
saw O
a O
recovery O
of O
FIP O
200 O
binding O
to O
wild O
- O
type O
( O
WT O
) O
Atg O
16 O
L O
1 O
( O
Figure O
S O
3 O
A O
) O
. O

Inhibition O
of O
Ptd O
Ins O
( O
3 O
) O
P O
binding O
through O
mutation B
of I
the I
Ptd I
Ins I
( I
3 I
) I
P I
binding I
motif I
FRRG I
to I
FTTG I
( O
GFP O
- O
WIPI O
2 O
b O
FTTG O
) O
had O
no O
significant O
effect O
on O
the O
ability O
of O
WIPI O
2 O
b O
to O
bind O
Atg O
16 O
L O
1 O
( O
Figures O
4 O
A O
and O
4 O
B O
) O
. O

As O
the O
site O
on O
Atg O
16 O
L O
1 O
is O
acidic O
, O
we O
looked O
for O
conserved O
basically O
charged O
residues O
proximal O
to O
the O
site O
of O
the O
18 O
amino O
acid O
insert O
in O
the O
WIPI O
2 O
a O
isoform O
( O
which O
does O
not O
bind O
Atg O
16 O
L O
1 O
) O
. O

Mutation B
of I
R I
108 I
to I
glutamate I
( O
WIPI O
2 O
b O
R O
108 O
E O
) O
reduced O
Atg O
16 O
L O
1 O
binding O
dramatically O
, O
while O
R O
125 O
E O
showed O
decreased O
binding O
( O
Figure O
4 O
D O
) O
. O

A O
mutation O
( O
Pro B
- I
30 I
to I
Leu I
) O
in O
CYP O
21 O
represents O
a O
potential O
nonclassic O
steroid O
21 O
- O
hydroxylase O
deficiency O
allele O
. O

( O
C O
) O
The O
short O
fragments O
( O
* O
) O
represent O
the O
previously O
described O
ε B
IVS I
11 I
+ I
10 I
del I
20 I
polymorphism I
in I
intron I
11 I
of O
the O
ε O
subunit O
gene O
, O
which O
has O
an O
allelic O
frequency O
of O
22 O
/ O
248 O
. O

Many O
forms O
of O
CAH O
exist O
resulting O
from O
various O
mutations O
of O
the O
CYP O
21 O
B O
gene O
. O

In O
the O
patient O
, O
a O
single O
base O
substitution O
replaced B
Ile I
172 I
( I
ATC I
) I
with I
Asn I
( I
AAC I
) I
in O
one O
allele O
while O
Arg B
356 I
( I
CGG I
) I
was I
converted I
to I
Trp I
( I
TGG I
) I
in O
the O
other O
. O

Analysis O
of O
the O
APP O
exon O
16 O
in O
the O
proband O
showed O
a O
GAC B
to I
AAC I
nucleotide I
substitution I
in I
codon I
678 I
of O
the O
APP O
gene O
, O
causing O
an O
amino O
acid O
substitution O
of O
Asp B
to I
Asn I
( I
D I
678 I
N I
) I
. O

Sequencing O
revealed O
the O
presence O
of O
a O
homozygous B
missense I
mutation I
( O
R O
80 O
W O
) O
in O
exon O
3 O
of O
the O
17 O
beta O
- O
HSD O
3 O
gene O
, O
which O
was O
also O
present O
in O
single O
doses O
in O
both O
parents O
, O
in O
accordance O
with O
the O
recessive O
inheritance O
of O
the O
defect O
. O

Confirming O
the O
abnormal O
delta O
4 O
- O
androstenedione O
/ O
testosterone O
ratios O
that O
suggested O
17 O
beta O
- O
HSD O
deficiency O
, O
a O
homozygous B
missense I
mutation I
in O
the O
gene O
coding O
for O
this O
enzyme O
was O
identified O
in O
the O
patient O
with O
MPH O
. O

Mutant O
proteins O
were O
expressed O
in O
E O
. O
coli O
as O
GST O
- O
chimeric O
molecules O
and O
analyzed O
in O
terms O
of O
their O
GTP O
- O
binding O
or O
GTP O
- O
hydrolysing O
ability O
in O
vitro O
. O

A O
point O
mutation O
of O
Asn B
at I
position I
72 I
for O
ARA O
- O
2 O
, O
or O
71 O
for O
ARA O
- O
4 O
, O
to B
Ile I
decreased O
GTP O
- O
binding O
and O
a O
point O
mutation O
of O
Gln B
at I
position I
126 I
for O
ARA O
- O
2 O
, O
or O
125 O
for O
ARA O
- O
4 O
, O
to B
Leu I
suppressed O
GTP O
- O
hydrolysis O
activity O
. O

This O
nucleotide O
change O
causes O
the O
amino O
- O
acid O
order O
from O
proline B
to I
leucine I
at I
codon I
233 I
. O

A O
novel O
SNP O
( O
698 O
C O
> O
T O
) O
causes O
the O
change O
in O
amino O
acids O
from O
proline B
to I
leucine I
at I
codon I
233 I
. O

The O
annealing O
temperature O
was O
63 O
° O
C O
. O

Michel O
et O
al O
. O

This O
was O
a O
non O
- O
synonymous O
mutation O
; O
it O
was O
an O
AGC O
→ O
ATC O
variant O
resulting O
in O
a O
S B
323 I
- I
to I
- I
I I
substitution O
which O
was O
associated O
with O
familial O
combined O
hyperlipidemia O
in O
a O
French O
– O
Canadian O
family O
. O

Recent O
studies O
have O
implicated O
mutations O
in O
the O
ATP O
- O
binding O
cassette O
transporter O
A O
1 O
, O
ABCA O
1 O
, O
as O
a O
cause O
of O
Tangier O
disease O
( O
TD O
) O
and O
familial O
hypoalphalipoproteinemia O
( O
FHA O
) O
. O

The O
second O
mutation O
was O
a O
single B
- I
nucleotide I
deletion I
of I
thymidine I
in I
a I
polypyrimidine I
tract I
located I
33 I
to I
46 I
bps I
upstream I
to I
the I
start I
of I
exon I
47 I
. O

Changes O
of O
residue B
401 I
to I
either I
leucine I
or I
alanine I
( I
but I
not I
phenylalanine I
) I
and O
residue B
414 I
to I
leucine I
resulted O
in O
major O
reductions O
in O
beta O
- O
galactosidase O
activity O
produced O
from O
the O
reporter O
gene O
as O
compared O
to O
yeast O
expressing O
wild O
- O
type O
p O
66 O
bait O
and O
p O
51 O
prey O
fusions O
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
identified O
several O
second O
- O
site O
suppressors O
in O
p O
66 O
that O
restored O
interaction O
of O
the O
p O
66 O
W O
401 O
A O
bait O
to O
the O
p O
51 O
W O
401 O
A O
prey O
. O

We O
conclude O
that O
mutations B
at I
codons I
401 I
and I
414 I
in O
p O
66 O
impair O
dimerization O
by O
altering O
the O
proper O
positioning O
of O
structural O
elements O
in O
between O
these O
residues O
that O
make O
important O
contacts O
with O
p O
51 O
. O

In O
the O
patient O
with O
a O
putative O
deletion B
of I
exons I
10 I
- I
16 I
we O
amplified O
the O
c O
DNA O
with O
primers O
that O
matched O
exons O
9 O
and O
17 O
, O
and O
confirmed O
the O
skipping O
of O
exons O
10 O
- O
16 O
( O
Figure O
2 O
D O
) O
. O

However O
, O
the O
electrophoretic O
pattern O
of O
bands O
after O
double O
restriction O
enzyme O
digestion O
( O
Mnl O
I O
+ O
Mbo O
I O
) O
of O
the O
exon O
5 O
fragment O
indicated O
that O
the O
mutation O
was O
in O
cis B
with I
the I
c I
. I
844 I
A I
allele O
( O
data O
not O
shown O
) O
. O

Two O
missense O
polymorphisms O
that O
have O
been O
proposed O
as O
modifiers O
of O
the O
clinical O
phenotype O
( O
p O
. O
Ser O
44 O
Leu O
and O
p O
. O
Pro O
45 O
Leu O
) O
were O
not O
found O
in O
our O
patients O
[ O
29 O
] O
. O

Modification B
of I
the I
methylation I
state I
of I
these I
lysine I
residues I
of I
histone I
H I
3 I
regulates O
chromatin O
structure O
and O
is O
implicated O
in O
transcriptional O
control O
3 O
. O

These O
data O
further O
elucidate O
the O
somatic O
genetic O
architecture O
of O
cc O
RCC O
and O
emphasize O
the O
marked O
contribution O
of O
aberrant O
chromatin O
biology O
. O

Deletion B
of I
the I
Ser I
- I
Arg I
- I
lle I
- I
Gly I
residues I
( I
amino I
acids I
79 I
- I
82 I
; I
SRIG I
) I
had O
no O
effect O
on O
the O
Vpr O
localization O
. O

However O
, O
deletion B
of I
the I
Arg I
- I
Gln I
- I
Arg I
- I
Arg I
residues I
( I
amino I
acids I
85 I
- I
88 I
; I
RQRR I
) I
resulted O
in O
a O
smooth O
perinuclear O
staining O
pattern O
. O

Substitution O
of O
five O
Arg O
residues O
with O
Asn O
( O
amino B
acids I
80 I
, I
85 I
, I
87 I
, I
88 I
, I
and I
90 I
; I
R I
- I
- I
> I
N I
5 I
) O
resulted O
in O
a O
diffuse O
cytoplasmic O
staining O
. O

Subcellular O
fractionation O
analyses O
support O
the O
immunofluorescence O
staining O
results O
. O

Both O
SRIG O
and O
R O
- O
- O
> O
N O
5 O
mutants O
lost O
their O
cell O
cycle O
arrest O
activities O
and O
the O
RQRR B
deletion I
only O
exhibited O
a O
low O
level O
of O
cell O
arrest O
activity O
. O

Both O
experiments O
demonstrated O
that O
the O
region O
of O
obscurin O
between O
aa O
6236 O
and O
6353 O
is O
capable O
to O
interact O
with O
ank O
1 O
. O
5 O
. O

( O
D O
) O
Mutagenesis B
of I
the I
aa I
in I
the I
COOH I
terminus I
of O
obscurin O
( O
aa O
6236 O
– O
6260 O
) O
capable O
of O
mediating O
binding O
to O
ank O
1 O
. O
5 O
was O
performed O
and O
mutant O
proteins O
were O
tested O
against O
GST O
– O
ank O
1 O
. O
5 O
in O
in O
vitro O
binding O
assays O
. O

1 O
B O
) O
. O

Site O
- O
directed O
mutagenesis O
of O
these O
25 O
aa O
indicated O
that O
the O
substitution B
of I
three I
threonine I
residues I
( I
T I
6238 I
, I
T I
6240 I
, I
and I
T I
6241 I
) I
drastically O
impaired O
the O
ability O
of O
obscurin O
to O
bind O
to O
ank O
1 O
. O
5 O
( O
Fig O
. O

( O
A O
) O
A O
schematic O
representation O
of O
the O
structure O
of O
the O
small O
muscle O
– O
specific O
ankyrin O
isoforms O
is O
presented O
: O
a O
color O
code O
identifies O
the O
different O
exons O
that O
, O
by O
undergoing O
alternative O
splicing O
, O
generate O
the O
different O
ank O
1 O
isoforms O
. O

( O
D O
) O
Site O
- O
directed O
mutagenesis B
of I
aa I
97 I
– I
123 I
of O
ank O
1 O
. O
5 O
was O
performed O
and O
the O
in O
vitro O
– O
transcribed O
and O
– O
translated O
mutant O
proteins O
were O
used O
in O
binding O
experiments O
with O
the O
GST O
– O
Obs O
6215 O
– O
6353 O
fusion O
protein O
. O

Mutagenesis B
of I
any I
of I
four I
aa I
residues I
( I
T I
99 I
, I
K I
101 I
, I
R I
104 I
, I
and I
K I
105 I
) I
of O
ank O
1 O
. O
5 O
strongly O
reduced O
the O
ability O
to O
bind O
to O
obscurin O
. O

To O
identify O
the O
critical O
aa O
that O
in O
ank O
1 O
. O
5 O
are O
required O
for O
the O
interaction O
with O
the O
COOH O
terminus O
of O
obscurin O
, O
site O
- O
directed O
mutagenesis B
of I
aa I
97 I
– I
123 I
of O
ank O
1 O
. O
5 O
was O
performed O
, O
and O
the O
in O
vitro O
– O
transcribed O
and O
– O
translated O
mutant O
proteins O
were O
used O
in O
binding O
experiments O
with O
the O
GST O
– O
Obs O
6215 O
– O
6353 O
fusion O
protein O
. O

D O
3 O
. O
49 O
( O
164 O
) O
in O
the O
highly O
conserved O
DRY B
motif I
was I
mutated I
to I
13 I
amino I
acids I
. O

Except O
for O
the O
D O
3 O
. O
49 O
( O
164 O
) O
E O
mutant O
, O
each O
mutant O
displayed O
little O
or O
no O
detectable O
[ O
( O
3 O
) O
H O
] O
diprenorphine O
binding O
, O
and O
pretreatment O
with O
naloxone O
greatly O
enhanced O
binding O
. O

D B
3 I
. I
49 I
( I
164 I
) I
H I
, I
- I
Q I
, I
- I
Y I
, I
- I
M I
, I
and I
- I
E I
mutants O
were O
further O
studied O
. O

D B
3 I
. I
32 I
( I
147 I
) I
was I
substituted I
with I
A I
or I
N I
. O
All O
seven O
mutants O
exhibited O
similar O
binding O
affinities O
for O
the O
antagonist O
[ O
( O
3 O
) O
H O
] O
diprenorphine O
as O
the O
wild O
- O
type O
. O

The O
D B
3 I
. I
49 I
( I
164 I
) I
H I
, I
- I
Q I
, I
- I
Y I
, I
and I
- I
M I
mutants O
, O
but O
not O
the O
D O
3 O
. O
49 O
( O
164 O
) O
E O
and O
D O
3 O
. O
32 O
( O
147 O
) O
mutants O
, O
exhibited O
enhanced O
basal O
[ O
( O
35 O
) O
S O
] O
GTPgamma O
S O
binding O
which O
was O
comparable O
to O
the O
maximally O
activated O
level O
of O
the O
wild O
- O
type O
and O
was O
related O
to O
expression O
levels O
. O

The O
D B
3 I
. I
49 I
( I
164 I
) I
H I
, I
- I
Y I
, I
- I
M I
, I
and I
- I
Q I
mutants O
had O
higher O
affinities O
for O
DAMGO O
than O
the O
wild O
- O
type O
, O
which O
were O
not O
significantly O
lowered O
by O
GTPgamma O
S O
. O

Thus O
, O
mutation O
of O
D B
3 I
. I
49 I
( I
164 I
) I
to I
H I
, I
Y I
, I
M I
, I
or I
Q I
in O
RMOR O
resulted O
in O
receptor O
assuming O
activated O
conformations O
. O

Consistent O
with O
this O
model O
, O
a O
truncated O
CDPK O
( O
Delta O
NC O
) O
in O
which O
the O
Ca B
M I
- I
LD I
has I
been I
deleted I
can O
be O
activated O
in O
a O
bimolecular O
interaction O
with O
an O
isolated O
Ca O
M O
- O
LD O
or O
calmodulin O
, O
similar O
to O
the O
activation O
of O
a O
calmodulin O
- O
dependent O
protein O
kinase O
( O
Ca O
MK O
) O
by O
calmodulin O
. O

Two O
mutations O
at O
either O
end O
of O
this O
core O
segment O
( O
F O
436 O
/ O
A O
and O
VI O
444 O
/ O
AA O
) O
severely O
disrupted O
bimolecular O
activation O
, O
whereas O
flanking O
mutations O
had O
only O
minor O
effects O
. O

Interestingly O
, O
intramolecular O
but O
not O
bimolecular O
activation O
was O
disrupted O
by O
insertion B
mutations I
placed I
immediately I
downstream I
of I
I I
444 I
. O

A O
mutation O
, O
which O
changes O
a O
highly O
conserved O
Cys B
to I
Tyr I
in I
transmembrane I
domain I
IS I
1 I
, O
identifies O
a O
residue O
important O
for O
channel O
function O
not O
only O
in O
Drosophila O
muscle O
but O
also O
in O
mammalian O
cardiac O
channels O
. O

Amino O
acid O
substitutions B
at I
this I
Cys I
position I
in I
the I
cardiac I
alpha I
1 I
subunit I
show O
that O
the O
size O
of O
the O
side O
chain O
, O
rather O
than O
its O
ability O
to O
form O
disulfide O
bonds O
, O
affects O
channel O
activation O
. O

ACAP O
2 O
was O
cloned O
from O
a O
Super O
Script O
human O
leukocyte O
c O
DNA O
library O
( O
Life O
Technologies O
) O
using O
a O
2 O
- O
kb O
Kpn O
I O
fragment O
from O
KIAA O
0041 O
( O
Dr O
. O
Takahiro O
Nagese O
) O
as O
a O
probe O
. O

2000 O
b O
) O
. O

Glutamine B
mutations I
in I
arginine I
448 I
of O
ACAP O
1 O
and O
arginine O
442 O
of O
ACAP O
2 O
were O
introduced O
using O
a O
kit O
( O
Quikchange O
; O
Stratagene O
) O
. O

In O
the O
absence O
of O
CHX O
, O
however O
, O
the O
transcript O
containing O
the O
c O
. O
694 O
C O
> O
T O
( O
p O
. O
Q O
232 O
X O
) O
was O
undetectable O
leaving O
the O
transcript O
containing O
the O
c O
. O
1289 O
A O
> O
G O
mutation O
as O
the O
predominant O
species O
, O
consistent O
with O
compound O
heterozygosity O
( O
Supplementary O
Fig O
. O

The O
c O
. O
1289 O
A O
> O
G O
mutation O
was O
inherited O
from O
the O
patient O
’ O
s O
mother O
, O
and O
is O
predicted O
to O
cause O
the O
substitution B
of I
a I
highly I
conserved I
asparagine I
residue I
with I
a I
serine I
( O
p O
. O
N O
430 O
S O
) O
( O
Supplementary O
Fig O
. O

Initial O
experiments O
using O
this O
vector O
did O
not O
rescue O
CI O
activity O
so O
site O
- O
directed O
mutagenesis O
was O
performed O
to O
change B
codon I
343 I
from I
CCA I
( I
proline I
) I
( I
db I
SNP I
rs I
17855445 I
) I
to I
the I
hg I
18 I
reference I
codon I
GCA I
( I
alanine I
) I
using O
Quik O
Change O
II O
XL O
site O
- O
directed O
mutagenesis O
kit O
( O
Stratagene O
) O
according O
to O
manufacturer O
’ O
s O
instructions O
( O
primers O
listed O
in O
Supplementary O
Table O
5 O
) O
to O
generate O
the O
Ref O
Seq O
FOXRED O
1 O
- O
V O
5 O
p O
Dest O
vector O
. O

Germline B
mutations I
in O
BHD O
are O
associated O
with O
the O
susceptibility O
for O
BHDS O
. O

In O
this O
report O
we O
describe O
the O
phenotype O
produced O
by O
stochastic B
mutations I
of I
the I
zinc I
finger I
region I
. O

Secondly O
, O
substitution B
of I
the I
conserved I
Lys I
461 I
results O
in O
an O
abnormal O
behavior O
of O
the O
mutated O
GR O
. O

In O
particular O
, O
the O
mutant O
Lys O
461 O
Tyr O
( O
61 O
Y O
) O
displays O
about O
the O
same O
transactivation O
when O
tested O
in O
form O
of O
a O
minimal O
GR O
fragment O
( O
amino O
acids O
407 O
/ O
556 O
) O
as O
when O
tested O
in O
the O
amino O
- O
prolongued O
GR O
fragment O
( O
amino O
acids O
3 O
- O
556 O
, O
which O
contains O
the O
major O
transactivation O
domain O
of O
the O
GR O
) O
. O

The O
I O
154 O
F O
mutation O
has O
been O
described O
in O
six O
patients O
from O
four O
families O
from O
South O
Italy O
[ O
3 O
] O
, O
[ O
18 O
] O
, O
[ O
19 O
] O
, O
[ O
22 O
] O
. O

The O
G B
> I
T I
transversion I
at I
nucleotide I
389 I
leading O
to O
the O
G O
130 O
V O
replacement O
is O
the O
most O
frequent O
missense O
mutation O
in O
FRDA O
, O
found O
in O
more O
than O
ten O
Caucasian O
patients O
from O
five O
families O
( O
[ O
18 O
] O
, O
[ O
23 O
] O
– O
[ O
25 O
] O
and O
MK O
unpublished O
data O
) O
. O

Complete O
frataxin O
deletion B
in O
murine O
fibroblasts O
is O
not O
viable O
and O
can O
be O
rescued O
by O
transgenic O
expression O
of O
m O
Fxn O

To O
confirm O
that O
frataxin O
deletion B
is O
the O
cause O
of O
cell O
detachment O
and O
subsequent O
death O
, O
we O
determined O
whether O
transgenic O
expression O
of O
murine O
frataxin O
( O
m O
Fxn O
) O
could O
rescue O
the O
phenotype O
. O

Nineteen O
clones O
overexpressing O
mouse O
frataxin O
( O
Frda O
L O
3 O
/ O
L O
- O
; O
m O
Fxn O
) O
presented O
a O
complete B
deletion I
of O
the O
endogenous O
frataxin O
gene O
( O
Fig O
. O

1 O
D O
, O
left O
panel O
) O
and O
growth O
, O
demonstrating O
that O
transgenic O
expression O
of O
frataxin O
rescues O
the O
lethality O
associated O
with O
complete O
deficiency O
of O
endogenous O
frataxin O
. O

In O
electron O
microscopy O
studies O
, O
apart O
from O
the O
retraction O
of O
the O
plasma O
membrane O
leading O
to O
an O
organelle O
dense O
cytoplasm O
, O
no O
structural O
anomaly O
in O
the O
mitochondria O
nor O
sign O
of O
necrosis O
or O
apoptosis O
was O
detected O
in O
Frda O
L O
3 O
/ O
L O
- O
; O
p O
SG O
5 O
sorted O
clones O
( O
Fig O
. O

Genotyping O
demonstrated O
a O
complete B
deletion I
of O
the O
endogenous O
murine O
frataxin O
gene O
for O
each O
clone O
, O
hereafter O
referred O
as O
h O
FXN O
, O
h O
FXNG O
130 O
V O
and O
h O
FXNI O
154 O
F O
clones O
( O
Fig O
. O

2 O
A O
, O
lanes O
8 O
– O
9 O
and O
11 O
– O
12 O
, O
respectively O
) O
. O

Through O
this O
novel O
in O
vitro O
system O
, O
we O
generated O
two O
humanized O
cell O
models O
by O
combining O
the O
deletion B
of O
the O
endogenous O
murine O
conditional O
frataxin O
allele O
with O
the O
expression O
of O
human O
frataxin O
carrying O
either O
the O
G O
130 O
V O
or O
I O
154 O
F O
missense O
mutations O
found O
in O
compound O
heterozygous O
FRDA O
patients O
. O

Further O
characterization O
of O
the O
mutants B
in I
position I
383 I
revealed O
that O
[ O
Y O
383 O
H O
] O
, O
[ O
Y O
383 O
F O
] O
, O
and O
[ O
Y O
383 O
Q O
] O
leukotriene O
A O
4 O
hydrolases O
catalyzed O
hydrolysis O
of O
leukotriene O
A O
4 O
into O
a O
novel O
enzymatic O
metabolite O
. O

From O
analysis O
by O
high O
performance O
liquid O
chromatography O
, O
gas O
chromatography O
/ O
mass O
spectrometry O
of O
material O
generated O
in O
the O
presence O
of O
H O
216 O
O O
or O
H O
218 O
O O
, O
steric O
analysis O
of O
the O
hydroxyl O
groups O
, O
treatment O
with O
soybean O
lipoxygenase O
, O
and O
comparison O
with O
a O
synthetic O
standard O
, O
the O
novel O
metabolite O
was O
assigned O
the O
structure O
5 O
S O
, O
6 O
S O
- O
dihydroxy O
- O
7 O
, O
9 O
- O
trans O
- O
11 O
, O
14 O
- O
cis O
- O
eicosatetraenoic O
acid O
( O
5 O
S O
, O
6 O
S O
- O
DHETE O
) O
. O

This O
FOXL O
2 O
c O
. O
402 O
C O
> O
G O
mutation O
changes B
a I
highly I
conserved I
cysteine I
residue I
to I
a I
tryptophan I
( O
p O
. O
C O
134 O
W O
) O
. O

A O
similar O
phenotype O
, O
including O
a O
3 O
- O
fold O
increase O
in O
the O
half O
- O
time O
of O
secretion O
, O
disruption O
of O
the O
disulfide O
bonding O
arrangement O
, O
and O
inefficient O
complement O
fixation O
, O
is O
observed O
when O
nearby O
glucosylgalactosyl B
hydroxylysine I
residues I
at I
positions I
27 I
and I
30 I
are I
replaced I
with I
arginine I
residues O
. O

Deleting B
APE I
1 I
’ I
s I
N I
- I
terminal I
41 I
amino I
acid I
( I
a I
. I
a I
. I
) I
residues I
( O
ND O
42 O
) O
caused O
no O
detectable O
effect O
on O
the O
MDM O
2 O
co O
- O
immunoprecipitation O
( O
lane O
2 O
) O
, O
suggesting O
that O
the O
N O
- O
terminal O
region O
was O
not O
required O
for O
the O
interaction O
. O

Interestingly O
, O
the O
C B
- I
terminal I
20 I
a I
. I
a I
. I
deletion I
of O
APE O
1 O
( O
CD O
20 O
) O
repeatedly O
resulted O
in O
much O
more O
efficient O
co O
- O
precipitation O
of O
MDM O
2 O
than O
the O
full O
- O
length O
APE O
1 O
. O

It O
is O
likely O
that O
the O
C B
- I
terminal I
deletion I
exposed O
the O
presumptive O
interaction O
domain O
of O
APE O
1 O
. O

Essentially O
the O
same O
results O
were O
obtained O
with O
the O
wild O
- O
type O
( O
wt O
) O
MDM O
2 O
and O
APE O
1 O
( O
Supplemental O
Fig O
. O

While O
ubiquitination O
of O
ND O
21 O
APE O
1 O
( O
20 B
a I
. I
a I
. I
N I
- I
terminal I
deletion I
) O
was O
comparable O
to O
that O
of O
the O
full O
- O
length O
APE O
1 O
( O
lane O
2 O
) O
, O
ubiquitination O
of O
the O
ND O
42 O
APE O
1 O
( O
42 B
a I
. I
a I
. I
N I
- I
terminal I
deletion I
) O
was O
not O
detected O
( O
lane O
3 O
) O
, O
indicating O
that O
the O
ubiquitination O
occurred O
inside O
of O
21 O
- O
42 O
from O
the O
APE O
1 O
N O
- O
terminus O
. O

Because O
there O
were O
still O
six O
Lys O
residues O
in O
the O
segment O
( O
i O
. O
e O
. O
, O
24 B
K I
, I
25 I
K I
, I
27 I
K I
, I
31 I
K I
, I
32 I
K I
, I
and I
35 I
K I
) I
, I
we I
mutated I
each I
individually I
to I
Arg I
in O
the O
ND O
21 O
background O
. O

4 O
) O
. O

4 O
) O
, O
while O
the O
other O
dual O
mutants O
exhibited O
the O
same O
level O
of O
ubiquitination O
as O
the O
wt O
APE O
1 O
( O
data O
not O
shown O
) O
. O

In O
seven O
patients O
with O
CPHD O
from O
four O
consanguineous O
pedigrees O
, O
four O
novel O
, O
recessive O
mutations O
were O
identified O
: O
a B
deletion I
of I
the I
entire I
gene I
( O
del O
/ O
del O
) O
, O
mutations O
causing O
truncated O
proteins O
( O
E O
173 O
ter O
, O
W O
224 O
ter O
) O
, O
and O
a O
mutation O
causing O
a O
substitution O
in O
the O
homeodomain O
( O
A O
210 O
V O
) O
. O

Direct O
DNA O
sequence O
analysis O
from O
all O
patients O
and O
obligate O
carriers O
reveals O
a O
c O
. O
812 O
G O
> O
T O
missense O
mutation O
in O
exon O
9 O
, O
which O
would O
result O
in O
a O
substitution B
of I
the I
cysteine I
residue I
at I
codon I
271 I
by I
a I
phenylalanine I
residue I
( O
C O
271 O
F O
, O
Figure O
2 O
A O
) O
. O

Sequence O
analysis O
revealed O
a O
c O
. O
70 O
G O
> O
T O
missense O
mutation O
in O
exon O
2 O
in O
all O
patients O
and O
obligate O
carriers O
, O
which O
would O
result O
in O
a O
substitution B
of I
the I
glycine I
residue I
at I
codon I
24 I
by I
a I
tryptophan I
residue I
( O
Figure O
2 O
D O
) O
. O

A O
direct O
sequence O
of O
all O
affected O
patients O
in O
families O
E O
and O
F O
revealed O
the O
same O
sequence O
change O
in O
exon O
9 O
, O
a O
c O
. O
782 O
G O
> O
A O
missense O
mutation O
, O
which O
would O
result O
in O
substitution B
of I
the I
arginine I
residue I
at I
codon I
260 I
by I
a I
glutamine I
residue I
( O
R O
260 O
Q O
, O
Figure O
2 O
E O
, O
F O
) O
. O

Sequence O
analysis O
of O
all O
patients O
and O
obligate O
carriers O
in O
family O
G O
revealed O
a O
c O
. O
910 O
C O
> O
T O
nonsense O
mutation O
in O
exon O
10 O
, O
which O
would O
result O
in O
substitution B
of I
the I
arginine I
residue I
at I
codon I
303 I
by I
a I
stop I
codon I
( O
R O
303 O
X O
, O
Figure O
2 O
G O
) O
. O

Case O
1 O
was O
a O
compound O
heterozygote O
for O
a O
previously O
described O
cytosine B
insertion I
into I
exon I
2 I
causing I
a I
frameshift I
and O
nonsense O
codon O
severely O
truncating O
the O
H O
6 O
PDH O
protein O
, O
and O
a O
novel O
p O
. O
P O
146 O
L O
missense O
mutation O
, O
which O
we O
have O
shown O
through O
in O
silico O
three O
- O
dimensional O
protein O
modelling O
to O
potentially O
impact O
upon O
cofactor O
binding O
, O
thus O
rendering O
NADPH O
production O
to O
be O
abolished O
. O

We O
removed O
the O
selenocysteine O
insertion O
sequence O
in O
the O
rat O
gene O
, O
and O
we O
changed B
the I
Se I
Cys I
( I
498 I
) I
encoded I
by I
TGA I
to I
Cys I
or I
Ser I
by O
mutagenesis O
. O

The O
truncated O
protein O
having O
the O
C B
- I
terminal I
Se I
Cys I
- I
Gly I
dipeptide I
deleted I
, O
expected O
in O
selenium O
deficiency O
, O
was O
also O
engineered O
. O

Thus O
selenium O
is O
required O
for O
the O
catalytic O
activities O
of O
Trx O
R O
explaining O
the O
essential O
role O
of O
this O
trace O
element O
in O
cell O
growth O
. O

Here O
we O
report O
that O
BRAF O
is O
modified O
by O
Lys O
63 O
- O
linked O
polyubiquitination O
at O
lysine O
578 O
within O
its O
kinase O
domain O
once O
it O
is O
activated O
by O
gain O
of O
constitutively O
active O
mutation O
or O
epidermal O
growth O
factor O
( O
EGF O
) O
stimulation O
. O

Substitution O
of O
BRAF O
lysine B
578 I
with I
arginine I
( O
K O
578 O
R O
) O
inhibited O
BRAF O
- O
mediated O
ERK O
activation O
. O

Since O
substitution O
of O
constitutively O
active O
BRAF O
V O
600 O
E O
or O
K O
601 O
E O
mutant O
Lys B
578 I
with I
Arg I
abolishes O
its O
Lys O
63 O
- O
linked O
polyubiquitination O
and O
BRAF O
V O
600 O
E O
or O
K O
601 O
E O
- O
mediated O
ERK O
activation O
, O
we O
conclude O
that O
the O
Lys O
63 O
- O
linked O
polyubiquitination O
is O
essential O
in O
BRAF O
V O
600 O
E O
or O
K O
601 O
E O
mutant O
- O
mediated O
oncogenic O
signaling O
. O

Ubiquitin O
K O
63 O
R O
, O
K O
48 O
R O
and O
ubiquitin O
with O
all B
lysine I
to I
arginine I
mutation I
except I
Lys I
63 I
or I
Lys I
48 I
were O
sub O
- O
cloned O
into O
mammalian O
expression O
vector O
pc O
DNA O
3 O
. O
1 O
with O
HA O
- O
tag O
at O
their O
N O
- O
terminal O
and O
verified O
by O
DNA O
sequencing O
analysis O
. O

The O
systematic O
use O
of O
antivitamin O
K O
anticoagulants O
( O
AVK O
) O
as O
rodenticides O
caused O
the O
selection O
of O
rats O
resistant O
to O
AVKs O
. O

In O
this O
report O
, O
we O
showed O
that O
mutations B
at I
Leu I
- I
120 I
and I
Tyr I
- I
139 I
dramatically O
affect O
the O
vitamin O
K O
epoxide O
reductase O
activity O
. O

7 O
) O
. O

All O
these O
observations O
are O
totally O
in O
agreement O
with O
the O
catalytic O
results O
obtained O
in O
this O
study O
. O

Only O
the O
resistance O
due O
to O
a O
mutation B
of I
the I
Tyr I
- I
139 I
residue O
might O
be O
associated O
with O
a O
biological O
cost O
. O

In O
this O
patient O
, O
the O
Tyr B
- I
139 I
residue I
is I
replaced I
by I
a I
His I
residue I
[ O
31 O
] O
. O

The O
mutation B
of I
Ser I
280 I
to I
aspartic I
acid I
( O
to O
mimic O
phosphorylation O
) O
reduced O
receptor O
desensitization O
by O
nonhallucinogenic O
agonists O
, O
whereas O
its B
mutation I
to I
alanine I
increased O
the O
ability O
of O
hallucinogens O
to O
desensitize O
the O
receptor O
. O

This O
study O
reveals O
a O
biased O
phosphorylation O
of O
the O
5 O
- O
HT O
2 O
A O
receptor O
in O
response O
to O
hallucinogenic O
versus O
nonhallucinogenic O
agonists O
, O
which O
underlies O
their O
distinct O
capacity O
to O
desensitize O
the O
receptor O
. O

They O
also O
provide O
convergent O
evidence O
indicating O
that O
the O
different O
effects O
of O
hallucinogenic O
versus O
non O
hallucinogenic O
agonists O
upon O
receptor O
desensitization O
reflect O
their O
differential O
capacity O
to O
promote O
Ser O
280 O
phosphorylation O
: O
( O
1 O
) O
mutating B
Ser I
280 I
into I
alanine I
or I
aspartate I
abolished O
the O
difference O
in O
the O
agonist O
effects O
upon O
receptor O
desensitization O
; O
( O
2 O
) O
hallucinogens O
were O
able O
to O
desensitize O
S O
280 O
A O
receptor O
to O
an O
extent O
comparable O
to O
that O
induced O
by O
nonhallucinogenic O
agonists O
in O
cells O
expressing O
wild O
type O
receptor O
and O
( O
3 O
) O
nonhallucinogenic O
agonists O
did O
not O
promote O
desensitization O
of O
the O
Ser O
280 O
D O
receptor O
mutant O
. O

Collectively O
, O
these O
observations O
establish O
a O
direct O
link O
between O
Ser O
280 O
phosphorylation O
and O
the O
low O
capacity O
of O
hallucinogens O
to O
desensitize O
the O
receptor O
and O
suggest O
that O
Ser O
280 O
is O
phosphorylated O
at O
a O
high O
stoichiometry O
following O
hallucinogen O
treatment O
. O

These O
findings O
contrast O
with O
a O
previous O
study O
which O
showed O
that O
mutating B
into I
alanine I
two I
serine I
residues I
, I
one I
( I
Ser I
421 I
) I
located I
in I
the I
receptor I
C I
terminus I
and I
the I
other I
( I
Ser I
188 I
) I
in O
the O
i O
2 O
loop O
, O
strongly O
reduced O
quipazine O
- O
mediated O
receptor O
desensitization O
, O
whereas O
the O
deletion O
of O
residues O
280 O
– O
296 O
or O
residues B
280 I
– I
310 I
in O
the O
i O
3 O
loop O
( O
i O
. O
e O
. O

Both O
fragments O
were O
cloned O
and O
sequenced O
; O
although O
the O
603 O
bp O
fragment O
did O
not O
exhibit O
any O
alteration O
within O
the O
region O
analysed O
, O
the O
smaller O
561 O
bp O
fragment O
was O
found O
to O
contain O
a O
69 B
bp I
in I
- I
frame I
deletion I
corresponding I
to I
the I
entire I
length I
of I
exon I
2 I
( O
Figure O
2 O
) O
. O

Although O
it O
is O
likely O
that O
the O
mutation O
directly O
abrogated O
the O
canonical O
exon O
2 O
donor O
splice O
site O
, O
it O
is O
also O
possible O
that O
the O
splicing O
machinery O
acted O
so O
as O
to O
restore O
the O
open O
reading O
frame O
simply O
by O
removing O
exon O
2 O
in O
its O
entirety O
[ O
Nissim O
- O
Rafinia O
and O
Kerem O
, O
2002 O
] O
. O

The O
analysis O
demonstrated O
normal O
splicing O
( O
unbroken O
red O
line O
) O
of O
the O
630 O
- O
bp O
fragment O
and O
abnormal O
splicing O
( O
dotted O
red O
line O
) O
of O
the O
561 O
- O
bp O
product O
resulting O
in O
a O
69 B
- I
bp I
in I
- I
frame I
deletion I
corresponding I
to I
the I
entire I
exon I
2 I
of O
GALC O
in O
the O
shorter O
product O
. O

The O
AAG B
> I
TAG I
transversion I
, I
affecting I
the I
last I
codon I
of I
exon I
2 I
, O
is O
given O
. O

M O
, O
marker O
= O
ϕ O
X O
174 O
DNA O
Hae O
III O
- O
digested O
; O
C O
1 O
, O
C O
2 O
, O
C O
3 O
= O
control O
samples O
. O

To O
confirm O
the O
pathological O
authenticity O
of O
the O
intronic O
mutation O
c O
. O
1489 O
+ O
1 O
G O
> O
A O
, O
RT O
- O
PCR O
analysis O
was O
performed O
on O
the O
m O
RNA O
of O
patient O
# O
20 O
. O

The O
junction O
between O
nucleotides O
c O
. O
1462 O
( O
exon O
13 O
) O
and O
c O
. O
1490 O
( O
exon O
14 O
) O
at O
the O
new O
donor O
splice O
- O
site O
( O
probably O
mediated O
by O
the O
use O
of O
the O
cryptic O
exonic O
GT O
dinucleotide O
at O
c O
. O
1463 O
- O
1464 O
) O
, O
gave O
rise O
to O
a O
serine B
to I
asparagine I
substitution I
at I
residue I
495 I
followed O
by O
a O
frameshift O
that O
is O
predicted O
to O
lead O
to O
the O
premature O
termination O
of O
translation O
( O
p O
. O
S O
488 O
Nfs O
X O
200 O
) O
. O

Consistent O
with O
previous O
studies O
, O
the O
common O
30 B
kb I
deletion I
( I
c I
. I
1161 I
+ I
6532 I
_ I
poly I
A I
+ I
9 I
kbdel I
) I
was I
invariably I
found I
in I
cis I
to I
c I
. I
550 I
T I
( I
502 I
T I
) I
, O
and O
frequently O
in O
patients O
with O
the O
infantile O
form O
of O
the O
disease O
( O
but O
sometimes O
also O
with O
the O
juvenile O
form O
, O
depending O
on O
the O
precise O
combination O
with O
the O
other O
mutant O
alleles O
) O
. O

The O
replacement B
of I
a I
cyclic I
uncharged I
proline I
( I
P I
) I
with I
a I
basic I
charged I
arginine I
( I
R I
) I
in I
position I
318 I
was O
predicted O
by O
Mut O
Pred O
to O
impact O
upon O
protein O
structure O
both O
in O
terms O
of O
solvent O
accessibility O
( O
P O
= O
0 O
. O
0179 O
) O
and O
secondary O
structure O
( O
loop O
→ O
helix O
; O
P O
= O
0 O
. O
0259 O
) O
( O
Table O
2 O
) O
. O

Another O
in O
silico O
hypothesis O
was O
available O
for O
the O
novel O
missense O
mutation O
p O
. O
Y O
490 O
N O
: O
the O
non O
- O
conservative O
substitution B
of I
tyrosine I
( I
Y I
) I
by I
asparagine I
( I
N I
) I
is O
predicted O
to O
lead O
to O
the O
loss O
of O
a O
phosphorylation O
site O
at O
residue O
490 O
( O
P O
= O
0 O
. O
0245 O
) O
, O
consistent O
with O
the O
severe O
infantile O
form O
of O
the O
patient O
# O
17 O
( O
Table O
1 O
) O
. O

The O
second O
allele O
in O
this O
patient O
( O
# O
17 O
) O
is O
the O
nonsense O
mutation O
( O
p O
. O
K O
88 O
X O
) O
, O
discussed O
above O
, O
that O
predicts O
premature O
termination B
of I
translation I
at I
codon I
88 I
. O

In O
accordance O
with O
in O
vitro O
expression O
studies O
which O
indicated O
that O
no O
GALC O
enzymatic O
activity O
was O
evident O
in O
association O
with O
p O
. O
G O
553 O
R O
( O
G O
537 O
R O
) O
[ O
De O
Gasperi O
et O
al O
. O
, O
1999 O
] O
, O
Mut O
Pred O
analysis O
postulated O
a O
change O
in O
the O
alpha O
- O
helical O
secondary O
structure O
as O
consequence O
of O
the O
replacement B
of I
a I
glycine I
with I
an I
arginine I
at I
residue I
553 I
. O

The O
lev O
- O
11 O
( O
x O
12 O
) O
mutation O
, O
isolated O
as O
an O
allele O
of O
levamisole O
resistance O
, O
occurred O
in O
exon O
7 O
and O
results O
in O
amino O
acid O
substitution B
at I
234 I
from I
Glu I
to I
Lys I
. O

There O
may O
be O
functional O
importance O
of O
this O
region O
for O
molecular O
interaction O
of O
the O
tropomyosin O
. O

Mutation O
site O
of O
pat O
- O
10 O
( O
st O
575 O
) O
was O
Asp B
64 I
to I
Asn I
and O
Trp B
153 I
to I
termination I
in O
the O
troponin O
C O
. O
The O
first O
mutation O
site O
was O
in O
the O
second O
calcium O
binding O
site O
and O
the O
second O
mutation O
raised O
the O
deletion B
of I
H I
helix I
in O
the O
troponin O
C O
. O
Both O
might O
affect O
the O
calcium O
binding O
or O
the O
retaining O
of O
the O
conformation O
for O
its O
function O
. O

During O
this O
process O
, O
NEMO O
is O
modified O
post O
- O
translationally O
through O
K O
63 O
- O
linked O
polyubiquitination O
. O

Mutagenesis O
identified O
the O
affected O
ubiquitination O
sites O
as O
three B
lysine I
residues I
located I
in I
the I
vicinity I
of I
A I
323 I
. O

We O
report O
the O
detection O
of O
a O
homozygous O
G O
to O
A O
mutation O
converting O
codon O
Gly B
15 I
into I
Asp I
15 I
in O
the O
type O
II O
3 O
beta O
- O
hydroxysteroid O
dehydrogenase O
/ O
delta O
5 O
- O
delta O
4 O
- O
isomerase O
( O
3 O
beta O
- O
HSD O
) O
gene O
in O
a O
male O
pseudo O
- O
hermaphrodite O
born O
from O
consanguineous O
parents O
and O
suffering O
from O
severe O
salt O
- O
losing O
3 O
beta O
- O
HSD O
deficiency O
. O

To O
investigate O
further O
the O
potential O
involvement O
of O
residue O
15 O
in O
the O
beta O
alpha O
beta O
dinucleotide O
- O
binding O
fold O
, O
we O
have O
studied O
the O
effect O
of O
substituting O
Gly B
15 I
for I
Ala I
15 I
. O

Moreover O
, O
the O
expressed O
G O
15 O
D O
and O
G O
15 O
A O
proteins O
had O
decreased O
affinities O
for O
NAD O
+ O
with O
Km O
values O
of O
113 O
micro O
M O
and O
148 O
micro O
M O
, O
respectively O
, O
compared O
with O
22 O
micro O
M O
for O
normal O
type O
II O
3 O
beta O
- O
HSD O
. O

2 O
, O
3 O
, O
7 O
, O
8 O
- O
Tetrachlorodibenzo O
- O
p O
- O
dioxin O
( O
TCDD O
) O
is O
the O
most O
potent O
dioxin O
. O

In O
the O
present O
study O
, O
molecular O
cloning O
and O
sequencing O
of O
the O
H O
/ O
W O
rat O
Ah O
R O
revealed O
that O
the O
reason O
for O
its O
smaller O
size O
is O
a O
deletion B
/ I
insertion I
- I
type I
change I
at I
the I
3 I
' I
end I
of I
exon I
10 I
in O
the O
receptor O
c O
DNA O
. O

This O
change O
emanates O
from O
a O
single B
point I
mutation I
at I
the I
first I
nucleotide I
of I
intron I
10 I
, O
resulting O
in O
altered O
m O
RNA O
splicing O
. O

At O
the O
protein O
level O
, O
the O
mutation O
leads O
to O
a O
total B
loss I
of I
either I
43 I
or I
38 I
amino I
acids I
( O
with O
altered O
sequence O
for O
the O
last O
seven O
amino O
acids O
in O
the O
latter O
case O
) O
toward O
the O
carboxyl O
- O
terminal O
end O
in O
the O
trans O
- O
activation O
domain O
of O
the O
Ah O
R O
. O

H O
/ O
W O
rats O
also O
harbor O
a O
point B
mutation I
in I
exon I
10 I
that O
will O
cause O
a O
Val B
- I
to I
- I
Ala I
substitution I
in I
codon I
497 I
, O
but O
this O
occurs O
in O
a O
variable O
region O
of O
the O
Ah O
R O
. O

Moreover O
, O
two B
G I
to I
D I
mutations I
near I
the I
DGH I
motif I
eliminated O
PP O
2 O
C O
activity O
but O
displayed O
opposite O
effects O
on O
ABA O
signaling O
. O

In O
contrast O
, O
these O
dominant O
mutants O
could O
trap O
cellular O
targets O
and O
prevent O
phosphorylation O
by O
PKs O
required O
for O
ABA O
signaling O
. O

The O
resultant O
frame B
- I
shift I
is I
predicted I
to I
replace I
the I
terminal I
15 I
amino I
acids I
with I
a I
novel I
43 I
amino I
acid I
terminal I
sequence I
( O
V O
232 O
fs O
) O
( O
figure O
1 O
F O
) O
. O

AIRE O
- O
PHD O
1 O
constitutes O
a O
stable O
pre O
- O
formed O
binding O
platform O
as O
formation O
of O
the O
complex O
does O
not O
induce O
significant O
conformational O
changes O
in O
the O
protein O
backbone O
with O
a O
RMSD O
of O
∼ O
1 O
Å O
between O
the O
free O
( O
32 O
) O
and O
bound O
AIRE O
- O
PHD O
1 O
( O
Supplementary O
Figure O
S O
2 O
A O
) O
. O

Indeed O
, O
mutation O
of O
R B
2 I
into I
lysine I
destabilizes O
the O
complex O
, O
as O
assessed O
by O
ITC O
and O
fluorescence O
measurements O
( O
Table O
2 O
) O
. O

Here O
, O
we O
demonstrate O
that O
also O
Asn O
295 O
plays O
a O
fundamental O
role O
in O
histone O
H O
3 O
recognition O
, O
as O
mutation B
into I
alanine I
has O
a O
detrimental O
effect O
on O
complex O
formation O
( O
Table O
2 O
) O
. O

Finally O
, O
the O
C O
- O
terminal O
residue O
S O
10 O
is O
highly O
disordered O
and O
does O
not O
contribute O
with O
stable O
interactions O
to O
complex O
formation O
. O

( O
B O
) O
Cartoon O
representation O
and O
( O
C O
) O
surface O
plot O
of O
the O
lowest O
energy O
complex O
structure O
. O

In O
particular O
, O
the O
side O
chain O
of O
Asp O
304 O
, O
which O
engages O
in O
multiple O
interactions O
with O
both O
K O
9 O
and O
R O
8 O
, O
seems O
to O
play O
an O
important O
role O
in O
complex O
stabilization O
, O
as O
mutation B
into I
alanine I
results O
in O
a O
strong O
enthalpic O
penalty O
, O
associated O
to O
a O
20 O
- O
fold O
reduction O
in O
binding O
affinity O
( O
Table O
2 O
) O
. O

In O
addition O
, O
one O
lipodystrophy O
- O
associated O
missense O
mutation O
has O
been O
described O
, O
causing O
substitution B
of I
alanine I
at I
codon I
212 I
for I
proline I
( O
4 O
) O
. O

Consistent O
with O
our O
Western O
blot O
data O
, O
R O
275 O
X O
- O
BSCL O
2 O
was O
undetectable O
by O
immunofluorescence O
( O
data O
not O
shown O
) O
. O

Analysis O
of O
naturally O
occurring O
pathogenic O
mutants O
of O
BSCL O
2 O
. O

A O
: O
Murine O
C O
3 O
H O
10 O
T O
1 O
/ O
2 O
pluripotent O
cells O
were O
transfected O
with O
empty O
vector O
( O
mock O
) O
, O
myc O
- O
tagged O
wild O
- O
type O
human O
BSCL O
2 O
( O
WT O
) O
, O
or O
myc O
- O
tagged O
wild O
- O
type O
human O
BSCL O
2 O
prematurely O
truncated B
at I
amino I
acid I
R I
275 I
( O
R O
275 O
X O
) O
or O
bearing O
a O
point O
mutation O
causing O
amino O
acid O
substitution O
A O
212 O
P O
. O

One O
of O
the O
mutations O
was O
the O
4 B
- I
bp I
deletion I
at I
nucleotides I
668 I
- I
671 I
, O
resulting O
in O
frameshift O
and O
truncation O
of O
the O
protein O
. O

The O
other O
was O
a O
nucleotide O
substitution O
leading O
to O
Ser B
- I
541 I
to I
Arg I
( O
S O
541 O
R O
) O
in O
helicase O
domain O
IV O
of O
the O
XPD O
protein O
. O

Thus O
, O
the O
parents O
were O
obligate O
carriers O
of O
the O
XP O
- O
D O
trait O
. O

Genetic O
factors O
influence O
alcohol O
consumption O
and O
alcoholism O
. O

When O
compared O
to O
Aldh O
21 O
of O
Sprague O
- O
Dawley O
, O
94 O
% O
of O
the O
UCh O
A O
( O
low O
drinker O
) O
rats O
( O
n O
= O
61 O
) O
, O
presented O
a O
mutation O
that O
changes O
Gln B
67 I
to I
Arg I
in O
the O
mature O
enzyme O
( O
allele O
referred O
to O
as O
Aldh O
22 O
) O
. O

In O
UCh O
B O
( O
high O
drinker O
) O
rats O
( O
n O
= O
69 O
) O
, O
58 O
% O
presented O
the O
Aldh O
21 O
allele O
, O
while O
42 O
% O
presented O
the O
Gln O
67 O
Arg O
change O
plus O
a O
second O
mutation O
that O
changed O
Glu B
479 I
to I
Lys I
( O
allele O
Aldh O
23 O
) O
. O

We O
detected O
point O
mutations O
in O
two O
cases O
by O
screening O
using O
polymerase O
chain O
reaction O
- O
single O
strand O
conformation O
polymorphism O
analysis O
. O

When O
we O
determined O
the O
sequences O
, O
one O
case O
with O
lymph O
node O
metastasis O
showed O
an O
ATG B
( I
Met I
) I
to I
ACG I
( I
Thr I
) I
missense I
mutation I
in I
codon I
168 I
. O

Another O
case O
showed O
a O
CGA B
( I
Arg I
) I
to I
GGA I
( I
Gly I
) I
mutation I
in I
codon I
201 I
, O
which O
might O
be O
a O
polymorphic O
change O
, O
and O
two O
other O
mutations O
resulting O
in O
no O
amino O
acid O
change O
. O

RT O
– O
PCR O
analysis O
for O
BRCA O
2 O
R O
2336 O
H O
in O
the O
last O
codon O
of O
exon O
13 O
was O
not O
yet O
described O
and O
revealed O
the O
wild O
- O
type O
allele O
and O
three O
smaller O
transcripts O
, O
representing O
a O
complete O
loss B
of I
exon I
13 I
, O
loss B
of I
exon I
12 I
and O
loss B
of I
exons I
12 I
and I
13 I
. O

RT O
– O
PCR O
on O
RNA O
from O
the O
patient O
carrying O
BRCA O
2 O
R O
2336 O
H O
( O
lane O
1 O
) O
showed O
a O
full O
- O
length O
fragment O
of O
767 O
bp O
and O
three O
faster O
migrating O
bands O
( O
697 B
bp I
: I
skipping I
of I
out I
of I
frame I
exon I
13 I
( I
stop I
2345 I
) I
; O
671 B
bp I
: I
skipping I
of I
in I
- I
frame I
exon I
12 I
( I
deletion I
of I
32 I
amino I
acids I
) I
; O
601 B
bp I
: I
skipping I
of I
out I
of I
frame I
exons I
12 I
and I
13 I
( I
stop I
2311 I
) I
) O
. O

The O
deletion B
of I
BRCA I
1 I
exon I
22 I
, O
the O
most O
recurrent O
Dutch O
mutation O
, O
was O
identified O
in O
one O
Belgian O
patient O
with O
a O
Dutch O
mother O
. O

The O
BRCA O
1 O
exon O
13 O
6 O
- O
kb O
duplication O
, O
a O
mutation O
likely O
to O
be O
derived O
from O
a O
British O
ancestor O
( O
The O
BRCA O
1 O
Exon O
13 O
Duplication O
Screening O
group O
, O
2000 O
) O
, O
was O
found O
once O
. O

In O
this O
study O
, O
we O
have O
investigated O
for O
the O
first O
time O
the O
molecular O
basis O
of O
beta O
- O
ETF O
deficiency O
in O
three O
GAII O
patients O
: O
two O
Japanese O
brothers O
, O
P O
411 O
and O
P O
412 O
, O
and O
a O
third O
unrelated O
patient O
, O
P O
485 O
. O

One O
allele O
is O
carrying O
a O
G B
to I
A I
transition I
at I
nucleotide I
518 I
, O
causing O
a O
missense B
mutation I
at I
codon I
164 I
. O

The O
other O
allele O
carries O
a O
G B
to I
C I
transversion I
at I
the I
first I
nucleotide I
of I
the I
intron I
donor I
site I
, O
downstream O
of O
an O
exon O
that O
is O
skipped O
during O
the O
splicing O
event O
. O

The O
sequence O
analysis O
of O
the O
beta O
- O
ETF O
coding O
sequence O
in O
P O
485 O
showed O
only O
a O
C B
to I
T I
transition I
at I
nucleotide I
488 I
that O
causes O
a O
Thr B
154 I
to I
Met I
substitution O
and O
the O
elimination O
of O
a O
Hga O
I O
restriction O
site O
. O

Changing O
the O
conserved O
residue O
His B
- I
16 I
either I
to I
Cys I
or I
to I
Val I
in O
a O
proposed O
zinc O
- O
finger O
region O
had O
minimal O
effect O
on O
IN O
activities O
. O

Two O
mutants O
, O
Asp O
- O
64 O
- O
- O
> O
Val O
and O
Arg O
- O
199 O
- O
- O
> O
Cys O
delta O
, O
each O
demonstrated O
differential O
effects O
on O
IN O
activities O
. O

Replacement B
of I
Ile I
( I
- I
3 I
) I
in I
eye I
- I
PKC I
with I
charged I
residues I
resulted O
in O
a O
drastic O
reduction O
of O
the O
PDZ O
2 O
interaction O
. O

Substitution O
of O
a O
conserved O
His B
with I
Arg I
at I
the I
second I
alpha I
- I
helix I
of I
PDZ I
2 I
led O
to O
a O
reduced O
binding O
; O
however O
, O
a O
Leu B
replacement I
resulted O
in O
an O
enhanced O
eye O
- O
PKC O
association O
. O

Translation O
of O
coding O
sequences O
from O
three O
wild O
- O
type O
alleles O
revealed O
three B
SNPs I
affecting I
residues I
, I
282 I
, I
319 I
, I
and I
333 I
of O
INAD O
. O

In O
summary O
, O
we O
evaluated O
the O
molecular O
basis O
of O
the O
eye O
- O
PKC O
and O
PDZ O
2 O
association O
by O
mutational O
analysis O
and O
concluded O
that O
PDZ O
2 O
of O
INAD O
is O
a O
type O
I O
domain O
important O
for O
the O
eye O
- O
PKC O
interaction O
. O

Functional O
role O
of O
a O
conserved O
motif O
in O
TM O
6 O
of O
the O
rat O
mu O
opioid O
receptor O
: O
constitutively O
active O
and O
inactive O
receptors O
result O
from O
substitutions B
of I
Thr I
6 I
. I
34 I
( I
279 I
) I
with I
Lys I
and I
Asp I
. O

In O
this O
study O
, O
T B
6 I
. I
34 I
( I
279 I
) I
at I
the I
X I
3 I
locus I
of I
the I
rat I
mu I
opioid I
receptor I
was I
mutated I
to I
Lys I
and I
Asp I
, O
and O
the O
mutants O
were O
examined O
for O
binding O
and O
signaling O
properties O
. O

This O
construct O
exhibited O
properties O
identified O
previously O
with O
constitutive O
activation O
: O
( O
1 O
) O
compared O
with O
the O
wild O
type O
, O
it O
produced O
much O
higher O
agonist O
- O
independent O
[ O
35 O
S O
] O
GTPgamma O
S O
binding O
, O
which O
was O
abolished O
by O
pertussis O
toxin O
treatment O
; O
( O
2 O
) O
it O
displayed O
an O
enhanced O
affinity O
for O
the O
agonist O
DAMGO O
similar O
to O
that O
of O
the O
high O
- O
affinity O
state O
of O
the O
wild O
type O
, O
which O
was O
not O
altered O
by O
GTPgamma O
S O
, O
while O
having O
unchanged O
affinity O
for O
the O
antagonist O
diprenorphine O
. O

The O
mutations B
on I
positions I
256 I
and I
267 I
strongly O
altered O
the O
interaction O
of O
the O
permeation O
pathway O
with O
external O
Ca O
2 O
+ O
ions O
. O

Point B
mutations I
on I
position I
256 I
in O
KAT O
1 O
affected O
the O
affinity O
towards O
Ca O
2 O
+ O
, O
the O
voltage O
dependence O
as O
well O
as O
kinetics O
of O
the O
Ca O
2 O
+ O
blocking O
reaction O
. O

Among O
these O
T O
256 O
S O
showed O
a O
Ca O
2 O
+ O
phenotype O
reminiscent O
of O
an O
inactivation O
- O
like O
process O
, O
a O
phenomenon O
unknown O
for O
K O
( O
in O
) O
channels O
so O
far O
. O

Mutating O
histidine B
267 I
to I
alanine I
, O
a O
substitution O
strongly O
affecting O
C O
- O
type O
inactivation O
in O
Shaker O
, O
this O
apparent O
inactivation O
could O
be O
linked O
to O
a O
very O
slow O
calcium O
block O
. O

The O
valine B
226 I
substitution I
has O
been O
identified O
in O
five O
patients O
with O
a O
Kim O
variant O
phenotype O
from O
Japan O
/ O
Korea O
. O

( O
c O
) O
Quantification O
of O
presence O
or O
absence O
of O
H O
3 O
K O
9 O
me O
3 O
signal O
in O
the O
Suv O
39 O
h O
1 O
- O
positive O
cells O
( O
left O
panel O
) O
, O
and O
punctate O
PCH O
localization O
or O
diffused O
distribution O
of O
Atrx O
( O
right O
panel O
) O
. O

( O
f O
) O
Deletion B
of I
Px I
Vx I
L I
motif I
resulted O
in O
partial O
loss O
of O
PCH O
localization O
. O

Histone O
H O
3 O
Ala O
1 O
– O
Ser O
10 O
containing O
K O
9 O
me O
3 O
modification O
is O
depicted O
as O
yellow O
sticks O
. O

R O
2 O
A O
, O
K O
4 O
A O
, O
K O
9 O
A O
: O
Arg O
2 O
, O
Lys O
4 O
, O
Lys B
9 I
to I
alanine I
substitution I
, O
respectively O
; O
AAH O
3 O
: O
H O
3 O
N O
- O
terminal O
double O
alanine O
extension O
; O
R O
2 O
me O
2 O
s O
: O
Arg O
2 O
symmetrical O
dimethylation O
; O
R O
2 O
me O
2 O
a O
: O
Arg O
2 O
asymmetrical O
dimethylation O
; O
K O
9 O
me O
3 O
: O
Lys O
9 O
trimethylation O
; O
K O
9 O
ac O
: O
Lys O
9 O
acetylation O
; O
n O
. O
d O
. O
, O
not O
determined O
. O

A O
synthetic O
microsatellite O
( O
16 O
. O
5 O
copies O
of O
the O
GT O
dinucleotide O
) O
was O
placed O
in O
frame O
with O
the O
URA O
3 O
gene O
and O
integrated O
at O
ten O
locations O
across O
the O
yeast O
genome O
and O
loss O
- O
of O
- O
function O
ura O
3 O
mutants O
were O
selected O
by O
growth O
on O
5 O
- O
fluoro O
- O
orotic O
acid O
( O
5 O
FOA O
) O
( O
Hawk O
et O
al O
. O

These O
ten O
strains O
show O
a O
16 O
- O
fold O
difference O
in O
the O
mutation O
rate O
to O
5 O
FOA O
resistance O
, O
and O
the O
majority O
of O
these O
mutations O
resulted O
from O
frameshift B
mutations I
within I
the I
poly I
GT I
tract I
( O
not O
mutations O
in O
the O
URA O
3 O
coding O
sequence O
) O
. O

The O
URA O
3 O
sequence O
of O
p O
GIL O
001 O
differs O
from O
the O
published O
genomic O
sequence O
for O
URA O
3 O
by O
eight O
mutations O
. O

One O
mutation O
( O
an B
insertion I
of I
a I
T I
to I
a I
run I
of I
seven I
T I
' I
s I
in I
the I
promoter I
region I
) O
was O
created O
during O
the O
construction O
of O
this O
plasmid O
. O

Only O
one O
of O
these O
seven O
mutations O
is O
in O
the O
coding O
sequence O
and O
results O
in O
the O
substitution B
of I
serine I
for I
alanine I
at I
position I
160 I
. O

Plasmid O
p O
GIL O
008 O
was O
constructed O
to O
facilitate O
deletion B
of I
ARS I
607 I
. O

To O
manipulate O
replication O
timing O
, O
a O
two O
- O
step O
method O
was O
used O
in O
order O
to O
create O
a O
clean O
deletion B
of I
the I
early I
and I
efficient I
origin I
, I
ARS I
607 I
( O
supplementary O
fig O
. O

Deletion B
of I
ARS I
607 I
was O
determined O
by O
PCR O
using O
primers O
ARS O
607 O
ext O
_ O
F O
1 O
and O
ARS O
607 O
ext O
_ O
R O
1 O
, O
which O
flank O
the O
ARS O
607 O
sequence O
. O

Following O
popout O
of O
URA O
3 O
at O
the O
deleted B
ARS I
607 I
locus O
, O
the O
URA O
3 O
gene O
was O
integrated O
in O
place O
of O
the O
Kan O
MX O
4 O
cassette O
to O
create O
the O
strain O
GL O
· O
36 O
ARS O
607 O
Δ O
. O

Deletion B
of I
REV I
1 I
was O
verified O
phenotypically O
by O
assaying O
for O
UV O
sensitivity O
and O
by O
PCR O
using O
primers O
REV O
1 O
int O
F O
1 O
/ O
REV O
1 O
ext O
R O
3 O
and O
Kan O
MXint O
F O
/ O
REV O
1 O
ext O
R O
3 O
. O

A O
green O
arrow O
above O
the O
mutation O
rate O
plot O
indicates O
the O
locations O
selected O
to O
test O
mutation O
rate O
following O
the O
deletion B
of I
rev I
1 I
( O
see O
fig O
. O

ARS O
601 O
and O
ARS O
602 O
overlap O
and O
comprise O
one O
origin O
; O
ARS O
600 O
and O
ARS O
610 O
are O
subtelomeric O
. O

ARS B
605 I
, I
ARS I
606 I
, I
and I
ARS I
608 I
are I
deleted I
in O
strains O
GL O
· O
25 O
, O
GL O
· O
31 O
, O
and O
GL O
· O
39 O
, O
respectively O
. O

Disruption B
of I
ARS I
605 I
should O
have O
a O
small O
effect O
due O
to O
its O
close O
proximity O
to O
earlier O
firing O
ARS O
603 O
. O
5 O
. O

Strain O
GL O
· O
31 O
was O
not O
used O
in O
the O
analysis O
because O
it O
affected O
growth O
on O
5 O
FOA O
( O
see O
Materials O
and O
Methods O
) O
; O
however O
, O
interestingly O
, O
this O
strain O
had O
a O
high O
mutation O
rate O
( O
6 O
. O
5 O
× O
10 O
− O
8 O
) O
compared O
with O
other O
URA O
3 O
reporters O
in O
the O
same O
region O
, O
which O
may O
be O
partly O
attributable O
to O
disruption B
of I
ARS I
606 I
. O

To O
test O
if O
disruption O
of O
an O
origin O
of O
replication O
can O
increase O
the O
local O
mutation O
rate O
in O
an O
early O
- O
replicating O
/ O
low O
mutation O
rate O
region O
, O
the O
earliest O
and O
most O
efficient O
origin O
, O
ARS B
607 I
, I
was I
deleted I
in O
strain O
GL O
· O
36 O
, O
where O
the O
URA O
3 O
gene O
is O
located O
3 O
kb O
away O
from O
the O
origin O
. O

Deletion B
of I
ARS I
607 I
increased O
the O
mutation O
rate O
at O
URA O
3 O
by O
30 O
% O
( O
from O
2 O
. O
21 O
× O
10 O
− O
7 O
to O
2 O
. O
88 O
× O
10 O
− O
7 O
) O
without O
increasing O
the O
mutation O
rate O
at O
CAN O
1 O
( O
0 O
. O
81 O
× O
10 O
− O
7 O
in O
GL O
· O
36 O
and O
0 O
. O
76 O
× O
10 O
− O
7 O
in O
GL O
· O
36 O
ARS O
607 O
Δ O
) O
. O

It O
is O
possible O
that O
deletion B
of I
ARS I
607 I
did O
not O
significantly O
delay O
replication O
timing O
in O
the O
region O
. O

We O
deleted B
the I
REV I
1 I
gene O
from O
four O
strains O
( O
two O
early O
- O
replicating O
/ O
low O
mutation O
rate O
and O
two O
late O
- O
replicating O
/ O
elevated O
mutation O
rate O
) O
. O

To O
test O
the O
hypothesis O
that O
the O
correlation O
between O
replication O
time O
and O
mutation O
rate O
is O
due O
to O
the O
temporal O
separation O
of O
template O
switching O
and O
translesion O
synthesis O
, O
REV O
1 O
( O
which O
encodes O
a O
translesion O
polymerase O
essential O
for O
translesion O
synthesis O
) O
was B
deleted I
in O
four O
strains O
that O
show O
variation O
in O
mutation O
rate O
and O
replication O
timing O
. O

This O
model O
, O
in O
turn O
, O
provides O
an O
explanation O
for O
the O
observation O
that O
early O
- O
replicating O
regions O
have O
a O
low O
mutation O
rate O
and O
late O
replication O
regions O
have O
a O
high O
mutation O
rate O
: O
Damaged O
bases O
in O
late O
- O
replicating O
regions O
are O
more O
likely O
to O
be O
subjected O
to O
mutagenic O
translesion O
synthesis O
than O
similar O
lesions O
in O
early O
- O
replicating O
regions O
. O

In O
support O
of O
this O
model O
, O
we O
show O
that O
deleting B
the I
translesion I
polymerase I
REV I
1 I
lowers O
the O
mutation O
specifically O
in O
late O
- O
replicating O
/ O
high O
mutation O
rate O
regions O
. O

The O
variation O
in O
mutation O
rate O
for O
the O
t O
RNA O
suppressor O
mutations O
can O
also O
be O
explained O
as O
variation O
in O
the O
effectiveness O
of O
mismatch O
repair O
. O

Ochre O
suppressors O
arise O
by O
a O
GC B
to I
TA I
transversion I
in I
the I
anticodon I
of I
t I
RNA I
- I
Tyr I
. O

Sequencing O
FRMD O
7 O
revealed O
a O
G O
> O
T O
transversion O
( O
c O
. O
812 O
G O
> O
T O
) O
in O
exon O
9 O
, O
which O
caused O
a O
conservative O
substitution B
of I
Cys I
to I
Phe I
at I
codon I
271 I
( O
p O
. O
C O
271 O
F O
) O
. O

Sequence O
analysis O
revealed O
a O
G B
> I
T I
transversion I
in I
exon I
9 I
( O
Figure O
3 O
) O
that O
caused O
a O
conservative O
substitution B
of I
Cys I
to I
Phe I
at I
codon I
271 I
( O
p O
. O
C O
271 O
F O
) O
. O

There O
is O
a O
single O
base O
G B
> I
T I
transversion I
in I
exon I
9 I
of O
FRMD O
7 O
that O
causes O
a O
conservative O
substitution B
of I
Cys I
to I
Phe I
at I
codon I
271 I
( O
p O
. O
C O
271 O
F O
) O
. O

The O
software O
determined O
that O
the O
substitution B
of I
Cys I
to I
Phe I
at I
position I
271 I
was O
deleterious O
. O

Among O
these O
22 O
mutations O
, O
a O
missense B
mutation I
of I
C I
271 I
Y I
in I
exon I
9 I
was O
detected O
in O
a O
Scottish O
family O
. O

In O
our O
study O
, O
the O
p O
. O
C O
271 O
F O
mutation O
is O
responsible O
for O
this O
disease O
. O

Class O
II O
AP O
endonucleases O
play O
a O
major O
role O
in O
the O
repair O
of O
abasic O
sites O
as O
well O
as O
of O
3 O
′ O
- O
modified O
termini O
. O

Mutation O
of O
the O
active O
- O
site O
residue O
Asp B
277 I
to I
Ala I
in O
Ape O
2 O
inactivates O
all O
these O
activities O
. O

We O
also O
made O
a O
similar O
construct O
expressing O
the O
Ape O
2 O
D O
277 O
A O
protein O
containing O
a O
point B
mutation I
at I
the I
D I
277 I
residue I
, O
which O
corresponds O
to O
a O
conserved O
metal O
- O
binding O
site O
in O
the O
active O
center O
of O
class O
II O
AP O
endonucleases O
( O
21 O
) O
( O
Figure O
1 O
A O
) O
. O

To O
confirm O
that O
the O
observed O
3 O
′ O
- O
exonuclease O
, O
3 O
′ O
- O
phosphodiesterase O
and O
the O
extremely O
weak O
AP O
- O
endonuclease O
activities O
are O
intrinsic O
to O
Ape O
2 O
, O
we O
also O
purified O
a O
mutant O
Ape O
2 O
protein O
, O
in O
which O
we O
altered O
the O
conserved O
Asp B
277 I
residue I
to I
Ala I
. O

To O
identify O
causative O
mutations O
for O
WWS O
, O
we O
previously O
performed O
homozygosity O
mapping O
in O
30 O
families O
with O
idiopathic O
WWS O
using O
the O
Affymetrix O
Gene O
Chip O
Human O
Mapping O
SNP O
Array O
( O
21 O
) O
. O

In O
one O
of O
these O
families O
( O
WWS O
- O
31 O
) O
, O
the O
homozygous O
region O
was O
delimited O
by O
SNP B
_ I
A I
- I
4215126 I
at I
11 I
q I
13 I
. I
1 I
and O
SNP B
_ I
A I
- I
2154685 I
at I
11 I
q I
13 I
. I
3 I
( O
UCSC O
hg O
19 O
database O
, O
http O
: O
/ O
/ O
genome O
. O
ucsc O
. O
edu O
, O
last O
accessed O
date O
on O
30 O
January O
, O
2013 O
) O
, O
representing O
a O
5 O
. O
24 O
Mb O
haplotype O
that O
was O
shared O
among O
the O
three O
affected O
individuals O
but O
different O
from O
that O
in O
an O
unaffected O
sibling O
. O

These O
studies O
revealed O
three O
heterozygous B
overlapping I
deletions I
solely I
affecting I
the I
forkhead I
box I
P I
1 I
( O
FOXP O
1 O
) O
gene O
. O

All O
three O
patients O
had O
moderate O
mental O
retardation O
and O
significant O
language O
and O
speech O
deficits O
. O

Since O
our O
results O
are O
consistent O
with O
a O
de O
novo O
occurrence O
of O
these O
deletions O
, O
we O
considered O
them O
as O
causal O
although O
we O
detected O
a O
single B
large I
deletion I
including O
FOXP O
1 O
and O
additional O
genes O
in O
4104 O
ancestrally O
matched O
controls O
. O

Copy O
number O
analysis O
revealed O
overlapping O
deletions B
at I
chromosome I
3 I
p I
14 I
. I
1 I
affecting O
solely O
the O
FOXP O
1 O
gene O
in O
three O
unrelated O
cases O
, O
two O
males O
and O
one O
female O
aged O
between O
5 O
. O
5 O
to O
7 O
years O
. O

Characterization O
of O
the O
breakpoints O
was O
achieved O
by O
amplification O
and O
sequencing O
of O
the O
respective O
junction O
fragments O
( O
Gen O
Bank O
EF O
504249 O
, O
HM O
124444 O
, O
and O
GU O
980955 O
; O
Figure O
1 O
C O
) O
. O

( O
A O
) O
Schematic O
presentation O
of O
the O
position O
and O
size O
of O
the O
deleted B
regions I
( I
grey I
bars I
) I
at I
chromosome I
3 I
p I
14 I
. I
1 I
in O
three O
patients O
with O
MR O
and O
in O
a O
control O
individual O
. O

To O
assess O
the O
significance O
of O
these O
findings O
, O
we O
checked O
the O
FOXP O
1 O
region O
for O
CNVs O
in O
the O
Database O
of O
Genomic O
Variants O
( O
DGV O
) O
( O
Iafrate O
, O
et O
al O
. O
, O
2004 O
) O
and O
in O
4104 O
ancestrally O
matched O
controls O
which O
have O
been O
investigated O
with O
different O
types O
of O
high O
- O
density O
SNP O
arrays O
containing O
at O
least O
500 O
, O
000 O
SNPs O
( O
Supp O
. O

Copy O
number O
analysis O
in O
the O
4104 O
control O
individuals O
revealed O
the O
presence O
of O
a O
single B
large I
3 I
p I
14 I
. I
1 I
p I
13 I
deletion I
of O
approximately O
1 O
. O
3 O
Mb O
affecting O
FOXP O
1 O
, O
EIF O
4 O
E O
3 O
( O
MIM O
# O
609896 O
) O
, O
PROK O
2 O
( O
MIM O
# O
607002 O
) O
and O
GPR O
27 O
( O
MIM O
# O
605187 O
) O
in O
an O
individual O
of O
the O
LLI O
study O
, O
with O
no O
indications O
of O
a O
comparable O
MR O
phenotype O
. O

This O
is O
the O
first O
report O
of O
3 B
p I
14 I
. I
1 I
deletions I
that O
solely O
affect O
the O
FOXP O
1 O
gene O
in O
three O
unrelated O
patients O
with O
moderate O
mental O
retardation O
in O
combination O
with O
a O
significant O
impairment O
of O
speech O
and O
language O
abilities O
. O

We O
investigated O
a O
large O
control O
population O
and O
the O
apparent O
finding O
of O
a O
large O
3 B
p I
14 I
. I
1 I
p I
13 I
deletion I
in O
this O
cohort O
affecting O
FOXP O
1 O
and O
further O
genes O
illustrates O
the O
difficulties O
to O
assess O
the O
significance O
of O
rare O
mutational O
events O
in O
extremely O
heterogeneous O
diseases O
and O
may O
point O
to O
incomplete O
penetrance O
. O

As O
our O
patients O
did O
not O
show O
any O
of O
the O
other O
clinical O
signs O
like O
contractures O
, O
hypertonia O
and O
blepharophimosis O
, O
present O
in O
the O
boy O
carrying O
the O
larger O
3 B
p I
14 I
. I
1 I
p I
13 I
deletion I
( O
Pariani O
, O
et O
al O
. O
, O
2009 O
) O
, O
these O
might O
rather O
be O
caused O
by O
the O
haploinsufficiency O
of O
the O
additionally O
affected O
genes O
. O

This O
change O
resulted O
in O
the O
substitution B
of I
a I
highly I
conserved I
cysteine I
for I
tyrosine I
at I
amino I
acid I
450 I
. O

Although O
we O
did O
not O
identify O
a O
mutation O
in O
the O
human O
CCT O
4 O
gene O
in O
a O
set O
of O
HSN O
patients O
, O
this O
result O
clearly O
demonstrates O
the O
pathological O
consequences O
of O
a O
defect O
in O
Cct O
4 O
, O
a O
subunit O
of O
CCT O
( O
cytosolic O
chaperonin O
- O
containing O
t O
- O
complex O
peptide O
- O
1 O
) O
, O
involved O
in O
folding O
tubulin O
, O
actin O
and O
other O
cytosolic O
proteins O
. O

In O
Abcg O
8 O
, O
a O
large O
insertional O
polymorphism O
was O
identified O
in O
exon O
13 O
, O
that O
resulted O
in O
the O
insertion B
of I
143 I
nucleotides I
in I
the I
3 I
' I
UTR I
( I
* I
2099 I
_ I
2100 I
ins I
143 I
nt I
) I
. O

In O
view O
of O
this O
, O
the O
Gly O
583 O
Cys O
missense O
mutation O
of O
Abcg O
5 O
might O
result O
from O
occurrence O
of O
a O
de O
novo O
mutation O
during O
breeding O
at O
the O
stage O
of O
developing O
inbred O
WKY O
strains O
and O
propagated O
into O
the O
SHR O
and O
SHRSP O
lines O
. O

In O
contrast O
, O
the O
143 B
nucleotide I
fragment I
insertion I
polymorphism I
in I
the I
3 I
' I
- I
UTR I
of O
Abcg O
8 O
may O
have O
resulted O
from O
acquisition O
of O
a O
foreign O
chromosomal O
fragment O
during O
the O
Wistar O
rat O
strain O
breeding O
and O
established O
as O
homozygous O
change O
in O
the O
WKY O
, O
SHR O
and O
SHRSP O
, O
as O
well O
as O
GH O
rat O
strains O
. O

To O
assess O
a O
role O
of O
each O
of O
these O
residues O
, O
we O
have O
expressed O
, O
purified O
, O
and O
characterized O
enzymes O
with O
the O
point B
mutations I
of O
putative O
active O
site O
residues O
( O
His O
311 O
, O
Asn O
312 O
, O
Glu O
341 O
, O
Asp O
343 O
, O
His O
356 O
, O
Glu O
390 O
, O
Lys O
438 O
, O
Lys O
440 O
, O
Ser O
522 O
, O
Arg O
549 O
, O
and O
Tyr O
551 O
) O
and O
residues O
from O
the O
hydrophobic O
ridge O
( O
Leu O
320 O
, O
Phe O
360 O
, O
and O
Trp O
555 O
) O
. O

The O
replacements B
of I
most I
active I
site I
residues I
by I
alanine I
resulted O
in O
a O
great O
reduction O
( O
1 O
, O
000 O
- O
200 O
, O
000 O
- O
fold O
) O
of O
PLC O
activity O
analyzed O
in O
an O
inositol O
lipid O
/ O
sodium O
cholate O
mixed O
micelle O
assay O
. O

Measurements O
of O
the O
enzyme O
activity O
toward O
phosphatidylinositol O
, O
phosphatidylinositol O
4 O
- O
monophosphate O
, O
and O
phosphatidylinositol O
4 O
, O
5 O
- O
bis O
- O
phosphate O
( O
PIP O
2 O
) O
identified O
Ser O
522 O
, O
Lys O
438 O
, O
and O
Arg O
549 O
as O
important O
for O
preferential O
hydrolysis O
of O
polyphosphoinositides O
, O
whereas O
replacement B
of I
Lys I
440 I
selectively O
affected O
only O
hydrolysis O
of O
PIP O
2 O
. O

When O
PLC O
activity O
was O
analyzed O
at O
different O
calcium O
concentrations O
, O
substitutions B
of I
Asn I
312 I
, I
Glu I
390 I
, I
Glu I
341 I
, I
and I
Asp I
343 I
resulted O
in O
a O
shift O
toward O
higher O
calcium O
concentrations O
required O
for O
PIP O
2 O
hydrolysis O
, O
suggesting O
that O
all O
these O
residues O
contribute O
toward O
Ca O
2 O
+ O
binding O
. O

C O
: O
Amino O
acid O
conservation O
map O
across O
species O
demonstrating O
that O
glycine B
at I
position I
603 I
is O
conserved O
lower O
down O
to O
sticklebacks O
and O
zebrafish O
. O

The O
novel O
c O
. O
1807 O
G O
> O
C O
change O
was O
not O
seen O
in O
360 O
control O
chromosomes O
, O
and O
the O
glycine B
at I
position I
603 I
is O
conserved O
in O
lower O
vertebrates O
such O
as O
stickleback O
and O
zebrafish O
( O
UCSC O
Conservation O
track O
; O
Figure O
1 O
C O
) O
. O

The O
p O
. O
G O
603 O
R O
was O
predicted O
to O
be O
possibly O
damaging O
by O
Polyphen O
v O
. O
2 O
. O
09 O
with O
a O
PSIC O
score O
difference O
of O
1 O
. O
525 O
. O

The O
first O
point O
mutation O
( O
A B
to I
T I
) I
was I
detected I
at I
the I
Xho I
I I
site I
, O
changing O
a O
threonine O
( O
ACG O
) O
to O
a O
serine O
( O
TCG O
) O
, O
and O
the O
second O
point B
mutation I
( I
A I
to I
G I
) I
was O
discovered O
in O
the O
vicinity O
of O
the O
first O
one O
, O
changing O
an O
isoleucine O
( O
ATA O
) O
to O
a O
methionine O
( O
ATG O
) O
. O

These O
amino O
acid O
substitutions O
, O
situated O
in O
the O
putative O
catalytic O
X O
domain O
of O
PLC O
- O
delta O
, O
may O
be O
the O
major O
cause O
of O
the O
augmented O
PLC O
activity O
observed O
in O
the O
SHR O
, O
possibly O
leading O
to O
hypertension O
- O
related O
phenonemoma O
such O
as O
abnormal O
calcium O
homeostasis O
and O
increased O
intracellular O
calcium O
ion O
concentrations O
. O

On O
the O
basis O
of O
our O
findings O
that O
mutations O
of O
T B
6 I
. I
34 I
( I
279 I
) I
to I
K I
and I
D I
produced O
, O
respectively O
, O
a O
constitutively O
active O
and O
an O
inactive O
form O
of O
the O
mu O
opioid O
receptor O
, O
we O
previously O
suggested O
that O
the O
functional O
role O
of O
the O
6 O
. O
30 O
( O
275 O
) O
residue O
could O
be O
assumed O
by O
T O
6 O
. O
34 O
( O
279 O
) O
, O
but O
the O
interplay O
between O
residues O
at O
positions O
6 O
. O
30 O
and O
6 O
. O
34 O
remained O
unresolved O
. O

In O
this O
study O
, O
we O
examined O
the O
effects O
of O
introducing B
an I
E I
in I
position I
6 I
. I
30 I
( I
275 I
) I
of O
the O
wild O
type O
( O
WT O
) O
and O
of O
the O
T O
6 O
. O
34 O
( O
279 O
) O
mutants O
of O
the O
mu O
opioid O
receptor O
to O
compare O
the O
participation O
of O
the O
6 O
. O
30 O
locus O
in O
molecular O
events O
during O
activation O
in O
this O
receptor O
with O
its O
role O
in O
other O
GPCRs O
. O

When O
L B
6 I
. I
30 I
( I
275 I
) I
is I
mutated I
to I
E I
, O
the O
favorable O
E O
6 O
. O
30 O
( O
275 O
) O
- O
R O
3 O
. O
50 O
( O
165 O
) O
interaction O
stabilizes O
an O
inactive O
state O
, O
as O
in O
rhodopsin O
, O
and O
hence O
reduces O
the O
activities O
of O
T O
6 O
. O
34 O
( O
279 O
) O
mutants O
. O

Our O
molecular O
modeling O
results O
suggest O
that O
some O
specific O
differences O
in O
local O
geometry O
at O
the O
cytoplasmic O
ends O
of O
TM O
5 O
and O
TM O
6 O
may O
account O
in O
part O
for O
the O
observed O
differences O
in O
the O
molecular O
mechanisms O
of O
receptor O
activation O
. O

Here O
we O
demonstrate O
that O
lfm O
( O
3 O
) O
7 O
contains O
a O
nonsense O
mutation B
within I
codon I
355 I
of O
the O
act O
88 O
F O
actin O
gene O
. O

A O
single B
G I
greater I
than I
A I
transition I
converts I
a I
tryptophan I
( I
TGG I
) I
codon I
to I
an I
opal I
( I
TGA I
) I
terminator I
, O
thus O
deleting B
the I
carboxy I
- I
terminal I
20 I
amino I
acids I
of O
an O
actin O
isoform O
that O
accumulates O
only O
in O
thoracic O
flight O
muscles O
. O

A O
non O
- O
synonymous O
coding O
change O
was O
identified O
in O
a O
single O
proband O
, O
yielding O
a O
proline B
- I
to I
- I
alanine I
change I
( O
P O
215 O
A O
) O
. O

We O
conclude O
that O
FOXP O
1 O
mutations O
are O
unlikely O
to O
represent O
a O
major O
cause O
of O
DVD O
. O

FOXP O
1 O
consists O
of O
16 O
coding O
exons O
spanning O
∼ O
586 O
kb O
on O
3 O
p O
14 O
. O
1 O
( O
Figure O
1 O
a O
) O
. O

This O
change O
constituted O
a O
heterozygous B
C I
- I
to I
- I
G I
transversion I
, O
yielding O
a O
proline B
- I
to I
- I
alanine I
substitution I
at I
position I
215 I
of O
the O
encoded O
protein O
. O

The O
same O
heterozygous B
C I
- I
to I
- I
G I
change I
was O
identified O
in O
a O
single O
chromosome O
within O
the O
controls O
( O
Figure O
1 O
b O
) O
. O

A O
heterozygous B
C I
- I
to I
- I
A I
transversion I
in I
the I
intron I
downstream I
of I
exon I
15 I
( O
Figure O
1 O
, O
Table O
1 O
) O
was O
found O
in O
10 O
of O
the O
49 O
probands O
( O
an O
SNP O
frequency O
of O
∼ O
10 O
% O
) O
. O

The O
resulting O
substitution O
( O
P O
215 O
A O
) O
replaced B
a I
proline I
with I
an I
alanine I
in I
the I
region I
encoded I
by I
exon I
5 I
. O

Although O
a O
proline O
may O
sometimes O
enhance O
structural O
stability O
( O
eg O
, O
as O
the O
first O
residue O
of O
an O
α O
- O
helix O
) O
, O
it O
often O
disrupts O
the O
secondary O
structure O
( O
eg O
, O
when O
located O
internally O
within O
an O
α O
- O
helix O
or O
a O
β O
- O
sheet O
) O
. O
17 O
Thus O
, O
P O
215 O
could O
be O
important O
for O
maintaining O
local O
structure O
. O

In O
one O
family O
, O
an O
in B
- I
frame I
3 I
nt I
deletion I
removes I
codon I
581 I
- I
( I
or I
582 I
) I
and O
, O
thereby O
, O
one O
of O
two O
phenylalanines O
that O
invariably O
occupy O
adjacent O
positions O
in O
the O
N O
- O
terminal O
alpha O
- O
helical O
region O
of O
the O
DBD O
in O
the O
steroid O
/ O
thyroid O
/ O
vitamin O
D O
receptor O
superfamily O
. O

In O
the O
second O
, O
an O
in B
- I
frame I
3 I
nt I
loss I
deletes I
Arg I
614 I
, O
an O
invariant O
residue O
in O
the O
C O
- O
terminal O
alpha O
- O
helix O
of O
the O
DBD O
. O

In O
genital O
skin O
fibroblasts O
with O
delta O
Phe O
581 O
or O
Arg O
614 O
His O
, O
androgen O
- O
binding O
, O
AR O
protein O
and O
AR O
m O
RNA O
are O
markedly O
reduced O
; O
in O
gonadal O
fibroblasts O
with O
delta O
Arg O
614 O
, O
AR O
m O
RNA O
may O
be O
reduced O
. O

Xrn O
1 O
p O
of O
Saccharomyces O
cerevisiae O
is O
a O
major O
cytoplasmic O
RNA O
turnover O
exonuclease O
which O
is O
evolutionarily O
conserved O
from O
yeasts O
to O
mammals O
. O

Deletion B
of O
the O
XRN O
1 O
gene O
causes O
pleiotropic O
phenotypes O
, O
which O
have O
been O
interpreted O
as O
indirect O
consequences O
of O
the O
RNA O
turnover O
defect O
. O

COL O
7 O
A O
1 O
gene O
mutations O
cause O
dystrophic O
epidermolysis O
bullosa O
, O
a O
skin O
blistering O
disorder O
. O

Three O
point B
mutations I
in I
exon I
73 I
caused O
glycine O
substitutions O
G O
2006 O
D O
, O
G O
2034 O
R O
, O
and O
G O
2015 O
E O
in O
the O
triple O
helical O
domain O
of O
collagen O
VII O
and O
interfered O
with O
its O
folding O
and O
secretion O
. O

Mutations O
have O
been O
identified O
in O
18 O
of O
20 O
possible O
alleles O
, O
including O
Glu O
80 O
Lys O
( O
2 O
patients O
) O
, O
Pro O
664 O
Leu O
( O
3 O
patients O
) O
, O
Asp O
69 O
Gly O
, O
Cys O
176 O
Arg O
, O
Cys O
227 O
Tyr O
, O
Ser O
265 O
Arg O
, O
Asp O
280 O
Ala O
, O
Asp O
283 O
Glu O
, O
Arg O
329 O
Pro O
, O
Asp O
461 O
Asn O
, O
Leu O
578 O
Ser O
, O
a O
single B
bp I
deletion I
in I
exon I
15 I
, O
a O
21 O
bp O
duplication O
of O
codons O
200 O
- O
206 O
and O
two O
large O
deletions O
. O

LDL O
- O
receptor O
activity O
in O
cultured O
cells O
from O
13 O
of O
the O
15 O
homozygous O
patients O
varied O
from O
undetectable O
to O
about O
30 O
% O
of O
normal O
, O
but O
there O
was O
no O
correlation O
between O
LDL O
- O
receptor O
activity O
and O
the O
untreated O
plasma O
cholesterol O
concentration O
in O
these O
patients O
. O

( O
iii O
) O
DNA O
variants O
in O
non O
- O
disease O
candidate O
genes O
with O
functions O
in O
mt O
DNA O
maintenance O
: O
( O
a O
) O
APEX O
2 O
: O
This O
gene O
is O
involved O
in O
post O
- O
replicative O
nuclear O
and O
mitochondrial O
base O
excision O
repair O
. O

( O
c O
) O
LONP O
1 O
: O
LONP O
1 O
functions O
in O
mitochondrial O
proteolysis O
and O
catalyzes O
the O
initial O
steps O
of O
protein O
degradation O
. O

In O
P O
22 O
we O
identified O
a O
novel O
heterozygous O
nonsense O
mutation O
p O
. O
Q O
172 O
X O
in O
exon O
5 O
( O
c O
. O
533 O
C O
> O
T O
) O
causing O
a O
termination B
( I
CAA I
- I
TAA I
) I
at I
peptide I
position I
172 I
likely O
leading O
to O
a O
truncated O
product O
and O
nonsense O
- O
mediated O
m O
RNA O
decay O
. O

When O
a O
transgene O
expressing O
the O
Glu B
- I
- I
> I
Lys I
substitution I
was O
introduced O
into O
Drosophila O
lines O
homozygous O
for O
the O
black O
mutation O
, O
the O
resulting O
flies O
exhibited O
the O
Su O
( O
b O
) O
phenotype O
. O

From O
these O
experiments O
, O
we O
conclude O
that O
this O
residue O
plays O
an O
essential O
role O
in O
the O
UTP O
allosteric O
response O
, O
probably O
in O
propagating O
the O
response O
between O
the O
effector O
binding O
site O
and O
the O
ATP O
binding O
site O
. O

Sequencing O
of O
the O
ACTA O
1 O
gene O
showed O
a O
" B
de I
novo I
" I
missense I
heterozygous I
mutation I
a I
> I
g I
in I
exon I
7 I
( O
Lys O
336 O
Glu O
) O
. O

Siiyama O
( O
serine B
53 I
( I
TCC I
) I
to I
phenylalanine I
53 I
( I
TTC I
) I
) O
. O

All O
the O
coding O
exons O
( O
exon O
Ic O
, O
II O
, O
III O
, O
IV O
, O
and O
V O
) O
of O
the O
alpha O
1 O
AT O
gene O
of O
the O
proband O
and O
his O
family O
were O
amplified O
by O
polymerase O
chain O
reaction O
and O
followed O
by O
direct O
sequencing O
. O

A O
single O
missense O
mutation O
, O
Ser B
53 I
( I
TCC I
) I
to I
Phe I
53 I
( O
TTC O
was O
identified O
in O
exon O
II O
of O
the O
proband O
' O
s O
alpha O
1 O
AT O
gene O
. O

This O
mutation O
, O
G B
to I
A I
at I
nucleotide I
6651 I
, O
may O
create O
a O
new O
splicing O
junction O
and O
affect O
the O
normal O
splicing O
of O
the O
messenger O
ribonucleic O
acid O
. O

In O
the O
other O
allele O
of O
both O
siblings O
, O
a O
missense O
mutation O
from O
GGG B
( I
Gly I
) I
to I
AGG I
( I
Arg I
) I
at I
codon I
129 I
( O
G O
129 O
R O
) O
in O
exon O
IV O
was O
found O
. O

In O
addition O
to O
an O
apparent O
decrease O
in O
affinity O
, O
the O
G O
129 O
R O
mutation O
caused O
a O
marked O
decrease O
in O
the O
apparent O
relative O
specific O
activity O
, O
thus O
leading O
to O
apparent O
relative O
specific O
efficiencies O
( O
relative O
specific O
activity O
/ O
Km O
) O
of O
2 O
. O
0 O
% O
and O
4 O
. O
7 O
% O
that O
of O
the O
normal O
type O
II O
3 O
beta O
HSD O
using O
pregnenolone O
or O
dehydroepiandrosterone O
as O
substrate O
, O
respectively O
. O

Previous O
studies O
have O
identified O
three O
mutations B
at I
APP I
codon I
717 I
which O
are O
pathogenic O
for O
Alzheimer O
disease O
( O
AD O
) O
. O

One O
variant O
at O
APP O
codon B
693 I
resulted I
in I
a I
Glu I
- I
- I
> I
Gly I
change I
. O

Another O
single B
- I
base I
change I
at I
APP I
codon I
708 I
did O
not O
alter O
the O
amino O
acid O
encoded O
at O
this O
site O
. O

Two O
point O
mutations O
and O
a O
6 B
- I
bp I
deletion I
were I
identified I
in I
the I
intronic I
sequences I
surrounding I
exon I
17 I
. O

These O
studies O
show O
that O
APP O
mutations O
account O
for O
AD O
in O
only O
a O
small O
fraction O
of O
FAD O
kindreds O
. O

In O
gastric O
carcinoma O
cells O
, O
CK O
2 O
α O
was O
bound O
to O
DBC O
1 O
and O
phosphorylated O
DBC O
1 O
. O

A O
mutation B
at I
the I
phosphorylation I
site I
of O
DBC O
1 O
also O
downregulated O
the O
signals O
related O
with O
the O
epithelial O
- O
mesenchymal O
transition O
. O

m O
Ang O
- O
4 O
, O
human O
angiogenin O
( O
h O
Ang O
) O
, O
and O
murine O
angiogenin O
- O
1 O
( O
m O
Ang O
- O
1 O
) O
stimulate O
the O
proliferation O
of O
IGR O
1 O
melanoma O
cells O
but O
do O
not O
stimulate O
the O
proliferation O
or O
migration O
of O
bovine O
corneal O
endothelial O
cells O
or O
primary O
mouse O
embryonic O
fibroblasts O
. O

In O
the O
putative O
cell O
- O
binding O
segment O
, O
the O
replacement B
of I
Lys I
59 I
with I
Asn I
( O
its O
counterpart O
at O
position O
61 O
of O
h O
Ang O
) O
does O
not O
abrogate O
enzymatic O
activity O
but O
abolishes O
angiogenic O
activity O
, O
the O
reason O
for O
which O
is O
unclear O
. O

Toxicol O
. O

Chimeric O
plasmids O
between O
the O
two O
c O
DNAs O
and O
site O
- O
directed O
mutagenesis O
revealed O
two O
critical O
alterations O
responsible O
for O
the O
reduced O
ligand O
binding O
activity O
: O
an O
Ala B
375 I
to I
Val I
alteration O
and O
an O
elongated O
carboxyl O
- O
terminal O
sequence O
due O
to O
a O
T B
to I
C I
mutation I
at I
the I
first I
letter I
of I
the I
termination I
codon I
of O
C O
57 O
BL O
Ah O
R O
. O

Importance O
of O
the O
amino O
acid O
at O
position O
381 O
of O
human O
Ah O
R O
( O
equivalent O
to O
position O
375 O
of O
mouse O
Ah O
R O
) O
in O
the O
ligand O
binding O
was O
confirmed O
by O
the O
fact O
that O
the O
mutation O
of O
Val B
381 I
to I
Asp I
completely O
abolished O
the O
ligand O
binding O
activity O
of O
human O
Ah O
R O
. O

Sj O
ö O
gren O
- O
Larsson O
syndrome O
( O
SLS O
) O
, O
a O
rare O
autosomal O
disorder O
characterized O
by O
ichthyosis O
, O
spastic O
neurological O
disorders O
and O
oligophrenia O
, O
is O
associated O
with O
deficiency O
of O
fatty O
aldehyde O
dehydrogenase O
encoded O
by O
a O
gene O
on O
chromosome O
17 O
q O
11 O
. O
2 O
. O

The O
examination O
of O
the O
ALDH O
3 O
locus O
of O
three O
additional O
SLS O
patients O
showed O
that O
two O
are O
heterozygous B
with I
C I
- I
- I
> I
G I
at I
nt I
985 I
( O
Pro B
- I
- I
> I
Ala I
at I
protein I
position I
329 I
) O
. O

The O
examination O
of O
the O
ALDH O
10 O
locus O
revealed O
the O
existence O
of O
a O
3 B
base I
deletion I
coupled I
with I
a I
21 I
base I
insertion I
at I
intron I
6 I
/ I
exon I
7 I
junction O
in O
one O
patient O
. O

One O
patient O
is O
associated O
with O
a O
2 B
base I
deletion I
at I
nt I
1297 I
and O
consequent B
premature I
chain I
termination I
at I
protein I
position I
434 I
. O

Another O
patient O
is O
a O
compound O
heterozygote O
for O
the O
same O
2 B
base I
deletion I
at I
nt I
1297 I
and O
a O
5 B
base I
insertion I
at I
nt I
1311 I
and O
premature B
chain I
termination I
at I
protein I
position I
457 I
. O

The O
693 O
C O
- O
- O
> O
A O
and O
914 O
C O
- O
- O
> O
A O
base O
changes O
, O
resulting O
in O
nonsense B
tyr I
231 I
- I
- I
> I
ter I
and O
missense B
ala I
305 I
- I
- I
> I
glu I
mutations O
, O
respectively O
, O
lead O
to O
complete O
loss O
of O
ASPA O
activity O
in O
in O
vitro O
expression O
studies O
. O

The O
854 B
A I
- I
- I
> I
C I
transversion I
converted I
glu I
to I
ala I
in I
codon I
285 I
. O

A O
fourth O
mutation O
, O
433 B
- I
- I
2 I
( I
A I
- I
- I
> I
G I
) I
transition I
, O
was O
identified O
at O
the O
splice O
- O
acceptor O
site O
in O
intron O
2 O
. O

The O
glu O
285 O
- O
- O
> O
ala O
mutation O
was O
predominant O
( O
82 O
. O
9 O
% O
) O
in O
this O
population O
, O
followed O
by O
the O
tyr O
231 O
- O
- O
> O
ter O
( O
14 O
. O
8 O
% O
) O
and O
433 O
- O
- O
2 O
( O
A O
- O
- O
> O
G O
) O
( O
1 O
. O
1 O
% O
) O
mutations O
. O

Because O
none O
of O
the O
pcd O
alleles O
analyzed O
at O
the O
time O
of O
the O
identification O
of O
Nna O
1 O
provided O
insight O
into O
the O
molecular O
basis O
of O
Nna O
1 O
loss O
- O
of O
- O
function O
, O
we O
obtained O
a O
recent O
pcd O
remutation O
- O
- O
pcd O
5 O
J O
, O
and O
after O
determining O
that O
its O
phenotype O
is O
comparable O
to O
existing O
pcd O
severe O
alleles O
, O
we O
sought O
its O
genetic O
basis O
by O
sequencing O
Nna O
1 O
. O

In O
this O
article O
we O
report O
that O
pcd O
5 O
J O
results O
from O
the O
insertion B
of I
a I
single I
GAC I
triplet I
encoding I
an I
aspartic I
acid I
residue I
at I
position I
775 I
of O
Nna O
1 O
. O

Sequence O
analysis O
reveals O
that O
the O
amino B
acid I
substitution I
occurs I
at I
position I
7 I
of I
the I
largest I
CNBr I
fragment I
, I
corresponding I
to I
position I
47 I
of I
the I
whole I
protein I
chain I
. O

The O
histidine B
/ I
arginine I
- I
47 I
mutational I
replacement I
corresponds O
to O
a O
position O
that O
binds O
the O
pyrophosphate O
group O
of O
the O
coenzyme O
NAD O
( O
H O
) O
; O
this O
explains O
the O
functional O
differences O
between O
the O
beta O
1 O
beta O
1 O
and O
beta O
2 O
beta O
2 O
isozymes O
, O
including O
both O
a O
lower O
p O
H O
optimum O
and O
higher O
turnover O
number O
of O
beta O
2 O
beta O
2 O
, O
which O
is O
likely O
to O
be O
the O
mutant O
form O
. O

Coactivator O
- O
associated O
arginine O
methyltransferase O
1 O
( O
CARM O
1 O
) O
, O
the O
histone O
arginine O
methyltransferase O
and O
coactivator O
for O
many O
transcription O
factors O
, O
is O
subject O
to O
multiple O
post O
- O
translational O
modifications O
( O
PTMs O
) O
. O

To O
probe O
function O
of O
automethylation O
, O
we O
mutated O
arginine B
551 I
to I
lysine I
to O
create O
an O
automethylation O
- O
deficient O
CARM O
1 O
. O

Third O
, O
we O
mapped O
the O
rat O
gpt O
c O
DNA O
to O
the O
syntenic O
region O
of O
rat O
chromosome O
7 O
. O

The O
two O
polymorphic O
GPT O
isozymes O
are O
the O
results O
of O
a O
nucleotide B
substitution I
in I
codon I
14 I
, I
coding I
for I
a I
histidine I
in I
GPT I
- I
1 I
and I
an I
asparagine I
in I
GPT I
- I
2 I
, O
which O
causes O
a O
gain O
or O
loss O
of O
an O
Nla O
III O
restriction O
site O
. O

Four O
nucleotide O
sequence O
variants O
were O
found O
: O
a O
coding O
mutation B
in I
nucleotide I
position I
371 I
which O
leads O
to O
an O
amino O
acid O
exchange O
( O
Phe B
- I
- I
> I
Cys I
) I
in I
position I
124 I
of O
the O
receptor O
protein O
and O
three O
mutations O
in O
the O
5 O
' O
flanking O
region O
. O

To O
our O
knowledge O
, O
the O
Phe O
- O
124 O
- O
Cys O
substitution O
is O
the O
first O
natural O
occurring O
molecular O
variant O
which O
has O
been O
identified O
for O
the O
5 O
- O
HT O
1 O
D O
beta O
receptor O
so O
far O
. O

The O
PPP O
2 O
R O
1 O
B O
gene O
has O
recently O
been O
implicated O
as O
a O
tumor O
suppressor O
based O
on O
the O
finding O
of O
somatic O
alterations O
in O
lung O
and O
colon O
cancers O
. O

A O
germline O
G B
> I
A I
transition I
( I
GGC I
> I
GAC I
) I
in I
codon I
90 I
was O
detected O
in O
4 O
/ O
76 O
tumors O
. O

The O
codon B
90 I
Gly I
> I
Asp I
alteration O
may O
represent O
a O
non O
- O
pathological O
polymorphism O
and O
consequently O
the O
mutation O
frequency O
reported O
in O
lung O
cancers O
may O
have O
been O
overstated O
and O
the O
designation O
of O
PPP O
2 O
R O
1 O
B O
as O
a O
tumor O
suppressor O
gene O
should O
be O
regarded O
with O
caution O
. O

In O
contrast O
, O
the O
substitution B
of I
residues I
at I
position I
Trp I
- I
117 I
and O
Asp O
- O
119 O
of O
MTH O
1 O
, O
which O
showed O
apparent O
chemical O
shift O
perturbations O
with O
8 O
- O
oxo O
- O
d O
GDP O
in O
NMR O
analyses O
but O
are O
not O
conserved O
in O
Mut O
T O
, O
affected O
the O
substrate O
specificity O
. O

RESULTS O
: O
Of O
the O
four O
mutations O
detected O
, O
two O
novel O
mutations O
were O
identified O
in O
the O
two O
patients O
, O
i O
. O
e O
. O
, O
F O
474 O
L O
, O
and O
an O
insertion B
of I
an I
adenine I
between I
nucleotide I
positions I
395 I
and I
396 I
. O

CONCLUSIONS O
: O
We O
established O
the O
molecular O
basis O
of O
butyrylcholinesterase O
deficiency O
in O
two O
Chinese O
patients O
. O

Substitution B
of I
aspartate I
79 I
with I
asparagine I
produced O
a O
mutant O
receptor O
that O
displays O
the O
expected O
affinity O
and O
stereoselectivity O
for O
antagonists O
but O
a O
40 O
- O
, O
140 O
- O
, O
and O
240 O
- O
fold O
reduction O
in O
its O
affinity O
for O
isoproterenol O
, O
epinephrine O
, O
and O
norepinephrine O
, O
respectively O
. O

These O
observations O
demonstrate O
that O
substitution B
of I
aspartate I
with I
asparagine I
at I
residue I
79 I
in O
the O
human O
beta O
- O
adrenergic O
receptor O
differentially O
affects O
the O
binding O
of O
catecholamines O
and O
produces O
a O
functional O
uncoupling O
of O
receptors O
and O
stimulatory O
guanine O
nucleotide O
regulatory O
proteins O
( O
Gs O
) O
. O

Phosphorylated O
tyrosines O
868 O
and O
972 O
were O
also O
identified O
by O
mass O
spectrometry O
analysis O
of O
JAK O
2 O
activated O
by O
an O
erythropoietin O
- O
bound O
chimeric O
erythropoietin O
receptor O
/ O
leptin O
receptor O
. O

Compared O
with O
wild O
- O
type O
JAK O
2 O
, O
which O
is O
constitutively O
active O
when O
overexpressed O
, O
JAK O
2 O
lacking B
tyrosine I
868 I
, I
966 I
, I
or I
972 I
has O
substantially O
reduced O
activity O
. O

In O
this O
study O
we O
describe O
a O
9 B
- I
bp I
deletion I
in I
exon I
2 I
of O
the O
amelogenin O
gene O
( O
AMGX O
) O
causing O
X O
- O
linked O
hypoplastic O
amelogenesis O
imperfecta O
, O
a O
disease O
characterized O
by O
defective O
enamel O
. O

The O
mutation B
results I
in I
the I
loss I
of I
3 I
amino I
acids I
and O
exchange B
of I
1 I
in I
the I
signal I
peptide I
of O
the O
amelogenin O
protein O
. O

RESULTS O
: O
A O
single O
G B
- I
> I
T I
transversion I
was I
identified I
within I
the I
first I
coding I
exon I
of O
the O
Lim O
2 O
gene O
in O
the O
To O
3 O
mutant O
DNA O
. O

This O
DNA O
change O
results O
in O
the O
nonconservative B
substitution I
of I
a I
valine I
for I
the I
normally I
encoded I
glycine I
at I
amino I
acid I
15 I
of O
the O
MP O
19 O
polypeptide O
. O

CONCLUSIONS O
: O
The O
identified O
genetic O
lesion O
in O
the O
Lim O
2 O
gene O
of O
the O
cataractous O
mouse O
mutant O
, O
To O
3 O
, O
confirms O
Lim O
2 O
as O
an O
ideal O
candidate O
gene O
. O

Mammalian O
chromatin O
remodeling O
complexes O
are O
involved O
in O
both O
activation O
and O
repression O
of O
transcription O
. O

Deletion B
of I
the I
C I
- I
terminal I
PHD I
finger I
and O
bromodomain O
abolishes O
the O
interaction O
of O
TIP O
5 O
and O
HDAC O
1 O
, O
and O
abrogates O
transcriptional O
repression O
. O

We O
found O
that O
two O
common O
alleles O
, O
C O
8 O
A O
* O
A O
and O
C O
8 O
A O
* O
B O
, O
are O
characterized O
by O
the O
substitution B
of I
a I
single I
amino I
acid I
( I
Gln I
to I
Lys I
) I
, I
which I
is I
caused I
by I
a I
point I
mutation I
of I
a I
single I
nucleotide I
( I
C I
to I
A I
) I
in I
exon I
3 I
at I
position I
187 I
of O
the O
mature O
C O
8 O
alpha O
c O
DNA O
sequence O
. O

Association O
of O
SHP O
- O
1 O
and O
SHP O
- O
2 O
to O
other O
receptors O
can O
involve O
recruitment O
to O
either O
a O
single O
receptor O
ITIM O
or O
to O
two O
receptor O
ITIMs O
. O

For O
human O
BTLA O
, O
mutations B
of I
either I
Y I
257 I
or I
Y I
282 I
, I
but I
not I
Y I
226 I
, O
abrogated O
association O
with O
both O
SHP O
- O
1 O
and O
SHP O
- O
2 O
. O

For O
murine O
BTLA O
, O
mutation B
of I
either I
Y I
274 I
or I
Y I
299 I
, I
but I
not I
Y I
245 I
, O
also O
abrogated O
association O
with O
both O
SHP O
- O
1 O
and O
SHP O
- O
2 O
. O

In O
contrast O
to O
wild O
- O
type O
caspase O
- O
8 O
, O
death O
effector O
domain O
mutant O
replacing O
Asp B
73 I
with I
Ala I
( O
caspase O
- O
8 O
( O
D O
73 O
A O
) O
) O
failed O
to O
activate O
NF O
- O
kappa O
B O
and O
to O
bind O
FLICE O
- O
associated O
huge O
protein O
( O
FLASH O
) O
in O
vitro O
and O
in O
vivo O
. O

Instead O
, O
caspase O
- O
8 O
( O
D O
73 O
A O
) O
mutant O
bound O
to O
caspase O
- O
8 O
and O
blocked O
NF O
- O
kappa O
B O
activation O
triggered O
by O
TNF O
- O
alpha O
and O
caspase O
- O
8 O
. O

A O
hitherto O
undescribed O
single B
nucleotide I
transversion I
was I
found I
within I
exon I
11 I
( O
G O
1260 O
- O
- O
- O
- O
C O
; O
Trp O
420 O
- O
- O
- O
- O
Cys O
) O
. O

The O
mutation O
can O
be O
identified O
rapidly O
and O
reliably O
because O
it O
abolishes O
one O
of O
the O
two O
Kpn O
I O
sites O
in O
the O
coding O
sequence O
. O

In O
affected O
relatives O
, O
we O
found O
a O
previously O
unreported O
G B
to I
A I
transition I
in I
exon I
9 I
leading I
to I
a I
Gly I
to I
Arg I
substitution I
at I
amino I
acid I
position I
420 I
. O

G O
420 O
R O
has O
been O
reported O
previously O
with O
a O
G B
to I
C I
transversion I
. O

A O
lysophospholipase O
( O
Lyso O
PLA O
I O
) O
has O
been O
purified O
and O
characterized O
from O
the O
mouse O
macrophage O
- O
like O
P O
388 O
D O
1 O
cell O
line O
( O
Zhang O
, O
Y O
. O
Y O
, O
and O
Dennis O
, O
E O
. O
A O
. O

Furthermore O
, O
site O
- O
directed O
mutagenesis O
was O
employed O
to O
change B
Ser I
- I
119 I
in I
the I
GXSXG I
motif I
to I
an I
Ala I
. O

Modification O
of O
the O
introduced B
Cys I
131 I
with O
4 O
- O
BEI O
and O
4 O
- O
CMI O
resulted O
in O
enhancements O
of O
up O
to O
threefold O
in O
catalytic O
activity O
. O

This O
is O
the O
first O
example O
of O
incorporation O
by O
chemical O
modification O
of O
an O
unnatural O
amino O
acid O
analog O
of O
histidine O
that O
can O
act O
as O
a O
proton O
shuttle O
in O
an O
enzyme O
. O

Aldolase O
A O
derived O
from O
a O
hemolytic O
anemia O
patient O
with O
aldolase O
A O
deficiency O
was O
shown O
to O
have O
an O
amino O
acid O
substitution O
of O
glycine B
for I
aspartic I
acid I
at I
the I
128 I
th I
position I
( O
Asp O
- O
128 O
) O
in O
the O
enzyme O
[ O
Kishi O
et O
al O
. O

Conversion O
of O
Asp B
to I
Gly I
at I
the I
128 I
th I
position I
in O
the O
enzyme O
rendered O
the O
enzyme O
thermolabile O
and O
susceptible O
to O
tryptic O
digestion O
. O

CD O
spectra O
analysis O
also O
revealed O
that O
the O
mutant O
enzyme O
had O
a O
remarkable O
conformation O
change O
with O
a O
decrease O
of O
regular O
form O
in O
the O
molecule O
. O

Changes B
at I
P I
183 I
of O
emerin O
weaken O
its O
protein O
- O
protein O
interactions O
resulting O
in O
X O
- O
linked O
Emery O
- O
Dreifuss O
muscular O
dystrophy O
. O

These O
alterations O
predict O
the O
replacement B
of I
a I
proline I
residue I
at I
position I
183 I
with I
either I
a I
histidine I
or I
a I
threonine I
. O

Biochemical O
analysis O
has O
demonstrated O
that O
the O
mobility O
and O
expression O
levels O
of O
the O
mutant O
forms O
of O
emerin O
are O
indistinguishable O
from O
that O
of O
wild O
- O
type O
emerin O
, O
but O
that O
they O
have O
weakened O
interactions O
with O
nuclear O
lamina O
components O
. O

In O
comparison O
with O
the O
usual O
EDMD O
phenotype O
, O
patients O
with O
P B
183 I
missense I
mutations I
have O
a O
later O
age O
at O
onset O
of O
first O
symptoms O
, O
elbow O
contractures O
, O
ankle O
contractures O
, O
upper O
limb O
weakness O
and O
lower O
limb O
weakness O
, O
but O
there O
is O
no O
difference O
for O
the O
age O
at O
onset O
of O
cardiac O
involvement O
. O

A O
mutation O
in O
the O
gene O
for O
3 O
beta O
- O
HSD O
type O
II O
was O
observed O
at O
codon B
173 I
( I
CTA I
- I
- I
> I
CGA I
) I
, O
leading O
in O
the O
affected O
patient O
to O
a O
homozygous O
substitution O
in O
which O
the O
leucine B
at I
residue I
173 I
was I
altered I
to I
an I
arginine I
( O
L O
173 O
R O
) O
. O

Three O
related O
heterozygous O
adult O
females O
showed O
evidence O
of O
a O
small O
over O
- O
production O
of O
delta O
5 O
steroids O
and O
steroid O
metabolites O
and O
a O
variable O
reduction O
in O
ovarian O
function O
. O

The O
latter O
polymorphisms B
were I
located I
88 I
bp I
apart I
at I
the I
3 I
' I
end I
of I
the I
type I
I I
coding I
sequence I
and O
could O
be O
physically O
resolved O
as O
haplotypes O
using O
DGGE O
. O

Cryptic O
or O
newly O
created O
sites O
were O
identified O
with O
SSS O
from O
0 O
. O
09 O
to O
1 O
. O
0 O
. O

We O
verified O
that O
a O
weak O
cryptic O
site O
( O
SSS O
= O
0 O
. O
09 O
) O
14 O
nucleotides O
downstream O
was O
activated O
and O
resulted O
in O
an O
insertion B
of I
14 I
bp I
and I
a I
frameshift I
stop I
at I
codon I
106 I
. O

The O
alteration B
of I
residue I
Thr I
278 I
is O
predicted O
to O
have O
a O
small O
but O
significant O
effect O
on O
the O
gamma O
1 O
actin O
structure O
owing O
to O
its O
close O
proximity O
to O
a O
methionine O
residue O
at O
position O
313 O
in O
helix O
11 O
. O

Met O
313 O
has O
no O
space O
in O
the O
structure O
to O
move O
away O
. O

To O
test O
the O
physiological O
importance O
of O
these O
sites O
, O
we O
generated O
a O
transgenic O
mouse O
model O
in O
which O
all O
three O
conserved O
ATM O
serine B
autophosphorylation I
sites I
( I
S I
367 I
/ I
1899 I
/ I
1987 I
) I
have I
been I
replaced I
with I
alanine I
. O

Mutation B
in I
codon I
713 I
of O
the O
beta O
amyloid O
precursor O
protein O
gene O
presenting O
with O
schizophrenia O
. O

Following O
reports O
of O
mutations B
of I
codon I
717 I
in I
exon I
17 I
of O
the O
amyloid O
precursor O
protein O
( O
APP O
) O
gene O
in O
early O
- O
onset O
familial O
Alzheimer O
' O
s O
disease O
, O
we O
screened O
exon O
17 O
for O
new O
mutations O
in O
presenile O
dementia O
. O

Sequencing O
revealed O
a O
C B
to I
T I
nucleotide I
substitution I
which I
produces I
an I
alanine I
to I
valine I
change I
at I
codon I
713 I
. O

The O
sequence O
of O
the O
c O
DNA O
clone O
coding O
for O
the O
variant O
differed O
from O
that O
coding O
for O
the O
wild O
- O
type O
DD O
by O
two O
nucleotides O
( O
substitutions B
of I
C I
with I
G I
at I
positions I
434 I
and I
931 I
) O
which O
caused O
two O
amino O
acid O
replacements O
, O
Ser B
145 I
to I
Cys I
( I
S I
145 I
C I
) I
and O
Leu B
311 I
to I
Val I
( O
L O
311 O
V O
) O
. O

The O
effects O
of O
the O
mutations O
on O
the O
catalytic O
properties O
were O
examined O
with O
the O
recombinant O
enzymes O
expressed O
in O
Escherichia O
coli O
. O

Heterodimers O
of O
BMAL O
1 O
and O
CLOCK O
drive O
rhythmic O
expression O
of O
clock O
- O
controlled O
genes O
, O
thereby O
generating O
circadian O
physiology O
and O
behavior O
. O

Interestingly O
, O
mutation B
of I
the I
sumoylation I
site I
( I
Lys I
( I
259 I
) I
) I
of O
BMAL O
1 O
markedly O
inhibited O
both O
its O
ubiquitination O
and O
its O
proteasome O
- O
mediated O
proteolysis O
, O
and O
these O
effects O
were O
reversed O
by O
covalent O
attachment O
of O
SUMO O
3 O
to O
the O
C O
terminus O
of O
the O
mutant O
BMAL O
1 O
. O

To O
model O
phosphorylation O
of O
the O
BATF O
DNA O
binding O
domain O
, O
serine B
- I
43 I
was I
replaced I
by I
an I
aspartate I
residue I
. O

Given O
that O
40 O
% O
of O
mammalian O
b O
ZIP O
transcription O
factors O
contain O
a O
residue O
analogous O
to O
serine O
- O
43 O
of O
BATF O
in O
their O
DNA O
binding O
domains O
, O
the O
phosphorylation O
event O
described O
here O
represents O
a O
mechanism O
that O
is O
potentially O
applicable O
to O
the O
regulation O
of O
many O
b O
ZIP O
proteins O
. O

Fifty O
normal O
Vietnamese O
were O
used O
as O
controls O
. O

DNA O
analysis O
revealed O
a O
nucleotide O
transversion O
at O
codon B
123 I
( I
GAC I
- I
- I
> I
CAC I
) I
, O
causing O
Asp O
- O
- O
> O
His O
substitution O
( O
D O
123 O
H O
) O
. O

Nearly O
all O
studies O
have O
associated O
the O
presence O
( B
insertion I
, I
I I
) I
or I
absence I
( I
deletion I
, I
D I
) I
of I
a I
287 I
- I
bp I
Alu I
repeat I
element I
in I
intron I
16 I
with O
the O
levels O
of O
circulating O
enzyme O
or O
cardiovascular O
pathophysiologies O
. O

Many O
epidemiological O
studies O
suggest O
that O
the O
DCP O
1 O
* O
D O
allele O
confers O
increased O
susceptibility O
to O
cardiovascular O
disease O
; O
however O
, O
other O
reports O
have O
found O
no O
such O
association O
or O
even O
a O
beneficial O
effect O
. O

Mutation B
of I
Cys I
341 I
in I
the I
carboxyl I
tail I
leads O
to O
an O
uncoupled O
nonpalmitoylated O
form O
of O
the O
receptor O
. O

Mutation O
of O
Cys B
341 I
to I
glycine I
results O
in O
a O
nonpalmitoylated O
form O
of O
the O
receptor O
that O
exhibits O
a O
drastically O
reduced O
ability O
to O
mediate O
isoproterenol O
stimulation O
of O
adenylyl O
cyclase O
. O

ETS O
- O
1 O
, O
the O
founding O
member O
of O
the O
family O
, O
is O
regulated O
by O
the O
Ras O
and O
Ca O
2 O
+ O
signaling O
pathways O
and O
is O
implicated O
in O
various O
physiological O
processes O
leading O
to O
cell O
growth O
, O
differentiation O
and O
apoptosis O
. O

Coexpressed O
hu O
UBC O
9 O
did O
not O
affect O
the O
ETS O
- O
1 O
protein O
level O
, O
and O
moreover O
, O
a O
point B
mutation I
at I
Cys I
93 I
, O
an O
amino O
acid O
known O
to O
be O
essential O
for O
ubiquitination O
, O
did O
not O
abolish O
the O
stimulation O
of O
the O
ETS O
- O
1 O
transcriptional O
activity O
. O

Two O
isoenzymes O
are O
responsible O
for O
3 O
beta O
- O
hydroxysteroid O
dehydrogenase O
/ O
delta O
5 O
- O
delta O
4 O
- O
isomerase O
( O
3 O
beta O
- O
HSD O
) O
activity O
in O
humans O
. O

We O
did O
not O
detect O
any O
mutation O
in O
the O
type O
I O
3 O
beta O
- O
HSD O
gene O
, O
but O
we O
found O
two O
different O
missense O
mutations O
in O
exon O
IV O
of O
the O
type O
II O
3 O
beta O
- O
HSD O
gene O
of O
the O
patient O
; O
a O
conversion O
of O
codon O
Leu B
108 I
into I
a I
Trp I
( O
L O
108 O
W O
) O
inherited O
from O
his O
mother O
and O
a O
conversion O
of O
codon O
Pro B
186 I
into I
a I
Leu I
( O
P O
186 O
L O
) O
inherited O
from O
his O
father O
. O

Sequencing O
of O
the O
gene O
- O
specific O
PCR O
products O
showed O
that O
the O
three O
common O
ORM O
1 O
alleles O
result O
from O
A B
- I
- I
> I
G I
transitions I
at I
the I
codons I
for I
amino I
acid I
positions I
20 I
in I
exon I
1 I
and O
156 B
in I
exon I
5 I
of O
the O
AGP O
1 O
gene O
: O
ORM B
1 I
* I
F I
1 I
was I
characterized I
by I
CAG I
( I
Gln I
) I
and I
GTG I
( I
Val I
) I
, O
ORM B
1 I
* I
F I
2 I
, I
by I
CAG I
( I
Gln I
) I
and I
ATG I
( I
Met I
) I
, O
and O
ORM B
1 I
* I
S I
, I
by I
CGG I
( I
Arg I
) I
and I
GTG I
( I
Val I
) I
. O

Aside O
from O
mutation B
of I
a I
catalytic I
tetrad I
residue I
, O
proline B
residues I
at I
positions I
670 I
and I
675 I
in O
h O
AGO O
1 O
introduce O
a O
kink O
in O
the O
c O
S O
7 O
loop O
, O
forming O
a O
convex O
surface O
within O
the O
h O
AGO O
1 O
nucleic O
- O
acid O
- O
binding O
channel O
near O
the O
inactive O
catalytic O
site O
. O

Because O
SLC O
4 O
A O
1 O
encodes O
RBC O
band O
3 O
and O
controls O
the O
expression O
of O
Diego O
blood O
group O
system O
antigens O
, O
the O
possible O
relationship O
of O
Fr O
( O
a O
) O
to O
the O
Diego O
blood O
group O
system O
was O
investigated O
by O
molecular O
analysis O
of O
SLC O
4 O
A O
1 O
. O

DNA O
sequencing O
revealed O
a O
GAG B
- I
- I
> I
AAG I
mutation I
that O
underlies O
a O
Glu O
480 O
Lys O
substitution O
in O
RBC O
band O
3 O
. O

Sequence O
analysis O
of O
the O
ABCA O
1 O
gene O
from O
the O
patients O
with O
TD O
revealed O
a O
homozygous B
G I
to I
A I
transition I
at I
nucleotide I
3805 I
of O
the O
c O
DNA O
resulting O
in O
the O
substitution B
of I
Asp I
1229 I
with I
Asn I
in I
exon I
27 I
, O
and O
a O
C B
to I
T I
at I
nucleotide I
6181 I
resulting O
in O
the O
substitution B
of I
Arg I
2021 I
with I
Trp I
in I
exon I
47 I
. O

Sequence O
analysis O
of O
the O
ABCA O
1 O
gene O
from O
the O
FHA O
patient O
revealed O
a O
homozygous B
4 I
bp I
CGCC I
deletion I
from I
nucleotide I
3787 I
to I
3790 I
resulting O
in O
premature B
termination I
by I
frameshift I
at I
codon I
1224 I
. O

C O
122 O
- O
independent O
dimerization O
of O
CTLA O
- O
4 O
involved O
N O
- O
glycosylation O
, O
because O
further O
mutation B
of I
the I
N I
78 I
and I
N I
110 I
glycosylation O
sites O
abrogated O
dimerization O
. O

Such O
functionality O
correlated O
with O
B O
7 O
- O
induced O
dimerization O
of O
these O
mutant O
molecules O
. O

Linoleic O
acid O
was O
metabolized O
to O
a O
similar O
extent O
by O
the O
latter O
enzyme O
to O
13 O
- O
hydro O
( O
pero O
) O
xyoctadecadienoic O
acid O
but O
not O
by O
the O
platelet O
enzyme O
. O

Mutagenesis O
and O
deletion B
of I
the I
highly I
conserved I
lipoxygenase I
C I
- I
terminal I
isoleucine I
( I
Ile I
663 I
) I
, O
a O
residue O
believed O
to O
be O
involved O
in O
the O
non O
- O
heme O
iron O
atom O
coordination O
of O
all O
lipoxygenases O
, O
was O
performed O
. O

Deletion B
of I
Ile I
663 I
and O
substitution O
with O
most O
amino O
acids O
abolished O
enzyme O
activity O
. O

Western O
blotting O
revealed O
absence O
of O
2 O
- O
MBCDase O
protein O
in O
fibroblast O
extracts O
; O
DNA O
sequencing O
identified O
a O
single B
778 I
C I
> I
T I
substitution I
in O
the O
2 O
- O
MBCDase O
coding O
region O
( O
778 O
C O
> O
T O
) O
, O
substituting B
phenylalanine I
for I
leucine I
at I
amino I
acid I
222 I
( O
L O
222 O
F O
) O
and O
absence O
of O
enzyme O
activity O
for O
the O
2 O
- O
MBCDase O
protein O
expressed O
in O
Escherichia O
coli O
. O

Switch O
of O
coenzyme O
specificity O
of O
mouse O
lung O
carbonyl O
reductase O
by O
substitution O
of O
threonine B
38 I
with I
aspartic I
acid I
. O

Using O
site O
- O
directed O
mutagenesis O
, O
we O
constructed O
a O
mutant O
mouse O
lung O
carbonyl O
reductase O
in O
which O
Thr B
- I
38 I
was I
replaced I
by I
Asp I
( O
T O
38 O
D O
) O
, O
and O
we O
compared O
kinetic O
properties O
of O
the O
mutant O
and O
wild O
- O
type O
enzymes O
in O
both O
forward O
and O
reverse O
reactions O
. O

The O
mutation O
resulted O
in O
increases O
of O
more O
than O
200 O
- O
fold O
in O
the O
Km O
values O
for O
NADP O
( O
H O
) O
and O
decreases O
of O
more O
than O
7 O
- O
fold O
in O
those O
for O
NAD O
( O
H O
) O
, O
but O
few O
changes O
in O
the O
Km O
values O
for O
substrates O
or O
in O
the O
kcat O
values O
of O
the O
reactions O
. O

Changing O
Thr B
- I
38 I
to I
Asp I
destabilized O
the O
binding O
energies O
of O
NADP O
( O
H O
) O
by O
3 O
. O
9 O
- O
4 O
. O
5 O
kcal O
/ O
mol O
and O
stabilized O
those O
of O
NAD O
( O
H O
) O
by O
1 O
. O
2 O
- O
1 O
. O
4 O
kcal O
/ O
mol O
. O

These O
mutants O
were O
expressed O
and O
purified O
from O
an O
ADA O
- O
deficient O
bacterial O
strain O
and O
characterized O
. O

Changing O
Asp B
295 I
to I
a I
glutamate I
decreases O
the O
kcat O
but O
does O
not O
alter O
the O
Km O
for O
adenosine O
, O
confirming O
the O
importance O
of O
this O
residue O
in O
the O
catalytic O
process O
and O
its O
minimal O
role O
in O
substrate O
binding O
. O

In O
contrast O
, O
Asp B
296 I
mutants I
exhibit O
markedly O
increased O
Km O
values O
, O
establishing O
this O
residue O
' O
s O
critical O
role O
in O
substrate O
binding O
. O

Site O
- O
directed O
mutagenesis O
studies O
on O
a O
putative O
fifth O
iron O
ligand O
of O
mouse O
8 O
S O
- O
lipoxygenase O
: O
retention O
of O
catalytic O
activity O
on O
mutation O
of O
serine B
- I
558 I
to I
asparagine I
, I
histidine I
, I
or I
alanine I
. O

Mouse O
8 O
- O
LOX O
and O
its O
homologues O
( O
e O
. O
g O
. O
, O
human O
15 O
- O
LOX O
- O
2 O
) O
are O
unique O
in O
having O
a O
serine B
in I
place I
of I
the I
usual I
Asn I
or I
His I
in I
this I
fifth I
position I
. O

To O
investigate O
the O
importance O
of O
the O
residue O
in O
mouse O
8 O
- O
LOX O
structure O
- O
function O
, O
the O
serine B
- I
558 I
was I
replaced I
by I
asparagine I
, I
histidine I
, I
or I
alanine I
using O
oligonucleotide O
- O
directed O
mutagenesis O
. O

The O
Ser O
558 O
Asn O
and O
Ser O
558 O
His O
mutants O
had O
equivalent O
or O
greater O
activity O
than O
wild O
- O
type O
8 O
- O
LOX O
. O

Canavan O
disease O
, O
an O
inherited O
leukodystrophy O
, O
is O
caused O
by O
mutations O
in O
the O
aspartoacylase O
( O
ASPA O
) O
gene O
. O

Of O
these O
, O
14 O
are O
novel O
, O
including O
five O
missense O
mutations O
( O
E O
24 O
G O
, O
D O
68 O
A O
, O
D O
249 O
V O
, O
C O
152 O
W O
, O
H O
244 O
R O
) O
, O
two O
nonsense O
mutations O
( O
Q O
184 O
X O
, O
E O
214 O
X O
) O
, O
three O
deletions O
( O
923 O
del O
T O
, O
33 O
del O
13 O
, O
244 O
del O
A O
) O
, O
one B
insertion I
mutation I
( I
698 I
ins I
C I
) I
, O
two O
sequence O
variations O
in O
one O
allele O
( O
[ O
10 O
T O
> O
G O
; O
11 O
ins O
G O
] O
) O
, O
an O
elimination B
of I
the I
stop I
codon I
( I
941 I
A I
> I
G I
, I
TAG I
- I
- I
> I
TGG I
, O
X O
314 O
W O
) O
, O
and O
one O
splice O
acceptor O
site O
mutation O
( O
IVS O
1 O
- O
2 O
A O
> O
T O
) O
. O

The O
IVS O
1 O
- O
2 O
A O
> O
T O
mutation O
caused O
the O
retention B
of I
40 I
nucleotides I
of I
intron I
1 I
upstream I
of I
exon I
2 I
. O

One O
was O
transition B
from I
guanine I
to I
adenine I
at I
nucleotide I
position I
1002 I
, O
resulting O
in O
substitution B
of I
aspartate I
for I
asparagine I
at I
codon I
103 I
, O
and O
the O
other O
was O
transition B
from I
cytosine I
to I
thymine I
at I
nucleotide I
1104 I
, O
leading B
to I
substitution I
of I
arginine I
for I
tryptophan I
at I
codon I
137 I
. O

Fibrinogen O
Lima O
: O
a O
homozygous O
dysfibrinogen O
with O
an O
A O
alpha O
- O
arginine B
- I
141 I
to I
serine I
substitution I
associated O
with O
extra O
N O
- O
glycosylation O
at O
A O
alpha O
- O
asparagine O
- O
139 O
. O

An O
A O
alpha O
- O
arginine B
- I
141 I
to I
serine I
substitution I
has O
been O
identified O
in O
a O
homozygous O
dysfibrinogen O
, O
fibrinogen O
Lima O
, O
associated O
with O
impaired O
fibrin O
polymerization O
. O

Thus O
the O
impaired O
fibrin O
gel O
formation O
could O
be O
attributed O
to O
the O
delay O
in O
their O
subsequent O
lateral O
association O
, O
most O
probably O
because O
of O
the O
repulsive O
forces O
generated O
by O
the O
negative O
electric O
charge O
of O
the O
extra O
sialic O
acids O
. O

The O
proband O
and O
affected O
individuals O
were O
heterozygotes O
for O
C O
254 O
T O
with O
proline B
converted I
to I
leucine I
( I
P I
85 I
L I
) I
. O

In O
the O
FHA O
kindred O
, O
family O
members O
heterozygous O
for O
the O
ABCA O
1 O
variant O
also O
exhibited O
corresponding O
low O
levels O
of O
HDL O
cholesterol O
. O

In O
this O
study O
, O
we O
found O
single O
- O
nucleotide O
polymorphisms O
in O
the O
human O
AADAC O
gene O
in O
a O
liver O
sample O
that O
showed O
remarkably O
low O
flutamide O
hydrolase O
activity O
. O

The O
latter O
would O
be O
predicted O
to O
cause O
a O
C B
- I
terminal I
one I
- I
amino I
acid I
( I
glutamine I
) I
extension I
. O

The O
aim O
of O
this O
study O
was O
to O
find O
possible O
mutations O
in O
this O
gene O
and O
to O
relate O
such O
findings O
to O
morbidity O
and O
prognosis O
in O
heart O
failure O
. O

A O
missense B
mutation I
was I
identified I
at I
nucleotide I
position I
145 I
in O
the O
beta O
( O
1 O
) O
- O
adrenergic O
receptor O
gene O
, O
which O
predicted O
an O
amino B
acid I
substitution I
at I
position I
49 I
( O
Ser O
49 O
Gly O
) O
. O

DESIGN O
AND O
PATIENTS O
: O
Five O
unrelated O
males O
( O
age O
range O
22 O
- O
52 O
yr O
) O
with O
clinical O
manifestations O
of O
KS O
and O
6 O
unrelated O
males O
( O
age O
range O
24 O
- O
47 O
yr O
) O
with O
NHH O
were O
analyzed O
. O

RESULTS O
: O
The O
1 O
st O
patient O
had O
a O
single O
missense O
mutation O
in O
his O
copy O
of O
the O
KAL O
1 O
gene O
, O
a B
T I
→ I
G I
transversion I
in I
codon I
134 I
that I
results I
in I
replacement I
of I
cysteine I
by I
gly I
cine I
. O

The O
2 O
nd O
affected O
subject O
had O
a O
single O
missense O
mutation O
in O
the O
KAL O
1 O
gene O
, O
a O
T B
→ I
C I
transition I
in I
codon I
163 I
that I
results I
in I
replacement I
of I
cysteine I
by I
arginine I
. O

The O
3 O
rd O
case O
was O
hemizygous O
for O
a O
nonsense B
mutation I
in I
codon I
424 I
of I
exon I
9 I
( I
c I
. I
CGA I
→ I
TGA I
) I
of O
the O
KAL O
1 O
gene O
. O

This O
result O
suggests O
that O
there O
are O
likely O
to O
be O
critical O
differences O
in O
the O
murine O
and O
human O
cyclin O
T O
1 O
proteins O
. O

A O
mouse O
cyclin O
T O
1 O
protein O
containing O
a O
substitution O
of O
tyrosine B
residue I
261 I
with I
a I
cysteine I
residue I
, O
was O
able O
to O
interact O
with O
Tat O
and O
stimulate O
tat O
- O
transactivation O
in O
rodent O
cells O
. O

Likewise O
, O
substitution O
of O
a O
cysteine B
residue I
for I
an I
asparagine I
residue I
at I
position I
260 I
of O
the O
cyclin O
T O
2 O
a O
and O
T O
2 O
b O
proteins O
also O
resulted O
in O
their O
ability O
to O
interact O
with O
Tat O
and O
stimulate O
tat O
- O
activation O
in O
rodent O
cells O
. O

However O
, O
the O
molecular O
cues O
that O
control O
14 O
- O
3 O
- O
3 O
dimerization O
are O
not O
well O
understood O
. O

Substitution B
of I
Ser I
58 I
to I
Ala I
completely O
abolished O
phosphorylation O
of O
14 O
- O
3 O
- O
3 O
zeta O
by O
PKA O
. O

A O
phospho O
- O
mimic O
mutant O
of O
14 O
- O
3 O
- O
3 O
zeta O
, O
Ser B
58 I
to I
Glu I
substitution I
, O
failed O
to O
form O
homodimers O
, O
showed O
reduced O
interaction O
with O
14 O
- O
3 O
- O
3 O
epsilon O
and O
p O
53 O
, O
and O
could O
not O
enhance O
transcriptional O
activity O
of O
p O
53 O
. O

RESULTS O
: O
The O
PFIC O
2 O
patient O
was O
compound O
heterozygous O
for O
a O
splicing O
mutation O
in O
intron B
4 I
( I
( I
+ I
3 I
) I
A I
> I
C I
) I
combined O
with O
an O
early B
stop I
codon I
at I
position I
930 I
( O
R O
930 O
X O
) O
, O
while O
the O
BRIC O
2 O
patient O
was O
compound O
heterozygous O
for O
two O
nonsynonymous O
mutations O
in O
exon O
9 O
( O
E O
297 O
G O
) O
and O
exon O
12 O
( O
R O
432 O
T O
) O
, O
respectively O
. O

In O
BRIC O
2 O
, O
taurocholate O
transport O
was O
decreased O
to O
13 O
% O
and O
20 O
% O
of O
reference O
levels O
for O
R O
432 O
T O
and O
E O
297 O
G O
, O
respectively O
. O

CONCLUSIONS O
: O
The O
intron B
4 I
( I
+ I
3 I
) I
A I
> I
C I
, O
R O
930 O
X O
and O
R O
432 O
T O
represent O
previously O
undescribed O
mutations O
of O
the O
ABCB O
11 O
gene O
that O
confer O
a O
PFIC O
2 O
and O
a O
BRIC O
2 O
phenotype O
, O
respectively O
. O

A O
polymorphism O
was O
identified O
in O
the O
third O
exon O
of O
h O
AGRP O
, O
c O
. O
199 O
G O
- O
- O
> O
A O
, O
that O
resulted O
in O
a O
nonconservative B
amino I
acid I
substitution I
, I
Ala I
( I
67 I
) I
Thr I
. O

Human O
studies O
showed O
no O
genotype O
effects O
in O
individuals O
with O
a O
mean O
age O
of O
25 O
yr O
. O

By O
using O
glutathione O
S O
- O
transferase O
pull O
- O
down O
techniques O
, O
we O
found O
that O
the O
beta O
1 O
AR O
carboxyl O
terminus O
directly O
interacts O
with O
the O
cystic O
fibrosis O
transmembrane O
conductance O
regulator O
- O
associated O
ligand O
( O
CAL O
; O
also O
known O
as O
PIST O
, O
GOPC O
, O
and O
FIG O
) O
, O
a O
protein O
known O
to O
be O
primarily O
localized O
to O
the O
Golgi O
apparatus O
. O

Mutation B
of I
the I
terminal I
valine I
residue I
resulted O
in O
markedly O
reduced O
association O
of O
the O
beta O
1 O
AR O
- O
CT O
with O
CAL O
. O

In O
cells O
, O
full O
- O
length O
beta O
1 O
AR O
robustly O
associates O
with O
CAL O
, O
and O
this O
interaction O
is O
abolished O
by O
mutation B
of I
the I
terminal I
valine I
to I
alanine I
of O
the O
receptor O
( O
V O
477 O
A O
) O
, O
as O
determined O
by O
co O
- O
immunoprecipitation O
experiments O
and O
immunofluorescence O
co O
- O
localization O
studies O
. O

Here O
we O
describe O
a O
new O
class O
of O
histone O
modification O
, O
methylation B
of I
glutamine I
, I
occurring I
on I
yeast I
histone I
H I
2 I
A I
at I
position I
105 I
( I
Q I
105 I
) I
and O
human O
H O
2 O
A O
at O
Q O
104 O
. O

Glutamine O
methylation O
of O
H O
2 O
A O
is O
restricted O
to O
the O
nucleolus O
. O

Methylation B
of I
Q I
105 I
or I
its I
substitution I
to I
alanine I
disrupts O
binding O
to O
FACT O
in O
vitro O
. O

Mutational O
experiments O
were O
performed O
by O
introducing B
a I
substitution I
, I
GG I
to I
AT I
, I
into I
the I
INSM I
1 I
core I
binding O
site O
of O
the O
rat O
insulin O
I O
/ O
II O
promoters O
. O

Moreover O
, O
INSM O
1 O
overexpression O
exhibited O
no O
inhibitory O
effect O
on O
the O
mutated O
insulin O
promoter O
. O

The O
analysis O
of O
the O
dinucleotide O
microsatellites O
located O
in O
chromosome O
9 O
q O
31 O
region O
demonstrated O
that O
the O
proband O
was O
homozygous O
for O
the O
alleles O
of O
D O
9 O
S O
53 O
, O
D O
9 O
S O
1784 O
and O
D O
9 O
S O
1832 O
. O

The O
sequence O
of O
ATP O
- O
binding O
cassette O
transporter O
1 O
( O
ABC O
1 O
- O
1 O
) O
c O
DNA O
obtained O
by O
reverse O
transcription O
- O
PCR O
( O
RT O
- O
PCR O
) O
of O
total O
RNA O
isolated O
from O
cultured O
fibroblasts O
showed O
that O
the O
proband O
was O
homozygous O
for O
a O
C B
> I
T I
transition I
in I
exon I
13 I
, O
which B
caused I
a I
tryptophane I
for I
arginine I
substitution O
( O
R O
527 O
W O
) O
. O

RESULTS O
: O
Five O
missense O
mutations O
producing O
amino O
acid O
substitutions O
were O
detected O
in O
the O
four O
colon O
cancer O
cases O
( O
13 O
. O
3 O
% O
; O
four O
of O
30 O
colorectal O
cancers O
) O
: O
( B
15 I
) I
glycine I
( I
GGT I
) I
to I
alanine I
( I
GCT I
) I
and O
( B
499 I
) I
leucine I
( I
TTA I
) I
to I
isoleucine I
( I
ATA I
) I
in O
the O
same O
case O
, O
and O
( B
498 I
) I
valine I
( I
GTG I
) I
to I
glutamic I
acid I
( I
GAG I
) I
, O
( B
500 I
) I
valine I
( I
GTA I
) I
to I
glycine I
( I
GGA I
) I
, O
and O
( B
365 I
) I
serine I
( I
TCT I
) I
to I
proline I
( I
CCT I
) I
. O

Of O
these O
five O
mutations O
, O
three O
( O
60 O
% O
) O
were O
located O
in O
HEAT O
repeat O
13 O
and O
four O
( O
80 O
% O
) O
showed O
T O
to O
other O
nucleotide O
substitutions O
. O

Presenile O
dementia O
and O
cerebral O
haemorrhage O
linked O
to O
a O
mutation B
at I
codon I
692 I
of O
the O
beta O
- O
amyloid O
precursor O
protein O
gene O
. O

Several O
families O
with O
an O
early O
- O
onset O
form O
of O
familial O
Alzheimer O
' O
s O
disease O
have O
been O
found O
to O
harbour O
mutations B
at I
a I
specific I
codon I
( I
717 I
) I
of O
the O
gene O
for O
the O
beta O
- O
amyloid O
precursor O
protein O
( O
APP O
) O
on O
chromosome O
21 O
. O

The O
mutation O
results O
in O
the O
substitution B
of I
alanine I
into I
glycine I
at I
codon I
692 I
. O

The O
F O
allele O
differed O
from O
the O
normal O
M O
1 O
( B
Val I
213 I
) I
alpha I
1 I
AT I
allele I
by I
a I
single I
nucleotide I
transversion I
of I
cytosine I
to I
thymidine I
, O
which O
results O
in O
the O
amino O
acid O
substitution O
Arg O
223 O
CGT O
- O
- O
- O
- O
Cys O
TGT O
. O

We O
identified O
five O
novel O
mutations O
in O
nine O
families O
with O
P O
5 O
N O
- O
I O
deficiency O
: O
two B
missense I
mutations I
( I
425 I
C I
, I
721 I
C I
) I
, I
one B
splice I
mutation I
( I
339 I
C I
) I
, O
one B
1 I
- I
bp I
insertion I
( I
251 I
- I
ins I
A I
- I
252 I
) I
and O
one O
9 B
- I
bp I
deletion I
( I
del I
192 I
- I
200 I
) I
. O

The O
mutant O
P O
5 O
N O
was O
then O
expressed O
in O
Cos O
- O
7 O
. O

Harlequin O
ichthyosis O
( O
HI O
) O
is O
one O
of O
the O
most O
devastating O
genodermatoses O
. O

This O
patient O
with O
moderate O
clinical O
severity O
was O
compound O
heterozygous O
for O
a O
novel O
de O
novo O
missense O
mutation O
1160 B
G I
> I
A I
( I
S I
387 I
N I
) I
in I
exon I
10 I
and O
a O
maternal O
deletion B
mutation I
4158 I
_ I
4160 I
del I
TAC I
( I
T I
1387 I
del I
) I
in I
exon I
28 I
of O
ABCA O
12 O
. O

T O
1387 O
del O
was O
a O
deletion B
of I
a I
highly I
conserved I
threonine I
residue I
within I
the I
first I
adenosine I
5 I
' I
triphosphate I
- I
binding I
domain I
and O
is O
thought O
to O
seriously O
affect O
the O
function O
of O
the O
ABCA O
12 O
protein O
. O

A O
homozygous B
G I
> I
A I
substitution I
( I
c I
. I
666 I
G I
> I
A I
) I
at I
the I
last I
nucleotide I
of I
exon I
6 I
in O
the O
ALDH O
1 O
A O
3 O
gene O
was O
identified O
in O
the O
first O
family O
. O

Further O
c O
DNA O
sequencing O
of O
ALDH O
1 O
A O
3 O
showed O
that O
the O
c O
. O
666 O
G O
> O
A O
mutation O
caused O
skipping O
of O
exon O
6 O
, O
which O
predicted O
in B
- I
frame I
loss I
of I
43 I
amino I
acids I
( O
p O
. O
Trp O
180 O
_ O
Glu O
222 O
del O
) O
. O

A O
novel B
missense I
c I
. I
1398 I
C I
> I
A I
mutation I
in I
exon I
12 I
of O
ALDH O
1 O
A O
3 O
that O
causes O
the O
substitution B
of I
a I
conserved I
asparagine I
by I
lysine I
at I
amino I
acid I
position I
466 I
( O
p O
. O
Asn O
466 O
Lys O
) O
was O
observed O
in O
the O
second O
family O
. O

Autistic O
- O
like O
behaviour O
and O
mental O
retardation O
were O
observed O
in O
three O
cases O
. O

The O
Ahrb O
- O
1 O
allele O
, O
found O
in O
the O
C O
57 O
BL O
and O
C O
57 O
BR O
strains O
, O
encodes O
a O
95 O
k O
Da O
receptor O
with O
an O
affinity O
for O
ligand O
15 O
- O
20 O
times O
higher O
than O
the O
affinity O
of O
the O
104 O
k O
Da O
receptor O
encoded O
by O
the O
Ahrd O
allele O
, O
found O
in O
the O
DBA O
/ O
2 O
strain O
. O

Of O
the O
other O
five O
, O
one O
changes O
the O
opal B
termination I
codon I
in I
Ahrb I
- I
1 I
to I
the I
codon I
for I
Arg I
in O
Ahrd O
, O
extending O
translation O
of O
the O
m O
RNA O
by O
43 O
amino O
acids O
and O
accounting O
for O
the O
larger O
size O
of O
the O
Ah O
R O
peptide O
in O
DBA O
/ O
2 O
mice O
. O

One O
of O
the O
four O
remaining O
differences O
causes O
the O
replacement B
of I
a I
leucine I
residue I
in I
Ahrb I
- I
1 I
by I
a I
proline I
residue I
in I
Ahrd I
, I
and I
breaks I
a I
potential I
alpha I
- I
helix I
near I
the I
Ah I
R I
Q I
- I
rich I
region I
; O
it O
is O
likely O
that O
structural O
changes O
associated O
with O
this O
amino O
acid O
change O
are O
responsible O
for O
the O
differences O
in O
agonist O
affinity O
observed O
between O
the O
Ah O
receptors O
of O
these O
two O
strains O
of O
mice O
. O

We O
found O
that O
the O
locus B
D I
17 I
S I
829 I
was I
homozygously I
deleted I
in O
23 O
out O
of O
70 O
patients O
, O
and O
identified O
a O
novel O
gene O
, O
CTNS O
, O
which O
mapped O
to O
the O
deletion O
interval O
. O

We O
also O
evaluated O
the O
functional O
properties O
of O
C O
5 O
as O
it O
was O
encoded O
in O
these O
patients O
. O

CONCLUSIONS O
: O
The O
functional O
capacity O
of O
C O
5 O
variants O
with O
mutations B
at I
Arg I
885 I
, O
together O
with O
their O
failure O
to O
undergo O
blockade O
by O
eculizumab O
, O
account O
for O
the O
poor O
response O
to O
this O
agent O
in O
patients O
who O
carry O
these O
mutations O
. O

Molecular O
basis O
of O
an O
adult O
form O
of O
Sandhoff O
disease O
: O
substitution B
of I
glutamine I
for I
arginine I
at I
position I
505 I
of O
the O
beta O
- O
chain O
of O
beta O
- O
hexosaminidase O
results O
in O
a O
labile O
enzyme O
. O

Sequence O
analysis O
of O
the O
entire O
c O
DNA O
prepared O
from O
poly O
- O
adenylated O
RNA O
showed O
that O
only O
one O
point O
mutation O
was O
present O
, O
consisting O
of O
a O
G B
- I
- I
> I
A I
transition I
at I
nucleotide I
position I
1514 I
. O

This O
mutation O
changes B
the I
electric I
charge I
at I
amino I
acid I
position I
505 I
by I
substitution I
of I
glutamine I
for I
arginine I
in O
a O
highly O
conserved O
part O
of O
the O
beta O
- O
chain O
, O
present O
even O
in O
the O
slime O
mold O
Dictyostelium O
discoideum O
. O

Transfection O
of O
COS O
cells O
with O
a O
c O
DNA O
construct O
containing O
the O
mutation O
but O
otherwise O
the O
normal O
sequence O
resulted O
in O
the O
expression O
of O
a O
labile O
form O
of O
beta O
- O
hexosaminidase O
. O

However O
, O
the O
extent O
to O
which O
resting O
heart O
rate O
is O
genetically O
determined O
is O
poorly O
understood O
, O
and O
no O
genes O
have O
been O
found O
that O
contribute O
to O
variation O
in O
resting O
heart O
rate O
. O

A O
cohort O
of O
> O
1 O
, O
000 O
individuals O
of O
Chinese O
and O
Japanese O
descent O
, O
from O
nuclear O
families O
, O
was O
genotyped O
for O
two O
polymorphisms O
, O
resulting O
in O
a O
serine B
/ I
glycine I
substitution I
at I
amino I
acid I
49 I
( O
Ser O
49 O
Gly O
) O
and O
an O
arginine B
/ I
glycine I
substitution I
at I
residue I
389 I
( O
Arg O
389 O
Gly O
) O
, O
in O
the O
beta O
1 O
adrenergic O
receptor O
. O

SLS O
has O
been O
reported O
to O
occur O
in O
many O
populations O
but O
the O
highest O
incidence O
is O
in O
the O
north O
of O
Sweden O
. O

The O
mutation O
consists O
of O
a O
C B
- I
to I
- I
T I
exchange I
at I
nucleotide I
position I
943 I
in O
the O
c O
DNA O
. O

Because O
ADAMTS O
- O
1 O
has O
a O
potential O
zinc O
- O
binding O
motif O
in O
the O
metalloproteinase O
domain O
, O
we O
examined O
in O
this O
study O
whether O
ADAMTS O
- O
1 O
is O
an O
active O
metalloproteinase O
by O
means O
of O
the O
proteinase O
trapping O
mechanism O
of O
alpha O
2 O
- O
macroglobulin O
. O

In O
addition O
, O
we O
showed O
that O
the O
removal B
of I
the I
pro I
- I
domain I
from O
the O
ADAMTS O
- O
1 O
precursor O
is O
impaired O
in O
the O
furin O
- O
deficient O
cell O
line O
, O
Lo O
Vo O
, O
and O
that O
the O
processing O
ability O
of O
the O
cells O
is O
restored O
by O
the O
co O
- O
expression O
of O
the O
furin O
c O
DNA O
. O

Extracellular O
- O
regulated O
kinase O
3 O
( O
ERK O
3 O
, O
MAPK O
6 O
) O
is O
an O
atypical O
member O
of O
the O
ERKs O
, O
lacking B
the I
threonine I
and I
tyrosine I
residues I
in I
the I
activation I
loop I
, O
carrying O
a O
unique O
C O
- O
terminal O
extension O
and O
being O
mainly O
regulated O
by O
its O
own O
protein O
stability O
and O
/ O
or O
by O
autophosphorylation O
. O

Deletion B
of I
MK I
5 I
leads O
to O
strong O
reduction O
of O
ERK O
3 O
protein O
levels O
and O
embryonic O
lethality O
at O
about O
stage O
E O
11 O
, O
where O
ERK O
3 O
expression O
in O
wild O
- O
type O
mice O
is O
maximum O
, O
indicating O
a O
role O
of O
this O
signalling O
module O
in O
development O
. O

A O
* O
2406 O
and O
A O
* O
2413 O
both O
have O
two O
adjacent O
( O
but O
different O
) O
nucleotide O
substitutions B
in I
codon I
156 I
in I
exon I
3 I
compared O
to O
A O
* O
2402 O
, O
resulting O
in O
a O
single O
amino O
acid O
replacement O
in O
each O
allele O
. O

The O
South O
American O
A O
* O
2414 O
is O
apparently O
a O
hybrid O
between O
A O
2 O
and O
A O
24 O
with O
a O
segment O
of O
the O
A O
* O
24 O
sequence B
between I
codons I
95 I
and I
107 I
in I
exon I
3 I
replaced I
with I
the I
A I
* I
02 I
sequence I
. O

The O
single B
amino I
acid I
replacements I
in I
position I
156 I
of O
the O
two O
Australian O
Aboriginal O
A O
* O
24 O
alleles O
may O
also O
have O
significant O
functional O
effects O
. O

In O
particular O
, O
Trp B
replacing I
Gln I
in I
position I
156 I
( O
A O
* O
2406 O
) O
is O
predicted O
to O
markedly O
reduce O
the O
volume O
of O
the O
peptide O
binding O
cleft O
, O
influence O
the O
interaction O
of O
HLA O
pockets O
with O
peptide O
side O
chains O
, O
and O
therefore O
, O
cause O
major O
changes O
in O
peptide O
presentation O
. O

Substituting B
Glu I
334 I
in I
motif I
I I
or I
Glu I
1086 I
in I
motif I
III I
with I
Lys I
produced O
mutant O
calcium O
channels O
that O
permeated O
sodium O
ions O
10 O
- O
fold O
more O
effectively O
than O
barium O
ions O
. O

More O
conservative O
changes O
such O
as O
substitution B
of I
Glu I
1086 I
with I
Gln I
or O
substitution B
of I
Glu I
1387 I
with I
Ala I
also O
increased O
sodium O
permeation O
through O
the O
mutant O
calcium O
channels O
. O

The O
gene O
encoding O
the O
human O
C O
( O
27 O
) O
3 O
beta O
- O
HSD O
enzyme O
was O
isolated O
previously O
, O
and O
a O
2 B
- I
bp I
deletion I
in I
exon I
6 I
of O
HSD O
3 O
B O
7 O
was O
identified O
in O
a O
well O
characterized O
subject O
with O
this O
disorder O
. O

Ten O
mutations O
were O
studied O
in O
detail O
and O
shown O
to O
cause O
complete O
loss O
of O
enzyme O
activity O
and O
, O
in O
two O
cases O
, O
alterations O
in O
the O
size O
or O
amount O
of O
the O
transcribed O
m O
RNA O
. O

Mprocida O
, O
a O
rare O
alpha O
1 O
AT O
allele O
associated O
with O
alpha O
1 O
AT O
serum O
levels O
less O
than O
10 O
mg O
/ O
dl O
( O
normal O
150 O
- O
350 O
mg O
/ O
dl O
) O
, O
codes O
for O
an O
alpha O
1 O
AT O
molecule O
that O
focuses O
on O
immobilized O
p O
H O
gradient O
isoelectric O
gels O
slightly O
cathodal O
to O
the O
common O
normal O
M O
1 O
( O
Val O
213 O
) O
protein O
. O

Sequencing O
of O
all O
the O
exons O
, O
exon O
- O
intron O
junctions O
, O
and O
the O
major O
promoter O
region O
demonstrated O
Mprocida O
to O
be O
identical O
to O
the O
M B
1 I
( I
Val I
213 I
) I
gene I
except I
for I
a I
single I
base I
substitution I
in I
exon I
II I
coding I
for I
amino I
acid I
41 I
of O
the O
mature O
protein O
( B
M I
1 I
( I
Val I
213 I
) I
Leu I
41 I
CTG I
- I
- I
- I
- I
Mprocida I
Pro I
41 I
CCG I
) I
. O

Evaluation O
of O
the O
crystallographic O
structure O
of O
alpha O
1 O
AT O
suggests O
the O
Leu B
41 I
to I
Pro I
41 I
mutation O
may O
disrupt O
alpha O
- O
helix O
A O
in O
the O
region O
of O
Pro O
21 O
- O
Ser O
45 O
, O
suggesting O
the O
possibility O
that O
the O
alpha O
1 O
AT O
Mprocida O
molecule O
is O
unstable O
and O
degraded O
intracellularly O
prior O
to O
secretion O
. O

The O
proto O
- O
oncogene O
c O
- O
kit O
encodes O
a O
transmembrane O
tyrosine O
protein O
kinase O
receptor O
for O
an O
unknown O
ligand O
and O
is O
allelic O
with O
the O
murine O
white O
- O
spotting O
locus O
( O
W O
) O
. O

We O
show O
that O
W O
37 O
, O
Wv O
and O
W O
41 O
are O
the O
result O
of O
missense O
mutations O
in O
the O
kinase O
domain O
of O
the O
c O
- O
kit O
coding O
sequence O
( O
W O
37 O
E O
- O
- O
- O
- O
K O
at O
position O
582 O
; O
Wv B
T I
- I
- I
- I
- I
M I
position I
660 I
and O
W O
41 O
V O
- O
- O
- O
- O
M O
position O
831 O
) O
, O
which O
affect O
the O
c O
- O
kit O
associated O
tyrosine O
kinase O
to O
varying O
degrees O
. O

The O
W O
mutation O
is O
the O
result O
of O
a O
78 B
amino I
acid I
deletion I
which I
includes I
the I
transmembrane I
domain I
of O
the O
c O
- O
kit O
protein O
. O

Membrane O
type O
matrix O
metalloproteinases O
( O
MT O
- O
MMPs O
) O
play O
a O
critical O
role O
in O
promoting O
cell O
growth O
and O
migration O
within O
the O
extracellular O
matrix O
by O
trafficking O
to O
specialized O
areas O
. O

Deletion B
of I
the I
EWV I
signal I
impairs O
the O
recycling O
of O
MT O
5 O
- O
MMP O
without O
affecting O
its O
internalization O
, O
leading O
to O
decreased O
activity O
on O
the O
cell O
surface O
. O

The O
insert B
contains I
the I
coding I
sequences I
for I
the I
mature I
alpha I
2 I
M I
polypeptide I
( I
1451 I
amino I
acids I
) I
and O
for O
a O
23 B
- I
amino I
acid I
signal I
peptide I
at I
the I
NH I
2 I
terminus I
of I
the I
precursor I
pro I
- I
alpha I
2 I
M I
. O

At B
the I
3 I
' I
end I
of I
the I
insert I
a I
poly I
( I
A I
) I
addition I
signal I
A I
- I
A I
- I
T I
- I
A I
- I
A I
- I
A I
and I
part I
of I
the I
poly I
( I
A I
) I
tail I
of I
the I
messenger I
RNA I
were I
found I
. O

Here O
we O
report O
the O
identification O
of O
a O
somatic O
mutation O
in O
human O
breast O
, O
colorectal O
and O
ovarian O
cancers O
that O
results O
in O
a O
glutamic B
acid I
to I
lysine I
substitution I
at I
amino I
acid I
17 I
( O
E O
17 O
K O
) O
in O
the O
lipid O
- O
binding O
pocket O
of O
AKT O
1 O
. O

Six O
patients O
were O
compound O
heterozygotes O
; O
7 O
of O
10 O
mutations O
found O
were O
novel O
, O
including O
one O
deletion O
( O
delta O
1019 O
- O
1020 O
) O
, O
three B
missense I
( I
Arg I
156 I
> I
His I
, O
Arg O
101 O
> O
Leu O
, O
Val O
177 O
> O
Met O
) O
, O
and O
three O
splicing O
defects O
( O
IVS B
5 I
, I
5 I
' I
ss I
T I
+ I
6 I
> I
A I
; O
IVS B
10 I
, I
5 I
' I
ss I
G I
+ I
1 I
> I
A I
; O
IVS B
10 I
, I
3 I
' I
ss I
G I
- I
34 I
> I
A I
) O
. O

The O
oldest O
patient O
diagnosed O
was O
homozygous O
for O
a O
single B
base I
change I
in I
intron I
10 I
, O
which O
activates O
a O
cryptic O
splice O
acceptor O
, O
resulting O
in O
a O
protein O
with O
100 O
extra O
amino O
acids O
. O

Tissue O
- O
specific O
variation O
in O
splicing O
efficiency O
may O
also O
ameliorate O
disease O
severity O
in O
patients O
with O
splicing O
mutations O
. O

The O
neurotransmitter O
serotonin O
( O
5 O
- O
hydroxytryptamine O
, O
5 O
- O
HT O
) O
mediates O
a O
multitude O
of O
central O
nervous O
functions O
by O
activating O
5 O
- O
HT O
receptor O
subtypes O
. O

However O
, O
IVS B
6 I
+ I
31 I
C I
> I
T I
, O
IVS B
6 I
+ I
40 I
C I
> I
A I
, O
and O
1386 O
T O
> O
C O
were O
solely O
detected O
in O
bipolar O
affective O
patients O
and O
in O
none O
of O
the O
controls O
. O

The O
p O
75 O
neurotrophin O
receptor O
( O
p O
75 O
( O
NTR O
) O
) O
is O
a O
member O
of O
the O
tumor O
necrosis O
factor O
receptor O
superfamily O
with O
a O
widespread O
pattern O
of O
expression O
in O
tissues O
such O
as O
the O
brain O
, O
liver O
, O
lung O
, O
and O
muscle O
. O

Deletion B
mutagenesis I
of I
the I
p I
75 I
( I
NTR I
) I
- I
luciferase I
reporter I
identified O
the O
- O
1039 O
conserved O
E O
- O
box O
necessary O
for O
the O
regulation O
of O
p O
75 O
( O
NTR O
) O
by O
CLOCK O
and O
BMAL O
1 O
. O

Moreover O
, O
deletion B
of I
p I
75 I
( I
NTR I
) I
also O
alters O
the O
circadian O
oscillation O
of O
glucose O
and O
lipid O
homeostasis O
genes O
. O

The O
family O
of O
GLI O
zinc O
finger O
transcription O
factors O
regulates O
the O
expression O
of O
genes O
involved O
in O
many O
important O
cellular O
processes O
, O
notably O
embryonal O
development O
and O
cellular O
differentiation O
. O

Here O
, O
we O
report O
the O
identification O
of O
a O
novel O
truncated O
GLI O
1 O
splice O
variant O
, O
t O
GLI O
1 O
, O
with O
an O
in B
- I
frame I
deletion I
of I
123 I
bases I
( I
41 I
codons I
) I
spanning I
the I
entire I
exon I
3 I
and I
part I
of I
exon I
4 I
of O
the O
GLI O
1 O
gene O
. O

Here O
we O
report O
on O
the O
isolation O
of O
a O
splice O
variant O
( O
gas O
6 O
SV O
) O
characterised O
by O
an O
in B
- I
frame I
129 I
bp I
insertion I
between I
the I
fourth I
EGF I
domain I
and I
the I
D I
domain I
. O

Levels O
were O
also O
normal O
in O
a O
HUVEC O
with O
deletion B
of I
S I
232 I
in O
the O
ATP O
binding O
site O
of O
ALK O
- O
1 O
. O

However O
, O
in O
the O
absence O
of O
ligand O
, O
ALK O
- O
1 O
and O
endoglin O
interactions O
were O
observed O
by O
immunoprecipitation O
/ O
western O
blot O
in O
HUVEC O
from O
normal O
as O
well O
as O
HHT O
1 O
and O
HHT O
2 O
patients O
. O

Clinical O
characteristics O
in O
a O
kindred O
with O
early O
- O
onset O
Alzheimer O
' O
s O
disease O
and O
their O
linkage O
to O
a O
G B
- I
- I
> I
T I
change I
at I
position I
2149 I
of O
the O
amyloid O
precursor O
protein O
gene O
. O

Three O
autopsies O
in O
affected O
members O
revealed O
cerebral O
amyloid O
deposits O
and O
neurofibrillary O
tangles O
. O

Direct O
DNA O
sequencing O
revealed O
a O
G B
- I
- I
> I
T I
change I
at I
position I
2149 I
of O
the O
amyloid O
precursor O
protein O
( O
APP O
) O
gene O
that O
resulted O
in O
the O
substitution B
of I
phenylalanine I
for I
valine I
in I
the I
transmembrane I
domain I
of O
the O
mature O
protein O
. O

Heterozygosity O
for O
a O
G B
- I
- I
> I
A I
mutation I
converting I
Val I
384 I
( I
GTG I
) I
to I
Met I
( I
ATG I
) I
associated O
with O
plasmin O
inhibitor O
( O
alpha O
2 O
- O
antiplasmin O
) O
deficiency O
was O
identified O
in O
three O
family O
members O
with O
bleeding O
tendency O
. O

The O
mutation O
was O
not O
present O
in O
the O
non O
- O
affected O
family O
member O
or O
30 O
blood O
donors O
. O

In O
addition O
to O
the O
Val B
384 I
Met I
mutation I
two I
new I
polymorphisms I
Ala I
- I
26 I
( I
GCG I
) I
/ I
Val I
( I
GTG I
) I
and O
Arg O
407 O
( O
AGG O
) O
/ O
Lys O
( O
AAG O
) O
and O
one O
previously O
reported O
polymorphism O
Arg O
6 O
( O
CGG O
) O
/ O
Trp O
( O
TGG O
) O
were O
identified O
in O
the O
plasmin O
inhibitor O
gene O
of O
the O
family O
. O

The O
allelic O
frequencies O
among O
30 O
blood O
donors O
with O
normal O
values O
of O
plasma O
plasmin O
inhibitor O
( O
functional O
) O
were O
0 O
. O
84 O
/ O
0 O
. O
16 O
for O
C O
/ O
T O
in O
codon O
- O
26 O
, O
0 O
. O
81 O
/ O
0 O
. O
19 O
for O
C O
/ O
T O
in O
codon O
6 O
and O
0 O
. O
83 O
/ O
0 O
. O
17 O
for O
G B
/ I
A I
in I
codon I
407 I
. O

Four O
of O
these O
changes O
result O
in O
G O
88 O
R O
, O
I O
154 O
N O
, O
H O
305 O
R O
and O
I O
352 O
V O
substitutions O
, O
whereas O
nine O
changes O
are O
silent O
. O

Replacement B
of I
Arg I
with I
the I
more I
ionizable I
His I
at I
position I
305 I
of O
a O
beta O
strand O
might O
directly O
affect O
catalytic O
activity O
of O
the O
enzyme O
. O

Furthermore O
, O
an O
A B
to I
C I
base I
change I
, I
at I
nucleotide I
854 I
, O
has O
been O
found O
in O
85 O
% O
of O
the O
34 O
Canavan O
alleles O
tested O
so O
far O
. O

This O
base O
change O
results O
in O
a O
missense B
Glu I
285 I
Ala I
mutation O
that O
is O
predicted O
to O
be O
part O
of O
the O
catalytic O
domain O
of O
aspartoacylase O
. O

The O
codons O
corresponding O
to O
His B
- I
295 I
, I
His I
- I
299 I
, I
or I
Glu I
- I
318 I
were I
replaced I
by I
codons I
encoding I
tyrosine I
, I
tyrosine I
, I
and I
glutamine I
, O
respectively O
. O

None O
of O
these O
mutants O
contained O
significant O
amounts O
of O
zinc O
, O
as O
determined O
by O
atomic O
absorption O
spectrometry O
, O
and O
all O
of O
them O
were O
practically O
devoid O
of O
both O
LTA O
4 O
hydrolase O
and O
peptidase O
enzyme O
activities O
. O

Codons B
encoding I
His I
- I
295 I
, I
His I
- I
299 I
, I
and I
Glu I
- I
318 I
were I
replaced I
by I
ones I
encoding I
tyrosine I
, I
leucine I
, I
and I
alanine I
, O
respectively O
, O
and O
the O
three O
mutants O
were O
expressed O
in O
E O
. O
coli O
. O

A O
polymorphism O
in O
the O
coding O
portion O
of O
the O
alpha O
4 O
gene O
was O
found O
( O
1587 B
A I
to I
G I
) O
which O
should O
result O
in O
a O
threonine B
/ I
alanine I
substitution I
at I
position I
529 I
( O
T O
529 O
A O
) O
. O

Thus O
, O
it O
may O
be O
that O
the O
Chrna O
4 O
T O
529 O
A O
substitution O
leads O
to O
a O
difference O
in O
the O
ratio O
of O
the O
two O
receptor O
forms O
which O
then O
promotes O
differences O
in O
receptor O
function O
, O
as O
well O
as O
differential O
behavioural O
sensitivity O
to O
nicotine O
. O

By O
analysis O
of O
Ba O
/ O
F O
3 O
cells O
retrovirally O
transduced O
to O
express O
c O
- O
Kit O
receptors O
, O
phenylalanine B
substitution I
of I
c I
- I
Kit I
tyrosine I
residue I
569 I
was O
shown O
to O
be O
associated O
with O
disruption O
of O
c O
- O
Kit O
- O
SHP O
- O
1 O
binding O
and O
induction O
of O
hyperproliferative O
responses O
to O
stem O
cell O
factor O
. O

Although O
phenylalanine B
substitution I
of I
c I
- I
Kit I
tyrosine I
residue I
567 I
in O
the O
Ba O
/ O
F O
3 O
- O
c O
- O
Kit O
cells O
did O
not O
alter O
SHP O
- O
1 O
binding O
to O
c O
- O
Kit O
, O
the O
capacity O
of O
a O
second O
c O
- O
Kit O
- O
binding O
tyrosine O
phosphatase O
, O
SHP O
- O
2 O
, O
to O
associate O
with O
c O
- O
Kit O
was O
markedly O
reduced O
, O
and O
the O
cells O
again O
showed O
hyperproliferative O
responses O
to O
stem O
cell O
factor O
. O

METHODS O
: O
Through O
clinical O
research O
, O
we O
study O
the O
clinical O
characteristic O
of O
the O
OI O
household O
. O

RESULTS O
: O
We O
found O
a O
G B
and I
A I
heterozygosis I
mutation I
at I
the I
exon I
48 I
causing O
an O
a O
1 O
( O
I O
) O
p O
. O
G O
1157 O
D O
substitution O
in O
the O
proband O
and O
his O
sister O
who O
is O
also O
a O
sufferer O
of O
OI O
. O

Finally O
, O
we O
analyzed O
the O
consequences O
of O
a O
genetic O
deletion B
of I
AMP O
- O
activated O
protein O
kinase O
in O
mouse O
adipocytes O
. O

Conversely O
, O
when O
AMP O
- O
activated O
protein O
kinase O
activity O
is O
decreased O
either O
by O
a O
dominant O
negative O
form O
or O
in O
AMP O
- O
activated O
protein O
kinase O
alpha O
( O
1 O
) O
knock B
- I
out I
mice O
, O
lipolysis O
is O
increased O
. O

We O
conclude O
that O
, O
in O
mature O
adipocytes O
, O
AMP O
- O
activated O
protein O
kinase O
activation O
has O
a O
clear O
anti O
- O
lipolytic O
effect O
. O

Direct O
sequencing O
of O
DNA O
from O
a O
family O
with O
autopsy O
- O
proven O
Alzheimer O
' O
s O
disease O
revealed O
a O
single B
amino I
acid I
substitution I
( I
Phe I
for I
Val I
) I
in I
the I
transmembrane I
domain I
of O
the O
amyloid O
precursor O
protein O
. O

Electrophysiological O
recordings O
from O
ventricular O
myocytes O
isolated O
from O
animals O
with O
a O
targeted O
deletion B
of I
the I
Kv I
1 I
. I
4 I
gene O
( O
Kv O
1 O
. O
4 O
- O
/ O
- O
mice O
) O
reveal O
that O
Ito O
, O
s O
is O
undetectable O
in O
cells O
isolated O
from O
the O
left O
ventricular O
septum O
( O
n O
= O
26 O
) O
. O

Ito O
, O
f O
density O
in O
both O
apex O
and O
septum O
cells O
, O
in O
contrast O
, O
is O
not O
affected O
by O
deletion B
of I
Kv I
1 I
. I
4 I
. O

In O
addition O
, O
a O
slowly O
inactivating O
transient O
outward O
K O
+ O
current O
similar O
to O
Ito O
, O
s O
in O
wild O
- O
type O
septum O
cells O
is O
evident O
in O
myocytes O
isolated O
from O
left O
ventricular O
apex O
of O
Kv O
4 O
. O
2 O
W O
362 O
F O
- O
expressing O
transgenics O
. O

The O
results O
presented O
here O
demonstrate O
that O
the O
molecular O
correlates O
of O
Ito O
, O
f O
and O
Ito O
, O
s O
in O
adult O
mouse O
ventricle O
are O
distinct O
. O

We O
describe O
the O
genetic O
and O
kinetic O
defects O
in O
a O
congenital O
myasthenic O
syndrome O
due O
to O
the O
mutation B
epsilon I
A I
411 I
P I
in O
the O
amphipathic O
helix O
of O
the O
acetylcholine O
receptor O
( O
ACh O
R O
) O
epsilon O
subunit O
. O

Prolines B
engineered I
into I
positions I
flanking I
residue I
411 I
of I
the I
epsilon I
subunit I
greatly O
increase O
the O
range O
of O
activation O
kinetics O
similar O
to O
epsilon O
A O
411 O
P O
, O
whereas O
prolines B
engineered I
into I
positions I
equivalent I
to I
epsilon I
A I
411 I
in I
beta I
and I
delta I
subunits I
are O
without O
effect O
. O

Thus O
, O
the O
amphipathic O
helix O
of O
the O
epsilon O
subunit O
stabilizes O
the O
channel O
, O
minimizing O
the O
number O
and O
range O
of O
kinetic O
modes O
accessible O
to O
individual O
ACh O
Rs O
. O

We O
detected O
two O
rare O
naturally O
occurring O
receptor O
variants O
( O
Pro O
- O
279 O
- O
Leu O
, O
Thr O
- O
92 O
- O
Lys O
) O
and O
a O
silent O
nucleotide O
substitution O
( B
A I
- I
- I
> I
G I
) I
at I
position I
+ I
1233 I
. O

The O
Lys O
- O
92 O
variant O
was O
found O
in O
a O
single O
individual O
who O
suffered O
from O
bipolar O
affective O
disorder O
. O

Ca O
BP O
4 O
phosphorylation O
is O
greater O
in O
light O
- O
adapted O
than O
dark O
- O
adapted O
mouse O
retinas O
. O

In O
electrophysiological O
recordings O
of O
cells O
transfected O
with O
Ca O
( O
v O
) O
1 O
. O
3 O
and O
Ca O
BP O
4 O
, O
mutation O
of O
the O
serine B
37 I
to I
alanine I
abolished O
the O
effect O
of O
Ca O
BP O
4 O
in O
prolonging O
the O
Ca O
2 O
+ O
current O
through O
Ca O
( O
v O
) O
1 O
. O
3 O
channel O
, O
whereas O
inactivating O
mutations O
in O
the O
Ca O
BP O
4 O
Ca O
2 O
+ O
- O
binding O
sites O
strengthened O
Ca O
( O
v O
) O
1 O
. O
3 O
modulation O
. O

Once O
formed O
, O
polarized O
radial O
glial O
cells O
divide O
either O
symmetrically O
or O
asymmetrically O
to O
balance O
appropriate O
production O
of O
progenitor O
cells O
and O
neurons O
. O

Using O
developmental O
stage O
- O
specific O
deletion B
of I
Arl O
13 O
b O
in O
mouse O
cortical O
progenitors O
, O
we O
found O
that O
early O
neuroepithelial O
deletion B
of I
ciliary O
Arl O
13 O
b O
led O
to O
a O
reversal O
of O
the O
apical O
- O
basal O
polarity O
of O
radial O
progenitors O
and O
aberrant O
neuronal O
placement O
. O

The O
paradigm O
for O
activation O
of O
Akt O
involves O
phosphatidylinositol O
3 O
- O
kinase O
- O
dependent O
membrane O
localization O
followed O
by O
activating O
phosphorylation O
of O
Thr O
- O
308 O
and O
Ser O
- O
473 O
. O

Substitution B
of I
Tyr I
- I
474 I
with I
phenylalanine I
abolished O
tyrosine O
phosphorylation O
of O
Akt O
and O
resulted O
in O
up O
to O
55 O
% O
inhibition O
of O
Akt O
activation O
, O
indicating O
phosphorylation O
at O
Tyr O
- O
474 O
is O
required O
for O
full O
activation O
of O
the O
kinase O
. O

The O
eight O
novel O
mutations O
identified O
included O
1 O
- O
and O
4 B
- I
bp I
deletions I
( I
32 I
delta I
T I
and O
876 O
delta O
AGAA O
, O
respectively O
) O
and O
I O
16 O
T O
, O
G O
27 O
R O
, O
D O
114 O
E O
, O
G O
123 O
E O
, O
C O
152 O
Y O
, O
and O
R O
168 O
C O
missense O
mutations O
. O

The O
homozygous O
32 O
delta B
T I
deletion I
was O
identified O
in O
the O
only O
known O
patient O
of O
African O
- O
American O
origin O
with O
Canavan O
disease O
. O

In O
vitro O
expression O
of O
mutant O
c O
DNA O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to O
a O
deficiency O
of O
ASPA O
and O
should O
therefore O
result O
in O
Canavan O
disease O
. O

Sequence O
analysis O
revealed O
a O
novel O
point O
mutation O
in O
exon O
4 O
of O
SUR O
1 O
, O
predicting O
a O
valine B
to I
aspartic I
acid I
change I
at I
amino I
acid I
187 I
( I
V I
187 I
D I
) I
. O

Thus O
, O
the O
mutation O
produces O
a O
nonfunctional O
channel O
and O
, O
thereby O
, O
continuous O
insulin O
secretion O
. O

A O
leucine B
55 I
- I
to I
- I
proline I
substitution O
causing O
a O
defective O
ACT O
allele O
( O
Bochum O
- O
1 O
) O
was O
observed O
in O
a O
family O
with O
COPD O
in O
three O
subsequent O
generations O
. O

Another O
mutation O
, O
proline B
229 I
- I
to I
- I
alanine I
( O
Bonn O
- O
1 O
) O
, O
was O
associated O
with O
ACT O
serum O
deficiency O
in O
four O
patients O
with O
a O
positive O
family O
history O
. O

The O
disease O
is O
caused O
by O
mutations O
in O
the O
aspartoacylase O
gene O
. O

A O
deletion B
of I
exon I
4 I
, O
which O
until O
now O
had O
only O
been O
described O
once O
, O
was O
revealed O
in O
all O
five O
alleles O
of O
Turkish O
origin O
tested O
, O
indicating O
that O
this O
is O
a O
founder O
effect O
in O
the O
Turkish O
population O
. O

Two O
splice O
variants O
of O
protein O
kinase O
B O
gamma O
have O
different O
regulatory O
capacity O
depending O
on O
the O
presence B
or I
absence I
of I
the I
regulatory I
phosphorylation I
site I
serine I
472 I
in I
the I
carboxyl I
- I
terminal I
hydrophobic I
domain I
. O

Chem O
. O

Here O
we O
report O
the O
isolation O
of O
human O
and O
mouse O
PKB O
gamma O
1 O
, O
a O
splice B
variant I
lacking I
the I
second I
regulatory I
phosphorylation I
site I
Ser I
- I
472 I
in I
the I
hydrophobic I
C I
- I
terminal I
domain I
. O

Mutation B
of I
this I
site I
( I
Ala I
( I
345 I
, I
346 I
) I
beta O
( O
2 O
) O
AR O
) O
significantly O
reduced O
the O
rate O
and O
extent O
of O
the O
rapid O
desensitization O
promoted O
by O
sustained O
treatment O
with O
the O
agonist O
isoproterenol O
. O

We O
found O
this O
mutant O
receptor O
to O
be O
phosphorylated O
upon O
receptor O
activation O
but O
not O
following O
direct O
activation O
of O
PKA O
, O
suggesting O
a O
role O
in O
receptor O
- O
specific O
( O
homologous O
) O
but O
not O
heterologous O
phosphorylation O
. O

Taken O
with O
the O
observation O
that O
mutation B
of I
either I
Ser I
( I
345 I
, I
346 I
) I
or O
of O
the O
beta O
ARK O
phosphorylation O
sites O
prevented O
both O
the O
hyper O
- O
phosphorylation O
and O
constitutive O
desensitization O
of O
a O
palmitoylation B
- I
less I
mutant I
( I
Gly I
( I
341 I
) O
beta O
( O
2 O
) O
AR O
) O
, O
our O
data O
suggest O
a O
concerted O
/ O
synergistic O
action O
of O
the O
two O
kinases O
that O
depends O
on O
the O
palmitoylation O
state O
of O
the O
receptor O
. O

One O
mutation O
present O
in O
homozygous O
form O
converted B
the I
negatively I
charged I
Asp I
107 I
, I
located I
in I
the I
third I
transmembrane I
domain I
, I
to I
an I
uncharged I
Asn I
residue I
. O

The O
second O
patient O
was O
a O
compound O
heterozygote O
: O
the O
paternal O
allele O
contained O
a O
one O
- O
nucleotide O
insertion O
leading O
to O
a O
stop O
codon O
within O
the O
third O
extracellular O
loop O
, O
and O
the O
maternal B
allele I
contained I
a I
point I
mutation I
converting I
Cys I
251 I
to I
Phe I
, O
also O
in O
the O
third O
extracellular O
loop O
. O

Normal O
and O
mutant O
ACTH O
receptor O
genes O
were O
expressed O
in O
the O
M O
3 O
cell O
line O
, O
and O
intracellular O
c O
AMP O
production O
in O
response O
to O
ACTH O
was O
measured O
. O

BTK O
* O
results O
from O
a O
single O
point O
mutation O
in O
the O
pleckstrin O
homology O
( O
PH O
) O
domain O
, O
where O
a O
Glu B
is I
replaced I
by I
Lys I
at I
residue I
41 I
. O

BTK O
* O
shows O
an O
increase O
in O
phosphorylation O
on O
tyrosine O
residues O
and O
an O
increase O
in O
membrane O
targeting O
. O

In O
a O
large O
family O
with O
multiple O
branches O
, O
we O
identified O
biallelic O
variants O
in O
DCPS O
in O
three O
affected O
individuals O
; O
a O
splice O
site O
variant O
( O
c O
. O
636 O
+ O
1 O
G O
> O
A O
) O
that O
results O
in O
an O
in B
- I
frame I
insertion I
of I
45 I
nucleotides I
and O
a O
missense O
variant O
( O
c O
. O
947 O
C O
> O
T O
; O
p O
. O
Thr O
316 O
Met O
) O
. O

EDC O
3 O
stimulates O
DCP O
2 O
, O
which O
decaps O
m O
RNAs O
at O
the O
beginning O
of O
the O
5 O
' O
to O
3 O
' O
degradation O
pathway O
. O

Characterization O
of O
the O
alpha O
1 O
AT O
Mmineral O
springs O
gene O
demonstrated O
that O
it O
differed O
from O
the O
common O
normal O
M O
1 O
( B
Ala I
213 I
) I
allele I
by I
a I
single I
- I
base I
substitution I
causing I
the I
amino I
acid I
substitution I
Gly I
- I
67 I
( I
GGG I
) I
- I
- I
- I
- I
Glu I
- I
67 I
( I
GAG I
) I
. O

Evaluation O
of O
in O
vitro O
translation O
of O
Mmineral O
springs O
alpha O
1 O
AT O
m O
RNA O
transcripts O
demonstrated O
a O
normal O
capacity O
to O
direct O
the O
translation O
of O
alpha O
1 O
AT O
. O

The O
patients O
carried O
a O
homozygous O
missense O
mutation O
converting O
Asn B
100 I
to I
Ser I
in O
exon O
3 O
of O
his O
type O
II O
3 O
beta O
HSD O
gene O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O

The O
neuroendocrine O
granule O
- O
associated O
protein O
7 O
B O
2 O
, O
unlike O
many O
other O
neuroendocrine O
precursor O
proteins O
stored O
in O
secretory O
granules O
, O
carries O
in O
its O
primary O
structure O
the O
Arg O
- O
Xaa O
- O
Arg O
/ O
Lys O
- O
Arg O
processing O
site O
usually O
found O
in O
constitutively O
secreted O
precursor O
proteins O
and O
recognized O
by O
the O
ubiquitously O
expressed O
convertase O
, O
furin O
. O

Mutation O
of O
the O
P B
4 I
Arg I
to I
Gly I
completely O
prevented O
this O
conversion O
. O

Using O
a O
positional O
candidate O
- O
gene O
approach O
, O
we O
determined O
the O
ttw O
phenotype O
is O
caused O
by O
a O
nonsense O
mutation O
( O
glycine B
568 I
to I
stop I
) O
in O
the O
Npps O
gene O
which O
encodes O
nucleotide O
pyrophosphatase O
. O

Here O
, O
we O
characterize O
the O
population O
genomics O
and O
signalling O
effects O
of O
a O
polymorphism O
within O
the O
coding O
region O
of O
the O
AC O
9 O
gene O
that O
results O
in O
an O
Ile B
to I
Met I
substitution I
at I
amino I
acid I
772 I
within O
the O
C O
1 O
b O
region O
of O
the O
enzyme O
. O

Allele O
frequencies O
were O
0 O
. O
300 O
and O
0 O
. O
375 O
in O
Caucasians O
and O
Asians O
but O
were O
lower O
in O
African O
- O
Americans O
( O
0 O
. O
163 O
) O
. O

The O
functional O
effects O
were O
studied O
in O
stably O
transfected O
HEK O
293 O
cells O
recombinantly O
expressing O
equivalent O
levels O
of O
wild B
- I
type I
( I
Ile I
772 I
) I
and I
polymorphic I
( I
Met I
772 I
) I
AC O
9 O
. O

We O
report O
here O
five O
mutations O
identified O
in O
four O
patients O
: O
a O
135 B
- I
bp I
deletion I
encompassing I
bases I
343 I
- I
477 I
, O
a B
C I
- I
1837 I
- I
to I
- I
T I
transition O
( O
R O
613 O
W O
) O
, O
3 B
- I
bp I
deletions I
at I
the I
nucleotide I
positions I
388 I
- I
390 I
( I
E I
130 I
del I
) I
and O
895 O
- O
897 O
( O
K O
299 O
del O
) O
, O
and O
an O
A O
- O
1144 O
- O
to O
- O
C O
transversion O
( O
K O
382 O
Q O
) O
. O

Sequencing O
of O
genomic O
DNA O
amplified O
by O
PCR O
revealed O
a O
135 B
- I
bp I
deletion I
caused I
by I
exon I
skipping I
due I
to I
a I
1 I
- I
bp I
deletion I
in I
a I
3 I
' I
splice I
site I
of I
an I
intron I
. O

In O
c O
DNA O
expression O
experiments O
using O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
, O
we O
found O
that O
each O
of O
the O
m O
RNAs O
derived O
from O
E O
130 O
del O
and O
K O
299 O
del O
clones O
were O
unstable O
and O
that O
translation O
products O
from O
R O
613 O
W O
, O
E O
130 O
del O
, O
K O
299 O
del O
, O
and O
K O
382 O
Q O
clones O
were O
labile O
. O

Mutant O
animals O
fed O
a O
HFD O
gained O
only O
slightly O
more O
weight O
than O
animals O
fed O
regular O
chow O
, O
and O
were O
protected O
from O
hepatic O
lipid O
accumulation O
. O

The O
phenotype O
was O
genetically O
linked O
to O
a O
5 O
. O
7 O
- O
Mb O
interval O
on O
chromosome O
12 O
, O
and O
sequencing O
of O
the O
entire O
interval O
identified O
a O
single O
coding O
mutation O
, O
predicted O
to O
cause O
a O
methionine B
- I
to I
- I
isoleucine I
substitution I
at I
position I
279 I
of O
the O
Adcy O
3 O
protein O
( O
Adcy O
3 O
M O
279 O
I O
, O
henceforth O
referred O
to O
as O
Adcy O
3 O
Jll O
) O
. O

The O
highly O
polymorphic O
human O
alpha O
- O
1 O
antitrypsin O
( O
AAT O
) O
gene O
codes O
for O
the O
most O
abundant O
circulating O
plasma O
serine O
protease O
inhibitor O
. O

Nucleotide O
sequence O
comparison O
with O
the O
human O
genome O
and O
the O
AAT O
sequences O
available O
in O
the O
Gen O
Bank O
( O
NCBI O
) O
demonstrated O
four O
unique O
variations O
- O
- O
( O
i O
) O
an O
A B
to I
G I
variation I
at I
position I
286 I
( I
Thr I
96 I
Ala I
) I
, O
( O
ii O
) O
an O
A B
to I
G I
variation I
at I
position I
839 I
( I
Asp I
280 I
Gly I
) I
, O
( O
iii O
) O
a O
T B
to I
C I
variation I
at I
position I
1182 I
that I
did I
not I
result I
in I
any I
change I
in I
the I
protein I
sequence I
( I
TTT I
to I
TTC I
both I
code I
for I
Phe I
) I
and O
( O
iv O
) O
an O
A B
to I
C I
variation I
at I
position I
1200 I
( I
Glu I
400 I
Asp I
) I
that O
resulted O
in O
replacement O
by O
an O
amino O
acid O
of O
similar O
nature O
. O

Other O
variations O
found O
were O
T B
to I
C I
at I
position I
710 I
( I
Val I
273 I
Ala I
) I
and O
T B
to I
C I
position I
863 I
( I
Val I
288 I
Glu I
) I
, O
which O
were O
also O
reported O
earlier O
. O

We O
have O
identified O
a O
single B
point I
mutation I
between I
M I
1 I
Val I
213 I
and I
M I
3 I
at I
codon I
position I
376 I
which I
is I
a I
GAA I
( I
Glu I
) I
to I
GAC I
( I
Asp I
) I
transversion I
. O

Two O
common O
mutations O
were O
identified O
: O
( O
I O
) O
a O
novel O
in B
- I
frame I
deletion I
of I
three I
nucleotides I
( I
nt I
) I
in I
exon I
34 I
, O
resulting B
in I
deletion I
of I
the I
codon I
for I
F I
1388 I
( I
delta I
F I
1388 I
) I
and O
( O
II O
) O
a O
previously O
described O
g B
- I
- I
> I
a I
transition I
at I
position I
- I
9 I
of I
the I
3 I
' I
splice I
site I
of I
intron I
32 I
( I
designated I
3992 I
- I
9 I
g I
- I
- I
> I
a I
) I
. O

Extended O
haplotype O
analyses O
indicated O
that O
the O
delta O
F O
1388 O
mutation O
was O
associated O
with O
a O
single O
specific O
haplotype O
whereas O
the O
3992 B
- I
9 I
g I
- I
- I
> I
a I
mutation I
was O
primarily O
associated O
with O
a O
single O
haplotype O
but O
also O
occurred O
in O
the O
context O
of O
several O
other O
different O
haplotypes O
. O

SADB O
exerted O
this O
action O
through O
phosphorylation O
of O
gamma O
- O
tubulin O
on O
Ser O
131 O
, O
as O
expression O
of O
a O
phosphomimetic O
Ser B
131 I
- I
to I
- I
Asp I
gamma O
- O
tubulin O
mutant O
alone O
increased O
centrosome O
numbers O
, O
whereas O
non O
- O
phosphorylatable O
Ala O
131 O
- O
gamma O
- O
tubulin O
impaired O
centrosome O
duplication O
. O

To O
examine O
this O
, O
we O
studied O
its O
genomic O
structure O
by O
PCR O
and O
direct O
sequencing O
in O
a O
5 O
- O
yr O
- O
old O
proband O
with O
the O
disease O
, O
his O
parents O
, O
and O
grandparents O
. O

The O
proband O
was O
a O
compound O
heterozygote O
for O
two O
different O
point O
mutations O
, O
one O
in O
each O
allele O
: O
( O
a O
) O
a O
substitution O
( O
C O
- O
- O
> O
T O
) O
, O
also O
found O
in O
one O
allele O
of O
the O
mother O
and O
maternal O
grandmother O
, O
which O
introduced O
a O
premature B
stop I
codon I
( I
TGA I
) I
at I
position I
201 I
of O
the O
protein O
; O
this O
mutant B
receptor I
lacks I
its I
entire I
carboxy I
- I
terminal I
third I
and O
, O
if O
expressed O
, O
should O
be O
unable O
to O
transduce O
the O
signal O
; O
and O
( O
b O
) O
a O
substitution O
( O
C O
- O
- O
> O
G O
) O
, O
also O
found O
in O
one O
of O
the O
paternal O
alleles O
, O
which O
changed B
neutral I
serine I
120 I
in I
the I
apolar I
third I
transmembrane I
domain I
of I
the I
receptor I
to I
a I
positively I
charged I
arginine I
, O
probably O
disrupting O
the O
ligand O
- O
binding O
site O
. O

Previously O
, O
a O
missense O
mutation O
in O
the O
human O
ABC O
7 O
gene O
was O
shown O
to O
be O
the O
defect O
in O
members O
of O
a O
family O
affected O
with O
X O
- O
linked O
sideroblastic O
anemia O
with O
cerebellar O
ataxia O
( O
XLSA O
/ O
A O
) O
. O

A O
single B
missense I
mutation I
was I
found I
in I
exon I
10 I
of O
the O
ABC O
7 O
gene O
in O
2 O
affected O
brothers O
with O
XLSA O
/ O
A O
. O

The O
mutation O
was O
a O
G B
- I
to I
- I
A I
transition I
at I
nucleotide I
1305 I
of O
the O
full O
- O
length O
c O
DNA O
, O
resulting O
in O
a O
charge O
inversion O
caused O
by O
the O
substitution B
of I
lysine I
for I
glutamate I
at I
residue I
433 I
C I
- I
terminal I
to I
the I
putative I
sixth I
transmembrane I
domain I
of O
ABC O
7 O
. O

Expression O
of O
normal O
ABC O
7 O
almost O
fully O
complemented O
the O
defect O
in O
the O
maturation O
of O
cytosolic O
Fe O
/ O
S O
proteins O
in O
a O
yeast O
strain O
in O
which O
the O
ATM B
1 I
gene I
had I
been I
deleted I
( O
Deltaatm O
1 O
cells O
) O
. O

By O
positional O
cloning O
, O
we O
demonstrate O
that O
a O
novel O
spontaneous O
mutation O
ringelschwanz O
( O
rs O
) O
in O
the O
mouse O
is O
caused O
by O
a O
point O
mutation O
in O
Lrp O
6 O
, O
leading B
to I
an I
amino I
acid I
substitution I
of I
tryptophan I
for I
the I
evolutionarily I
conserved I
residue I
arginine I
at I
codon I
886 I
( O
R O
886 O
W O
) O
. O

Together O
, O
we O
propose O
that O
Lrp O
6 O
is O
one O
of O
the O
key O
genetic O
components O
for O
the O
pathogenesis O
of O
vertebral O
segmentation O
defects O
and O
of O
osteoporosis O
in O
humans O
. O

We O
describe O
a O
highly O
disabling O
congenital O
myasthenic O
syndrome O
( O
CMS O
) O
associated O
with O
rapidly O
decaying O
, O
low O
- O
amplitude O
synaptic O
currents O
, O
and O
trace O
its O
cause O
to O
a O
valine B
to I
leucine I
mutation I
in I
the I
signature I
cystine I
loop I
( I
cys I
- I
loop I
) I
of O
the O
ACh O
R O
alpha O
subunit O
. O

By O
contrast O
, O
mutation O
of O
the O
equivalent O
valine O
residue O
in O
the O
delta O
subunit O
impairs O
channel O
gating O
approximately O
fourfold O
with O
little O
effect O
on O
ACh O
binding O
, O
while O
corresponding O
mutations O
in O
the O
beta O
and O
epsilon O
subunits O
are O
without O
effect O
. O

Abnormalities O
in O
the O
localization O
of O
epidermal O
lipids O
as O
well O
as O
abnormal O
lamellar O
granule O
formation O
are O
features O
of O
HI O
skin O
. O

A O
combination O
of O
oligonucleotide O
arrays O
, O
multiplex O
PCR O
analysis O
and O
single O
- O
nucleotide O
polymorphism O
genotyping O
revealed O
a O
heterozygous B
intragenic I
deletion I
in I
exon I
8 I
. O

OBJECTIVE O
: O
To O
report O
the O
spectrum O
of O
ophthalmic O
findings O
in O
patients O
with O
Stargardt O
dystrophy O
or O
fundus O
flavimaculatus O
who O
have O
a O
specific O
sequence O
variation O
in O
the O
ABCR O
gene O
. O

In O
phenotype O
I O
, O
9 O
of O
12 O
patients O
had O
a O
sequence O
change O
in B
exon I
42 I
of I
the I
ABCR I
gene I
in I
which I
the I
amino I
acid I
glutamic I
acid I
was I
substituted I
for I
glycine I
( O
Gly O
1961 O
Glu O
) O
. O

In O
only O
4 O
of O
these O
9 O
patients O
was O
a O
second O
possible O
disease O
- O
causing O
mutation O
found O
on O
the O
other O
ABCR O
allele O
. O

It O
is O
implicated O
in O
the O
anemia O
of O
lead O
poisoning O
and O
is O
possibly O
associated O
with O
learning O
difficulties O
. O

Three O
homozygous O
mutations O
were O
identified O
in O
this O
gene O
in O
4 O
subjects O
with O
P O
5 O
' O
N O
- O
1 O
deficiency O
: O
codon B
98 I
GAT I
- I
- I
> I
GTT I
, I
Asp I
- I
- I
> I
Val I
( O
linked O
to O
a O
silent O
polymorphism O
codon B
92 I
, I
TAC I
- I
- I
> I
TAT I
) O
, O
codon B
177 I
, I
CAA I
- I
- I
> I
TAA I
, I
Gln I
- I
- I
> I
termination I
, O
and O
IVS O
9 O
- O
1 O
, O
G O
- O
- O
> O
T O
. O

The O
latter O
mutation O
results O
in O
the O
loss B
of I
exon I
9 I
( I
201 I
bp I
) O
from O
the O
c O
DNA O
. O

Human O
y O
+ O
LAT O
- O
1 O
is O
a O
new O
member O
of O
a O
family O
of O
polytopic O
transmembrane O
proteins O
that O
are O
homologous O
to O
the O
yeast O
high O
affinity O
methionine O
permease O
MUP O
1 O
. O

Mutation O
of O
the O
human O
4 O
F O
2 O
hc O
residue O
cysteine B
109 I
( I
Cys I
- I
109 I
) I
to I
serine I
abolishes O
the O
formation O
of O
this O
heterodimer O
and O
drastically O
reduces O
the O
co O
- O
expressed O
transport O
activity O
. O

Molecular O
characterisation O
of O
three O
alpha O
- O
1 O
- O
antitrypsin O
deficiency O
variants O
: O
proteinase O
inhibitor O
( O
Pi O
) O
nullcardiff O
( O
Asp O
256 O
- O
- O
- O
- O
Val O
) O
; O
Pi O
Mmalton O
( O
Phe B
51 I
- I
- I
- I
- I
deletion I
) O
and O
Pi O
I O
( O
Arg O
39 O
- O
- O
- O
- O
Cys O
) O
. O

In O
the O
Pi O
( O
proteinase O
- O
inhibitor O
) O
nullcardiff O
gene O
, O
the O
codon B
for I
aspartate I
at I
position I
256 I
has I
mutated I
to I
encode I
valine I
. O

In O
Pi O
Mmalton O
and O
Pi O
I O
, O
the O
respective O
mutations O
are O
the O
deletion B
of I
the I
codon I
for I
a I
phenylalanine I
residue I
at I
position I
51 I
or I
52 I
, O
and O
a O
single B
base I
substitution I
resulting I
in I
arginine I
being I
replaced I
by I
cysteine I
at I
position I
39 I
. O

This O
region O
also O
shows O
no O
apparent O
similarity O
to O
the O
e O
IF O
2 O
- O
binding O
domains O
of O
other O
partners O
of O
e O
IF O
2 O
. O

Expression O
of O
a O
mutant O
of O
ABC O
50 O
in O
which O
both B
sites I
are I
mutated I
to I
alanine I
markedly O
decreased O
the O
association O
of O
e O
IF O
2 O
with O
80 O
S O
ribosomal O
and O
polysomal O
fractions O
. O

The O
most O
frequent O
mechanism O
of O
activation O
is O
disruption O
of O
the O
juxtamembrane O
autoregulatory O
domain O
by O
internal O
tandem O
duplications O
( O
ITDs O
) O
. O

Tyrosine B
to I
phenylalanine I
substitution I
of I
residues I
589 I
and I
591 I
in O
the O
context O
of O
the O
FLT O
3 O
- O
ITD O
did O
not O
affect O
tyrosine O
kinase O
activity O
, O
but O
abrogated O
STAT O
5 O
activation O
. O

The O
most O
common O
deficiency O
allele O
of O
the O
plasma O
protease O
inhibitor O
alpha O
1 O
- O
antitrypsin O
( O
alpha O
1 O
AT O
) O
is O
PI O
* O
Z O
. O

We O
have O
cloned O
and O
sequenced O
one O
of O
these O
, O
PI O
* O
QOludwigshafen O
, O
which O
has O
a O
base B
substitution I
in I
exon I
II I
, I
replacing I
isoleucine I
92 I
in I
the I
normal I
sequence I
with I
an I
asparagine I
. O

Novel O
amyloid O
precursor O
protein O
gene O
mutation B
( I
codon I
665 I
Asp I
) I
in O
a O
patient O
with O
late O
- O
onset O
Alzheimer O
' O
s O
disease O
. O

We O
found O
a O
novel O
point O
mutation O
, O
substitution B
of I
cytosine I
for I
guanine I
, I
at I
nucleotide I
2119 I
( O
amyloid O
precursor O
protein O
770 O
messenger O
RNA O
transcript O
) O
in O
a O
patient O
with O
late O
- O
onset O
Alzheimer O
' O
s O
disease O
. O

This O
substitution O
deletes B
a I
Bgl I
II I
site I
and O
substitutes B
aspartate I
for I
glutamine I
at I
codon I
665 I
. O

Denaturing O
gradient O
gel O
electrophoresis O
analysis O
showed O
that O
this O
mutation O
was O
absent O
in O
40 O
control O
subjects O
and O
127 O
dementia O
patients O
. O

The O
polymorphism O
was O
analyzed O
by O
restriction O
fragment O
length O
polymorphism O
analysis O
with O
Nsi O
I O
. O

The O
Met B
/ I
Met I
genotype I
at I
codon I
83 I
was O
very O
rare O
in O
both O
control O
and O
patient O
groups O
. O

Val B
/ I
Met I
genotype I
tended O
to O
be O
more O
frequent O
in O
the O
whole O
type O
1 O
diabetic O
patients O
than O
in O
controls O
. O

On O
the O
other O
hand O
, O
in O
female O
type O
1 O
diabetic O
patients O
, O
the O
Val B
/ I
Met I
genotype I
was O
more O
frequent O
than O
in O
female O
controls O
( O
corrected O
P O
= O
0 O
. O
102 O
) O
. O

A O
serine B
- I
to I
- I
alanine I
mutation I
at I
position I
121 I
of O
ATF O
- O
2 O
represses O
the O
c O
- O
Jun O
- O
dependent O
transcription O
of O
AP O
- O
1 O
/ O
cyclic O
AMP O
- O
response O
element O
reporter O
genes O
and O
also O
the O
p O
300 O
- O
mediated O
activation O
of O
a O
Gal O
4 O
- O
reporter O
gene O
in O
response O
to O
TPA O
. O

Four O
genes O
were O
screened O
for O
mutations O
and O
a O
homozygous O
substitution O
was O
identified O
in O
ACAD O
9 O
( O
c O
. O
1594 O
C O
> O
T O
) O
, O
changing B
the I
highly I
conserved I
arginine I
- I
532 I
into I
tryptophan I
. O

To O
test O
whether O
the O
ACAD O
9 O
mutation O
caused O
the O
complex O
I O
deficiency O
, O
we O
transduced O
fibroblasts O
of O
patients O
with O
wild O
- O
type O
and O
mutant O
ACAD O
9 O
. O

An O
unrelated O
patient O
with O
the O
same O
phenotype O
was O
compound O
heterozygous O
for O
c O
. O
380 O
G O
> O
A O
and O
c O
. O
1405 O
C O
> O
T O
, O
changing O
arginine B
- I
127 I
into I
glutamine I
and O
arginine B
- I
469 I
into I
tryptophan I
, O
respectively O
. O

Four O
new O
COL O
4 O
A O
5 O
mutations O
were O
detected O
. O

A O
duplication B
of I
the I
nine I
most I
3 I
' I
located I
nucleotides I
of I
exon I
49 I
and I
the I
first I
nucleotide I
of I
intron I
49 I
was O
identified O
in O
the O
COL O
4 O
A O
5 O
gene O
of O
one O
patient O
. O

Two O
patients O
displayed O
single O
base O
substitutions O
leading O
to O
, O
respectively O
, O
a O
proline B
to I
threonine I
and I
an I
arginine I
to I
glutamine I
substitution I
in I
the I
C I
- I
terminal I
end O
. O

In O
COL O
4 O
A O
5 O
intron B
41 I
a I
mutation I
changing I
the I
splice I
acceptor I
site I
from I
AG I
to I
AA I
was O
identified O
. O

We O
report O
here O
the O
sequence O
of O
the O
PI O
Mmalton O
allele O
, O
which O
contains O
a O
3 B
- I
bp I
deletion I
coding I
for I
one I
of I
two I
adjacent I
phenylalanine I
residues I
( I
amino I
acid I
51 I
or I
52 I
of O
the O
mature O
protein O
) O
. O

To O
judge O
on O
the O
basis O
of O
X O
- O
ray O
crystallography O
data O
for O
the O
normal O
alpha O
1 O
AT O
protein O
, O
the O
deletion B
of I
aa I
51 I
/ I
52 I
would O
shorten O
one O
strand O
of O
the O
beta O
sheet O
, O
B O
6 O
, O
apparently O
preventing O
normal O
processing O
and O
secretion O
. O

Phosphorylation O
and O
activation O
of O
Chk O
2 O
are O
ataxia O
telangiectasia O
- O
mutated O
( O
ATM O
) O
dependent O
in O
response O
to O
IR O
, O
whereas O
Chk O
2 O
phosphorylation O
is O
ATM O
- O
independent O
when O
cells O
are O
exposed O
to O
UV O
or O
HU O
. O

Substitution O
of O
Thr B
68 I
with I
Ala I
reduced O
the O
extent O
of O
phosphorylation O
and O
activation O
of O
Chk O
2 O
in O
response O
to O
IR O
, O
and O
mutation O
of O
all O
seven O
SQ O
/ O
TQ O
moti O
fs O
blocked O
all O
phosphorylation O
and O
activation O
of O
Chk O
2 O
after O
IR O
. O

Here O
we O
identified O
the O
sites O
of O
phosphorylation O
of O
alpha O
- O
adducin O
by O
Rho O
- O
kinase O
as O
Thr O
445 O
and O
Thr O
480 O
. O

The O
microinjection O
of O
Botulinum O
C O
3 O
ADP O
- O
ribosyl O
- O
transferase O
, O
dominant O
negative O
Rho O
- O
kinase O
, O
or O
alpha O
- O
adducin O
T O
445 O
A O
, O
T O
480 O
A O
( O
substitution B
of I
Thr I
445 I
and O
Thr B
480 I
by I
Ala I
) O
inhibited O
the O
TPA O
- O
induced O
membrane O
ruffling O
in O
MDCK O
cells O
and O
wound O
- O
induced O
migration O
in O
NRK O
49 O
F O
cells O
. O

alpha O
- O
Adducin O
T O
445 O
D O
, O
T O
480 O
D O
( O
substitution B
of I
Thr I
445 I
and O
Thr B
480 I
by I
Asp I
) O
, O
but O
not O
alpha O
- O
adducin O
T O
445 O
A O
, O
T O
480 O
A O
, O
counteracted O
the O
inhibitory O
effect O
of O
the O
dominant O
negative O
Rho O
- O
kinase O
on O
the O
TPA O
- O
induced O
membrane O
ruffling O
in O
MDCK O
cells O
. O

In O
humans O
, O
the O
non B
- I
conservative I
amino I
acid I
substitution I
Alanine I
( I
Ala I
) I
67 I
Threonine I
( I
Thr I
) I
has O
been O
associated O
with O
Anorexia O
Nervosa O
and O
with O
leanness O
. O

Also O
, O
no O
differences O
were O
observed O
between O
the O
potencies O
of O
bacterially O
expressed O
Ala O
67 O
and O
Thr O
67 O
Ag O
RP O
to O
stimulate O
MC O
4 O
R O
in O
a O
reporter O
gene O
assay O
or O
inhibit O
food O
intake O
in O
rats O
. O

We O
found O
a O
somatic O
mutation O
and O
a O
gene O
variation O
in O
human O
lung O
cancer O
cells O
that O
change B
glycine I
to I
cysteine I
in I
the I
DGR I
domain I
, O
introducing O
local O
conformational O
changes O
that O
reduce O
Keap O
1 O
' O
s O
affinity O
for O
Nrf O
2 O
. O

Recently O
, O
PDE O
has O
been O
shown O
to O
be O
caused O
by O
a O
defect O
of O
alpha O
- O
amino O
adipic O
semialdehyde O
( O
AASA O
) O
dehydrogenase O
( O
antiquitin O
) O
in O
the O
cerebral O
lysine O
degradation O
pathway O
. O

Furthermore O
, O
a O
novel B
deletion I
of I
exon I
7 I
was O
identified O
. O

Although O
site O
- O
specific O
DNA O
binding O
by O
EKLF O
is O
unaffected O
by O
the O
acetylation O
status O
of O
either O
of O
these O
lysines O
, O
directed O
mutagenesis B
of I
Lys I
- I
288 I
( I
but I
not I
Lys I
- I
302 I
) I
decreases O
the O
ability O
of O
EKLF O
to O
transactivate O
the O
beta O
- O
globin O
promoter O
in O
vivo O
and O
renders O
it O
unable O
to O
be O
superactivated O
by O
coexpressed O
p O
300 O
or O
CBP O
. O

These O
results O
demonstrate O
that O
the O
acetylation O
status O
of O
EKLF O
is O
critical O
for O
its O
optimal O
activity O
and O
suggest O
a O
mechanism O
by O
which O
EKLF O
acts O
as O
an O
integrator O
of O
remodeling O
and O
transcriptional O
components O
to O
alter O
chromatin O
structure O
and O
induce O
adult O
beta O
- O
globin O
expression O
within O
the O
beta O
- O
like O
globin O
cluster O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
glycosylation O
on O
AADAC O
enzyme O
activity O
. O

Immunoblot O
analysis O
of O
mutant O
AADACs O
that O
contained O
an O
asparagine B
( I
N I
, I
Asn I
) I
to I
glutamine I
( I
Q I
, I
Gln I
) I
substitution I
at I
either I
residue I
78 I
or I
282 I
( O
N O
78 O
Q O
or O
N O
282 O
Q O
) O
showed O
a O
different O
migration O
compared O
with O
the O
wild O
- O
type O
protein O
. O

A O
mutant O
AADAC O
that O
contained O
N B
to I
Q I
substitutions I
at I
both I
residue I
78 I
and I
282 I
( O
N O
78 O
Q O
/ O
N O
282 O
Q O
) O
showed O
a O
similar O
migration O
to O
AADAC O
in O
human O
liver O
microsomes O
( O
HLM O
) O
treated O
with O
endoglycosidase O
H O
( O
Endo O
H O
) O
, O
which O
produces O
deglycosylated O
proteins O
. O

A O
similar O
peptide O
with O
glutamic B
acid I
replacing I
Ser I
( I
748 I
) I
was O
preferentially O
phosphorylated O
by O
PKCepsilon O
, O
suggesting O
that O
PKD O
containing O
phosphate O
at O
Ser O
( O
748 O
) O
is O
rapidly O
targeted O
by O
this O
isoform O
at O
Ser O
( O
744 O
) O
. O

When O
incubated O
in O
the O
presence O
of O
phosphatidylserine O
, O
phorbol O
12 O
, O
13 O
- O
dibutyrate O
and O
ATP O
, O
intact O
PKD O
slowly O
autophosphorylated O
in O
the O
activation O
loop O
but O
only O
at O
Ser O
( O
748 O
) O
. O

The O
high O
constitutive O
activity O
of O
the O
pleckstrin O
homology O
( O
PH O
) O
domain O
deletion O
mutant O
PKD O
- O
delta O
PH O
was O
not O
abrogated O
by O
mutation B
of I
Ser I
( I
744 I
) I
and O
Ser B
( I
748 I
) I
to I
alanines I
, O
suggesting O
that O
one O
function O
of O
activation O
loop O
phosphorylation O
in O
the O
PKD O
activation O
mechanism O
is O
to O
relieve O
autoinhibition O
by O
the O
PH O
domain O
. O

Employing O
liver O
E O
3 O
c O
DNA O
, O
a O
human O
cerebellar O
c O
DNA O
library O
was O
screened O
and O
a O
2 O
. O
0 O
kb O
c O
DNA O
fragment O
was O
isolated O
. O

The O
cerebellar O
c O
DNA O
yielded O
a O
derived O
primary O
structure O
which O
differed O
from O
the O
liver O
E O
3 O
amino O
acid O
sequence O
by O
a O
single B
serine I
- I
to I
- I
cysteine I
substitution I
at I
position I
88 I
( I
position I
84 I
in I
the I
liver I
sequence I
) O
. O

Upon O
conservative O
mutation B
of I
Tyr I
- I
838 I
located O
in O
the O
tyrosine O
kinase O
domain O
, O
the O
catalytic O
activity O
of O
Eph O
A O
8 O
was O
strikingly O
reduced O
both O
in O
vitro O
and O
in O
vivo O
, O
whereas O
a O
mutation B
at I
Tyr I
- I
615 I
in O
the O
juxtamembrane O
domain O
did O
not O
impair O
the O
tyrosine O
kinase O
activity O
. O

Additionally O
, O
a O
high O
level O
of O
Eph O
A O
8 O
was O
detected O
in O
Fyn O
immunoprecipitates O
in O
intact O
cells O
, O
indicating O
that O
Eph O
A O
8 O
and O
Fyn O
can O
physically O
associate O
in O
vivo O
. O

In O
contrast O
, O
the O
association O
of O
full O
- O
length O
Fyn O
to O
Eph O
A O
8 O
containing O
mutation B
at I
either I
Tyr I
- I
615 I
or I
Tyr I
- I
838 I
was O
greatly O
reduced O
. O

NEPH O
1 O
, O
a O
member O
of O
the O
immunoglobulin O
superfamily O
, O
is O
structurally O
related O
to O
nephrin O
. O

All O
three O
NEPH O
proteins O
share O
a O
conserved O
podocin O
- O
binding O
motif O
; O
mutation B
of I
a I
centrally I
located I
tyrosine I
residue I
dramatically O
lowers O
the O
affinity O
of O
NEPH O
1 O
for O
podocin O
. O

We O
previously O
demonstrated O
increased O
LCAD O
lysine O
acetylation O
in O
SIRT O
3 O
knockout B
mice O
concomitant O
with O
reduced O
LCAD O
activity O
and O
reduced O
fatty O
acid O
oxidation O
. O

To O
study O
the O
effects O
of O
acetylation O
on O
LCAD O
and O
determine O
sirtuin O
3 O
( O
SIRT O
3 O
) O
target O
sites O
, O
we O
chemically O
acetylated O
recombinant O
LCAD O
. O

Arginine B
substitutions I
at I
Lys I
- I
318 I
and I
Lys I
- I
322 I
prevented O
the O
acetylation O
- O
induced O
activity O
loss O
. O

We O
investigated O
the O
molecular O
mechanism O
by O
which O
a O
single B
phenylalanine I
deletion I
in O
SUR O
1 O
( O
Delta O
F O
1388 O
) O
causes O
PHHI O
. O

Trafficking O
of O
K O
( O
ATP O
) O
channels O
requires O
that O
the O
endoplasmic O
reticulum O
- O
retention O
signal O
, O
RKR O
, O
present O
in O
both O
SUR O
1 O
and O
Kir O
6 O
. O
2 O
, O
be O
shielded O
during O
channel O
assembly O
. O

To O
ask O
whether O
Delta O
F O
1388 O
SUR O
1 O
forms O
functional O
channels O
with O
Kir O
6 O
. O
2 O
, O
we O
inactivated O
the O
RKR O
signal O
in O
Delta B
F I
1388 I
SUR I
1 I
by I
mutation I
to I
AAA I
( I
Delta I
F I
1388 I
SUR I
1 I
( I
AAA I
) I
) I
. O

By O
using O
RNA O
- O
interference O
methods O
, O
we O
have O
shown O
that O
worm O
homologues O
of O
two O
HERG O
- O
interacting O
proteins O
, O
Hyperkinetic O
and O
K O
channel O
regulator O
1 O
( O
KCR O
1 O
) O
, O
modify O
unc O
- O
103 O
function O
. O

Examination O
of O
the O
human O
KCR O
1 O
sequence O
in O
patients O
with O
drug O
- O
induced O
cardiac O
repolarization O
defects O
revealed O
a O
sequence O
variation O
( O
the O
substitution B
of I
isoleucine I
447 I
by I
valine I
, O
I O
447 O
V O
) O
that O
occurs O
at O
a O
reduced O
frequency O
( O
1 O
. O
1 O
% O
) O
relative O
to O
a O
matched O
control O
population O
( O
7 O
. O
0 O
% O
) O
, O
suggesting O
that O
I O
447 O
V O
may O
be O
an O
allele O
for O
reduced O
a O
LQTS O
susceptibility O
. O

The O
Vmunich O
allele O
differed O
from O
the O
common O
normal O
M O
1 O
( O
Val B
213 I
) I
alpha I
1 I
AT I
allele I
by I
a I
single I
nucleotide I
substitution I
of I
cytosine I
for I
adenosine I
, O
with O
the O
resultant O
amino B
acid I
change I
Asp I
2 I
GAT I
- I
- I
- I
- I
Ala I
GCT I
. O

The O
Asp B
2 I
- I
- I
- I
- I
Ala I
mutation I
explains O
the O
cathodal O
position O
of O
the O
Vmunich O
protein O
on O
IEF O
, O
as O
there O
is O
a O
substitution O
of O
a O
negatively O
charged O
amino O
acid O
by O
a O
neutral O
one O
. O

Interestingly O
, O
the O
G B
/ I
C I
substitution I
at I
position I
- I
98 I
relative I
to I
the I
start I
codon I
was O
common O
and O
in O
complete O
linkage O
with O
a O
previously O
identified O
insertion O
/ O
deletion O
polymorphism O
in O
the O
coding O
region O
which O
was O
showed O
to O
affect O
alpha O
2 O
B O
- O
adrenergic O
receptor O
function O
. O

Based O
on O
transfection O
data O
and O
computer O
- O
assisted O
sequence O
analysis O
, O
the O
- B
98 I
G I
/ I
C I
single I
nucleotide I
polymorphism I
was O
located O
within O
a O
portion O
of O
the O
5 O
' O
- O
UTR O
( O
- O
127 O
/ O
+ O
3 O
) O
affecting O
luciferase O
activity O
and O
it O
created O
additional O
putative O
binding O
site O
for O
Sp O
1 O
. O

However O
, O
G O
/ O
C O
substitution O
had O
no O
significant O
incidence O
on O
promoter O
activity O
in O
BHK O
- O
21 O
or O
He O
La O
cells O
. O

The O
deficiency O
is O
assigned O
to O
the O
XP O
- O
D O
complementation O
group O
, O
and O
we O
have O
identified O
two O
causative O
mutations O
in O
the O
XPD O
gene O
: O
a B
gly I
- I
- I
> I
arg I
change I
at I
amino I
acid I
675 I
in O
the O
allele O
inherited O
from O
the O
patient O
' O
s O
mother O
and O
a O
- B
1 I
frameshift I
at I
amino I
acid I
669 I
in O
the O
allele O
inherited O
from O
his O
father O
. O

The O
mitogen O
- O
activated O
protein O
( O
MAP O
) O
kinases O
are O
essential O
signaling O
molecules O
that O
mediate O
many O
cellular O
effects O
of O
growth O
factors O
, O
cytokines O
, O
and O
stress O
stimuli O
. O

Our O
results O
indicated O
the O
following O
: O
( O
i O
) O
p O
38 O
alpha O
phosphorylated O
at O
both O
Thr O
- O
180 O
and O
Tyr O
- O
182 O
was O
10 O
- O
20 O
- O
fold O
more O
active O
than O
p O
38 O
alpha O
phosphorylated O
at O
Thr O
- O
180 O
only O
, O
whereas O
p O
38 O
alpha O
phosphorylated O
at O
Tyr O
- O
182 O
alone O
was O
inactive O
; O
( O
ii O
) O
the O
dual O
- O
specific O
MKP O
5 O
, O
the O
tyrosine O
- O
specific O
hematopoietic O
protein O
- O
tyrosine O
phosphatase O
, O
and O
the O
serine O
/ O
threonine O
- O
specific O
PP O
2 O
Calpha O
are O
all O
highly O
specific O
for O
the O
dephosphorylation O
of O
p O
38 O
alpha O
, O
and O
the O
dephosphorylation O
rates O
were O
significantly O
affected O
by O
different O
phosphorylated O
states O
of O
p O
38 O
alpha O
; O
( O
iii O
) O
the O
N O
- O
terminal O
domain O
of O
MPK O
5 O
has O
no O
effect O
on O
enzyme O
catalysis O
, O
whereas O
deletion B
of I
the I
MAP I
kinase I
- I
binding I
domain I
in O
MKP O
5 O
leads O
to O
a O
370 O
- O
fold O
decrease O
in O
k O
( O
cat O
) O
/ O
K O
( O
m O
) O
for O
the O
dephosphorylation O
of O
p O
38 O
alpha O
. O

The O
first O
SCAD O
- O
deficient O
patient O
was O
a O
compound O
heterozygote O
for O
two O
mutations O
, O
274 O
G O
- O
- O
> O
T O
and O
529 O
T O
- O
- O
> O
C O
. O

The O
second O
patient O
carried O
a O
1147 B
C I
- I
- I
> I
T I
mutation I
and O
the B
625 I
G I
- I
- I
> I
A I
polymorphism O
in O
one O
allele O
, O
and O
a O
single O
point O
mutation O
, O
511 O
C O
- O
- O
> O
T O
, O
in O
the O
other O
. O

The O
1147 O
C O
- O
- O
> O
T O
mutation O
was O
not O
present O
in O
98 O
normal O
alleles O
, O
but O
was O
detected O
in O
three O
alleles O
of O
133 O
patients O
with O
elevated O
EMA O
excretion O
, O
consistently O
as O
a O
625 B
A I
- I
1147 I
T I
allele I
. O

On O
the O
other O
hand O
, O
the O
511 B
C I
- I
- I
> I
T I
mutation I
was O
present O
in O
13 O
of O
130 O
and O
15 O
of O
67 O
625 O
G O
alleles O
, O
respectively O
, O
of O
normal O
controls O
and O
patients O
with O
elevated O
EMA O
excretion O
, O
and O
was O
never O
associated O
with O
the O
625 O
A O
variant O
allele O
. O

Expression O
of O
the O
variant O
R O
147 O
W O
SCAD O
protein O
, O
encoded O
by O
the O
511 O
T O
- O
625 O
G O
allele O
, O
in O
COS O
- O
7 O
cells O
showed O
45 O
% O
activity O
at O
37 O
degrees O
C O
in O
comparison O
with O
the O
wild O
- O
type O
protein O
, O
comparable O
levels O
of O
activity O
at O
26 O
degrees O
C O
, O
and O
13 O
% O
activity O
when O
incubated O
at O
41 O
degrees O
C O
. O
This O
temperature O
profile O
is O
different O
from O
that O
observed O
for O
the O
variant O
G O
185 O
S O
SCAD O
protein O
, O
encoded O
by O
the O
511 O
C I
- I
625 I
A I
allele I
, I
where O
higher O
than O
normal O
activity O
was O
found O
at O
26 O
and O
37 O
degrees O
C O
, O
and O
58 O
% O
activity O
was O
present O
at O
41 O
degrees O
C O
. O
These O
results O
corroborate O
the O
notion O
that O
the O
511 O
C I
- I
625 I
A I
variant I
allele I
is I
one O
of O
the O
possible O
underlying O
causes O
of O
ethylmalonic O
aciduria O
, O
and O
suggest O
that O
the O
511 O
C O
- O
- O
> O
T O
mutation O
represents O
a O
second O
susceptibility O
variation O
in O
the O
SCAD O
gene O
. O

Here O
, O
we O
show O
that O
the O
Duffy O
antigen O
/ O
chemokine O
receptor O
gene O
( O
DARC O
) O
is O
composed O
of O
a O
single O
exon O
and O
that O
most O
Duffy O
- O
negative O
blacks O
carry O
a O
silent O
FY O
* O
B O
allele O
with O
a O
single B
T I
to I
C I
substitution I
at I
nucleotide I
- I
46 I
. O

Deletion B
of I
chromosome I
11 I
q I
23 I
is O
a O
common O
alteration O
in O
parathyroid O
adenomas O
and O
hyperplasias O
. O

A O
previously O
identified O
germline B
G I
- I
A I
transition I
( I
GGC I
- I
GAC I
) I
in I
codon I
90 I
, I
changing I
glycine I
( I
Gly I
) I
to I
aspartic I
acid I
( I
Asp I
) I
, O
was O
detected O
in O
one O
adenoma O
. O

A O
chimeric O
protein O
MTH O
1 O
- O
Ec O
, O
in O
which O
the O
23 B
- I
residue I
sequence I
of I
MTH I
1 I
was I
replaced I
with I
that I
of I
Mut I
T I
, O
retains O
its O
capability O
to O
hydrolyze O
8 O
- O
oxo O
- O
d O
GTP O
, O
thereby O
indicating O
that O
the O
23 O
- O
residue O
sequences O
of O
MTH O
1 O
and O
Mut O
T O
are O
functionally O
and O
structurally O
equivalent O
and O
constitute O
functional O
modules O
. O

For O
the O
other O
9 O
residues O
( O
40 O
, O
42 O
, O
44 O
, O
46 O
, O
47 O
, O
49 O
, O
50 O
, O
54 O
, O
and O
58 O
) O
, O
positive O
mutants O
were O
obtained O
, O
and O
Arg B
( I
50 I
) I
can I
be I
replaced I
with I
hydrophobic I
residues I
( I
Val I
, I
Leu I
, I
or I
Ile I
) I
, O
with O
a O
greater O
stability O
and O
higher O
specific O
activity O
of O
the O
enzyme O
. O

Cleavage O
at O
Lys O
( O
91 O
) O
is O
context O
- O
dependent O
: O
mutation B
of I
the I
charged I
Arg I
( I
93 I
) I
to I
Ala I
on I
the I
P I
2 I
' I
position I
enhanced O
cleavage O
, O
and O
triple O
mutations O
( O
K O
90 O
A O
/ O
K O
91 O
A O
/ O
R O
93 O
A O
) O
abolished O
cleavage O
. O

Importantly O
, O
the O
two O
isoforms O
of O
CTRP O
12 O
differ O
in O
oligomeric O
structures O
and O
are O
functionally O
distinct O
. O

Molecular O
analysis O
of O
alpha O
1 O
- O
antitrypsin O
( O
alpha O
1 O
AT O
) O
Wbethesda O
revealed O
that O
it O
differs O
from O
the O
normal O
M O
1 O
( B
Ala I
213 I
) I
allele I
by I
a I
single I
base I
mutation I
causing I
an I
amino I
acid I
substitution I
Ala I
336 I
GCT I
- I
- I
- I
- I
Thr I
ACT I
. O

Two O
naturally O
occurring O
amino O
acid O
substitutions O
in O
the O
human O
5 O
- O
HT O
1 O
A O
receptor O
: O
glycine B
22 I
to I
serine I
22 I
and O
isoleucine B
28 I
to I
valine I
28 I
. O

The O
polymorphisms O
encode O
amino O
acid O
substitutions O
in O
the O
5 O
- O
HT O
1 O
A O
receptor O
of O
a O
glycine B
to I
serine I
at I
amino I
acid I
22 I
and O
an O
isoleucine B
to I
valine I
at I
amino I
acid I
28 I
, O
respectively O
. O

This O
is O
the O
first O
report O
of O
a O
polymorphism O
in O
the O
human O
5 O
- O
HT O
1 O
A O
receptor O
gene O
that O
alters O
the O
structure O
of O
the O
5 O
- O
HT O
1 O
A O
receptor O
protein O
composition O
. O

One O
novel O
cryptic O
splicing O
mutation O
of O
the O
BRCA O
1 O
gene O
, O
found O
in O
two O
unrelated O
families O
, O
was O
shown O
to O
be O
a O
deletion B
of I
10 I
bp I
near I
the I
branch I
site I
in I
intron I
7 I
. O

This O
mutation O
causes O
an O
insertion B
of I
59 I
nucleotides I
derived I
from I
intron I
7 I
and O
results O
in O
a O
frameshift O
, O
leading O
to O
premature O
translational O
termination O
of O
BRCA O
1 O
m O
RNA O
in O
exon O
8 O
. O

Nucleotide O
sequence O
analysis O
of O
mutant O
complementary O
DNAs O
revealed O
a O
missense B
mutation I
that I
replaces I
aspartic I
acid I
with I
asparagine I
at I
position I
790 I
in O
the O
c O
- O
kit O
protein O
product O
. O

Aspartic O
acid O
- O
790 O
is O
a O
conserved O
residue O
in O
all O
protein O
kinases O
. O

One O
was O
detected O
in O
1 O
patient O
only O
and O
associated O
with O
an O
amino O
acid O
substitution O
( B
Val I
/ I
Met I
) I
at I
codon I
832 I
in O
the O
region O
essential O
for O
binding O
to O
beta O
- O
catenin O
. O

The O
M B
832 I
variant I
was O
detected O
not O
only O
in O
the O
proband O
but O
also O
in O
2 O
other O
gastric O
cancer O
patients O
in O
the O
family O
. O

However O
, O
no O
significant O
difference O
in O
the O
activity O
of O
beta O
- O
catenin O
binding O
was O
detected O
between O
the O
M B
832 I
variant I
and O
V O
832 O
wild O
- O
type O
E O
- O
cadherin O
in O
immunofluorescence O
and O
immunoprecipitation O
/ O
Western O
blot O
analyses O
. O

Thus O
, O
the O
M B
832 I
variant I
could O
be O
a O
germline O
mutation O
causative O
of O
familial O
aggregation O
of O
DGC O
, O
although O
further O
functional O
studies O
are O
needed O
to O
understand O
the O
pathogenic O
significance O
of O
this O
variant O
. O

We O
have O
recently O
delineated O
three O
naturally O
occurring O
polymorphisms O
of O
the O
human O
beta O
2 O
- O
adrenergic O
receptor O
caused O
by O
missense O
mutations O
encoding O
for O
amino O
acids O
16 O
and O
27 O
of O
the O
extracellular O
N O
- O
terminus O
of O
the O
receptor O
. O

The O
polymorphisms O
consist O
of O
substitutions B
of I
Gly I
for I
Arg I
at I
amino I
acid I
16 I
( O
Arg O
16 O
- O
- O
> O
Gly O
) O
, O
Glu B
for I
Gln I
at I
amino I
acid I
27 I
( O
Gln O
27 O
- O
- O
> O
Glu O
) O
, O
and O
a O
combination O
of O
both O
substitutions O
. O

A O
common O
single O
- O
nucleotide O
polymorphism O
in O
the O
brain O
- O
derived O
neurotrophic O
factor O
( O
BDNF O
) O
gene O
, O
a O
methionine B
( I
Met I
) I
substitution I
for I
valine I
( I
Val I
) I
at I
codon I
66 I
( O
Val O
66 O
Met O
) O
, O
is O
associated O
with O
alterations O
in O
brain O
anatomy O
and O
memory O
, O
but O
its O
relevance O
to O
clinical O
disorders O
is O
unclear O
. O

Cloning O
and O
sequencing O
of O
the O
10 O
, O
627 O
- O
bp O
- O
long O
region O
containing O
the O
Mnichinan O
gene O
and O
the O
normal O
M O
1 O
( O
Val O
213 O
) O
alpha O
1 O
- O
AT O
gene O
revealed O
all O
five O
exons O
of O
the O
Mnichinan O
gene O
to O
be O
identical O
with O
the O
M O
1 O
( O
Val O
213 O
) O
alpha O
1 O
- O
AT O
gene O
, O
except O
for O
two O
changes O
: O
a O
TTC B
trinucleotide I
deletion I
in I
the I
codon I
for I
amino I
acid I
Phe I
52 I
and O
a O
G B
- I
A I
substitution I
, I
by I
which I
the I
normal I
Gly I
148 I
( I
GGG I
) I
became I
Arg I
148 I
( I
AGG I
) I
. O

The O
G B
- I
A I
substitution I
in I
codon I
148 I
of O
the O
Mnichinan O
gene O
could O
not O
be O
responsible O
for O
the O
alpha O
1 O
- O
AT O
deficiency O
phenotype O
because O
Arg O
- O
and O
not O
Gly O
- O
was O
located O
at O
the O
corresponding O
position O
of O
the O
protein O
C O
inhibitor O
belonging O
to O
the O
serine O
protease O
inhibitor O
superfamily O
. O

The O
deletion B
of I
Phe I
52 I
may O
cause O
the O
newly O
synthesized O
alpha O
1 O
- O
AT O
protein O
to O
aggregate O
, O
resulting O
in O
alpha O
1 O
- O
AT O
deficiency O
. O

Comparison O
of O
the O
alpha O
1 O
- O
AT O
gene O
sequences O
available O
indicated O
that O
the O
C B
- I
T I
substitution I
at I
the I
Cp I
G I
dinucleotide I
has O
an O
important O
role O
in O
generation O
of O
variants O
and O
nucleotide O
changes O
in O
the O
noncoding O
regions O
of O
the O
alpha O
1 O
- O
AT O
gene O
. O

The O
frequency O
for O
the O
variant O
allele O
was O
estimated O
at O
. O
217 O
+ O
/ O
- O
. O
017 O
. O

Furthermore O
, O
amino O
acid O
analyses O
of O
the O
tryptic O
peptides O
indicated O
that O
CA O
1 O
3 O
N O
is O
characterized O
by O
the O
substitution B
253 I
Gly I
leads I
to I
Arg I
, O
confirming O
the O
identity O
of O
this O
variant O
with O
CA O
1 O
Guam O
. O

The O
enhancing O
effects O
of O
PKA O
activation O
on O
this O
isoform O
required O
the O
phosphorylation O
of O
Ser B
( I
937 I
) I
, I
since I
replacing I
this I
residue I
with I
alanine I
eliminated O
the O
positive O
effects O
of O
PKA O
activation O
. O

These O
results O
provide O
a O
mechanism O
responsible O
for O
the O
enhanced O
Ca O
( O
2 O
+ O
) O
signaling O
following O
PKA O
activation O
in O
cells O
that O
express O
predominantly O
Ins O
P O
( O
3 O
) O
R O
2 O
. O

Cloning O
and O
sequencing O
of O
the O
two O
exons O
that O
encode O
the O
amyloid O
protein O
from O
two O
patients O
with O
this O
amyloidosis O
revealed O
a O
cytosine O
- O
to O
- O
guanine O
transversion O
, O
a O
mutation O
that O
caused O
a O
single O
amino O
acid O
substitution O
( B
glutamine I
instead I
of I
glutamic I
acid I
) I
at I
position I
22 I
of O
the O
amyloid O
protein O
. O

Scd O
1 O
ab O
- O
Xyk O
: O
a O
new O
asebia O
allele O
characterized O
by O
a O
CCC B
trinucleotide I
insertion I
in I
exon I
5 I
of O
the O
stearoyl O
- O
Co O
A O
desaturase O
1 O
gene O
in O
mouse O
. O

By O
haplotype O
analysis O
and O
direct O
sequencing O
of O
PCR O
products O
, O
we O
show O
that O
this O
mutation O
is O
a O
new O
allele O
of O
the O
asebia O
locus O
with O
a O
naturally O
occurring O
mutation O
in O
the O
Scd O
1 O
gene O
( O
a B
CCC I
insertion I
at I
nucleotide I
position I
835 I
in I
exon I
5 I
) O
, O
which O
codes O
for O
stearoyl O
- O
Co O
A O
desaturase O
1 O
. O

This O
mutation O
introduces O
an O
extra B
proline I
residue I
at I
position I
279 I
in O
the O
Scd O
1 O
protein O
. O

In O
a O
cross O
between O
Kunming O
- O
ab O
Xyk O
/ O
ab O
Xyk O
and O
ABJ O
/ O
Le O
- O
ab O
J O
/ O
ab O
J O
mice O
, O
all O
the O
progeny O
showed O
the O
same O
phenotype O
, O
indicating O
that O
the O
two O
mutations O
were O
non O
- O
complementing O
and O
therefore O
allelic O
. O

This O
AIR O
pattern O
suggested O
a O
K O
( O
ATP O
) O
channel O
defect O
because O
it O
resembled O
that O
seen O
in O
children O
with O
recessive O
hyperinsulinism O
due O
to O
two O
common O
SUR O
1 O
mutations O
, O
g O
3992 O
- O
9 O
a O
and O
del O
Phe O
1388 O
. O

Mutation O
analysis O
identified O
a O
novel O
trinucleotide B
deletion I
in I
SUR I
1 I
exon I
34 I
that I
results I
in I
the I
loss I
of I
serine I
1387 I
. O

PPNAD O
can O
be O
part O
of O
the O
Carney O
complex O
( O
CNC O
) O
, O
an O
autosomal O
dominant O
multiple O
neoplasia O
syndrome O
. O

A O
somatic B
16 I
- I
bp I
deletion I
of O
PRKAR O
1 O
A O
gene O
was O
also O
found O
in O
this O
macronodule O
. O

A O
locus O
for O
HI O
was O
assigned O
by O
linkage O
analyses O
to O
human O
chromosome O
11 O
p O
15 O
. O
1 O
. O

In O
this O
study O
, O
we O
evaluated O
disease O
- O
associated O
chromosomes O
from O
41 O
Ashkenazi O
Jewish O
and O
2 O
non O
- O
Jewish O
HI O
patients O
carrying O
the O
3992 B
- I
9 I
g I
- I
- I
> I
a I
mutation I
by O
assessing O
haplotypes O
defined O
by O
nine O
common O
single O
nucleotide O
polymorphisms O
( O
SNPs O
) O
, O
six O
in O
the O
SUR O
1 O
gene O
, O
and O
three O
in O
the O
KIR O
6 O
. O
2 O
gene O
. O

Our O
results O
indicate O
that O
all B
54 I
chromosomes I
carrying I
the I
3992 I
- I
9 I
g I
- I
- I
> I
a I
mutation I
in O
the O
Jewish O
patients O
appear O
to O
have O
originated O
from O
one O
founder O
mutation O
, O
whereas O
the O
same O
mutation O
on O
chromosomes O
from O
non O
- O
Jewish O
patients O
originated O
independently O
. O

Ezrin O
is O
localized O
to O
the O
apical O
membrane O
of O
parietal O
cells O
and O
couples O
the O
protein O
kinase O
A O
activation O
cascade O
to O
regulated O
HCl O
secretion O
in O
gastric O
parietal O
cells O
. O

Furthermore O
, O
our O
study O
shows O
that O
PALS O
1 O
is O
essential O
for O
the O
apical O
localization O
of O
ezrin O
, O
as O
either O
suppression O
of O
PALS O
1 O
protein O
accumulation O
or O
deletion B
of I
the I
PALS I
1 I
- I
binding I
domain I
of O
ezrin O
eliminated O
the O
apical O
localization O
of O
ezrin O
. O

Genetic O
sequencing O
studies O
of O
the O
entire O
coding O
( O
exon O
) O
sequences O
of O
ATP O
8 O
B O
1 O
and O
ABCB O
11 O
uncovered O
a O
novel O
heterozygous B
missense I
3035 I
G I
> I
T I
mutation O
( O
S O
1012 O
I O
) O
and O
a O
synonymous B
696 I
T I
> I
C I
mutation O
in O
ATP O
8 O
B O
1 O
. O

Deletion B
of I
amino I
acids I
Asp I
487 I
- I
Ser I
488 I
- I
Phe I
489 I
in O
human O
cytochrome O
P O
450 O
c O
17 O
causes O
severe O
17 O
alpha O
- O
hydroxylase O
deficiency O
. O

Analysis O
of O
her O
P O
450 O
c O
17 O
gene O
by O
polymerase O
chain O
reaction O
amplification O
and O
sequencing O
showed O
a O
nine O
- O
base O
deletion O
, O
eliminating B
codons I
487 I
- I
489 I
( I
Asp I
- I
Ser I
- I
Phe I
) I
near O
the O
carboxy O
- O
terminus O
of O
P O
450 O
c O
17 O
. O

Such O
transfected O
cells O
produced O
immunodetectable O
P O
450 O
c O
17 O
protein O
, O
but O
had O
no O
17 O
alpha O
- O
hydroxylase O
or O
17 O
, O
20 O
- O
lyase O
activity O
, O
whereas O
cells O
similarly O
transfected O
with O
a O
vector O
expressing O
normal O
human O
P O
450 O
c O
17 O
could O
17 O
alpha O
- O
hydroxylate O
either O
pregnenolone O
or O
progesterone O
and O
convert O
17 O
alpha O
- O
hydroxypregnenolone O
to O
dehydroepiandrosterone O
, O
showing O
the O
presence O
of O
both O
activities O
. O

Sequence O
analysis O
revealed O
a O
novel O
mutation O
G O
617 O
T O
in O
exon O
8 O
resulting O
in O
an O
arginine B
to I
leucine I
substitution I
at I
codon I
206 I
( I
R I
206 I
L I
) I
. O

Antithrombin O
- O
III O
- O
Stockholm O
: O
a O
codon B
392 I
( I
Gly I
- I
- I
- I
- I
Asp I
) I
mutation O
with O
normal O
heparin O
binding O
and O
impaired O
serine O
protease O
reactivity O
. O

Antithrombin O
- O
III O
- O
Stockholm O
is O
a O
new O
structural O
variant O
of O
antithrombin O
- O
III O
( O
AT O
- O
III O
) O
with O
normal O
heparin O
affinity O
but O
defective O
serine O
protease O
inhibitory O
activity O
. O

Only O
exon O
7 O
provided O
evidence O
for O
the O
presence O
of O
a O
mutation O
, O
with O
the O
second O
base O
of O
codon B
392 I
having I
a I
G I
- I
- I
- I
- I
A I
substitution I
. O

An O
A B
to I
G I
transition I
at I
position I
985 I
that O
causes O
a O
lysine B
- I
304 I
to I
glutamate I
substitution I
in O
the O
mature O
protein O
is O
the O
single O
prevalent O
mutation O
. O

In O
all O
three O
patients O
, O
an O
A B
to I
G I
transition I
was I
identified I
at I
position I
985 I
of I
the I
coding I
region I
. O

When O
c O
DNA O
or O
genomic O
DNA O
from O
fibroblasts O
of O
nine O
MCAD O
- O
deficient O
patients O
were O
tested O
with O
this O
method O
, O
the O
copies O
from O
all O
of O
them O
completely O
cleaved O
into O
two O
shorter O
fragments O
by O
Nco O
I O
, O
indicating O
their O
homozygosity O
for O
the O
A B
- I
- I
- I
- I
G I
- I
985 I
transition I
. O

Thus O
, O
this O
A B
- I
- I
- I
- I
G I
- I
985 I
transition I
is O
the O
single O
prevalent O
mutation O
causing O
MCAD O
deficiency O
, O
a O
highly O
unusual O
feature O
for O
any O
genetic O
disorder O
. O

Most O
( O
approximately O
80 O
% O
) O
cases O
are O
homozygous O
for O
a O
single O
mutation O
: O
A B
to I
G I
replacement I
at I
nucleotide I
985 I
( I
A I
985 I
G I
) I
. O

Normal O
and O
mutant O
c O
DNAs O
were O
expressed O
in O
bacteria O
, O
and O
enzymatic O
activity O
was O
assayed O
by O
the O
ferricenium O
hexaflurophosphate O
method O
. O

Four O
compound O
heterozygote O
individuals O
from O
two O
unrelated O
families O
with O
A O
985 O
G O
on O
one O
allele O
and O
a O
novel O
G B
to I
A I
mutation I
at I
nucleotide I
583 I
( O
G O
583 O
A O
) O
as O
the O
second O
mutant O
allele O
presented O
with O
MCAD O
deficiency O
in O
the O
first O
week O
of O
life O
. O

Sequence O
analysis O
of O
the O
proband O
' O
s O
ferrochelatase O
c O
DNA O
revealed O
a O
T B
to I
C I
point I
mutation I
at I
nucleotide I
557 I
. O

This O
mutation O
resulted O
in O
the O
replacement B
of I
Ile I
by I
Thr I
at I
amino I
acid I
position I
186 I
, O
a O
novel O
mutation O
in O
erythropoietic O
protoporphyria O
. O

Act O
R O
- O
IIB O
are O
phosphoproteins O
with O
demonstrable O
affinity O
for O
each O
other O
. O

Mutation B
of I
conserved I
serines I
and I
threonines I
in I
the I
GS I
domain I
, I
a I
region I
just I
upstream I
of I
the I
kinase I
domain I
in O
Act O
R O
- O
IB O
, O
abrogates O
both O
phosphorylation O
and O
signal O
propagation O
, O
suggesting O
that O
this O
domain O
contains O
phosphorylation O
sites O
required O
for O
signalling O
. O

Act O
R O
- O
IB O
activation O
can O
be O
mimicked O
by O
mutation B
of I
Thr I
- I
206 I
to I
aspartic I
acid I
, O
which O
yields O
a O
construct O
, O
Act O
R O
- O
IB O
( O
T O
206 O
D O
) O
, O
that O
signals O
in O
the O
absence O
of O
ligand O
. O

Molecular O
characterization O
of O
medium O
- O
chain O
acyl O
- O
Co O
A O
dehydrogenase O
( O
MCAD O
) O
deficiency O
: O
identification O
of O
a O
lys B
329 I
to I
glu I
mutation I
in O
the O
MCAD O
gene O
, O
and O
expression O
of O
inactive O
mutant O
enzyme O
protein O
in O
E O
. O
coli O
. O

Demonstration O
of O
intra O
- O
mitochondrial O
mature O
MCAD O
indistinguishable O
in O
size O
( O
42 O
. O
5 O
- O
k O
Da O
) O
from O
control O
MCAD O
, O
and O
of O
m O
RNA O
with O
the O
correct O
size O
of O
2 O
. O
4 O
kb O
, O
indicated O
a O
point O
- O
mutation O
in O
the O
coding O
region O
of O
the O
MCAD O
gene O
to O
be O
disease O
- O
causing O
. O

All O
clones O
sequenced O
from O
the O
patient O
exhibited O
a O
single B
base I
substitution I
from I
adenine I
( I
A I
) I
to I
guanine I
( I
G I
) I
at I
position I
985 I
in O
the O
MCAD O
c O
DNA O
as O
the O
only O
consistent O
base O
- O
variation O
compared O
with O
control O
c O
DNA O
. O

All O
the O
experiments O
are O
consistent O
with O
the O
contention O
that O
the O
G B
985 I
mutation I
, O
resulting B
in I
a I
lysine I
to I
glutamate I
shift I
at I
position I
329 I
in O
the O
MCAD O
polypeptide O
chain O
, O
is O
the O
genetic O
cause O
of O
MCAD O
deficiency O
in O
this O
family O
. O

Substitutions B
for I
glycine I
alpha I
1 I
- I
637 I
and I
glycine I
alpha I
2 I
- I
694 I
of O
type O
I O
procollagen O
in O
lethal O
osteogenesis O
imperfecta O
. O

One O
was O
a O
substitution B
of I
valine I
for I
glycine I
alpha I
1 I
- I
637 I
, O
and O
the O
other O
was O
a O
substitution B
of I
arginine I
for I
glycine I
alpha I
2 I
- I
694 I
. O

The O
collagenase O
A O
fragment O
from O
the O
collagen O
containing O
the O
arginine B
alpha I
2 I
- I
694 I
substitution I
was O
cleaved O
at O
about O
amino O
acid O
700 O
when O
incubated O
with O
trypsin O
at O
30 O
- O
35 O
degrees O
C O
. O
Therefore O
, O
there O
was O
micro O
- O
unfolding O
of O
the O
triple O
helix O
at O
a O
site O
close O
to O
the O
glycine O
substitution O
. O

Surprisingly O
, O
however O
, O
the O
collagenase O
A O
fragment O
with O
the O
valine B
alpha I
1 I
- I
637 I
substitution I
was O
also O
cleaved O
at O
about O
amino O
acid O
700 O
under O
the O
same O
conditions O
. O

Here O
, O
we O
analyze O
the O
effects O
of O
a O
mutation O
in O
1 O
of O
4 O
homologous O
subunits O
in O
the O
ACh O
R O
from O
a O
CM O
patient O
, O
a O
Leu B
to I
Pro I
mutation I
at I
position I
42 I
of O
the O
delta O
subunit O
. O

Substitutions B
of I
Gly I
, I
Lys I
, I
or I
Asp I
for I
delta I
L I
42 I
, I
or I
substitutions I
of I
Pro I
along O
the O
local O
protein O
chain O
, O
also O
slowed O
channel O
opening O
. O

Substitution B
of I
Pro I
for I
Leu I
in I
the I
epsilon I
subunit I
slowed O
opening O
, O
whereas O
this O
substitution O
had O
no O
effect O
in O
the O
beta O
subunit O
and O
actually O
sped O
opening O
in O
the O
alpha O
subunit O
. O

We O
describe O
the O
haematological O
and O
molecular O
characteristics O
of O
six O
unrelated O
Italian O
patients O
affected O
by O
pyrimidine O
5 O
' O
- O
nucleotidase O
deficiency O
( O
one O
from O
northern O
and O
five O
from O
southern O
Italy O
) O
. O

The O
sequence O
of O
the O
complete O
P O
5 O
' O
N O
- O
1 O
gene O
showed O
the O
presence O
of O
four O
different O
new O
mutations O
: O
a O
missense B
mutation I
AAT I
- I
AGT I
at I
codon I
190 I
( I
Asn I
- I
Ser I
) I
, I
one B
splicing I
mutation I
( I
IVS I
9 I
- I
1 I
g I
- I
c I
) I
and O
two B
frameshift I
mutations I
, I
Del I
G I
576 I
and I
Ins I
GG I
743 I
. O

The O
familial B
mutation I
substitutes I
a I
proline I
for I
a I
highly I
conserved I
alanine I
at I
position I
114 I
in O
the O
ANT O
1 O
protein O
. O

In O
five O
members O
of O
a O
family O
and O
another O
unrelated O
person O
affected O
by O
a O
slow O
- O
channel O
congenital O
myasthenic O
syndrome O
( O
SCCMS O
) O
, O
molecular O
genetic O
analysis O
of O
acetylcholine O
receptor O
( O
ACh O
R O
) O
subunit O
genes O
revealed O
a O
heterozygous O
G B
to I
A I
mutation I
at I
nucleotide I
457 I
of I
the I
alpha I
subunit I
, O
converting B
codon I
153 I
from I
glycine I
to I
serine I
( I
alpha I
G I
153 I
S I
) I
. O

One O
mutation O
was O
a O
G O
3295 O
T O
substitution O
with O
conversion O
of O
asparagine B
to I
tyrosine I
( I
D I
1099 I
Y I
) I
in O
ABCA O
1 O
. O

The O
single B
- I
base I
substitution I
at I
codon I
1099 I
resulted O
in O
the O
abolition O
of O
an O
Rsa O
I O
cleavage O
site O
. O

The O
proband O
and O
affected O
individuals O
having O
another O
mutation O
were O
heterozygotes O
for O
T O
5966 O
C O
with O
phenylalanine B
converted I
to I
serine I
( I
F I
2009 I
S I
) I
. O

In O
the O
kindred O
, O
family O
members O
heterozygous O
for O
the O
ABCA O
1 O
variant O
exhibited O
low O
levels O
of O
HDL O
cholesterol O
. O

This O
variant O
ACT O
was O
a O
point O
mutation O
of O
exon B
V I
of I
ACT I
, I
with I
the I
substitution I
of I
Met I
by I
Val I
. O

We O
show O
that O
mutation O
of O
the O
conserved B
Glu I
- I
165 I
beta I
in O
human O
ETF O
leads O
to O
drastically O
modulated O
rates O
of O
interprotein O
electron O
transfer O
with O
both O
medium O
chain O
acyl O
- O
Co O
A O
dehydrogenase O
and O
dimethylglycine O
dehydrogenase O
. O

Inhibition O
of O
AFMID O
by O
organophosphorus O
insecticides O
in O
developing O
chicken O
embryos O
is O
correlated O
with O
lowered O
NAD O
levels O
and O
severe O
teratogenesis O
. O

Residues O
identified O
as O
potential O
catalytic O
triad O
members O
( B
S I
162 I
, I
D I
247 I
, I
and I
H I
279 I
) I
through I
sequence I
motif I
and I
homology I
modeling I
were I
mutated I
to I
alanine I
to O
probe O
their O
contributions O
to O
enzyme O
activity O
. O

The O
entire O
acid O
sphingomyelinase O
coding O
region O
from O
an O
Ashkenazi O
Jewish O
Type O
B O
patient O
was O
polymerase O
chain O
reaction O
- O
amplified O
, O
subcloned O
, O
and O
completely O
sequenced O
. O

A O
three B
- I
base I
deletion I
was I
identified I
of I
nucleotides I
1821 I
- I
1823 I
in O
the O
c O
DNA O
which O
predicted O
the O
removal B
of I
an I
arginine I
residue I
from I
position I
608 I
of O
the O
acid O
sphingomyelinase O
polypeptide O
( O
delta O
R O
608 O
) O
. O

Identification O
, O
expression O
, O
and O
pharmacology O
of O
a O
Cys B
23 I
- I
Ser I
23 I
substitution I
in O
the O
human O
5 O
- O
HT O
2 O
c O
receptor O
gene O
( O
HTR O
2 O
C O
) O
. O

Using O
SSCP O
analysis O
, O
we O
identified O
a O
Cys B
23 I
- I
Ser I
23 I
substitution I
( O
designated O
5 O
- O
HT O
2 O
Ccys O
and O
5 O
- O
HT O
2 O
Cser O
) O
in O
the O
first O
hydrophobic O
region O
of O
the O
human O
5 O
- O
HT O
2 O
C O
receptor O
. O

To O
evaluate O
whether O
this O
amino O
acid O
substitution O
causes O
a O
variant O
function O
of O
this O
receptor O
, O
recombinant O
human O
5 O
- O
HT O
2 O
Ccys O
and O
5 O
- O
HT O
2 O
Cser O
receptors O
were O
expressed O
in O
Xenopus O
oocytes O
and O
tested O
for O
responses O
to O
5 O
- O
HT O
using O
electrophysiological O
techniques O
. O

It O
was O
confirmed O
that O
the O
alleles O
coding O
for O
A O
26 O
. O
1 O
and O
A O
26 O
. O
3 O
are O
identical O
with O
A O
* O
2602 O
and O
A O
* O
2601 O
, O
respectively O
. O

A O
26 O
. O
4 O
( O
A O
* O
2603 O
) O
was O
different B
from I
the I
other I
A I
26 I
splits I
at I
three I
positions I
: I
74 I
histidine I
, I
76 I
valine I
, I
and I
77 I
aspartate I
. O

A O
10 O
SA O
( O
A O
* O
2604 O
) O
was O
different O
from O
A O
26 O
. O
3 O
( O
A O
* O
2601 O
) O
by O
a O
single O
substitution B
of I
arginine I
by I
leucine I
at I
position I
163 I
. O

The O
four B
nucleotides I
deletion I
located I
at I
the I
junction I
of I
exon I
/ I
intron I
16 I
( O
5 O
' O
- O
TTGGTCGgtgagt O
- O
3 O
' O
) O
is O
the O
first O
GPI O
mutation O
affecting O
a O
splice O
site O
. O

Correlation O
was O
made O
between O
mutations O
, O
biochemical O
characteristics O
of O
the O
enzyme O
, O
and O
clinical O
course O
of O
the O
disease O
. O

In O
this O
study O
, O
we O
show O
that O
deletion B
of I
both O
BCAP O
and O
CD O
19 O
leads O
to O
an O
almost O
complete O
block O
of O
BCR O
- O
mediated O
Akt O
activation O
and O
to O
severe O
defects O
in O
generation O
of O
immature O
and O
mature O
B O
cells O
. O

To O
characterize O
the O
molecular O
basis O
of O
the O
" O
new O
" O
alpha O
1 O
- O
antitrypsin O
( O
alpha O
1 O
AT O
) O
deficient O
variant O
, O
PI O
Y O
barcelona O
, O
DNA O
sequence O
analysis O
of O
the O
coding O
exons O
of O
the O
alpha O
1 O
AT O
gene O
was O
carried O
out O
using O
an O
amplification O
DNA O
technique O
and O
direct O
sequencing O
. O

The O
PI O
Y O
barcelona O
allele O
differs O
from O
the O
normal O
M O
1 O
( B
Val I
213 I
) I
allele I
sequence I
by I
two I
point I
substitutions I
: I
a I
transversion I
of I
GAT I
TO I
GTT I
in I
exon I
III I
in I
the I
codon I
for I
residue I
256 I
, O
resulting B
in I
the I
amino I
acid I
change I
of I
Asp I
256 I
to I
Val I
256 I
, O
and O
a O
transversion B
of I
CCC I
to I
CAC I
in I
exon I
V I
in I
the I
codon I
for I
residue I
391 I
, O
resulting O
in O
the O
amino O
acid O
substitution O
of O
Pro B
391 I
to I
His I
391 I
. O

Amino B
acid I
substitution I
in I
postion I
391 I
occurs O
in O
the O
C O
- O
terminal O
peptide O
region O
, O
which O
shows O
a O
high O
degree O
of O
homology O
with O
the O
family O
of O
serpins O
. O

Nine B
different I
point I
mutations I
were I
found I
in I
both I
heterozygous I
and I
homozygous I
forms I
at I
nucleic I
acid I
residues I
46 I
, I
79 I
, I
100 I
, I
252 I
, I
491 I
, I
523 I
, I
1053 I
, I
1098 I
, I
and I
1239 I
. O

Of O
these O
nine O
polymorphisms O
, O
four O
were O
found O
to O
cause B
changes I
in I
the I
encoded I
amino I
acids I
at I
residues I
16 I
, I
27 I
, I
34 I
, I
and I
164 I
. O

The O
most O
frequent O
polymorphisms O
were O
arginine B
16 I
to I
glycine I
( O
Arg O
16 O
- O
- O
> O
Gly O
) O
and O
glutamine B
27 I
to I
glutamic I
acid I
( O
Gln O
27 O
- O
- O
> O
Glu O
) O
. O

The O
other O
two O
polymorphisms O
, O
valine B
34 I
to I
methionine I
, O
and O
threonine B
164 I
to I
isoleucine I
, O
occurred O
in O
only O
four O
subjects O
. O

Some O
subjects O
were O
found O
to O
have O
both O
of O
these O
polymorphisms O
simultaneously O
, O
but O
there O
was O
no O
difference O
in O
incidence O
between O
the O
two O
groups O
, O
with O
23 O
% O
of O
asthmatics O
and O
28 O
% O
of O
normal O
subjects O
being O
homozygous O
for O
both O
polymorphisms O
. O

Site O
- O
directed O
mutagenesis B
of I
active I
site I
glutamate I
- I
217 I
in O
mouse O
adenosine O
deaminase O
. O

The O
proposed O
catalytic O
mechanism O
of O
ADA O
based O
on O
the O
recent O
elucidations O
of O
the O
crystal O
structure O
of O
this O
enzyme O
with O
transition O
- O
and O
ground O
- O
state O
analogs O
hypothesized O
that O
Glu O
217 O
was O
involved O
in O
this O
proton O
donation O
step O
[ O
Wilson O
, O
D O
. O
K O
. O
, O
Rudolph O
, O
F O
. O
B O
. O
, O
& O
Quiocho O
, O
F O
. O
A O
. O

Glu B
217 I
was I
mutated I
to I
Asp I
, I
Gly I
, I
Gln I
, I
and I
Ser I
, O
and O
all O
mutants O
were O
successfully O
expressed O
and O
purified O
. O

Argonaute O
2 O
( O
Ago O
2 O
) O
has O
a O
P O
- O
element O
- O
induced O
wimpy O
testis O
( O
PIWI O
) O
domain O
, O
which O
folds O
like O
RNase O
H O
and O
is O
responsible O
for O
target O
RNA O
cleavage O
in O
RNA O
interference O
. O

Furthermore O
, O
mutation B
of I
proline I
700 I
to I
alanine I
also O
resulted O
in O
destabilization O
of O
Ago O
2 O
, O
thus O
linking O
Ago O
2 O
P O
700 O
and O
hydroxylation O
at O
this O
residue O
to O
its O
stability O
regulation O
. O

The O
specific O
phosphorylation O
of O
Ser O
( O
280 O
) O
by O
hallucinogens O
was O
further O
validated O
by O
quantitative O
mass O
spectrometry O
analysis O
of O
immunopurified O
receptor O
digests O
and O
by O
Western O
blotting O
using O
a O
phosphosite O
specific O
antibody O
. O

The O
mutation O
of O
Ser B
( I
280 I
) I
to I
aspartic I
acid I
( O
to O
mimic O
phosphorylation O
) O
reduced O
receptor O
desensitization O
by O
nonhallucinogenic O
agonists O
, O
whereas O
its O
mutation O
to O
alanine O
increased O
the O
ability O
of O
hallucinogens O
to O
desensitize O
the O
receptor O
. O

The O
gp O
D O
c O
DNAs O
isolated O
by O
reverse O
transcription O
/ O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
from O
Fy O
( O
a O
+ O
b O
- O
) O
and O
Fy O
( O
a O
- O
b O
+ O
) O
donors O
differed O
by O
only O
one O
base O
substitution O
( O
G O
131 O
A O
) O
changing O
Gly B
to I
Asp I
at I
position I
44 I
of O
the O
gp O
D O
protein O
. O

Ala I
also O
abolishes O
the O
ability O
of O
C O
/ O
EBPalpha O
to O
cause O
growth O
arrest O
because O
of O
a O
lack O
of O
interactions O
with O
cdk O
2 O
and O
E O
2 O
F O
- O
Rb O
complexes O
. O

